0001628280-21-021750.txt : 20211104 0001628280-21-021750.hdr.sgml : 20211104 20211104160340 ACCESSION NUMBER: 0001628280-21-021750 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 211379847 BUSINESS ADDRESS: STREET 1: 3730 KIRBY DRIVE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 3730 KIRBY DRIVE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 10-Q 1 blcm-20210930.htm 10-Q blcm-20210930
000135840312/312021Q3false0.12.5P2YP10DP10D00013584032021-01-012021-09-30xbrli:shares00013584032021-10-27iso4217:USD00013584032021-09-3000013584032020-12-31iso4217:USDxbrli:shares0001358403us-gaap:ConvertiblePreferredStockMember2021-09-300001358403us-gaap:ConvertiblePreferredStockMember2020-12-310001358403blcm:SupplyAgreementMember2021-07-012021-09-300001358403blcm:SupplyAgreementMember2020-07-012020-09-300001358403blcm:SupplyAgreementMember2021-01-012021-09-300001358403blcm:SupplyAgreementMember2020-01-012020-09-300001358403blcm:LicenseRevenueMember2021-07-012021-09-300001358403blcm:LicenseRevenueMember2020-07-012020-09-300001358403blcm:LicenseRevenueMember2021-01-012021-09-300001358403blcm:LicenseRevenueMember2020-01-012020-09-3000013584032021-07-012021-09-3000013584032020-07-012020-09-3000013584032020-01-012020-09-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2020-12-310001358403us-gaap:CommonStockMember2020-12-310001358403us-gaap:TreasuryStockMember2020-12-310001358403us-gaap:AdditionalPaidInCapitalMember2020-12-310001358403us-gaap:RetainedEarningsMember2020-12-310001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001358403us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100013584032021-01-012021-03-310001358403us-gaap:CommonStockMember2021-01-012021-03-310001358403us-gaap:RetainedEarningsMember2021-01-012021-03-310001358403us-gaap:RedeemableConvertiblePreferredStockMember2021-03-310001358403us-gaap:CommonStockMember2021-03-310001358403us-gaap:TreasuryStockMember2021-03-310001358403us-gaap:AdditionalPaidInCapitalMember2021-03-310001358403us-gaap:RetainedEarningsMember2021-03-310001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100013584032021-03-310001358403us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000013584032021-04-012021-06-300001358403us-gaap:CommonStockMember2021-04-012021-06-300001358403us-gaap:RetainedEarningsMember2021-04-012021-06-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2021-06-300001358403us-gaap:CommonStockMember2021-06-300001358403us-gaap:TreasuryStockMember2021-06-300001358403us-gaap:AdditionalPaidInCapitalMember2021-06-300001358403us-gaap:RetainedEarningsMember2021-06-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000013584032021-06-300001358403us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001358403us-gaap:RetainedEarningsMember2021-07-012021-09-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2021-09-300001358403us-gaap:CommonStockMember2021-09-300001358403us-gaap:TreasuryStockMember2021-09-300001358403us-gaap:AdditionalPaidInCapitalMember2021-09-300001358403us-gaap:RetainedEarningsMember2021-09-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2019-12-310001358403us-gaap:CommonStockMember2019-12-310001358403us-gaap:TreasuryStockMember2019-12-310001358403us-gaap:AdditionalPaidInCapitalMember2019-12-310001358403us-gaap:RetainedEarningsMember2019-12-310001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100013584032019-12-310001358403us-gaap:CommonStockMember2020-01-012020-03-310001358403us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100013584032020-01-012020-03-310001358403us-gaap:RedeemableConvertiblePreferredStockMember2020-01-012020-03-310001358403us-gaap:RetainedEarningsMember2020-01-012020-03-310001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001358403us-gaap:RedeemableConvertiblePreferredStockMember2020-03-310001358403us-gaap:CommonStockMember2020-03-310001358403us-gaap:TreasuryStockMember2020-03-310001358403us-gaap:AdditionalPaidInCapitalMember2020-03-310001358403us-gaap:RetainedEarningsMember2020-03-310001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100013584032020-03-310001358403us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000013584032020-04-012020-06-300001358403us-gaap:CommonStockMember2020-04-012020-06-300001358403us-gaap:RetainedEarningsMember2020-04-012020-06-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2020-06-300001358403us-gaap:CommonStockMember2020-06-300001358403us-gaap:TreasuryStockMember2020-06-300001358403us-gaap:AdditionalPaidInCapitalMember2020-06-300001358403us-gaap:RetainedEarningsMember2020-06-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000013584032020-06-300001358403us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001358403us-gaap:RetainedEarningsMember2020-07-012020-09-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001358403us-gaap:RedeemableConvertiblePreferredStockMember2020-09-300001358403us-gaap:CommonStockMember2020-09-300001358403us-gaap:TreasuryStockMember2020-09-300001358403us-gaap:AdditionalPaidInCapitalMember2020-09-300001358403us-gaap:RetainedEarningsMember2020-09-300001358403us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-3000013584032020-09-30blcm:subsidiaryblcm:segment00013584032020-02-0400013584032020-02-0500013584032020-06-1400013584032020-06-150001358403blcm:A2130W.HolcombeBlvd.Member2020-04-142020-04-140001358403srt:MaximumMember2020-05-012021-09-300001358403blcm:ResearchAndDevelopmentFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-12-310001358403blcm:ResearchAndDevelopmentFacilityMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-10-012020-12-310001358403blcm:ReedRoadHoustonTXMember2021-02-260001358403blcm:SanFranciscoOfficeSpaceMember2021-03-152021-03-150001358403blcm:SanFranciscoOfficeSpaceMember2021-06-012021-06-300001358403blcm:SanFranciscoOfficeSpaceMember2021-03-260001358403us-gaap:EquipmentMemberblcm:SanFranciscoOfficeSpaceMember2021-03-260001358403blcm:SanFranciscoOfficeSpaceMember2021-01-012021-03-310001358403us-gaap:ScenarioAdjustmentMember2020-09-300001358403us-gaap:RedeemablePreferredStockMember2021-01-012021-09-300001358403us-gaap:RedeemablePreferredStockMember2020-01-012020-09-300001358403us-gaap:WarrantMember2021-01-012021-09-300001358403us-gaap:WarrantMember2020-01-012020-09-300001358403us-gaap:PrivatePlacementMember2021-01-012021-09-300001358403us-gaap:PrivatePlacementMember2020-01-012020-09-300001358403us-gaap:StockOptionMember2021-01-012021-09-300001358403us-gaap:StockOptionMember2020-01-012020-09-300001358403us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001358403us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-30xbrli:pure00013584032020-02-052020-02-050001358403us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300001358403us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-09-300001358403us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-09-300001358403us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001358403us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001358403us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2020-12-310001358403us-gaap:FairValueInputsLevel1Member2021-09-300001358403us-gaap:FairValueInputsLevel2Member2021-09-300001358403us-gaap:FairValueInputsLevel3Member2021-09-300001358403us-gaap:FairValueInputsLevel1Member2020-12-310001358403us-gaap:FairValueInputsLevel2Member2020-12-310001358403us-gaap:FairValueInputsLevel3Member2020-12-310001358403blcm:WarrantDerivativeLiabilityMember2021-01-012021-09-300001358403blcm:WarrantDerivativeLiabilityMember2020-01-012020-12-310001358403blcm:PrivatePlacementOptionDerivativeLiabilityMember2021-01-012021-09-300001358403blcm:PrivatePlacementOptionDerivativeLiabilityMember2020-01-012020-12-310001358403srt:MinimumMember2021-09-300001358403srt:MaximumMember2021-09-3000013584032020-11-3000013584032020-11-012020-11-300001358403srt:MaximumMember2020-11-012020-11-300001358403srt:MinimumMember2020-11-012020-11-300001358403blcm:PublicStockOfferingMemberus-gaap:RedeemableConvertiblePreferredStockMember2019-08-162019-08-160001358403blcm:PublicStockOfferingMember2019-08-160001358403us-gaap:CommonStockMemberblcm:PublicStockOfferingMember2019-08-1600013584032019-08-212019-08-210001358403blcm:PublicStockOfferingMemberus-gaap:RedeemableConvertiblePreferredStockMember2019-08-160001358403us-gaap:CommonStockMemberblcm:PublicStockOfferingMembersrt:MinimumMember2019-08-160001358403us-gaap:CommonStockMemberblcm:PublicStockOfferingMembersrt:MaximumMember2019-08-160001358403blcm:Series2PreferredStockMemberus-gaap:PrivatePlacementMember2019-08-162019-08-160001358403blcm:Series2PreferredStockMemberus-gaap:PrivatePlacementMember2019-08-160001358403blcm:Series3PreferredStockMemberus-gaap:PrivatePlacementMember2019-08-162019-08-160001358403us-gaap:PrivatePlacementMemberus-gaap:PreferredStockMember2019-08-160001358403blcm:PublicWarrantsPrivateWarrantsAndStockOptionsMember2021-01-012021-09-300001358403us-gaap:FairValueInputsLevel3Memberblcm:WarrantDerivativeLiabilityMember2020-12-310001358403us-gaap:FairValueInputsLevel3Memberblcm:PrivatePlacementOptionDerivativeLiabilityMember2020-12-310001358403us-gaap:FairValueInputsLevel3Memberblcm:WarrantDerivativeLiabilityMember2021-01-012021-09-300001358403us-gaap:FairValueInputsLevel3Memberblcm:PrivatePlacementOptionDerivativeLiabilityMember2021-01-012021-09-300001358403us-gaap:FairValueInputsLevel3Member2021-01-012021-09-300001358403us-gaap:FairValueInputsLevel3Memberblcm:WarrantDerivativeLiabilityMember2021-09-300001358403us-gaap:FairValueInputsLevel3Memberblcm:PrivatePlacementOptionDerivativeLiabilityMember2021-09-300001358403blcm:Series2PreferredStockMember2021-01-012021-09-300001358403blcm:Series2PreferredStockMemberus-gaap:PrivatePlacementMember2021-01-012021-09-300001358403blcm:Series3PreferredStockMemberus-gaap:PrivatePlacementMember2021-01-012021-09-300001358403blcm:Series2PreferredStockMember2021-09-300001358403blcm:Series3PreferredStockMember2021-09-300001358403blcm:Series1and2PreferredStockMember2021-09-300001358403blcm:Series1and2PreferredStockMember2021-01-012021-09-300001358403blcm:Series3PreferredStockMember2021-01-012021-09-30blcm:plan0001358403us-gaap:EmployeeStockOptionMembersrt:MinimumMember2021-01-012021-09-300001358403us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-01-012021-09-300001358403us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001358403blcm:A2019EquityIncentivePlanMember2021-09-300001358403blcm:A2019EquityIncentivePlanMember2020-01-012020-01-310001358403blcm:A2019EquityIncentivePlanMember2020-06-012020-06-300001358403blcm:A2019EquityIncentivePlanMember2021-06-012021-06-300001358403srt:MaximumMemberblcm:A2019EquityIncentivePlanMember2021-09-300001358403blcm:EmployeeStockOptionsAndInducementOptionAwardsMember2020-12-310001358403blcm:EmployeeStockOptionsAndInducementOptionAwardsMember2021-01-012021-09-300001358403blcm:EmployeeStockOptionsAndInducementOptionAwardsMember2021-09-300001358403blcm:RestrictedStockandRestrictedStockUnitsMember2020-12-310001358403blcm:RestrictedStockandRestrictedStockUnitsMember2021-01-012021-09-300001358403blcm:RestrictedStockandRestrictedStockUnitsMember2021-09-300001358403blcm:A2014EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-09-300001358403us-gaap:EmployeeStockMember2021-01-012021-09-300001358403us-gaap:EmployeeStockMember2020-01-012020-09-300001358403us-gaap:EmployeeStockMember2021-09-300001358403us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001358403us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001358403us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001358403us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001358403us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001358403us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001358403us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001358403us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001358403blcm:BaylorMemberus-gaap:LicensingAgreementsMember2019-01-012019-12-310001358403blcm:BaylorMemberus-gaap:LicensingAgreementsMember2021-04-012021-06-300001358403blcm:BaylorMemberus-gaap:LicensingAgreementsMember2021-07-012021-09-300001358403blcm:AgensysInc.Memberus-gaap:LicensingAgreementsMember2015-12-102015-12-100001358403blcm:BioVecPharmaIncMemberus-gaap:LicensingAgreementsMember2015-06-102015-06-10blcm:product0001358403blcm:TakedaMember2021-01-012021-09-300001358403blcm:MDAndersonMember2021-07-012021-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from ____ to ____                     
 
Commission File Number: 001-36783
 
BELLICUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter) 
Delaware20-1450200
(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)
    
3730 Kirby Drive, Suite 1200, Houston, TX                            77098
(Address of principal executive offices)                         (Zip code)

(832384-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBLCM
The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes    ☒   No    ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes    ☒   No    ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes    ☐   No  

As of October 27, 2021, there were 8,397,803 outstanding shares of Bellicum’s common stock, par value, $0.01 per share.



TABLE OF CONTENTS
 
Page


2


PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Bellicum Pharmaceuticals, Inc.
 Condensed Consolidated Balance Sheets
(in thousands, except par value and share data)
September 30, 2021December 31, 2020
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$19,266 $35,495 
Restricted cash1,501 1,501 
Accounts receivable, interest and other receivables
556 2 
Prepaid expenses and other current assets
1,019 802 
Assets held for sale 1,643 
Total current assets
22,342 39,443 
Operating lease right-of-use assets
 645 
Property and equipment, net
27 189 
Other assets
4 307 
Total assets
$22,373 $40,584 
LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable
$521 $891 
Accrued expenses and other current liabilities
5,339 4,165 
Warrant derivative liability
7,842 10,345 
Private placement option liability
2,800 7,803 
Current portion of lease liabilities
 825 
Liabilities held for sale 672 
Total current liabilities
16,502 24,701 
    Long-term lease liabilities
 344 
Total liabilities
16,502 25,045 
Commitments and contingencies
Redeemable Preferred stock: $0.01 par value; 10,000,000 shares authorized
   Series 1 redeemable convertible preferred stock, $0.01 par value, 1,517,500 shares authorized at September 30, 2021 and December 31, 2020; 452,000 shares issued and outstanding at September 30, 2021 and December 31, 2020
18,036 18,036 
Stockholders’ deficit:
   Common stock, $0.01 par value; 80,000,000 shares authorized at September 30, 2021 and December 31, 2020; 8,465,549 shares issued and 8,397,803 shares outstanding at September 30, 2021; 8,385,650 shares issued and 8,317,904 shares outstanding at December 31, 2020
84 84 
Treasury stock: 67,746 shares held at September 30, 2021 and December 31, 2020
(5,056)(5,056)
Additional paid-in capital
546,138 543,561 
Accumulated other comprehensive loss
(348)(339)
Accumulated deficit
(552,983)(540,747)
Total stockholders’ deficit
(12,165)(2,497)
Total liabilities, redeemable preferred stock and stockholders' deficit
$22,373 $40,584 

See accompanying notes, which are an integral part of these unaudited consolidated financial statements.
3


Bellicum Pharmaceuticals, Inc.
 Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(Unaudited) 
Three Months EndedNine Months Ended
September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Revenues
Supply agreement$ $ $700 $ 
License revenue
5,000  5,000  
Total revenues
5,000  5,700  
Operating expenses
Research and development
6,348 8,140 19,531 30,346 
General and administrative
1,681 4,163 5,458 12,095 
Total operating expenses
8,029 12,303 24,989 42,441 
(Gain) loss on dispositions, net14  478 (3,761)
Loss from operations
(3,043)(12,303)(19,767)(38,680)
Other income (expense):
Interest income
6 10 24 392 
Interest expense
 (725)(4)(2,473)
   Change in fair value of warrant and private placement option liabilities
4,264 12,131 7,506 14,256 
Other income
6
0
5
Total other income (expense)
4,276 11,416 7,531 12,175 
Net income (loss)
$1,233 $(887)$(12,236)$(26,505)
Less: undistributed earnings to participating securities(469)   
Net income (loss) attributable to common shareholders$764 $(887)$(12,236)$(26,505)
Net income (loss) per common share attributable to common shareholders, basic$0.08 $(0.18)$(1.21)$(5.25)
Net income (loss) per common share attributable to common shareholders, diluted$0.07 $(0.18)$(1.21)$(5.25)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Weighted-average shares outstanding, diluted
10,194,668 5,059,779 10,086,246 5,050,603 
Net income (loss)
$1,233 $(887)$(12,236)$(26,505)
Other comprehensive loss:
Foreign currency translation adjustment
(9)36 (9)(26)
Net comprehensive income (loss)
$1,224 $(851)$(12,245)$(26,531)
 
See accompanying notes, which are an integral part of these unaudited consolidated financial statements.

4

Bellicum Pharmaceuticals, Inc.
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit
(amounts in thousands, except share data)
(Unaudited)
Nine Months Ended September 30, 2021
Series 1 PreferredCommon StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders' Deficit
SharesAmountSharesAmountSharesAmount
Balance, December 31, 2020
452,000 $18,036 8,385,650 $84 (67,746)$(5,056)$543,561 $(540,747)$(339)$(2,497)
Share-based compensation— — — — — — 903 — — 903 
Exercise of restricted stock unit awards— — 369 — — — — — —  
Comprehensive loss— — — — — — — (11,267)— (11,267)
Balance, March 31, 2021452,000 $18,036 8,386,019 $84 (67,746)$(5,056)$544,464 $(552,014)$(339)$(12,861)
Share-based compensation— — — — — — 821 — — 821 
Exercise of restricted stock unit awards— — 79,530 — — — — — —  
Comprehensive loss— — — — — — — (2,202)— (2,202)
Balance, June 30, 2021
452,000 $18,036 8,465,549 $84 (67,746)$(5,056)$545,285 $(554,216)$(339)$(14,242)
Share-based compensation— — — — — — 853 — — 853 
Comprehensive income— — — — — — — 1,233 (9)1,224 
Balance, September 30, 2021
452,000 $18,036 8,465,549 $84 (67,746)$(5,056)$546,138 $(552,983)$(348)$(12,165)
Nine Months Ended September 30, 2020
Series 1 PreferredCommon StockTreasury StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders' Deficit
SharesAmountSharesAmountSharesAmount
Balance, December 31, 2019
538,000 21,468 5,076,593 507 (67,746)(5,056)511,684 (533,025)(327)(26,217)
1-for-10 Reverse Stock Split— — — (457)— — 457 — —  
Share-based compensation— — — — — — 1,323 — — 1,323 
Issuance of common stock upon vesting of restricted stock units— — 1,045 — — — — — — — 
Conversion of redeemable convertible preferred stock into common stock(4,000)(160)40,000 1 — — 159 — — 160 
Comprehensive loss— — — — — — — 17,576 (13)17,563 
Balance, March 31, 2020
534,000 $21,308 5,117,638 $51 (67,746)$(5,056)$513,623 $(515,449)$(340)$(7,171)
Share-based compensation— — — — — — 1,564 — — 1,564 
Issuance of common stock - Employee Stock Purchase Plan— — 9,526  — — 65 — — 65 
Issuance of common stock upon vesting of restricted stock units— — 361 — — — — — — — 
Comprehensive loss— — — — — — — (43,194)(49)(43,243)
Balance, June 30, 2020
534,000 $21,308 5,127,525 $51 (67,746)$(5,056)$515,252 $(558,643)$(389)$(48,785)
Share-based compensation— — — — — — 1,606 — — 1,606 
Comprehensive loss— — — — — — — (887)36 (851)
Balance, September 30, 2020
534,000 $21,308 5,127,525 $51 (67,746)$(5,056)$516,858 $(559,530)$(353)$(48,030)

See accompanying notes, which are an integral part of these unaudited consolidated financial statements.

5


Bellicum Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited) 
Nine Months Ended
September 30, 2021September 30, 2020
Cash flows from operating activities:
     Net loss
$(12,236)$(26,505)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
2,577 4,493 
Depreciation and amortization expense
90 1,229 
Change in fair value of warrant and private placement option liabilities
(7,506)(14,256)
(Gain) loss on dispositions, net478 (3,761)
      Amortization of right-of-use assets
33 297 
      Accretion of lease liability
23 371 
      Amortization of deferred issuance costs
 550 
Changes in operating assets and liabilities:
Accounts receivable, interest and other receivables
(181)178 
Prepaid expenses and other assets
(216)103 
Accounts payable
(370)(1,345)
Accrued liabilities and other
230 (4,629)
Net cash used in operating activities
(17,078)(43,275)
Cash flows from investing activities:
Proceeds from sale of property and equipment, net900 14,909 
Purchases of property and equipment
(7)(807)
Net cash provided by investing activities
893 14,102 
Cash flows from financing activities:
 Payment on debt (10,000)
 Proceeds from issuance of stock from employee stock purchase plan  65 
    Payment on financing lease obligations
(35)(56)
Net cash used in financing activities
(35)(9,991)
Effect of exchange rate changes on cash
(9)(26)
Net change in cash, cash equivalents, and restricted cash
(16,229)(39,190)
Cash, cash equivalents and restricted cash at beginning of period
36,996 93,816 
Cash, cash equivalents and restricted cash at end of period
$20,767 $54,626 
Supplemental cash flow information:
Cash paid during the period for interest
$ $1,973 
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payables and accrued liabilities  859 
Leasehold improvements paid by landlord 113 
Conversion of redeemable preferred stock into common stock 160 
Reclassification of property and equipment, net to assets held for sale 199 
See accompanying notes, which are an integral part of these unaudited consolidated financial statements.
6


Bellicum Pharmaceuticals, Inc.
 
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 1 - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Bellicum Pharmaceuticals, Inc. (“Bellicum”) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer. Bellicum is devoting substantially all of its present efforts to developing next-generation CAR-T product candidates in cellular immunotherapy.

Bellicum has two wholly-owned subsidiaries, Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom, and Bellicum Pharma GmbH, a private limited liability company organized under German law. Both were formed for the purpose of developing product candidates in Europe. Bellicum, Bellicum Pharma Limited and Bellicum Pharma GmbH are collectively referred to herein as the “Company”. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation.

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company’s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.
Reverse Stock Split
On February 5, 2020, the Company filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to (i) effect a reverse stock split of all issued and outstanding shares of the Company’s common stock at a ratio of 1-for-10 and (ii) reduce the number of authorized shares of the Company’s common stock from 200,000,000 to 40,000,000. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented.

On June 15, 2020, the Company filed with the Secretary of State of the State of Delaware a Second Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 40,000,000 shares to 80,000,000 shares.
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.

7

The accompanying interim condensed financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. However, as of September 30, 2021, and December 31, 2020, the Company had an accumulated deficit of $553.0 million and $540.7 million, respectively, and at September 30, 2021, the Company had cash, cash equivalents and restricted cash of approximately $20.8 million. Based on the Company’s current business plan, management believes that existing cash and cash equivalents, revenues and other cash inflows will be insufficient to fund its operations for one year from the date these financial statements are issued, and therefore, substantial doubt about the entity’s ability to continue as a going concern exists. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has recorded losses from operations since its inception and if the Company does not successfully obtain regulatory approval and commercialize any of its product candidates, the Company will not be able to achieve profitability.

The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry.

The Company believes that there is substantial doubt that its current capital resources, which consist of cash and cash equivalents are sufficient to fund operations through at least the next twelve months from the date the accompanying interim financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of additional equity, incurrence of debt, the entry into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals. Moreover, if the Company does not obtain such additional funds, there could be substantial doubt about its ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to the Company's stockholders and other security holders.
Use of Estimates
The preparation of the interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.
Revenue Recognition
The Company’s sources of revenue during the nine months ended September 30, 2021 are from its supply agreement with Takeda Development Center Americas, Inc. (“Takeda”) and from its licensing agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”).
Supply of Product
The promised product in supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.
Licenses of Intellectual Property
The promised services in license agreement with MD Anderson consists of certain option and license rights to the Company’s intellectual property. If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement and when management believes the license to its intellectual property and products has stand-alone value, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the
8

Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments
At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.
Significant Accounting Policies
There have been no significant changes to the accounting policies during the nine months ended September 30, 2021 as compared to the significant accounting policies described in Note 1 of the “Notes to Consolidated Financial Statements” in the Company’s audited financial statements included in its Annual Report for the fiscal year ended December 31, 2020.
Cash, Cash Equivalents and Restricted Cash
The Company considers all short-term, highly liquid investments with maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.
(in thousands)September 30, 2021December 31, 2020
Cash and cash equivalents$19,266 $35,495 
Restricted cash1,501 1,501 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$20,767 $36,996 
In connection with the closing of the Asset Purchase Agreement with M.D. Anderson on April 14, 2020, $1.5 million of the cash proceeds received are subject to certain escrow provisions and recorded as restricted cash. The funds are required to be held for a period of 18 months subsequent to the April 14, 2020 closing date or until any outstanding claims against the escrow are resolved, and are listed as Restricted cash at September 30, 2021, and December 31, 2020.
Disposition of Assets and Liabilities Held for Sale and Held for Use
In the fourth quarter of 2020, in connection with the Company's restructuring plan, Management elected to seek an exit to its leased manufacturing facility in Houston, Texas. As a result of this decision, the Company reclassified the assets and liabilities associated with the leased facility as held for sale. The reclassified assets and liabilities included a right-of-use asset of $0.5 million, property and equipment of $2.3 million and the related lease liability of $0.7 million. Based on the cost to exit the lease and the net realizable value of the related assets the Company recognized an impairment charge of $1.3 million in the fourth quarter of 2020.

The disposal of the assets and liabilities associated with the Houston facility was completed on February 26, 2021. Under the terms of the agreement a third party assumed the lease for the facility. In addition, the third party paid $1.1 million to the Company for substantially all of the property, and equipment associated with the location. The consideration included $0.9 million in cash and an unsecured promissory note for $0.2 million.

9

On March 15, 2021 the Company entered an agreement to terminate its sub-lease of the South San Francisco office space contingent upon consent of the prime lessor. Under the terms of the agreement, the company agreed to pay a lease termination fee of $0.9 million while the security deposit of $0.2 million was returned to the Company in June 2021. The decision to exit this lease reflects the ability of the Company to carry on administrative function remotely. On March 26, 2021, the Company met all of the conditions of the agreement and disposed of substantially all of the assets and liabilities associated with the lease including the right-of-use asset of $0.6 million, leased equipment with net book value less than $0.1 million, and the related lease liability of $1 million. The Company recognized a loss on termination of $0.5 million during the first quarter of 2021.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other liabilities consist of the following:
(in thousands)September 30, 2021December 31, 2020
Accrued payroll$278 $1,071 
Accrued patient treatment costs2,507 899 
Accrued clinical research costs1,658 1,562 
Accrued manufacturing costs252 41 
Accrued professional services289 279 
Accrued other355 313 
Total accrued expenses and other current liabilities $5,339 $4,165 

Certain prior year amounts have been reclassified to conform to the 2021 presentation. Expenses related to clinical studies totaling $1.2 million were reclassified from Accrued Other to Accrued Clinical Research Costs. Another $0.1 million for expenses related to drug manufacture and professional consulting services were reclassified from Accrued Other to Accrued Manufacturing Costs and Accrued Professional Services.
Warrant Derivatives
Freestanding warrants are classified as liabilities in the accompanying condensed consolidated balance sheets as they are exercisable for multiple underlying instruments that are potentially redeemable. The Company accounts for these warrants at fair value on the date of issuance and are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit.

The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Private Placement Option
The Company has entered into a security purchase agreement that contains a call option on preferred shares that are puttable outside the control of the Company. The Company recorded the option as a liability and measured the fair value of the option at the time of issuance. The Company will re-measure the option to fair value at each balance sheet date and record changes in fair value in other income (expense) in the accompanying condensed consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.

The Company estimates the fair value of these liabilities using a binomial lattice model, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Preferred Stock
Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying condensed consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally
10

redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified within mezzanine equity in the accompanying condensed consolidated balance sheets. At all other times, preferred shares are classified within stockholders’ deficit.
Operating Leases
At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company’s obligation to make lease payments arising from the lease, and a corresponding right-of-use (“ROU”) asset which represents the Company’s right to use an underlying asset during the lease term.

Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company's incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.
Fair Value of Financial Instruments
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.

Accounting standards include disclosure requirements around fair values used for certain financial instruments and establish a fair value hierarchy. The three-tier hierarchy defines a three-tiered valuation hierarchy for disclosures that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market, as described further in Note 2.
Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.
These inputs are classified into the following hierarchy:
Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;
Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and
Level 3 Inputs - unobservable inputs for the assets.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of these instruments.
Financial Instruments and Credit Risks
Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.
11

Equity Issuance Costs
Equity issuance costs represent costs paid to third parties in order to obtain equity financing. The costs related to preferred and common stock have been netted against the proceeds of the equity issuances.
Net Income (Loss) and Net Income (Loss) per Share of Common Stock Attributable to Common Stockholders

Basic and diluted net income (loss) per share attributable to common stockholders is based on the more dilutive method of either the two-class method or the treasury stock method. Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. Diluted net income (loss) per share gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period, assuming the exercise of all “in-the-money” common stock equivalents based on the average market price during the period. For periods of a net loss position, since the participating securities are not contractually obligated to share losses with the common stockholders, the diluted loss per share is calculated similarly to basic loss per share.

For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

The following table sets forth the computation of basic and diluted earnings per share:

Three Months EndedNine Months Ended
(in thousands, except share and per share amounts)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Net income (loss) per share - basic:
Net income (loss)
$1,233 $(887)$(12,236)$(26,505)
Less: undistributed earnings to participating securities(469)   
Net income (loss) attributable to common shareholders$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Basic net income (loss) per share $0.08 $(0.18)$(1.21)$(5.25)
Net income (loss) per share - diluted:
Net income (loss) attributable to common shareholders, basic$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Effect of dilutive securities:
Stock options and restricted stock units86,280    
Weighted-average shares outstanding, diluted
10,194,668 5,059,779 10,086,246 5,050,603 
Diluted net income (loss) per share$0.07 $(0.18)$(1.21)$(5.25)

12

The following outstanding shares of common stock equivalents were excluded from the computations of diluted net income (loss) per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.
September 30, 2021September 30, 2020
Common Stock Equivalents:Number of Shares
Redeemable convertible series 1 preferred stock4,520,000 5,340,000 
Warrants to purchase common stock11,616,080 5,750,000 
Private placement option9,675,000 9,675,000 
Options to purchase common stock1,985,277 1,142,470 
Unvested shares of restricted stock units168,980 182,227 
Total common stock equivalents27,965,337 22,089,697 

New Accounting Requirements and Disclosures

Fair Value Measurement

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies fair value disclosures and removes some disclosure requirements for both public and private companies. In addition, public companies are subject to some new disclosure requirements which requires to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.

Financial Instruments – Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.

13

Investments

In January 2020, the FASB issued Accounting Standards Update No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.

NOTE 2 - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES
 
Investment Securities

The following table presents the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)
Level 1
Level 2
 Level 3
Level 1Level 2 Level 3
Cash equivalents:
Money market funds and treasury bills$12,481 $ $ $27,463 $ $ 
Total cash equivalents$12,481 $ $ $27,463 $ $ 
As of September 30, 2021 and December 31, 2020, $1.5 million of restricted cash on the Company's balance sheet is held in a money market fund.

Money market funds, U.S. Treasury, U.S. government agency-backed securities, corporate debt securities and municipal bonds are valued based on various observable inputs such as benchmark yields, reported trades, broker/dealer quotes, benchmark securities and bids.

Warrant Derivative Liability and Private Placement Option Liability

The Company's financial liabilities recorded at fair value on a recurring basis include the fair values of the warrant derivative liability and the private placement option liability. As of September 30, 2021, the fair values of the warrant derivative liability and the private placement option liability are classified as current liabilities in the accompanying condensed consolidated balance sheets. These liabilities will be shown as current liabilities on the balance sheet when it is deemed more probable than not by management to be exercised within one year.

Inputs used to determine estimated fair value (Level 3) of the warrants include the fair value of the underlying stock relative to the warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the warrants, and risk-free interest rates.

The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:

September 30, 2021December 31, 2020
Risk-free interest rate
0.95%0.46%
Volatility
95.00%90.00%
Expected term (years)
4.895.64

Inputs used to determine estimated fair value (Level 3) of the private placement option include the fair value of the underlying stock relative to the preferred share conversion price and warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the call option on the preferred shares and expected term of the warrants, and risk-free interest rates.

14

The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:
September 30, 2021December 31, 2020
Risk-free interest rate1.33 %0.77 %
Volatility95.00 %90.00 %
Expected term (years)7.007.00

The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Warrant derivative liability$ $ $7,842 $ $ $10,345 
Private placement option liability  2,800   7,803 
Total fair value$ $ $10,642 $ $ $18,148 

The ending balance of the Level 3 financial instruments presented above represents the Company's best estimate of valuation and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

NOTE 3 - LEASES

The Company determines whether an arrangement is a lease at its inception. Operating leases relate primarily to office space and manufacturing facilities with remaining lease terms of one year to seven years, some of which include options to extend the lease term for up to five years. Management considered the options in determining the lease term used to establish the Company's ROU assets and lease liabilities.

As most of the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate based on the information available at lease commencement date was used to determine the present value of lease payments.

Components of lease cost are as follows:
Three Months EndedNine Months Ended
(in thousands)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Finance lease cost:
Amortization of leased asset$ $18 $16 $54 
Interest on lease liabilities 5 5 17 
Operating lease cost1 169 56 668 
Short-term lease cost 235 53 476 
Total lease cost$1 $427 $130 $1,215 


NOTE 4 - PUBLIC OFFERING AND PRIVATE PLACEMENT
November 2020 Underwritten Offering
In November 2020, the Company closed an underwritten offering of 1,040,000 shares of its common stock, pre-funded warrants to purchase 3,109,378 shares of its common stock, and accompanying common warrants to purchase up to an aggregate of 4,149,378 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $6.025 and $6.024 for each pre-funded warrant. The pre-funded warrants were immediately exercisable at a price of $0.001 per share of common stock. The common warrants were immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance, or November 3, 2025. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company were approximately $25.0 million before deducting underwriting discounts and commissions and other offering expenses.
15

August 2019 Public Offering
On August 16, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 575,000 shares of the Series 1 Redeemable Convertible Non-Voting Preferred Stock of the Company (the “Series 1 Preferred Stock”) and warrants (the “Public Warrants”) to purchase up to 5,750,000 shares of its common stock. Each share of Series 1 Preferred Stock was sold together with a warrant to purchase 10 shares of common stock at a combined price to the public of $100.00. Under certain circumstances, each warrant to purchase 10 shares of common stock will be exercisable, at the irrevocable election of the holder, for one share of Series 1 Preferred Stock. The offering closed on August 21, 2019, and the net proceeds to the Company from the Offering was approximately $53.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding any proceeds that the Company may receive upon exercise of the Public Warrants.

All of the Public Warrants sold in the Offering have an exercise price of $13.00 per share of common stock or, in certain circumstances, for $130.00 per share of Series 1 Preferred Stock, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Public Warrants will be immediately exercisable upon issuance, provided that the holder will be prohibited, subject to certain exceptions, from exercising a warrant for shares of common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 19.99% upon 61 days’ notice to the Company. The Public Warrants will expire on August 21, 2026, unless exercised prior to that date. No Public Warrants have been exercised as of the balance sheet date.

Private Placement

On August 16, 2019, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue in a private placement (i) 350,000 shares of its Series 2 Redeemable Convertible Non-Voting Preferred Stock (the “Series 2 Preferred Stock”), at a purchase price of $100.00 per share, and related warrants (the “Private Warrants”) to purchase up to 2,800,000 shares of common stock at an exercise price of $10.00 per share, and (ii) 250,000 shares of its Series 3 Redeemable Convertible Non-Voting Preferred Stock (the “Series 3 Preferred Stock” and, together with the Series 1 Preferred Stock and Series 2 Preferred Stock, the “Preferred Stock”), at a purchase price of $140.00 per share, and related warrants (also, “Private Warrants”) to purchase up to 875,000 shares of common stock at an exercise price of $14.00 per share. The purchase and sale of the securities issuable under the private placement agreement may occur in two or more separate closings, each to be conducted at the Purchasers’ discretion within five days’ notice to the Company. The purchase and sale were subject to the Company’s obtaining stockholder approval for additional authorized shares of Common Stock or a reverse stock split (the “Required Stockholder Approval”), which occurred in the first quarter of 2020. The right of the Purchasers to purchase such securities will expire two and a half years after the Required Stockholder Approval, on June 15, 2022, with respect to the Series 2 Preferred Stock, and three years after such stockholder approval, on January 15, 2023, with respect to the Series 3 Preferred Stock, if not exercised prior to that date. No shares have been exercised as of the balance sheet date.

The Company received $11.2 million in option proceeds, net of offering costs, upon the execution of the Securities Purchase Agreement. Total offering costs incurred by the Company related to the Public Warrants, Private Warrants and options amounted to $3.0 million.

Decrease in the Company's common stock price and the time to expiration of both warrant derivative and private placement option had the most impact on the fair value. The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:
(in thousands)Warrant Derivative LiabilityPrivate Placement Option LiabilityTotal
Balance, December 31, 2020
$10,345 $7,803 $18,148 
Change in fair value(2,503)(5,003)(7,506)
Balance, September 30, 2021
$7,842 $2,800 $10,642 

16

NOTE 5 - REDEEMABLE CONVERTIBLE PREFERRED STOCK

In August 2019, the Company sold Series 1 Preferred Stock pursuant to the Offering. The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.01, of which the Company has designated 1,517,500 shares as Series 1 redeemable convertible non-voting preferred stock, 350,000 shares as Series 2 redeemable convertible non-voting preferred stock and 250,000 shares as Series 3 redeemable convertible non-voting preferred stock. There were 452,000 shares of Series 1 preferred stock issued and outstanding as of September 30, 2021. There were no shares of Series 2 or 3 preferred stock issued and outstanding as of September 30, 2021.

As of September 30, 2021, the Company classified the Series 1 Preferred Stock as mezzanine equity, as the Series 1 preferred stock will be redeemable at the option of the holders upon passage of time, which is outside of the Company’s control to prevent.

The Series 1 Preferred Stock is not currently redeemable and is only redeemable upon the fifth (5th) anniversary of the initial issue date or upon a fundamental change in a redemption price. The Company does not believe a fundamental change is considered probable until it occurs. Subsequent adjustment of the amount presented in mezzanine equity to its redemption amount is unnecessary if it is not probable that the instrument will become redeemable. As of September 30, 2021, the Company did not accrete the Series 1 Preferred Stock to its redemption amount.

Optional Conversion

Each share of Preferred Stock is initially convertible into 10 shares of Common Stock. The conversion price at which Preferred Stock may be converted into shares of common stock, is subject to adjustment in connection with certain specified events.

Redemption

Until the applicable Transition Date (defined below), at any time on or after the date that is the fifth (5th) anniversary of the initial issue date of the applicable series of preferred stock, all or any portion of the preferred stock is redeemable at the option of the holder at a redemption price of $100.00 per share (for Series 1 and Series 2 Preferred Stock) and $140.00 per share (for Series 3 Preferred Stock).  The “Transition Date” means:

With respect to the Series 1 preferred stock, the first date following August 21, 2021, on which each of the Conditions (as defined below) is met (the “Series 1 Transition Date”);

With respect to the Series 2 preferred stock, the first date following the six-month anniversary of the Series 1 Transition Date on which each of the Conditions is met (the “Series 2 Transition Date”); and

With respect to the Series 3 preferred stock, the first date following the six-month anniversary of the Series 2 Transition Date on which each of the Conditions is met.

The “Conditions” mean: (1) the closing price of the Company’s common stock has been equal to or exceeded $25.00 per share for 180 calendar days (for determining if the Conditions are met for the Series 1 preferred stock and Series 2 preferred stock) and $35.00 per share (for the Series 3 preferred stock) for 180 calendar days; (2) the 50-day average trading volume of the Company’s common stock on the Nasdaq stock market is greater than 50,000 shares; and (3) a Phase 3 or Phase 2 pivotal clinical trial for one of the Company’s CAR T product candidates has been initiated, meaning that at least one clinical trial site has been activated.

Dividends

Shares of Preferred Stock will be entitled to receive dividends equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.

Liquidation

Until the applicable Transition Date, in the event of a liquidation, dissolution, winding up or deemed liquidation, holders of the Preferred Stock will receive a payment equal to the applicable per share purchase price of their Preferred Stock before any proceeds are distributed to the holders of Common Stock. The liquidation preferences, protective voting provisions and redemption rights of the Preferred Stock will terminate upon the occurrence of certain events.
17


Voting

Shares of Preferred Stock will generally have no voting rights, except to the extent expressly provided in the Company’s certificate of incorporation or as otherwise required by law.

NOTE 6 - SHARE-BASED COMPENSATION PLANS

Share-Based Compensation Plans

The Company has five share-based compensation plans, including the 2019 Equity Incentive Plan (the "2019 Plan"), which was adopted in June 2019. Each plan authorizes the granting of shares of common stock and options to purchase common stock to employees and directors of the Company, as well as non-employee consultants, and allows the holder of the option to purchase common stock at a stated exercise price. The only plan under which the Company may currently grant equity awards is the 2019 Plan although there remain outstanding awards under the other four plans. Options vest according to the terms of the grant, which may be immediately or based on the passage of time, generally over two to four years, and have a term of up to 10 years. Unexercised stock options terminate on the expiration date of the grant. The Company recognizes the share-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period.

2019 Equity Incentive Plan

The 2019 Plan, is designed to secure and retain the services of the Company’s employees and directors. The 2019 Plan is successor to and continuation of the 2014 Equity Incentive Plan, as amended, the (“2014 Plan”), and no additional awards may be issued from the 2014 Plan. Subject to adjustment for certain changes in the Company’s capitalization, the aggregate number of shares of common stock that may be issued under the 2019 Plan (the “Share Reserve”) will not exceed the sum of (i) 250,000 new shares, (ii) an additional 600,000 shares that were approved at the Company’s Special Meeting of Stockholders in January 2020, (iii) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2020, (iv) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2021 and plus (v) the Prior Plans’ Returning Shares, as defined in the 2019 Plan documents, in an amount not to exceed 600,540 shares, including any stock award granted under the 2014 Plan, 2011 Stock Option Plan, as amended, or 2006 Stock Option Plan, as amended, that were outstanding as of the date the 2019 Plan were approved by the Company's stockholders, as such shares become available from time to time.

The following shares of common stock (the “2019 Plan Returning Shares”) will also become available again for issuance under the 2019 Plan: (i) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award is settled in cash; and (iii) any shares issued pursuant to a stock award granted under the 2019 Plan that are forfeited back to or repurchased by the Company because of a failure to vest.

The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock awards.

18


The following table summarizes the stock option activity for all stock plans during the nine months ended September 30, 2021:
Options and Inducement Awards
Outstanding at December 31, 2020
1,510,968 
Granted
823,000 
Exercised
 
Forfeited
(348,691)
Outstanding at September 30, 2021
1,985,277 
Exercisable at September 30, 2021
466,587 

The following table summarizes the stock award activity for all stock plans during the nine months ended September 30, 2021:
Restricted Stock Awards and Units
Outstanding at December 31, 2020
129,861 
Granted
136,626 
Vested
(95,001)
Forfeited
(2,506)
Outstanding at September 30, 2021
168,980 

2014 Employee Stock Purchase Plan

The 2014 Employee Stock Purchase Plan (the “ESPP”) provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase the Company's common stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to 55,000 shares of the Company’s common stock to participating employees and allows eligible employees to purchase shares of common stock at a 15% discount from the lesser of the grant date or purchase date fair market value. During the nine-month periods ended September 30, 2020, there were 9,526 shares purchased by employees under the ESPP. The ESPP has been suspended since December 2020, resulting in the inactivity during the first, second, and third quarter of 2021. As of September 30, 2021, there were 18,488 shares available for issuance under the ESPP.

A summary of activity within the ESPP follows:
Nine Months Ended
(in thousands)September 30, 2021September 30, 2020
Deductions from employees$ $116 
Share-based compensation expense recognized 70 
Remaining share-based compensation expense 113 


Share-Based Compensation Expense

The fair value of option grants is determined using the Black-Scholes option-pricing model and has been estimated with the following weighted-average assumptions:
Nine Months Ended
September 30, 2021September 30, 2020
Risk-free interest rate
0.84 %1.18 %
Volatility
90.35 %81.78 %
Expected life (years)
5.636.03
Expected dividend yield
  

19


Share-based compensation expense by classification for the three and nine months ended September 30, 2021 and 2020 are as follows:
Three Months Ended
Nine Months Ended
(in thousands)
September 30, 2021
September 30, 2020
September 30, 2021
September 30, 2020
Research and development$296 $668 $829 $1,877 
General and administrative557 938 1,748 2,616 
     Total$853 $1,606 $2,577 $4,493 

At September 30, 2021, total compensation cost not yet recognized was $4.0 million and the weighted-average period over which this amount is expected to be recognized is 1.6 years.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Co-Development and Co-Commercialization Agreement - Adaptimmune Therapeutics plc

On December 16, 2016, the Company entered into a Co-Development and Co-Commercialization Agreement with and Adaptimmune Therapeutics plc (“Adaptimmune”) in order to facilitate a staged collaboration to evaluate, develop and commercialize next generation T cell therapies. Under the Agreement, the parties agreed to evaluate the Company’s GoTCR technology (inducible MyD88/CD40 co-stimulation, or “iMC”) with Adaptimmune’s affinity-optimized SPEAR® T cells for the potential to create enhanced TCR product candidates. Depending on results of the preclinical proof-of-concept phase, the parties expect to progress to a two-target co-development and co-commercialization phase. To the extent necessary, and in furtherance of the parties’ proof-of-concept and co-development efforts, the parties granted each other a royalty-free, non-transferable, non-exclusive license covering their respective technologies for purposes of facilitating such proof-of-concept and co-development efforts. In addition, as to covered therapies developed under the agreement, the parties granted each other a reciprocal exclusive license for the commercialization of such therapies. With respect to any joint commercialization of a covered therapy, the parties agreed to negotiate in good faith the commercially reasonable terms of a co-commercialization agreement. The parties also agreed that any such agreement shall provide for, among other things, equal sharing of the costs of any such joint commercialization and the calculation of profit shares as set forth in the Agreement. The Agreement will expire on a country-by-country basis once the parties cease commercialization of the T cell therapies covered by the Agreement, unless earlier terminated by either party for material breach, non-performance or cessation of development, bankruptcy/insolvency, or failure to progress to co-development phase.

License Agreements - Baylor

In 2008, 2010, 2014 and 2016, the Company and Baylor College of Medicine (“BCM”) entered into license agreements pursuant to which the Company obtained exclusive rights to certain technologies and patent rights owned by BCM.

Under the 2014 license agreement, the Company is required to pay BCM a low annual maintenance fee on each anniversary of the agreement date. The Company is also required to make royalty payments in the low single digits, subject to certain annual minimums, on net sales of products covered by the license, and, to the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is also required to pay BCM a percentage in the low double-digits on all non-royalty income received from sublicensing revenue.

During the second quarter of 2021, the Company determined that $0.6 million of sublicense expense was incurred in 2019 through 2020 related to the Company's obligation to pay BCM a percentage of sublicense revenue earned by the Company under the 2014 license agreement. Management evaluated the impact of the adjustment and determined that the amount was immaterial to the consolidated financial statements for the current year and prior years. As such, the entire amount of $0.6 million was recorded during the second quarter in 2021. During the third quarter of 2021, the Company earned additional sublicense revenue and therefore recorded an obligation to pay the sublicense expense of $0.5 million.
20

License Agreement - Agensys, Inc.

On December 10, 2015, the Company and Agensys, Inc. (“Agensys”), entered into a license agreement (the “Agensys Agreement”), pursuant to which (i) Agensys granted the Company, within the field of cell and gene therapy of diseases in humans, an exclusive, worldwide license and sublicense to its patent rights directed to prostate stem cell antigen 1 (“PSCA”) and related antibodies, and (ii) the Company granted Agensys a non-exclusive, fully paid license to the Company’s patents directed to inventions that were made by the Company in the course of developing the Company’s licensed products, solely for use with Agensys therapeutic products containing a soluble antibody that binds to PSCA or, to the extent not based upon the Company’s other proprietary technology, to non-therapeutic applications of antibodies not used within the field. As consideration for the rights granted to the Company under the Agreement, the Company agreed to pay to Agensys a non-refundable upfront fee of $3.0 million, which was included in license fee expense. The Company is also required to make aggregate milestone payments to Agensys of up to (i) $5.0 million upon the first achievement of certain specified clinical milestones for its licensed products, (ii) $50.0 million upon the achievement of certain specified clinical milestones for each licensed product, and (iii) $75.0 million upon the achievement of certain sales milestones for each licensed product. The Agreement additionally provides that the Company will pay to Agensys a royalty that ranges from the mid to high single digits based on the level of annual net sales of licensed products by the Company, its affiliates or permitted sublicensees. The royalty payments are subject to reduction under specified circumstances. These milestone and royalty payments will be expensed as incurred. Under the Agreement, Agensys also was granted the option to obtain an exclusive license, on a product-by-product basis, from the Company to commercialize in Japan each licensed product developed under the Agensys Agreement that has completed a phase 2 clinical trial. As to each such licensed product, if Agensys or its affiliate, Astellas Pharma, Inc., exercises the option, the Agensys Agreement provides that the Company will be paid an option exercise fee of $5.0 million. In addition, the Agensys Agreement provides that the Company will be paid a royalty that ranges from the mid to high single digits based on the level of annual net sales in Japan of each such licensed product. If the option is exercised, the aggregate milestone payments payable by the Company to Agensys, described above with respect to each licensed product, would be reduced by up to an aggregate of $65.0 million upon the achievement of certain specified clinical and sales milestones. The Agensys Agreement will terminate upon the expiration of the last royalty term for the products covered by the Agensys Agreement, which is the earlier of (i) the date of expiration or abandonment of the last valid claim within the licensed patent rights covering any licensed products under the Agreement, (ii) the expiration of regulatory exclusivity as to a licensed product, and (iii) 10 years after the first commercial sale of a licensed product. Either party may terminate the Agensys Agreement upon a material breach by the other party that remains uncured following 60 days after the date of written notice of such breach (or 30 days if such material breach is related to failure to make payment of amounts due under the Agensys Agreement) or upon certain insolvency events. In addition, Agensys may terminate the Agensys Agreement immediately upon written notice to the Company if the Company or any of its affiliates or permitted sublicensees commences an interference proceeding or challenges the validity or enforceability of any of Agensys’ patent rights.

License Agreement - BioVec

On June 10, 2015, the Company and BioVec Pharma, Inc. (“BioVec”) entered into a license agreement (the “BioVec Agreement”) pursuant to which BioVec agreed to supply the Company with certain proprietary cell lines and granted to the Company a non-exclusive, worldwide license to certain of its patent rights and related know-how related to such proprietary cell lines. As consideration for the products supplied and rights granted to the Company under the BioVec Agreement, the Company agreed to pay to BioVec an upfront fee of $100,000 within ten business days of the effective date of the BioVec Agreement and a fee of $300,000 within ten business days of its receipt of the first release of GMP lot of the products licensed under the BioVec Agreement. In addition, the Company agreed to pay to BioVec an annual fee of $150,000, commencing 30 days following the first filing of an Investigational New Drug Application or its foreign equivalent, for a product covered by the license; with such annual fees being creditable against any royalties payable by the Company to BioVec under the BioVec Agreement. The Company also is required to make a $250,000 milestone payment to BioVec for each of the first three licensed products to enter into a clinical phase trial and one-time milestone payments of $2.0 million upon receipt of a registration granted by the Federal Drug Administration or European Medicines Agency on each of the Company’s first three licensed products. The BioVec Agreement additionally provides that the Company will pay to BioVec a royalty in the low single digits on net sales of products covered by the BioVec Agreement. The Company may also grant sublicensees under the licensed patent rights and know-how to third parties for limited purposes related to the use, sale and other exploitation of the products licensed under the BioVec Agreement. The BioVec Agreement will continue until terminated. The BioVec Agreement may be terminated by the Company, in its sole discretion, at any time upon 90 days written notice to BioVec. Either party may terminate the BioVec Agreement in the event of a breach by the other party of any material provision of the BioVec Agreement that remains uncured on the date that is 60 days after written notice of such failure or upon certain insolvency events that remain uncured following the date that is 30 days after the date of written notice to a party regarding such insolvency event.

21

Takeda Supply Agreement

On May 4, 2021, the Company entered a multi-year supply agreement with Takeda Development Center Americas, Inc. (Takeda). The Company will supply Takeda with rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The Company generated revenue of $0.7 million for the nine months ended September 30, 2021, with the possibility of additional revenue from future sales.
MD Anderson License Agreements

On January 22, 2019, the Company entered into a licensing and commercialization agreement with MD Anderson (the "2019 MD Anderson License Agreement"). Under the 2019 MD Anderson License Agreement, the Company granted MD Anderson non-exclusive rights in certain Caspase-9 and related technologies and use of a small molecule known as rimiducid in a certain cell therapy program. During the fourth quarter of 2019, and under the terms of the 2019 MD Anderson License Agreement, MD Anderson exercised an option to grant a non-exclusive sublicense of the rights licensed by the Company to MD Anderson. MD Anderson, as a result of this exercise, granted a sublicense that entitled the Company to receive as consideration an upfront license fee as well as additional future annual maintenance fees, milestone payments related to the achievement of pre-specified development, regulatory, and commercialization events, and royalties on net sales of licensed products.

On August 31, 2021, the Company entered into a second licensing and commercialization agreement with MD Anderson (the “2021 MD Anderson Option and License Agreement”). Under the 2021 MD Anderson Option and License Agreement, MD Anderson has certain rights to the use of CaspaCIDe and rimiducid in product candidates nominated under the agreement, and receives an option to a non-exclusive license to the technology in these candidates. Upon exercise of an option and sublicense of a product candidate to a third party, the Company is entitled to a sublicense execution fee, a percentage of certain consideration received by MD Anderson for the sublicense, an annual maintenance fee, and a percentage royalty on net sales of licensed products. During the third quarter of 2021, the Company received an upfront payment of $5.0 million upon execution of the agreement and granted licenses for two nominated programs.
Litigation

On May 29, 2019, Bellicum was served with a second amended complaint indicating that the Company had been added as an additional defendant in an ongoing civil tort lawsuit, captioned Kelly v. Children’s Hospital of Los Angeles et al., filed in the Los Angeles County Superior Court, Case No. BC681477. On July 10, 2019 plaintiffs filed a third amended complaint seeking unspecified monetary damages including punitive damages and alleging claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability - failure to warn, breach of express warranty and products liability design or manufacturing defect. Bellicum filed a demurrer and motion to strike plaintiffs’ third amended complaint, which were granted in part on August 5, 2020 with the Court dismissing (without prejudice) all claims against Bellicum with the exception of the breach of express warranty and products liability design or manufacturing defect causes of action. The Court also granted Bellicum’s motion to strike plaintiffs’ claim for punitive damages. On September 15, 2020, plaintiffs filed a fourth amended complaint alleging the same causes of action and damages against Bellicum as were pled in the third amended complaint. On November 3, 2020 Bellicum filed a demurrer and motion to strike the fourth amended complaint, which currently is set for hearing on November 23, 2021. A trial date has not been set in the case.
Compliance with NASDAQ Listing Rules

On May 5, 2021, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”), that the Company was in breach of Listing Rule 5450(b)(2)(A) (the “Market Value Rule”), for continued listing on The Nasdaq Capital Market because the market value of the Company's listed securities for 30 consecutive business days had been less than $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a grace period until November 1, 2021, to regain compliance with the Market Value Rule by maintaining a market value of listed securities $35 million or more for a minimum of 10 consecutive business days any time prior to November 1, 2021. On November 2, 2021, Nasdaq notified the Company that it had not regained compliance with the Market Value Rule by November 1, 2021, and unless the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) by November 9, 2021, the Company’s securities will be delisted from Nasdaq. The Company intends to timely request a hearing before the Panel to appeal this determination, which the Company expects will stay any further action by Nasdaq until the conclusion of the hearing process.

22


Item 2.          Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 31, 2021, or our Annual Report, as well as our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q, or this Quarterly Report.

Forward-Looking Statements

This report contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipate,” “believe,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, “Risk Factors” in this Quarterly Report on Form 10-Q, Part I, Item 1A, “Risk Factors” in our Annual Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.

Overview

We are a clinical stage biopharmaceutical company focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. We are advancing CAR-T cell therapies, which are an innovative approach in which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors, or CARs. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better efficacy and safety outcomes than are seen with current cellular immunotherapies.

Cell behavior is controlled by cascades of specialized signaling proteins. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. We genetically introduce these molecular switches into the appropriate immune cells and deliver the cells to the patient in the manner of conventional cellular immunotherapy. We have developed two such switches: an “activation switch,” designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a “safety switch,” designed to initiate programmed cell death, or apoptosis, of the immunotherapy cells. Each of our product candidates incorporates one or both switches, for enhanced, real time control of efficacy and safety:

The inducible MyD88/CD40 (iMC) activation switch that is incorporated into our GoCAR product candidates is designed to enhance CAR-based cell therapies by augmenting multiple mechanisms of action, including: 1) boosting effector cell proliferation; 2) enhancing functional persistence by resisting exhaustion and inhibitory signals found in the tumor microenvironment; and 3) stimulating the cancer patient’s own immune system to intensify tumor killing. Unlike other CAR therapies that can behave unpredictably due to their autonomous activity, GoCAR antitumor effects are controlled through scheduled administration of rimiducid. In the event of severe side effects, GoCAR activity can be attenuated by extending the interval between rimiducid doses or suspending further rimiducid administration.

Our CaspaCIDe™ safety switch (also known as inducible Caspase-9, or iC9) is designed to be inactive unless the patient experiences a serious side effect (e.g., CRS, neurologic toxicities or off-tumor / on-target toxicities). In that event, rimiducid or temsirolimus is administered to induce Caspase-9 and eliminate the cells, with the goal of attenuating the therapy and resolving the serious side effect.

23


Some of our product candidates are “dual-switch” GoCARs that are designed to provide a user-controlled system for managing proliferation, persistence and safety of tumor antigen-specific CAR cells by incorporating both our iMC and CaspaCIDe switches.

By incorporating our novel switch technologies, we are developing product candidates with the potential to elicit positive clinical outcomes and ultimately change the treatment paradigm in various areas of cellular immunotherapy. Our most advanced programs are described below.

BPX-601 is an autologous GoCAR-T product candidate containing our proprietary iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen, or PSCA. We believe iMC enhances T cell proliferation and persistence, enhances host immune activity, and modulates the tumor microenvironment to improve the potential to treat solid tumors compared to traditional CAR-T therapies. A Phase 1/2 clinical trial, called BP-012, in patients with metastatic castration-resistant prostate cancer or pancreatic cancer expressing PSCA is ongoing.

BPX-603 is an autologous dual-switch GoCAR-T product candidate containing both the iMC activation and CaspaCIDe safety switches. BPX-603 is our first controllable dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2. A Phase 1/2 clinical trial called BPX-603-201A in patients with HER2+ solid tumors is ongoing.

Rivo-cel (rivogenlecleucel, formerly known as BPX-501), is a product candidate containing our proprietary CaspaCIDe safety switch that is intended to improve outcomes of hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. We are pursuing a strategic partner for rivo-cel to assume future development and commercialization responsibilities. Concurrently, we have reduced and expect to continue to reduce our rivo-cel related activities.

We have developed efficient and scalable processes to manufacture genetically modified T cells of high quality, which are currently being used to generate products for our clinical trials. We are leveraging this know how in combination with our proprietary cellular control technologies, resources, capabilities and expertise for the manufacture of CAR product candidates to create and develop first and best-in-class product candidates.

On May 5, 2021, we were notified by Nasdaq that we were in breach of Listing Rule 5450(b)(2)(A) (the “Market Value Rule”) for continued listing on The Nasdaq Capital Market because the market value of our listed securities for 30 consecutive business days had been less than $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we were granted a grace period until November 1, 2021, to regain compliance with the Market Value Rule by maintaining a market value of listed securities $35 million or more for a minimum of 10 consecutive business days any time prior to November 1, 2021. On November 2, 2021, Nasdaq notified us that we had not regained compliance with the Market Value Rule by November 1, 2021, and unless we request a hearing before the Nasdaq Hearings Panel (the “Panel”) by November 9, 2021, our securities will be delisted from Nasdaq. We intend to timely request a hearing before the Panel to appeal this determination, which we expect will stay any further action by Nasdaq until the conclusion of the hearing process.

Impact of COVID-19

In 2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To slow the proliferation of COVID-19, governments have implemented extraordinary measures, which have included the mandatory closure of businesses, restrictions on travel, and quarantine and physical distancing requirements. We have not experienced and do not anticipate a substantial impact to our operations as a result of the pandemic or these government measures. However, depending the duration and severity of the pandemic, we could experience impact in the future, including with respect to the operations of our manufacturing partners, clinical trial sites and regulatory agencies, all of which we are substantially dependent upon for our business. We are continuing to closely monitor the impact of the COVID-19 pandemic on our business.
24


Results of Operations
The following table sets forth a summary of our statement of operations for the periods indicated:
Three Months EndedChange
Nine Months Ended
Change
(in thousands)
September 30, 2021
September 30, 2020
September 30, 2021
September 30, 2020
Revenues
Supply agreement$— $— $— $700 $— $700 
License revenue5,000 — 5,000 5,000 — 5,000 
Total revenues5,000 — 5,000 5,700 — 5,700 
Operating expenses:
Research and development6,348 8,140 (1,792)19,531 30,346 (10,815)
General and administrative1,681 4,163 (2,482)5,458 12,095 (6,637)
Total operating expenses8,029 12,303 (4,274)24,989 42,441 (17,452)
(Gain) loss on dispositions, net14 — 14 478 (3,761)4,239 
Loss from operations(3,043)(12,303)9,260 (19,767)(38,680)18,913 
Other income (expense):
Interest income10 (4)24 392 (368)
Interest expense— (725)725 (4)(2,473)2,469 
Change in fair value of warrant and private placement option liabilities4,264 12,131 (7,867)7,506 14,256 (6,750)
Other income— — 
Total other income (expense)4,276 11,416 (7,140)7,531 12,175 (4,644)
Net income (loss)$1,233 $(887)$2,120 $(12,236)$(26,505)$14,269 

Revenues

The increase in revenues for the three months ended September 30, 2021, compared to the same periods last year, was related to the license agreement with The University of Texas M. D. Anderson Cancer Center (“MD Anderson”) for certain option and license rights to CaspaCIDe and related technologies. An upfront fee under the agreement of $5.0 million was recognized as revenue. This constitutes a majority of the revenue increase for the nine months ended September 30, 2021, together with the supply agreement with Takeda Development Center Americas, Inc. (Takeda) for the supply of rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The supply was fulfilled in the second quarter of 2021 generating revenue of $0.7 million.

Research and Development Expenses (R&D)

The decrease in R&D expenses for the three months ended September 30, 2021, compared to the same period last year, was primarily due to reduced expenses related to the sale of the manufacturing facility, and the reduction in force that was implemented during the second half of 2020. This resulted in a $3.4 million reduction in salaries, benefits, travel, and share-based compensation related charges. This was partially offset by a $1.1 million increase in sublicense payment as a result of the license agreement with Baylor College of Medicine. There was also a $0.5 million increase in clinical trial cost and associated consulting expenses.

The decrease in R&D expenses for the nine months ended September 30, 2021, compared to the same period last year, was primarily due to reduced expenses related to the sale of the manufacturing facility, and the reduction in force that was implemented during the second half of 2020. This resulted in a $9.9 million reduction in salaries, benefits, travel, and share-based compensation related charges, and a $0.3 million reduction from general R&D expenses primarily due to lower clinical trial activities. Additionally, depreciation expense and R&D related overhead expense decreased by $0.6 million due to the exit of manufacturing facility, related laboratories and office space.

General and Administrative Expenses (G&A)

25


The decrease in G&A expenses for the three months ended September 30, 2021, compared to the same period last year, was primarily due to the aforementioned reduction in force that reduced employee-related charges by $1.7 million as well as the reduction in clinical facility and depreciation expenses by $0.8 million related to exit of manufacturing facility and office space.

The decrease in G&A expenses for the nine months ended September 30, 2021, compared to the same period last year, was primarily due to the aforementioned reduction in force that reduced employee-related charges by $4.9 million as well as the reduction in clinical facility and depreciation expenses by $1.7 million related to exit of manufacturing facility and office space.

Loss (gain) on dispositions, net

The loss on dispositions, net, for the three months ended September 30, 2021, compared to the same period last year, was a result of early termination of the operating lease for office equipment with a lump sum payment. The increase in the loss on dispositions, net, for the nine months ended September 30, 2021 was primarily from the loss on the termination of the South San Francisco office space in the amount of $0.5 million, whereas in the same period last year, there was a gain on disposal of the clinical supply manufacturing facility to M.D. Anderson.

Other Income (Expense)

Other expense primarily consists of interest expense, partially offset by interest income, and changes in fair values of our warrant liability and the private placement option, which are remeasured at each reporting period. Due to the nature of the inputs in the model used to assess the fair value of the warrant liability and private placement option, we may experience significant fluctuations at each reporting period. These fluctuations may be due to a variety of factors, including changes in our stock price and changes in stock price volatility over the remaining term of the warrants and options.

The decrease in other income for the three months ended September 30, 2021, compared to the same period last year, was primarily due to a $4.3 million gain recognized from the change in fair value of our warrant and private placement option liabilities, compared to $12.1 million gain in the same period last year. The gain recognized during the three months ended September 30, 2021 was driven primarily by a decrease in our stock price over the period.

The decrease in other income for the nine months ended September 30, 2021, compared to the same period last year, was primarily due to a $7.5 million gain recognized from the change in fair value of our warrant and private placement option liabilities, compared to $14.2 million gain in the same period last year. The gain recognized during the nine months ended September 30, 2021 was driven primarily by a decrease in our stock price over the period.

Liquidity and Capital Resources

Going Concern and Management's Plans

The accompanying consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2021, we had cash, cash equivalents and restricted cash of $20.8 million and net cash used in operations of approximately $17.1 million for the nine months ended September 30, 2021.

Our cash resources are primarily consumed by operating activities and we expect negative cash flows from operations to continue for at least the next 12 months. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs. Based on our current research and development plans and our timing expectations related to the progress of our programs, we believe there is substantial doubt that our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2022.

We plan to continue to attempt to obtain future financing and/or engage in strategic transactions, but we cannot predict, with certainty, the outcome of our actions to generate liquidity, including the availability of additional equity or debt financing, or whether such actions would generate the expected liquidity as currently planned. To continue as a going concern, we may postpone or eliminate some of our research and development programs and reduce our administrative costs. We may also intend to seek additional funding including, but not limited to any or all of the following potential sources:

We have an effective shelf registration statement on Form S-3 for the offer and sale of up to $400.0 million of our securities, of which approximately $290.5 million remains available for future offerings. We may pursue additional funding through the sale of our securities in one or more offerings under this registration statement, however we cannot assure you that we will be able to do so on favorable terms. Our ability to offer and sell our securities in a primary offering on our Form S-3 is currently limited by Instruction I.B.6 of Form S-3, commonly referred to as the “baby shelf” limitation. If we raise additional capital through the
26


sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that could adversely affect the rights of our existing stockholders. If we raise additional capital through the issuance of debt securities, we could incur fixed payment obligations and become subject to certain restrictive covenants, including limitations on our ability to incur additional debt and acquire or license intellectual property rights, and other operating restrictions that could restrict our ability to conduct our business.

In addition, we may receive additional capital through the exercise of outstanding warrants to purchase our stock if our stock price sufficiently increases. As of September 30, 2021, warrants to purchase 5,750,000 shares of our Series 1 preferred stock at an exercise price of $130.00 per share (equivalent to $13.00 per share of common stock) and warrants to purchase 4,149,378 shares of our common stock at an exercise price of $6.50 per share were outstanding. The preferred stock warrants expire on August 21, 2026 and the common warrants expire on November 3, 2025.

As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. Moreover, if we do not obtain such additional funds, there could be substantial doubt about our ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to our stockholders and other security holders.

Cash Flows

Operating Activities

Net cash used in operating activities during the nine months ended September 30, 2021 was $17.1 million compared to $43.3 million for the same period last year. The changes in cash flow from operating activities during the nine months ended September 30, 2021 were due to $12.2 million of net losses, a non-cash gain of $7.5 million recognized from the change in the derivative warrant and private placement option fair value liability and a $0.5 million decrease from changes in operating assets and liabilities. This was partially offset by $2.6 million of share-based compensation and $0.1 million of depreciation expense.

Investing Activities

Net cash provided by investing activities during the nine months ended September 30, 2021 was $0.9 million compared to $14.1 million for the same period last year. The change in cash flow from investing activities during the nine months ended September 30, 2021 was due to $0.9 million net proceeds received from the sale of property and equipment. Cash provided by investing activities for the same period last year was due to $14.9 million of proceeds from the sale of property and equipment.

Financing Activities

Net cash used in financing activities during the nine months ended September 30, 2021 was less than $0.1 million on financing lease obligations compared to net cash used in financing activities of $10.0 million for the same period last year primarily due to principal debt repayments.

Critical Accounting Policies and Estimates

There have been no material changes to the Company's critical accounting policies and use of estimates from those disclosed in the Company’s Form 10-K for the year ended December 31, 2020. For a discussion of our critical accounting policies and use of estimates, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020.

Recent Accounting Pronouncements

The Company is subject to several recently issued accounting pronouncements. Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies – New Accounting Requirements and Disclosures which is contained in Part I,
27

Item 1 of this Quarterly Report on Form 10-Q, describes these new accounting pronouncements and is incorporated herein by reference.
Off-Balance Sheet Arrangements
 
During the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.

Item 3. Quantitative and Qualitative Disclosures about Market Risks
 
There have been no material changes to the information provided under Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” which is included and described in the Form 10-K for the year ended December 31, 2020.
28


Item 4. Controls and Procedures
 
Management’s Evaluation of our Disclosure Controls and Procedures
Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its Principal Executive and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our Principal Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting

An evaluation was also performed under the supervision and with the participation of our management, Principal Executive Officer and Principal Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during the quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
    
29


PART II. OTHER INFORMATION
 
Item 1. Legal Proceedings

The information set forth under the “Litigation” subheading in Note 7 - Commitments and Contingencies of Notes to Consolidated Financial Statements in Part I, Item I of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 1A. Risk Factors

Summary of Risk Factors

There are a number of risks related to our business and our securities. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading “Risk Factors” below.
We have incurred net losses from operations in every year since our inception and anticipate that we will continue to incur these net losses in the future.
We will require significant funding to complete the development and commercialization of our product candidates. If we fail to obtain additional financing, we may have to delay, reduce or eliminate our development programs or commercialization efforts.
Many of our current product candidates are in early stage clinical trials, and we may experience unfavorable results in the future.
Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.
If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.
We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
If we fail to satisfy applicable listing standards, our common stock may be delisted from the Nasdaq Capital Market.
Our principal stockholders own a significant percentage of our stock and can exert significant control over matters subject to stockholder approval.

Risk Factors

Our business and results of operations are subject to a number of risks and uncertainties. You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. We have marked with an asterisk (*) those risk factors that reflect additional risk factors since the issuance of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 31, 2021, or our Annual Report.

30


Risks Related to Our Business and Industry
We have incurred net losses from operations in every year since our inception and anticipate that we will continue to incur these net losses in the future.*
We are a clinical stage biopharmaceutical company, with a limited operating history. We have no products approved for commercial sale and have incurred significant losses since our inception in 2004. To date, we have financed our operations primarily through equity and debt financings. As of September 30, 2021, we had an accumulated deficit of $553.0 million. We expect to continue to incur significant losses from operations for the foreseeable future, and we expect these accumulated losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates.
In addition, if we obtain regulatory approval of and seek to commercialize any of our product candidates, we will likely incur significant sales, marketing and manufacturing expenses and may continue to incur substantial research and development expenses for additional post-marketing approval development requirements related to such product.

We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital.
We will require significant funding to complete the development and commercialization of our product candidates. If we fail to obtain additional financing, we may have to delay, reduce or eliminate our development programs or commercialization efforts.*
This report includes disclosures stating that our existing cash resources and our accumulated stockholders’ deficit raise substantial doubt about our ability to continue as a going concern. Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates and other research and development programs.
As of September 30, 2021, we had cash, restricted cash and cash equivalents of approximately $20.8 million. We maintain our cash and cash equivalents with high quality, accredited financial institutions. These amounts at times may exceed federally insured limits. Currently, substantial doubt exists that our cash, restricted cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through the first half of 2022. Our cash position, together with our short-term liabilities and anticipated operating losses due to continued research and development projects, raises substantial doubt about our ability to continue as a going concern.
We expect to finance future cash needs through public or private equity offerings, debt financings, strategic partnerships and alliances or licensing arrangements. We cannot be certain that additional funding will be available on acceptable terms, or at all. In addition, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the pandemic. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity to fund research and development programs, including discovery research, preclinical and clinical development activities. In addition, the securities purchase agreement for the August 2019 private placement transaction requires us to obtain investor consent prior to taking a range of corporate financing actions, including issuing equity securities that are senior or pari passu to the Series 3 preferred stock and incurring new debt in excess of $1,000,000. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will need to significantly delay, scale back or discontinue the development or commercialization of our product candidates. We also could be required to:
seek collaborators for one or more of our current or future product candidates on terms that are less favorable than might otherwise be available;
relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or
seek a third party to acquire us or our assets.
If we are unable to raise additional funds on a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment of our development programs, or implement further reduction of costs for administration. For example, in
31


October 2020, we announced that we implemented a restructuring plan, which included, among other things, a 79% reduction in staff, from 68 to 14 full-time employees, by the end of 2020 and discontinuation of discovery research and new product development. We have incurred $2.5 million in restructuring expenses, including severance expenses of $1.2 million and the Houston office's impairment of $1.3 million. Moreover, if we do not raise such additional funds, there will continue to be substantial doubt about our ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to our stockholders and other security holders.
The FDA and other regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.
Our business and future success depends, in part, on our ability to obtain regulatory authority assent to conduct human clinical trials, obtain regulatory approval to launch a product based on evidence of clinical safety and efficacy and then successfully commercialize our clinical product candidates. All of our product candidates will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, and access to sufficient commercial manufacturing capacity and significant marketing efforts before we can expect to generate any revenue from product sales.
Our product candidates could fail to receive regulatory approval for many reasons, including the following:
The FDA or comparable regulatory authority or an Institutional Review Board or comparable ethics oversight body may decline to clear the applicable Investigational New Drug Application (IND) or equivalent regulatory submission necessary to conduct human clinical trials;
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates have the necessary safety, purity, and potency for any of their proposed indications;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
we may be unable to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;
we may encounter serious and unexpected adverse events during clinical trials that render our products unsafe for use in humans;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in Europe, the U.S. or elsewhere;
the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes and/or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.
We have devoted substantially all of our financial resources and efforts to developing our proprietary CID technology platform, identifying potential product candidates and conducting preclinical studies and clinical trials. We are in the early stages of developing our product candidates, and we have not completed development of any products. Our ability to generate revenue and achieve profitability depends in large part on our ability, alone or with partners, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future. Our ability to generate future revenues from product sales depends heavily on our success in:
completing requisite clinical trials through all phases of clinical development of our current product candidates;
seeking and obtaining marketing approvals for product candidates that successfully complete clinical trials, if any;
32


launching and commercializing product candidates for which we obtain marketing approval, if any, with a partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;
identifying and developing new product candidates;
progressing our pre-clinical programs into human clinical trials;
establishing and maintaining supply and manufacturing relationships with third parties;
developing new molecular switches based on our proprietary CID technology platform;
maintaining, protecting, expanding and enforcing our intellectual property; and
attracting, hiring and retaining qualified personnel.

Because of the numerous risks and uncertainties associated with biologic product development, we are unable to predict the likelihood or timing for when we may receive regulatory approval of any of our current or future product candidates or when we will be able to achieve or maintain profitability, if ever. If we do not receive regulatory approvals, our business, prospects, financial condition and results of operations will be adversely affected. Even if we obtain the regulatory approvals to market and sell one or more of our product candidates, we may never generate significant revenues from any commercial sales for several reasons, including because the market for our products may be smaller than we anticipate, or products may not be adopted by physicians and payors or because our products may not be as efficacious or safe as other treatment options. If we fail to successfully commercialize one or more products, we may be unable to generate sufficient revenues to sustain and grow our business and our business, prospects, financial condition and results of operations will be adversely affected. In addition, our expenses could increase beyond expectations if we are required by the FDA, or foreign regulatory agencies, to perform studies and clinical trials in addition to those that we currently anticipate for our product candidates, or if there are any delays in our or our partners completing clinical trials or the development of any of our product candidates. Further, if one or more of the product candidates that we independently develop is approved for commercial sale, we expect to incur significant costs associated with commercializing any such product candidates. Finally, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
Our CID technology is novel and largely unproven.
Our proprietary CID technology platform is novel and there are no approved products or third-party product candidates in late-stage clinical trials based on this technology. Additionally, the safety and efficacy profile of rimiducid has not been subject to large scale clinical testing. If rimiducid is found to have a poor safety profile in clinical trials, or if our technology is not effective, we may be required to redesign all of our product candidates, which would require significant time and expense. In addition, our CID platform technology may not be applicable or effective in the development of additional cellular immunotherapies beyond our current programs which would adversely affect our business and prospects.
Cell therapies are novel and present significant challenges.
CAR-T and other cell therapy product candidates represent a relatively new field of cellular immunotherapy. Advancing this novel and personalized therapy creates significant challenges for us, including:
obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with commercial development of cell therapies for cancer;
sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates;
developing a consistent and reliable process, while limiting contamination risks, for engineering and manufacturing T cells and other immune cell types ex vivo and infusing the engineered cells into the patient;
educating medical personnel regarding the potential safety benefits, as well as the challenges, of incorporating our product candidates into their treatment regimens;
establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy; and
the availability of coverage and adequate reimbursement from third-party payors for our novel and personalized therapy.
33


Our inability to successfully develop CAR T and other cell therapies or develop processes related to the manufacture or commercialization of these therapies would adversely affect our business, results of operations and prospects.
Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
Clinical testing is expensive, takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our product candidates are subject to the risks of failure inherent in biologic drug development. Success in early clinical trials does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing, even at statistically significant levels. We will be required to demonstrate through clinical trials that our product candidates are safe and effective for use in the target indication before we can obtain regulatory approvals for commercial sale. Companies frequently suffer significant setbacks in late-stage clinical trials, even after earlier clinical trials have shown promising results and most product candidates that commence clinical trials are never approved as products. We expect there may be greater variability in results for cellular immunotherapy products processed and administered on a patient-by-patient basis like some of our CID technology-based development and product candidates than for “off-the-shelf” products, like many drugs.
If any of our product candidates fail to demonstrate sufficient safety or efficacy, we would experience potentially significant delays in, or be required to abandon our development of the product candidate, which would have a material and adverse impact on our business, prospects, financial condition and results of operations.
Many of our current product candidates are in early stage clinical trials, and we may experience unfavorable results in the future.*

Phase 1/2 clinical trials are ongoing for BPX-601 for the treatment of prostate and pancreatic cancer and for BPX-603 in HER2-positive solid tumors. We may not be able to enroll clinical trials in the time frames we expect or we may encounter delays. For example, in December 2020, we announced that the FDA had placed a clinical hold on our BPX-601 trial in pancreatic cancer due to the death of a patient in the trial. Although the FDA released the hold in January 2021, there can be no assurance that future patient deaths in this or any of our clinical trials will not trigger additional clinical holds. As these product candidates are in early stages of development, we face significant uncertainty regarding how effective and safe they will be in human patients and the results from preclinical studies, such as in vitro and in vivo studies, of BPX-601 and BPX-603 may not be indicative of the results of clinical trials of these product candidates. For example, in October 2020, we announced that the first four pancreatic cancer patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation but clinically meaningful efficacy as measured by RECIST criteria was not observed. Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

Even if clinical trials are successfully completed, the FDA or foreign regulatory authorities may not interpret the results as we do, and more clinical trials could be required before we submit our product candidates for approval. To the extent that the results of our clinical trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional clinical trials in support of potential approval of our product candidates.
We may not be successful in our efforts to use and expand our CID platform to build a pipeline of product candidates and develop marketable products.
We believe that our CID platform, which serves as the foundation of our CaspaCIDe and GoCAR-T technologies, can be further leveraged to discover other novel technologies, therapeutic applications and market opportunities. We are at an early stage of development and our platform has not yet, and may never lead to, approved or marketable products. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including for reasons related to their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not be able to
34


obtain product or partnership revenues in future periods, which would adversely affect our business, prospects, financial condition and results of operations.
We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, and strategic partners to conduct our preclinical and clinical trials under agreements with us. Negotiations of budgets and contracts with study sites may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities could require us to perform additional clinical trials before approving our marketing applications. It is possible that, upon inspection, such regulatory authorities could determine that any of our clinical trials fail to comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under current good manufacturing practices, or cGMPs, and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.
Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with these third parties, we cannot control whether they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.

Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.

Also, we are conducting clinical trials in Europe and may plan additional testing of our technology and product candidates in other foreign jurisdictions. We currently have limited staffing and capabilities in foreign countries and may not be able to effectively resolve potential disputes with our independent investigators and collaborators.
Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.*
Our business could be adversely affected by health epidemics in regions in which we have operations or conduct research activities or clinical trials. Such health epidemics could also affect the business or operations of contract manufacturers, raw material suppliers, clinical trial sites, and other third parties with whom we conduct business.
For example, the effects of government stay-at-home orders or related adjustments in our business are likely to negatively impact productivity, disrupt our business and delay our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.
Severe and/or long-term disruptions in our operations will negatively impact our business, operating results and financial condition. Specifically, COVID-19 related delays in clinical trial enrollment, patient care, data availability, or monitoring may
35


delay the timeline to our integrity of data from our trials and could affect their acceptability to the FDA or other regulatory authorities, which would represent significant setbacks for the applicable program. To date, we have experienced COVID-19-related impacts on screening and enrollment which may impact the speed of enrollment and the timing of data presentations from our ongoing studies. More significant disruptions may occur if the pandemic worsens in the geographies in which our study sites or manufacturing facilities are located. In addition, quarantines, stay-at-home, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In fact, in April 2020 M.D. Anderson temporarily halted all research activity in order to reduce the spread and impact of COVID-19 on their institution and their patients and this included temporarily suspending activity in the manufacturing facility in which the product candidates for our clinical development programs are manufactured. M.D. Anderson subsequently restarted manufacturing but if the pandemic worsens and they again suspend research activities, we may be unable to enroll patients in our clinical trials until manufacturing resumes at the facility.
The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.
The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, the effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely. In addition, to the extent the ongoing COVID-19 outbreak adversely affects our business, financial condition, results of operations and growth prospects, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this “Risk Factors” section.
If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:
the patient eligibility criteria defined in the protocol;
the size of the patient population required for analysis of the trial’s primary endpoints;
the proximity of patients to study sites;
the design of the clinical trial;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
our ability to obtain and maintain patient consents;
the impact of the COVID-19 pandemic;
the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion; and
competing clinical trials and approved therapies available for patients.
In particular, some of our clinical trials will look to enroll patients with characteristics, which are found in a very small population, for example, patients with rare cancers with specific attributes that are targeted with our product candidates. Our clinical trials will compete with other companies' clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in these clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and antibody therapy, rather than enroll patients in any of our future clinical trials. Patients may also be unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology or gene therapy industries.
36


Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates.
Any adverse developments that occur during any clinical trials conducted by academic investigators, our collaborators or other entities conducting clinical trials under independent INDs may affect our ability to obtain regulatory approval or commercialize our product candidates.
Rimiducid and CaspaCIDe-containing cell therapy constructs are being used by third parties in clinical trials for which we are collaborating or in clinical trials which are completely independent of our development programs. We have little to no control over the conduct of those clinical trials. If serious adverse events occur during these or any other clinical trials using our product candidates, the FDA and other regulatory authorities may delay, limit or deny approval of our product candidate or require us to conduct additional clinical trials as a condition to marketing approval, which would increase our costs. If we receive regulatory approval for any product candidate and a new and serious safety issue is identified in clinical trials conducted by third parties, the applicable regulatory authorities may withdraw their approval of the product or otherwise restrict our ability to market and sell our product. In addition, treating physicians may be less willing to administer our product due to concerns over such adverse events, which would limit our ability to commercialize our product.
Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.*
Adoptive cell therapy with T cells is associated with a range of potentially severe immune-mediated adverse effects. In third party clinical trials involving CAR-T cells, the most prominent acute toxicities included symptoms thought to be associated with the release of cytokines, such as fever, low blood pressure and kidney dysfunction. Some patients also experienced toxicity of the central nervous system, such as confusion, cranial nerve dysfunction and speech impairment. Adverse side effects attributed to CAR-T cells were severe and life-threatening in some patients. The life-threatening events were related to kidney dysfunction and toxicities of the central nervous system. Severe and life-threatening toxicities occurred primarily in the first two weeks after cell infusion and generally resolved within three weeks. In the past, several patients have also died in clinical trials by others involving CAR-T cells.
Undesirable side effects observed in our clinical trials, whether or not they are caused by our product candidates, could result in the delay, suspension or termination of clinical trials by us, the FDA or other regulatory authorities for a number of reasons. In addition, because the patients in our clinical trials are suffering from life-threatening diseases, are often suffering from multiple complicating conditions and, in the case of transplant patients, are in a position of extreme immune deficiency at the time that they receive our therapy, it may be difficult to accurately assess the relationship between our product candidates and adverse events experienced by very ill patients. If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.
Clinical trials are expensive, time-consuming and difficult to design and implement.
Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on relatively new technology, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. Costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from therapies such as our current and future product candidates can be significant. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products. In addition, our proposed product candidates involve several complex and costly manufacturing and processing steps, the costs of which will be borne by us. The costs of our clinical trials may increase if the FDA does not agree with our clinical development plans or requires us to conduct additional clinical trials to demonstrate the safety and efficacy of our product candidates.
37


We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.*
The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.

Specifically, genetically engineering T cells faces significant competition from multiple companies, including, Adaptimmune, Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics plc, bluebird bio, Inc., Bristol-Meyer Squibb Co., CARsgen Therapeutics, Ltd., Cellectis SA, Celularity Inc., Fate Therapeutics Inc., GlaxoSmithKline plc, Immune Design Corp., Gilead Sciences, Inc., Iovance Biotherapeutics, Inc., Janssen Pharmaceutical, Legend Biotech, Lyell Immunopharma, Inc., Medigene AG, Mustang Bio, Inc., Novartis AG, Obsidian Therapeutics, Poseida Therapeutics, Inc. Precigen, Inc., Precision Biosciences, Inc., Takeda Pharmaceutical Co, Tmunity Therapeutics Inc., and Ziopharm Oncology, Inc.

Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors’ products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see “Item 1. Business Competition” under Part I of our Annual Report.
We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Workforce and expense reductions may have an adverse impact on our internal programs, our ability to hire and retain key personnel and may be distracting to management, and could harm our internal control over financial reporting.*
Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.
Primarily due to our restructuring plan announced in October 2020, we have reduced our staff to 7 employees as of September 30, 2021. This reduction in our staff included our Chief Financial Officer, our Chief Legal and Strategy Officer and various scientific personnel. Depending on our need for additional funding and expense control, we may be required to implement further workforce and expense reductions in the future. Further workforce and expense reductions may not result in efficiencies and anticipated savings and could result in reduced progress on our internal programs. In addition, employees, whether or not directly affected by a reduction, may seek future employment with our business partners or competitors. Although our employees are required to sign a confidentiality agreement at the time of hire, the confidentiality of certain proprietary information and knowledge may not be maintained in the course of any such future employment. Further, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled personnel. We may have difficulty retaining and attracting such personnel as a result of a perceived risk of future workforce and expense reductions. In addition, the implementation of expense reduction programs may result in the diversion of efforts of our executive management team and other key employees, which could adversely affect our business.
Furthermore, we have identified and may continue to identify deficiencies in our internal control over financial reporting due in part to our limited staffing and resources. If we are unable to maintain effective controls over financial reporting, it is possible
38


that a misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis . We have implemented and continue to implement measures designed to improve our internal control over financial reporting, including the retention of accounting consultants to assist in areas of complex accounting and financial reporting. However, if we are unsuccessful in maintaining the effectiveness of our internal control over financial reporting, the accuracy and timing of our financial reporting may be harmed, which could result in, among other things, restatements of our financial statements, failure to comply with SEC requirements, loss of investor confidence in our financial reporting, and a decline in our stock price.
To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock units, or RSUs, that vest over time. The value to employees of stock options and RSUs that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain “key man” insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled scientific and medical personnel.
The terms of our 2019 private placement of equity restrict our operating and financial flexibility, and give priority to certain investors, both of which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline.*
In August 2019, we completed an underwritten public offering of 575,000 shares of our Series 1 preferred stock and warrants to purchase up to 5,750,000 shares of our common stock. Concurrent with the public offering we entered into an agreement with certain institutional investors providing for a private placement, pursuant to which we agreed to sell at two or more separate closings, each at the option of the investors and subject to certain conditions, shares of Series 2 preferred stock and warrants to purchase common stock, and shares of Series 3 preferred stock and warrants to purchase common stock, for aggregate gross proceeds of up to $70.0 million. Pursuant to the terms of the securities purchase agreement for the private placement transaction, the investors in the private placement transaction have consent rights over certain significant matters of our business. These include decisions to authorize or issue equity securities that are senior or pari passu to the Series 3 preferred stock with respect to liquidation preference, the incurrence of indebtedness in excess of $1,000,000, the sale or license of certain of the Company's technology and the payment of dividends. As a result, these stockholders, acting together, will have significant influence over certain matters affecting our business. The investors in the private placement may not exercise their rights to purchase additional tranches of preferred stock and may not consent to us seeking additional funds through debt or other equity financings. In addition, potential additional investors in the Company may decline to do so because of the preferential rights granted under the private placement agreement. Each of these factors could negatively impact our liquidity, financial condition, operating results, business and prospects and cause the price of our common stock to decline.
We are reliant on a third party to manufacture our clinical product candidates and may not be able to secure adequate manufacturing capacity.*
In April 2020, we announced the closing of the sale of our U.S. manufacturing facility to M.D. Anderson. When M.D. Anderson assumed ownership of the facility, we became reliant on M.D. Anderson to supply our current clinical product candidates. We have endeavored to structure the transaction in a manner that ensures availability of adequate capacity and priority access thereto for the continued clinical development of our product candidates. Given the complexity of the manufacturing processes for cellular therapies, M.D. Anderson may be unable to effectively manufacture or release our products in accordance with applicable cGMP standards, or may not have sufficient capacity to fulfill demand for products for our clinical trials, which could result in significant costs or delays to our programs.
We oversee a complex manufacturing supply chain of cellular therapy product candidates, viral vectors and small molecule drugs.*
Because of the complex nature of our cell therapy products, we need to oversee the manufacture of multiple components that require a diverse knowledge base and appropriate manufacturing personnel. The supply chain for these components is separate and distinct, and no single manufacturer can supply more than one component of each of our products. Additionally, it is likely that the cell therapy products will need to be made within an appropriate geographic location for the area in which the products will be utilized, so one cell therapy manufacturing facility may not be able to supply diverse geographic areas. Any lack of capabilities to store, freeze, thaw and infuse our cell therapies would adversely affect our business and prospects.
39


Our autologous GoCAR-T product candidates, including BPX-601 and BPX-603 are manufactured on a patient-by-patient basis using each patient’s own cells. Efficient manufacturing of these products relies upon our ability to sufficiently expand and activate the cells of patients who have undergone multiple lines of prior therapy, often including immunosuppressive chemotherapy. Manufacturing of GoCAR-T cells requires adequate supply of viral vector to genetically modify them. We rely on third parties to manufacture viral vector, and they may be unable to manufacture sufficient quantity and quality of virus to meet the demand from our clinical trials. Rimiducid, the small molecule drug used to activate both our iMC and iC9 switches, is a complex molecule to synthesize and is relatively insoluble and lipophilic, rendering it difficult to formulate. We have limited internal expertise in small molecule drug development and manufacturing, and we have identified specialty contract manufacturers to produce the rimiducid drug substance and drug product. It is uncertain whether the drug substance and drug product manufacturers will be able to manufacture sufficient quantity and quality of rimiducid to conduct the necessary non-clinical and clinical trials.
We have not yet caused our product candidates to be manufactured or processed on a commercial scale. We may not be able to scale patient-by-patient manufacturing and processing to satisfy clinical or commercial demands for any of our product candidates. In addition, our anticipated reliance on a limited number of third-party manufacturers for manufacturing exposes us to the following risks:

We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and any replacement contractor must be approved by regulatory authorities. This approval would require new testing and compliance inspections. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory approval, if any.
Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.
Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.
Manufacturers are subject to ongoing periodic unannounced inspection by regulatory agencies to ensure strict compliance with cGMP and other government regulations and standards. We do not have control over third-party manufacturers’ compliance with these regulations and standards.
We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.
Our third-party manufacturers could breach or terminate their agreement with us.
Each of these risks could delay our clinical trials, the approval, if any of our product candidates or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.
We have limited information available regarding the ultimate cost of our products, and cannot estimate what the cost of our products will be upon commercialization, should that occur.
We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product. Because of the patient-specific nature of our manufacturing process, it is not amenable to traditional “scale up” to manufacture larger lots as is performed for traditional drugs and biological agents.
Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.
Gene-modified cell therapy manufacture requires many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product. Some suppliers typically support biomedical researchers or blood-based hospital businesses and may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine
40


circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have commercial supply arrangements with many of these suppliers and may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing.
In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose.
A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.*
We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
differing regulatory requirements in foreign countries;
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign taxes, including withholding of payroll taxes;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
difficulties staffing and managing foreign operations;
workforce uncertainty in countries where labor unrest is more common than in the U.S.;
potential liability under the FCPA or comparable foreign regulations;
challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; and
business interruptions resulting from geo-political actions, including war and terrorism.
These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.
We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
We may form or seek strategic alliances, create joint ventures or collaborations and enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. It is possible that, following a strategic transaction or license, we may not achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.
41


If we are unable to identify a strategic partner for rivo-cel, we may not realize value from this asset and we will continue to incur substantial costs.
We are actively pursuing a strategic partner for our CaspaCIDe-containing polyclonal T cell product candidate called rivogenleceucel, or rivo-cel. A partner would assume current and future development and commercialization responsibilities for this product candidate on a worldwide basis. Concurrently, we have substantially reduced and will continue to reduce our rivo-cel-related activities and spending. For example, we have closed our UK office, which was established to prepare for commercialization in Europe. If we are unable to identify an appropriate strategic partner or to negotiate and consummate a license agreement with such a partner, then it will be impossible to submit the planned Marketing Authorisation Applications, or MAA required to seek approval to commercialize this product candidate in Europe. Such a delay in the process of preparing and submitting the MAA will make it more difficult for us or any possible strategic partner to restart the process in the future and ultimately obtain approval for the product, increasing the likelihood that we may be unable to derive any meaningful revenue from this asset. In addition, we are obligated to continue certain regulatory and clinical activities following conclusion of the rivo-cel clinical trials and if we are unable to identify a strategic partner, we will continue to incur the costs for the internal and external resources required to complete those activities.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to manufacture our drug substance and our drug product, and because we collaborate with various organizations and academic institutions on the advancement of our technology platform, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.
We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.
We and our contractors utilize hazardous materials in our business operations, and any claims relating to improper handling, storage, or disposal of these materials could harm our business.
Our activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. governing the use, manufacture, storage, handling and disposal of medical and hazardous materials, and similar laws in other geographic regions. Although we believe that our manufacturers’ procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any
42


insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.
Our internal computer systems, or those used by our clinical investigators, contractors or consultants, may fail or suffer security breaches.
Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.
System outages, network disruptions and cyber-security threats could interrupt the operation of our business.
We are dependent on the use of information technology systems for our operations. Outages, disruptions and threats could have an adverse impact on our ability to conduct operations. Cyber-security threats, such as malware, phishing and network attacks, are on the rise. These attacks can affect the availability of our information technology systems, including their data, as well as the confidentiality and integrity of these systems. A security breach poses a risk to confidential data, including but not limited to intellectual property and trade secrets resulting in financial, legal or reputational harm to us. Insider threats may exist if an individual authorized to access our technology systems improperly discloses sensitive data to unauthorized persons or the public. We also have outsourced elements of our operations, including elements of our information technology infrastructure, and thus manage several independent vendor relationships with third parties who may have access to our confidential information. Confidentiality agreements are in place for authorized users and third parties to support the prevention of confidential information being improperly disclosed. We have policies and procedures in place, including controls around the access and activity of authorized users, active system monitoring, back-up and recovery, information technology security and mandatory annual information technology security awareness training to assist in the prevention and mitigation of an outage, disruption or threat. In addition, we have invested in high availability, redundant technologies that will reduce the risk of an outage, disruption or threat. However, our efforts may not prevent an outage, disruption or threat that would materially adversely affect us. We also may not have sufficient liability insurance, either type or amount, to cover us against claims related to a cyber-security threat.
Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
Our operations, and those of our clinical investigators, contractors and consultants, could be subject to power shortages, telecommunications failures, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates on a patient by patient basis. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. In particular, certain third-party manufacturers may be unable to comply with their contractual obligations to us due to disruptions caused by COVID-19, including reduced operations or headcount reductions, or otherwise, and in certain cases we may have limited recourse if the non-compliance is due to factors outside of the manufacturer’s control.
Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product
43


candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The laws that may affect our ability to operate include, but are not limited to:
the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;
44


federal civil and criminal false claims laws and civil monetary penalties law, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;
HIPAA, as amended by the Health and Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on covered entities, including certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information and their covered subcontractors, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;
the federal Physician Payments Sunshine Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as require certain manufacturers and group purchasing organizations to report annually ownership and investment interests held by such physicians and their immediate family members, and beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided in the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and
foreign laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by or are in conflict with HIPAA, including the European Union General Data Protection Regulation, or the GDPR, which became effective on May 25, 2018, and which imposes privacy and security obligations on any entity that collects and/or processes health data from individuals located in the European Union. Under the GDPR, fines of up to 20 million euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance. As well as complicating our compliance efforts, non-compliance with these laws could result in penalties or significant legal liability. The GDPR includes more stringent operational requirements for processors and controllers of personal data and creates additional rights for data subjects.

Additionally, we are subject to state and foreign equivalents of each of the U.S. healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor.
We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results
45


of operations. In addition, the approval and commercialization of any of our product candidates outside the U.S. will also subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. We may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. For example, in May 2019, we were added as an additional defendant in an ongoing civil tort lawsuit in federal court in Los Angeles, California. The complaint alleges claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability-failure to warn, breach of express warranty and products liability design or manufacturing defect. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, federal or state liability claims may result in:
decreased demand for our product candidates;
injury to our reputation;
withdrawal of clinical trial participants;
initiation of investigations by regulators;
costs to defend the related litigation;
a diversion of management’s time and our resources;
substantial monetary awards to clinical trial participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue;
exhaustion of any available insurance and our capital resources;
the inability to commercialize any product candidate; and
a decline in our share price.
Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop, alone or with corporate collaborators. We currently carry product liability insurance covering our clinical trials, with other coverage limits as appropriate for certain foreign jurisdictions. Although we maintain such insurance, our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which provides temporary relief from certain aspects of the Tax Cuts and Jobs Act that had imposed limitations on the utilization of certain losses, interest expense deductions, and minimum tax credits. We are currently in the process of assessing the tax-related provisions of the CARES Act and its potential impact on us.
As of December 31, 2020, we had aggregate U.S. net operating loss carryforwards of approximately $448.3 million, and aggregate U.S. federal and Texas state research and development credits of approximately $12.5 million and $5.3 million, respectively. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Act and Cares Act, federal net operating losses incurred in taxable years ending after
46


December 31, 2017 may be carried forward indefinitely, but the deductibility of federal net operating losses generated in tax years beginning after December 31, 2017 may be limited to 80% of current year taxable income for years beginning on or after January 1, 2021. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change” (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We may have experienced one or more ownership changes in the past, including with respect to our August 2019 public offering, and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.
Risks Related to Government Regulation
The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
We have not previously submitted a BLA to the FDA, or similar approval filings to other foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate’s safety, purity and potency for each desired indication. It must also include significant information regarding the chemistry, manufacturing and controls for the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, FDA’s Office of Tissues and Advanced Therapies, or OTAT, has limited experience with combination products that include a small molecule component. Approval of our GoCAR-T product candidates, will likely require this FDA office to consult with other divisions of the FDA, which may result in further challenges in obtaining regulatory approval, including in developing final product labeling. The regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.
We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:
the availability of financial resources to commence and complete our planned clinical trials;
reaching agreement on acceptable terms with prospective clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites;
recruiting suitable patients to participate in a clinical trial;
having patients complete a clinical trial or return for post-treatment follow-up;
clinical trial sites deviating from clinical trial protocol, failing to follow GCPs, or dropping out of a clinical trial;
adding new clinical trial sites; or
manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials.
We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such clinical trials are being conducted, the Data Monitoring Committee for such clinical trial, or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, in December 2020 we announced that the FDA had placed a clinical hold on our BPX-601 trial in pancreatic cancer due to the death of a patient in the trial. Although the FDA released the hold in January 2021, there can be no assurance that future patients’ deaths in this or any of our clinical trials will not trigger additional clinical holds. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.
47


Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the EU or U.S., including additional preclinical studies or clinical trials. Studies and clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the EU and U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties and/or withdrawal of product approval if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.*
Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Additionally, a company may not promote “off-label” uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product’s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;
fines, warning letters or holds on clinical trials;
refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;
suspension or termination of manufacturing at one or more manufacturing facilities;
product seizure or detention, or refusal to permit the import or export of our product candidates; and
injunctions or the imposition of civil or criminal penalties.
48


The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.
Foreign legislative changes may also affect our ability to commercialize our product candidates. Effective as of May 25, 2018, the GDPR imposes privacy and security obligations on any entity that collects and/or processes personal information from individuals located in the European Union. Under the GDPR, fines of up to 20 million euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance.
Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.*
The use of engineered T cells as potential cancer treatments is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Many factors will influence whether our product candidates are accepted in the market, including:
the clinical indications for which our product candidates are approved;
physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;
the potential and perceived advantages of our product candidates over alternative treatments;
the prevalence and severity of any side effects;
product labeling or product insert requirements of the FDA or other regulatory authorities;
limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;
the extent and quality of the clinical evidence supporting the efficacy and safety of our product candidates;
the timing of market introduction of our product candidates as well as competitive products;
the cost of treatment in relation to alternative treatments;
the pricing of our product candidates and the availability of adequate reimbursement by third-party payors and government authorities;
the willingness and ability of patients to pay out-of-pocket in the absence of coverage by third-party payors, including government authorities;
relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies;
confusion or lack of understanding regarding the effects of rimiducid and optimal dose and schedule of rimiducid after immune cell therapy; and
the effectiveness of our sales and marketing efforts.
In addition, although we are not utilizing embryonic stem cells or replication competent vectors, adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such clinical trials to demonstrate that these therapies are safe and effective may limit market acceptance our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.
Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.
Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.
49


Market acceptance and sales of our product candidates will depend in large part on global reimbursement policies and may be affected by future healthcare reform measures, both in the United States and other key international markets. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Therefore, successful commercialization of our products will depend in part on the availability of governmental and third-party payor reimbursement for the cost of our product candidates and/or payment to the physician for administering our product candidates. In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. One third-party payor’s decision to cover a particular medical product or service does not assure that other payors will also provide coverage for the medical product or service, or to provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that adequate coverage and reimbursement will be obtained. Further, a third-party payor’s decision to provide coverage for a medical product or service does not imply that an adequate reimbursement rate will be approved. The market for our product candidates will depend significantly on access to third-party payors’ formularies or lists of treatments for which third-party payors provide coverage and reimbursement. Third party payors may also have difficulty in determining the appropriate coverage of our product candidates, if approved, due to the fact that they are combination products that include a small molecule drug, rimiducid.
Third-party payors establish coverage and reimbursement policies for new products, including our product candidates. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for treatments based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. In the United States, the EEA and other significant or potentially significant markets for our product candidate, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in Canada and the EEA will put additional pressure on product pricing, coverage, reimbursement and utilization, which may adversely affect our product sales and results of operations. These pressures can arise from policies and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, coverage and reimbursement policies and pricing in general. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the PPACA, became law in the United States. PPACA substantially changed the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. Among the provisions of the PPACA of greatest importance to the pharmaceutical industry are the following: (i) an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; (ii) an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; (iii) a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; (iv) extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (v) expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers’ Medicaid rebate liability; (vi) expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; (vii) expansion of health care fraud and abuse laws, including the federal civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; and (viii) a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.


50


There have been executive, judicial and Congressional challenges to other aspects of the PPACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the PPACA have been signed into law. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the PPACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace, which began on February 15, 2021 and will remain open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the PPACA and our business.
In addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, following passage of the Bipartisan Budget Act of 2018, will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through December 31, 2021 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers.
Further, recently there has been heightened governmental scrutiny in the United States over the manner in which drug manufacturers set prices for their marketed products, in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the Trump administration’s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. The Most Favored Nation regulations mandate participation by identified Medicare Part B providers and will apply in all U.S. states and territories for a seven-year period, beginning January 1, 2021 and ending December 31, 2027. On December 28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction against implementation of the interim final rule. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN model interim final rule shall not commence earlier than sixty(60) days after publication of that regulation in the Federal Register. In addition, based on a recent executive order, the Biden administration expressed its intent to pursue policy initiatives to reduce drug prices. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional federal and state healthcare reform measures will be adopted in the future, any of which could result in reduced demand for our products or other adverse effects on our business. For example, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

51


We expect that additional federal and state healthcare reform measures will be adopted in the future, any of which could result in reduced demand for our products or other adverse effects on our business.
Certain countries have a very difficult reimbursement environment and we may not obtain reimbursement or pricing approval, if required, in all countries where we expect to market a product, or we may obtain reimbursement approval at a level that would make marketing a product in certain countries not viable.
We expect to experience pricing pressures in connection with the sale of any products that we may develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, prospects, financial condition and results of operations.
Due to the novel nature of our technology and the small size of our target patient populations, we face uncertainty related to pricing and reimbursement for these product candidates.
Our target patient populations for our potential product candidates are relatively small, as a result, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial and manufacturing infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates, for example, reimbursement for administration of our product candidates to patients, is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products.
We are subject to extensive laws and regulations related to data privacy, and our failure to comply with these laws and regulations could harm our business.
We are subject to laws and regulations governing data privacy and the protection of personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. There are foreign and state law versions of these laws and regulations to which we are currently and/or may in the future, be subject. For example, the collection and use of personal health data in the European Union is governed by the GDPR. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large monetary penalties for noncompliance. The GDPR requirements apply not only to third-party transactions, but also to transfers of information within our company, including employee information. The GDPR and similar data privacy laws of other jurisdictions place significant responsibilities on us and create potential liability in relation to personal data that we or our third-party service providers process, including in clinical trials conducted in the United States and European Union. In addition, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.
Additionally, California recently enacted legislation that has been dubbed the first “GDPR-like” law in the United States. Known as the California Consumer Privacy Act, or the CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. As of January 1, 2020, the CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As currently written, the CCPA will likely impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information.

52


We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws. We can face serious consequences for violations.
Among other matters, Trade Laws prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We also expect our non-U.S. activities to increase in time. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.
Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If repeated or prolonged government shutdowns occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
53


Risks Related to Our Intellectual Property
We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We license from Baylor College of Medicine, or Baylor, certain intellectual property related to methods for activating antigen presenting cells, to certain genetic constructs and to certain methods for inducing apoptosis. Baylor may terminate or modify our licenses in the event of a material breach by us that remains uncured following the date that is 90 days after written notice of such breach or upon certain insolvency events that remain uncured following the date that is 30 days following written notice of such insolvency event. In addition, we have funded certain of our clinical development activities and may fund certain of our future clinical development with funds from the State of Texas. The State of Texas may have rights to commercialize the results of those clinical trials if it determines that we have failed, after notice and an opportunity to cure, to use diligent and commercially reasonable efforts to commercialize or otherwise bring to practical application the results of the funded clinical trials. We are also dependent on our license agreements with Agensys, Inc. (a subsidiary of Astellas Pharma, Inc.) with respect to PSCA-targeted CARs, and BioVec Pharma Inc. with respect to making retrovirus for all of our programs. The termination of any of these licenses could have a material adverse effect on our business.
Any termination of these agreements, or other agreements to which we are a party could result in the loss of significant rights and could harm our ability to commercialize our product candidates.
Disputes may also arise between us and our licensors and other partners regarding intellectual property subject to a license agreement, including:
the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
our right to sublicense patent and other rights to third parties under collaborative development relationships;
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.
If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be able to compete effectively in our market.
Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Certain intellectual property which is covered by our in-license agreements has been developed at academic institutions which have retained non-commercial rights to such intellectual property.
There are several pending U.S. and foreign patent applications in our portfolio, and we anticipate additional patent applications will be filed both in the U.S. and in other countries, as appropriate. However, we cannot predict:
54


if and when patents will issue;
the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;
whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or
whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.
Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property. We cannot be certain that the claims in our pending patent applications directed to compositions of matter for our product candidates will be considered patentable by the U.S. Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid by courts in the U.S. or foreign countries. Method of use patents have claims directed to the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label.” Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.
The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the U.S. or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, it is possible that patent applications in our portfolio may not be the first filed patent applications related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law with the passage of the America Invents Act (2012) which brings into effect significant changes to the U.S. patent laws that are yet untried and untested, and which introduces new procedures for challenging pending patent applications and issued patents. A primary change under this reform is creating a “first to file” system in the U.S. This will require us to be cognizant going forward of the time from invention to filing of a patent application.

We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. We require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements; however, it is possible that our trade secrets and other confidential proprietary information could be disclosed or that competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.
Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.
55


Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Recently, under U.S. patent reform, new procedures including inter parties review and post grant review have been implemented. As stated above, this reform is untried and untested and will bring uncertainty to the possibility of challenge to our patents in the future. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware or have not sufficiently analyzed with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications, which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, methods of use, including combination therapy or patient selection methods or any final product itself, the holders of any such patents may be able to block our ability to develop and commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.

Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. It is possible that any such license would not be available at all or on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.

For example, we are aware of a third-party patent having claims directed to chimeric DNA comprising DNA segments encoding (1) a single chain antibody domain and (2) transmembrane and cytoplasmic domains of an endogenous protein. Even though we have reason to believe that our product candidates are not covered by claims of this patent, an owner or licensee of the patent still might bring a patent infringement suit against us. If the patent is asserted against us, we may not prevail in defending against claims of infringement and/or challenging the validity of claims in the patent. We may not successfully develop alternative technologies or enter into an agreement by which we obtain rights to the patent. These rights, if necessary, may not be available on terms acceptable to us.

We are aware of third-party patents having claims that may be considered as being directed to single-chain antibody fragments that bind to PSCA and these patents may be considered relevant to BPX-601 and related technologies we are developing. We currently are evaluating whether or not we need to obtain rights to these patents under a license, and if it is determined that we need to obtain such rights, whether these rights can be obtained. We are also aware of third-party patent applications having claims that may be considered as being directed to cellular therapy constructs utilizing a heterodimer domain for activation of caspase 9. We are monitoring these applications and if they are granted with the claims as drafted, they may be relevant to our potential dual-switch product candidates containing such a heterodimer activation domain.


56


Also, while we are aware there are other third-party patents having claims that may be considered relevant to technologies for which we are seeking, or plan to seek, regulatory approval, we believe those patents have a patent term that may expire prior to the time we expect to obtain regulatory approval for these technologies. The estimated expiration dates for those patents were determined according to information on the face pages of the patents, and certain factors that could influence patent term, such as patent term adjustment and patent term extension, for example, were not factored into these estimates. Accordingly, the estimated expiration dates of those patents may not be accurate and one or more of those patents may not expire before we obtain regulatory approval for an applicable technology. Owners or licensees of one or more of those patents may bring a patent infringement suit against us. If one or more of those patents are asserted against us, we may be able to assert a defense for a safe harbor to patent infringement under 35 U.S.C. 271(e)(1) if certain requirements are met. It is possible that (1) certain of these requirements may not be met, and/or (2) one or more of the third-party patents might expire after one or more of our technologies obtain regulatory approval, and consequently we may not successfully assert such a defense to patent infringement. If we are unsuccessful in asserting a defense under 35 U.S.C. 271(e)(1), it is possible we may not prevail in defending against claims of infringement and/or challenging the validity of claims in those patents. We may not successfully develop alternative technologies or enter into agreements by which we obtain rights to applicable patents. These rights, if necessary, may not be available on terms acceptable to us.
We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.

Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.

Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.

The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

We may not be able to successfully complete negotiations and ultimately acquire the rights to the intellectual property that we may seek to acquire in the future.
We may be involved in lawsuits or other proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. It also is possible that a competitor we sue for patent infringement could countersue us for allegedly infringing one or more of their own patents or one or more patents they licensed from another entity. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.

57


Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. It also is possible that third parties could institute a patent office post-grant proceeding against one or more of our patents, or one or more patents licensed to us, such as a post grant review proceeding, inter parties review proceeding or reexamination proceeding at the USPTO, or an opposition proceeding in a jurisdiction outside the U.S. An unfavorable outcome in a post-grant proceeding could result in a loss of our patent rights. Litigation, interference proceedings or patent office post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We also may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.
Obtaining and maintaining our patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent position could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1) non-U.S. patents and patent applications owned by us, and (2) patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.
Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions, for example, opposition proceedings. Any such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art and that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patents directed to our product candidates. A loss of patent rights could have a material adverse impact on our business.

58


Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the recent case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.
We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors’ patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees’ former employers. Litigation may be necessary to defend against these claims. Even if we
59


are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.
Risks Related to Ownership of our Common Stock
If we fail to satisfy applicable listing standards, our common stock may be delisted from the Nasdaq Capital Market.*
Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. On May 5, 2021, we were notified by The Nasdaq Stock Market LLC (“Nasdaq”), that we were in breach of Listing Rule 5450(b)(2)(A) (the “Market Value Rule”), for continued listing on The Nasdaq Capital Market because the market value of our listed securities for 30 consecutive business days had been less than $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we were granted a grace period until November 1, 2021, to regain compliance with the Market Value Rule by maintaining a market value of listed securities $35 million or more for a minimum of 10 consecutive business days any time prior to November 1, 2021. On November 2, 2021, Nasdaq notified us that we had not regained compliance with the Market Value Rule by November 1, 2021, and unless we request a hearing before the Nasdaq Hearings Panel (the “Panel”) by November 9, 2021, our securities will be delisted from Nasdaq. We intend to timely request a hearing before the Panel to appeal this determination, which we expect will stay any further action by Nasdaq until the conclusion of the hearing process.
If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing.
In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.
If our common stock is delisted by The Nasdaq Capital Market, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. Further, if we are delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our shareholders to sell our common stock in the secondary market.
The price of our stock is volatile and you could lose all or part of your investment.
The trading price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including market conditions in general and a limited trading volume for our shares. In addition to the factors discussed in this “Risk Factors” section and elsewhere in our Annual Report, these factors include:
the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;
any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information;
adverse results or delays in our ongoing or future clinical trials;
our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;
adverse developments concerning our CID technology platform and our small molecule drug rimiducid;
adverse developments concerning our contract manufacturers;
60


changes in the structure of healthcare payment systems;
our inability to maintain successful collaborations or to establish new collaborations if needed;
our failure to commercialize our product candidates;
additions or departures of key scientific or management personnel;
unanticipated serious safety concerns related to the use of our product candidates;
introduction of new products or services offered by us or our competitors;
announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;
our ability to effectively manage our growth;
the size and growth of our initial target markets;
our ability to successfully treat additional types of diseases and cancers or at different stages;
actual or anticipated variations in quarterly operating results;
our cash position;
our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;
publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;
changes in the market valuations of similar companies;
overall performance of the equity markets;
sales of our common stock by us or our stockholders in the future;
trading volume of our common stock;
changes in accounting practices;
ineffectiveness of our internal controls;
disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
significant lawsuits, including patent or stockholder litigation;
general political and economic conditions; and
other events or factors, many of which are beyond our control.

In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would harm our business, operating results or financial condition.
We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.
We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.
61


As of December 31, 2019, we are no longer an “emerging growth company” and, as a result, are required to comply with increased disclosure and governance requirements.
As more than five fiscal years have passed since the December 18, 2014, we ceased to be an “emerging growth company” as defined in the JOBS Act as of December 31, 2019. However, we currently qualify as a “Smaller Reporting Company” under applicable SEC rules, which limits some of the otherwise applicable public company requirements. Below are specific requirements to which we are now subject that did not previously apply to us. These requirements include the “say on pay” provisions (requiring a non-binding stockholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding stockholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Act and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of our chief executive officer.
Compliance with such requirements is expensive and time-consuming for management, as the loss of “emerging growth company” status and compliance with the additional requirements substantially increases our legal and financial compliance costs and makes some activities more time-consuming and costly.
Changes in accounting rules, assumptions and/or judgments could materially and adversely affect us.
Accounting rules and interpretations for certain aspects of our operations are highly complex and involve significant assumptions and judgment. These complexities could lead to a delay in the preparation and dissemination of our financial statements. Furthermore, changes in accounting rules and interpretations or in our accounting assumptions and/or judgments, such as asset impairments, could significantly impact our financial statements. In some cases, we could be required to apply a new or revised standard retroactively, resulting in restating prior period financial statements. Any of these circumstances could have a material adverse effect on our business, prospects, liquidity, financial condition and results of operations.
Our consolidated financial statements, including our liabilities and statements of operations are subject to quarterly changes in our accounting of our outstanding Series 1 Preferred Stock, warrants and related option fee proceeds.
In accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities, and ASC Topic 480, Liabilities-Distinguishing from Equity, convertible preferred shares are accounted for as temporary equity and warrants are accounted for as liabilities at their fair value during periods where they can be net cash settled in case of a change in control transaction. The warrants are accounted for as a liability at their fair value at each reporting period. The value of the derivative warrant liability is re-measured at each reporting period with changes in fair value recorded in earnings. To derive an estimate of the fair value of these warrants, the binomial model is utilized, adjusted for the effect of dilution, which embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to determine the fair value of these instruments. This process requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Additionally, in connection with our August 2019 private placement we received option fee proceeds, or the Option Fee, which is accounted for as a liability. The value of the Option Fee is re-measured at each reporting period with changes in fair value recorded through earnings. As a result, our consolidated financial statements and results of operations may fluctuate quarterly, based on factors, such as the trading value of our common stock and certain assumptions, which are outside of our control. Consequently, our liabilities and consolidated statements of operations may vary quarterly, based on factors other than our revenues and expenses. The liabilities and accounting line items associated with our derivative securities on our balance sheet and statement of operations are non-cash items, and the inclusion of such items in our financial statements may materially affect the outcome of our quarterly and annual results, even though such items are non-cash and do not affect the cash we have available for operations. Investors should take such derivative accounting matters and other non-cash items into account when comparing our quarter-to-quarter and year-to-year operating results and financial statements.
Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
Certain holders of our outstanding shares of common stock, are entitled to rights with respect to the registration of their shares under the Securities Act of 1933, as amended, or the Securities Act. Any sales of these shares by such stockholders could have a material adverse effect on the trading price of our common stock.
We register on Form S-8 all shares of common stock that are issuable under our 2019 Equity Incentive Plan, as amended, or the EIP. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.
62


Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our EIP and shelf registration statement, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
We expect that significant additional capital will be needed in the future to continue our planned operations, including conducting clinical trials, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time, including pursuant to our shelf registration statement on Form S-3 that we filed with the SEC. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Any such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the existing holders of our common stock.
We completed a public offering of our Series 1 preferred stock on August 21, 2019 and are obligated to issue shares of Series 2 and Series 3 preferred stock in connection with the concurrent private placement, and if we are required to redeem shares of preferred stock, our cash position will be negatively impacted. In addition, we may not have sufficient funds to redeem such shares of preferred stock.
We issued 575,000 shares of Series 1 preferred stock in connection with our August 2019 public offering and are obligated to issue up to 350,000 shares of Series 2 preferred stock and 250,000 shares of Series 3 preferred stock pursuant to the purchase agreement governing our August 2019 private placement.
Subject to the terms of our certificate of incorporation, at any time on or after August 21, 2024, some or all of our outstanding shares of preferred stock will be redeemable at the option of the holder at a redemption price of $100.00 per share of Series 1 and Series 2 preferred stock and $140.00 per share of Series 3 preferred stock, upon delivery of an irrevocable written notice to us. If a holder of preferred stock requests redemption we will be required to redeem such shares of preferred stock. However, we may be unable to redeem such preferred stock if restrictions under applicable law or contractual obligations prohibit such redemption. For example, Delaware law provides that a redemption on capital stock may only be paid from “surplus” or, if there is no “surplus,” from a corporation’s net profits for the then-current or the preceding fiscal year. Unless we operate profitably, our ability to redeem the preferred stock would require the availability of adequate “surplus,” which is defined as the excess, if any, of our net assets (total assets less total liabilities) over our capital. To date, we have operated at a loss. Accordingly, if we do not have sufficient “surplus” under Delaware law, we would be unable to effect such redemption. If we do have sufficient “surplus” to effect such redemption, our available cash will be negatively impacted and our ability to use the net proceeds from this offering could be substantially limited. In addition, such reduction in our available cash could decrease the trading price of our common stock, and, accordingly, the preferred stock and our warrants.
The issuance or sale of shares of our common stock, or rights to acquire shares of our common stock, including the issuance of our securities pursuant to our August 2019 private placement, could depress the trading price of our common stock.
Under the terms of the private placement transaction, we are obligated to issue (i) up to 350,000 shares of Series 2 preferred stock, at a purchase price of $100.00 per share, and related warrants to purchase up to 2,800,000 shares of our common stock at an exercise price of $10.00 per share, and (ii) 250,000 shares of Series 3 preferred stock, at a purchase price of $140.00 per share, and related warrants to purchase up to 875,000 shares of our common stock at an exercise price of $14.00 per share, for aggregate gross proceeds of up to $70,000,000, to certain institutional investors in two or more separate closings, each to occur at such investors’ discretion. In addition, we may conduct future offerings of our common stock, preferred stock or other securities that are convertible into or exercisable for our common stock to finance our operations or fund acquisitions, or for other purposes. If we issue additional shares of our common stock or rights to acquire shares of our common stock, if any of our existing stockholders sells a substantial amount of our common stock, or if the market perceives that such issuances or sales may occur, then the trading price of our common stock, and, accordingly, the trading price of our common stock may significantly decrease. In addition, our issuance of additional shares of common stock will dilute the ownership interests of our existing common stockholders.
Certain investors in the private placement will have the ability to control or significantly influence certain business decisions.
Pursuant to the terms of the securities purchase agreement for the private placement transaction, certain investors in the private placement transaction have consent rights over certain significant matters of the Company’s business. These include decisions
63


to authorize or issue equity securities that are senior or pari passu to the Series 3 preferred stock with respect to liquidation preference, the incurrence of indebtedness in excess of $1,000,000, the sale or license of the Company’s iMC switch technology and the payment of dividends. As a result, these stockholders, acting together, will have significant influence over certain matters affecting our business.
Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:
a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;
a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;
a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;
advance notice requirements for stockholder proposals and nominations for election to our board of directors;
a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;
a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and
the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.
In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated certificate of incorporation and our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; or (iv) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.
These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.
64


These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts that cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Effective December 1, 2021, our Board of Directors appointed Charity Scripture, MS, PharmD, 47, to serve as our Chief Development Officer.
Prior to her appointment as our Chief Development Officer, Dr. Scripture served as Vice President, Business and Development Operations at ACELYRIN, INC., a private biotechnology company, from November 2020 to November 2021. Dr. Scripture also served as our Senior Director, US and Global Medical Affairs from October 2018 to October 2019, and as our Vice President, Clinical & Medical Affairs on a full-time basis from November 2019 to December 2020 and on a part-time basis from January 2021 to November 2021. Dr. Scripture previously held clinical development leadership positions with Stemcentrx, Inc., an AbbVie subsidiary, from October 2016 to October 2018, and Pharmacyclics, Inc. (acquired by AbbVie in May 2015), from January 2015 to October 2016. Prior to AbbVie, Dr. Scripture held positions in clinical development and medical affairs at Amgen Inc., a public biopharmaceutical company, for approximately nine years. Prior to joining Amgen, Dr. Scripture was employed by Dartmouth-Hitchcock Medical Center where she was involved with the clinical care of cancer patients. Dr. Scripture completed her post- doctoral fellowship in Clinical Pharmacology Drug Development at the National Cancer Institute. She holds a Pharm. D from University of North Carolina at Chapel Hill, a M.S. in Pharmacology and Toxicology from Dartmouth Medical School, and a B.S. in Biochemistry and Molecular Biology from Hamilton College.
In connection with her appointment, we entered into an employment agreement with Dr. Scripture that governs the current terms of her employment with us. Among other things, the employment agreement provides for an annual base salary of $400,000, and, at the sole discretion of our Board of Directors (or an authorized committee thereof), cash performance bonus eligibility based on a target annual bonus equal to 40% of base salary. In addition, Dr. Scripture is entitled to severance benefits upon a termination of her employment without “cause” (as defined in her employment agreement), including continued payment of base salary for 12 months and a pro-rated lump sum amount equal to her target performance bonus for the applicable bonus period in which such termination occurs. If such termination occurs immediately prior to, or within the 12 months following, a “change of control” (as defined in her employment agreement), she will be entitled to continued payment of base salary for 12 months, a lump sum amount equal to her target performance bonus for one calendar year and acceleration of vesting of all outstand equity awards subject to time-based vesting. Dr. Scripture may also be entitled to receive tax gross up payments in the event any payments made in connection with a change in control are subject to the excise taxes imposed by Sections 280G and 4999 of the Internal Revenue Code. In order to receive any severance benefits under the employment agreement, Dr. Scripture is required to execute a release of claims and comply with certain other post-employment covenants set forth in the employment agreement.
65

Dr. Scripture will also enter into our standard form of indemnification agreement for our directors and executive officers.
There are no family relationships between Dr. Scripture and any of our current or former directors or executive officers. Dr. Scripture is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933.
66

Item 6. Exhibits
 
The exhibits filed as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.
Exhibit
Number
Description
3.1
3.2
3.3
4.1
Reference is made to Exhibits 3.1 3.2 and 3.3.
4.2
4.3
4.4
4.5
4.6
4.7
4.8
31.1
32.1
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
67

101.DEFInline XBRL Taxonomy Extension Definition
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).
68


Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Bellicum Pharmaceuticals, Inc.
Date: November 4, 2021
By:/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer
and Principal Financial Officer
Date: November 4, 2021
By:/s/ Charles S. Grass
Charles S. Grass
Principal Accounting Officer

69
EX-31.1 2 a2021q3exhibit311.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Richard A. Fair, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of Bellicum Pharmaceuticals, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.     I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2021By:/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)


EX-32.1 3 a2021q3exhibit321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Report”) of Bellicum Pharmaceuticals, Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, the undersigned, in his capacity as an officer of the Registrant, does hereby certify, that, to the best of his knowledge:
(1)   The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)
November 4, 2021
 
 
This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.


EX-101.SCH 4 blcm-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2109102 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2114103 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417410 - Disclosure - LEASES - Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2118104 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421412 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2122105 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 2124106 - Disclosure - SHARE-BASED COMPENSATION PLANS link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - SHARE-BASED COMPENSATION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - SHARE-BASED COMPENSATION PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2427415 - Disclosure - SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2430418 - Disclosure - SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details) link:presentationLink link:calculationLink link:definitionLink 2132107 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 blcm-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 blcm-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 blcm-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Warrants, limitations on ownership after exercise Class of Warrants or Rights, Limitations on Ownership After Exercise Class of Warrants or Rights, Limitations on Ownership After Exercise Discontinued operation, consideration, note receivable Disposal Group, Including Discontinued Operation, Consideration, Note Receivable Disposal Group, Including Discontinued Operation, Consideration, Note Receivable Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Security deposit returned Increase (Decrease) in Security Deposits Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders Earnings Per Share, Policy [Policy Text Block] Current portion of lease liabilities Lease Liability, Current Lease Liability, Current Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income (loss) Net loss Net income (loss) Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Reed Road, Houston, TX Reed Road, Houston, TX [Member] Reed Road, Houston, TX Income Statement Location [Axis] Income Statement Location [Axis] Accrued patient treatment costs Patient Treatment Costs Patient Treatment Costs Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Finance lease cost: Amortization of Deferred Charges [Abstract] Total fair value Derivative Liability Amount paid upon closing of asset sale Disposal Group, Including Discontinued Operation, Consideration Proceeds from sale of property and equipment, net Proceeds from Sale of Property, Plant, and Equipment Discount rate from grant date fair market value Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period COMMITMENTS AND CONTINGENCIES Commitments Contingencies and Guarantees [Text Block] Private Placement Option Private Placement Option Policy [Policy Text Block] Private Placement Option Policy [Policy Text Block] Preferred stock, outstanding (in shares) Preferred stock, beginning balance (in shares) Preferred stock, ending balance (in shares) Temporary Equity, Shares Outstanding Other assets Other Assets, Noncurrent 50-day trading volume on Nasdaq stock market (in shares) Common Stock Redemption, 50 Day Average Trading Volume, Shares Common Stock Redemption, 50 Day Average Trading Volume, Shares Purchases of property and equipment in accounts payables and accrued liabilities Noncash or Part Noncash Acquisition, Fixed Assets Acquired Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Warrant Derivatives Derivatives, Policy [Policy Text Block] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net change in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Sublicense expense Sublicense Expense Sublicense Expense Volatility Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Accrued clinical research costs Accrued Clinical Research Costs, Current Accrued Clinical Research Costs, Current (Gain) loss on dispositions, net Gain (Loss) on Disposition of Assets Document Fiscal Year Focus Document Fiscal Year Focus Deductions from employees Employee Stock Purchase Plan Cash Contributions Employee Stock Purchase Plan Cash Contributions Series 1 and 2 Preferred Stock Series 1 and 2 Preferred Stock [Member] Series 1 and 2 Preferred Stock [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Additional revenue from sales Contract with Customer, Liability, Revenue Recognized Schedule of Derivative Liabilities at Fair Value Schedule of Derivative Liabilities at Fair Value [Table Text Block] Research and development Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Private placement option Private Placement Private Placement [Member] Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Award Type [Domain] Award Type [Domain] Options to purchase common stock Equity Option [Member] ASSETS Assets [Abstract] Options and inducement awards, exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Warrants to purchase aggregate shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Employee Stock Options And Inducement Option Awards Employee Stock Options And Inducement Option Awards [Member] Employee Stock Options And Inducement Option Awards [Member] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Conversion of redeemable convertible preferred stock into common stock Stock Issued During Period, Value, Conversion of Convertible Securities Options and Inducement Awards Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Agensys, Inc. Agensys, Inc. [Member] Agensys, Inc. [Member] Lease termination fee Lessee, Operating Sublease, Termination Fee Lessee, Operating Sublease, Termination Fee MD Anderson MD Anderson [Member] MD Anderson [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Payment on financing lease obligations Finance Lease, Principal Payments Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Net income (loss) per common share attributable to common shareholders, basic (in dollars per share) Basic net income (loss) per share (in dollars per share) Earnings Per Share, Basic Document Type Document Type Termination notice period for any other breach License Agreement Termination Notice License Agreement Termination Notice Loss on termination of lease Gain (Loss) on Termination of Lease License costs due upon first release of product, period of payment License Agreement, First Release Fee Period License Agreement, First Release Fee Period Net income (loss) per share - diluted: Earnings Per Share, Diluted [Abstract] Entity Current Reporting Status Entity Current Reporting Status Long-term lease liabilities Lease Liability, Noncurrent Lease Liability, Noncurrent Accounts receivable, interest and other receivables Accounts and Other Receivables, Net, Current Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized License agreement, annual fee period, from first IND filing License Agreement, Annual Fee Period, From First IND Filing License Agreement, Annual Fee Period, From First IND Filing Milestone payments upon achievement of sales milestones Milestone Payments For Each Licensed Product, Achievement Of Sales Milestones Milestone Payments For Each Licensed Product, Achievement Of Sales Milestones Preferred stock, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Plan Name [Axis] Plan Name [Axis] Supply agreement Supply Agreement [Member] Supply Agreement Level 1 Fair Value, Inputs, Level 1 [Member] Document Transition Report Document Transition Report Accrued manufacturing costs Accrued Manufacturing Costs Current Accrued Manufacturing Costs Current Total liabilities, redeemable preferred stock and stockholders' deficit Liabilities and Equity Accrued other Other Accrued Liabilities, Current Accrued professional services Accrued Professional Fees Other income (expense): Other Income and Expenses [Abstract] Scenario [Axis] Scenario [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable 1-for-10 Reverse Stock Split Adjustments to Additional Paid in Capital, Stock Split Derivative [Line Items] Derivative [Line Items] Total accrued expenses and other current liabilities Accounts Payable and Accrued Liabilities, Current Warrant derivative liability Derivative Liability, Current Operating expenses Operating Expenses [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Exercise of restricted stock unit awards Stock Issued During Period, Value, Stock Options Exercised Proceeds from issuance of redeemable convertible preferred stock in a public offering, net Proceeds From Public Offering Proceeds From Public Offering Minimum Minimum [Member] Upfront fee payment period, number of days from effective date License Agreement Upfront Fee Period License Agreement Upfront Fee Period Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Scenario, Adjustment Scenario, Adjustment [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Trading Symbol Trading Symbol BioVec Pharma Inc BioVec Pharma Inc [Member] BioVec Pharma Inc [Member] Warrant Derivative Liability Warrant Derivative Liability [Member] Warrant Derivative Liability [Member] Current liabilities: Liabilities, Current [Abstract] General and administrative General and Administrative Expense Warrant exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price SHARE-BASED COMPENSATION PLANS Share-based Payment Arrangement [Text Block]  Level 3 Fair Value, Inputs, Level 3 [Member] Operating Leases Lessee, Leases [Policy Text Block] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of reportable segments Number of Reportable Segments Private placement option liability Private placement option liability Derivative Liability, Private Placement Option Derivative Liability, Private Placement Option Impairment charges Impairment Charge on Reclassified Assets Operating lease, liability Operating Lease, Liability Common stock, $0.01 par value; 80,000,000 shares authorized at September 30, 2021 and December 31, 2020; 8,465,549 shares issued and 8,397,803 shares outstanding at September 30, 2021; 8,385,650 shares issued and 8,317,904 shares outstanding at December 31, 2020 Common Stock, Value, Issued Total other income (expense) Nonoperating Income (Expense) Period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies Commitments and Contingencies LEASES Lessee, Operating Leases [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Amortization of leased asset Finance Lease, Right-of-Use Asset, Amortization Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Milestone payments, number of initial products Milestone Payments, Number Of Initial Products Milestone Payments, Number Of Initial Products Document Period End Date Document Period End Date Stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Treasury stock, shares (in shares) Treasury Stock, Shares Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Redeemable preferred stock: $0.01 par value; 10,000,000 shares authorized, Series 1 redeemable convertible preferred stock, $0.01 par value, 1,517,500 shares authorized at September 30, 2021 and December 31, 2020; 452,000 shares issued and outstanding at September 30, 2021 and December 31, 2020 Preferred stock, beginning balance Preferred stock, ending balance Temporary Equity, Carrying Amount, Attributable to Parent Accrued expenses and other current liabilities Accrued Liabilities, Current Revenues Revenue from Contract with Customer, Excluding Assessed Tax Proceeds upon entering into private placement agreement Proceeds from Issuance of Private Placement Shares issuable per warrants (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Baylor Baylor [Member] Baylor [Member] Change in fair value of warrant and private placement option liabilities Change in fair value of warrant and private placement option liabilities Change in fair value Fair Value Adjustment of Warrants Liabilities held for sale Liabilities Held-For-Sale, Not Part Of Disposal Group, Current Liabilities Held-for-sale, Not Part of Disposal Group, Current Common Stock Common Stock [Member] Loss from operations Operating Income (Loss) Series 3 Preferred Stock Series 3 Preferred Stock [Member] Series 3 Preferred Stock [Member] Equity Issuance Costs Equity Method Investments Issuances, Policy [Policy Text Block] ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Research And Development Facility Research And Development Facility [Member] Research And Development Facility Share-based compensation Remaining share-based compensation expense Share-based Payment Arrangement, Noncash Expense San Francisco Office Space San Francisco Office Space [Member] San Francisco Office Space Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payment on debt Repayments of Debt Reclassification of property and equipment, net to assets held for sale Transfer Of Property And Equipment To Held-For Sale Transfer Of Property And Equipment To Held-For Sale Treasury Stock Treasury Stock [Member] Termination period, notice of failure on uncured items License Agreement Period of Notice of Failure on Uncured Items License Agreement Period of Notice of Failure on Uncured Items Accrued liabilities and other Increase (Decrease) in Accrued Liabilities Shares issuable under warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Restricted Stock Awards and Units Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units [Member] Notice period for percentage change Class Of Warrant Or Right, Notice Period For Percentage Change Class Of Warrant Or Right, Notice Period For Percentage Change Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities License costs due upon first release of product License Costs, Due Upon First Release of Product License Costs, Due Upon First Release of Product 2130 W. Holcombe Blvd. 2130 W. Holcombe Blvd. [Member] 2130 W. Holcombe Blvd. [Member] Accrued Expenses and Other Liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Average trading volume period Common Stock Redemption, Average Trading Volume Period Common Stock Redemption, Average Trading Volume Period Total stockholders’ deficit Balance, beginning of period Balance, end of period Stockholders' Equity Attributable to Parent Common stock, issued (in shares) Common Stock, Shares, Issued Preferred stock, issued (in shares) Preferred Stock, Shares Issued Shares purchased by selling common stock and pre-funded warrant (in shares) Class of Warrant or Right, Number of Securities Purchased, Called by Each Warrant or Right Class of Warrant or Right, Number of Securities Purchased, Called by Each Warrant or Right Redeemable convertible series 1 preferred stock Redeemable Preferred Stock [Member] Public Offering Public Stock Offering [Member] Public Stock Offering [Member] Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Financial Instruments and Credit Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] REDEEMABLE CONVERTIBLE PREFERRED STOCK Convertible Redeemable Preferred Stock [Text Block] Convertible Redeemable Preferred Stock Escrow deposits cash proceeds received Escrow Deposits Related to Property Sales Public Warrants, Private Warrants And Stock Options Public Warrants, Private Warrants And Stock Options [Member] Public Warrants, Private Warrants And Stock Options Interest expense Interest Expense Licensing Agreements Licensing Agreements [Member] City Area Code City Area Code Accumulated deficit Retained Earnings (Accumulated Deficit) Takeda Takeda [Member] Takeda Remaining lease term Lessee, Operating Lease, Term of Contract Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Unvested shares of restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Issuance of common stock - Employee Stock Purchase Plan (in shares) Issuance of common stock ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Cash, Cash Equivalents and Restricted Cash, Reconciliation Restrictions on Cash and Cash Equivalents [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Accretion of lease liability Amortization of Lease Liability Amortization of Lease Liability ESPP Activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Amortization of right-of-use assets Operating Lease, Right-Of-Use Asset, Amortization Operating Lease, Right-Of-Use Asset, Amortization Discontinued operation, consideration, cash Disposal Group, Including Discontinued Operation, Consideration, Cash Disposal Group, Including Discontinued Operation, Consideration, Cash Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity File Number Entity File Number Fair Value Inputs, Assets, Quantitative Information [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other income Other Nonoperating Income Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Stock Award Activity for All Stock Plans Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block] Less: undistributed earnings to participating securities Less: undistributed earnings to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Entity Small Business Entity Small Business 2014 Employee Stock Purchase Plan 2014 Employee Stock Purchase Plan [Member] 2014 Employee Stock Purchase Plan [Member] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Escrow deposits related to property sales, period up to Escrow Deposits Related to Property Sales, Term Escrow Deposits Related to Property Sales, Term Equity Component [Domain] Equity Component [Domain] Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Short-term lease cost Short-term Lease, Cost Disposal Group Name [Domain] Disposal Group Name [Domain] Milestone payments upon achievement of specified clinical milestones for each licensed product Milestone Payments For Each Licensed Product, Achievement Of Clinical Milestones Milestone Payments For Each Licensed Product, Achievement Of Clinical Milestones Statement [Line Items] Statement [Line Items] Restricted cash Restricted Cash, Noncurrent Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Nonrefundable upfront fee License Costs for Rights Granted Under Agreement License Costs for Rights Granted Under Agreement Share-Based Compensation Expense by Classification Share-based Payment Arrangement, Cost by Plan [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Entity Address, State or Province Entity Address, State or Province Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Interest income Interest Income, Domestic Deposits Interest on lease liabilities Finance Lease, Interest Expense License agreement, milestone payments upon receipt of FDA or EMA registration License Agreement, Milestone Payments upon Registration with FDA License Agreement, Milestone Payments upon Registration with FDA Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Earnings Per Share, Potentially Dilutive Securities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Milestone payments upon first achievement of specified clinical milestones Milestone Payments for First Licensed Products Milestone Payments for First Licensed Products Proceeds from issuance of stock Proceeds from Issuance of Common Stock Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Net income (loss) attributable to common shareholders Net income (loss) attributable to common shareholders, basic Net Income (Loss) Available to Common Stockholders, Basic Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Leas term option to extend Lessee, Operating Lease, Renewal Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Leasehold improvements paid by landlord Other Significant Noncash Transaction, Consideration Paid By Third-Party Other Significant Noncash Transaction, Consideration Paid By Third-Party Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Series 1 Preferred Series 1 redeemable convertible non-voting preferred stock Redeemable Convertible Preferred Stock [Member] Components of Lease Cost Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Net income (loss) per share - basic: Earnings Per Share, Basic [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Weighted-average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net income (loss) per common share attributable to common shareholders, diluted (in dollars per shares) Diluted net income (loss) per share (in dollars per shares) Earnings Per Share, Diluted Closing price of common stock threshold period Common Stock Redemption Requirement, Closing Price, Threshold Period Common Stock Redemption Requirement, Closing Price, Threshold Period Price per share (in dollars per share) Sale of Stock, Price Per Share Termination period, number of years after first commercial sale of licensed product License Agreement, Termination Period After First Commercial Sale Of Licensed Product License Agreement, Termination Period After First Commercial Sale Of Licensed Product Net comprehensive income (loss) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, authorized (in shares) Temporary Equity, Shares Authorized Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Treasury stock: 67,746 shares held at September 30, 2021 and December 31, 2020 Treasury Stock, Value Number of share-based compensation plans Number of Share-based Compensation Plans Number of Share-based Compensation Plans Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Conversion of redeemable preferred stock into common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization expense Depreciation, Depletion and Amortization Accrued payroll Accrued Salaries, Current Milestone payments reduced upon exercise of option License Agreement, Exclusive License Option Exercised, Maximum Reduction In Aggregate Milestone Payments License Agreement, Exclusive License Option Exercised, Maximum Reduction In Aggregate Milestone Payments Summary of Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] License revenue License Revenue [Member] License Revenue [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Derivative [Table] Derivative [Table] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Revenues Revenues [Abstract] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Accrued manufacturing costs and accrued professional fees, current Accrued Manufacturing Costs And Accrued Professional Fees, Current Accrued Manufacturing Costs And Accrued Professional Fees, Current Closing price of common stock (in dollars per share) Common Stock Redemption Requirement, Closing Price Minimum, Per Share Common Stock Redemption Requirement, Closing Price Minimum, Per Share Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Total lease cost Lease, Cost Income Statement Location [Domain] Income Statement Location [Domain] Additional authorized shares approved (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Disposal Group, Held-for-sale, Not Discontinued Operations Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Preferred stock, shares issued (in shares) Temporary Equity, Shares Issued Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Price of each share of common stock and accompanying common warrant (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Conversion of redeemable preferred stock into common stock Conversion of Stock, Amount Issued Derivative Liability Rollforward [Roll Forward] Derivative Liability Rollforward [Roll Forward] Derivative Liability Rollforward Period of notice of failure on uncured items, if material breach is related to failure to make payments License Agreement, Period Of Notice Of Failure On Uncured Items, Failure To Make Payments License Agreement, Period Of Notice Of Failure On Uncured Items, Failure To Make Payments Private Placement Option Liability Private Placement Option, Derivative Liability [Member] Private Placement Option, Derivative Liability [Member] Document Quarterly Report Document Quarterly Report Option exercise fee License Agreement, Exclusive License Option Exercise Fee License Agreement, Exclusive License Option Exercise Fee Warrants exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Number of wholly-owned subsidiaries formed Number Of Wholly-Owned Subsidiaries Formed Number Of Wholly-Owned Subsidiaries Formed Equipment Equipment [Member] Warrants to purchase common stock Warrant [Member] Entity Common Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Share-based compensation expense recognized Share-based Payment Arrangement, Expense Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] License agreement, annual fee License Agreement, Annual Fee License Agreement, Annual Fee Document Fiscal Period Focus Document Fiscal Period Focus Amortization of deferred issuance costs Amortization of Debt Issuance Costs Restricted cash Restricted Cash, Current Preferred Stock Temporary Equity [Policy Text Block] Temporary Equity Counterparty Name [Axis] Counterparty Name [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash equivalents, restricted cash Total cash, cash equivalents and restricted cash shown in the statements of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance, beginning of period (in shares) Balance, end of period (in shares) Shares, Issued Number of shares of common stock sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Current assets: Assets, Current [Abstract] Shares available for issuance under ESPP (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Entity Central Index Key Entity Central Index Key Upfront payment received Upfront Payment Received Upfront Payment Received Security Exchange Name Security Exchange Name Total cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Disposal Group Classification [Domain] Disposal Group Classification [Domain] Termination period, after insolvency event License Agreement Period after Insolvency Event License Agreement Period after Insolvency Event Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Exercise of restricted stock unit awards (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted-average shares outstanding, diluted (in shares) Weighted-average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Balance, December 31, 2020 Balance, September 30, 2021 Warrants and Rights Outstanding Series 2 Preferred Stock Series 2 Preferred Stock [Member] Series 2 Preferred Stock [Member] Current Fiscal Year End Date Current Fiscal Year End Date Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] PUBLIC OFFERING AND PRIVATE PLACEMENT Stockholders' Equity Note Disclosure [Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Issuance of common stock - Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current ESPP Employee Stock [Member] Class of Stock [Domain] Class of Stock [Domain] Money market funds and treasury bills Money Market Funds [Member] Loss Contingencies [Table] Loss Contingencies [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of stock from employee stock purchase plan Proceeds from Stock Plans Statement [Table] Statement [Table] Restricted Stock Awards and Units Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] New Accounting Requirements and Disclosures New Accounting Pronouncements, Policy [Policy Text Block] Assets held for sale Assets Held-for-sale, Not Part of Disposal Group, Current Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Accounts receivable, interest and other receivables Increase (Decrease) in Other Receivables 2019 Equity Incentive Plan 2019 Equity Incentive Plan [Member] 2019 Equity Incentive Plan [Member] Cover [Abstract] Preferred Stock Preferred Stock [Member] Total offering costs related to warrants and options Other Nonoperating Expense Scenario [Domain] Scenario [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating lease cost Operating Lease, Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] EX-101.PRE 8 blcm-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 blcm-20210930_htm.xml IDEA: XBRL DOCUMENT 0001358403 2021-01-01 2021-09-30 0001358403 2021-10-27 0001358403 2021-09-30 0001358403 2020-12-31 0001358403 us-gaap:ConvertiblePreferredStockMember 2021-09-30 0001358403 us-gaap:ConvertiblePreferredStockMember 2020-12-31 0001358403 blcm:SupplyAgreementMember 2021-07-01 2021-09-30 0001358403 blcm:SupplyAgreementMember 2020-07-01 2020-09-30 0001358403 blcm:SupplyAgreementMember 2021-01-01 2021-09-30 0001358403 blcm:SupplyAgreementMember 2020-01-01 2020-09-30 0001358403 blcm:LicenseRevenueMember 2021-07-01 2021-09-30 0001358403 blcm:LicenseRevenueMember 2020-07-01 2020-09-30 0001358403 blcm:LicenseRevenueMember 2021-01-01 2021-09-30 0001358403 blcm:LicenseRevenueMember 2020-01-01 2020-09-30 0001358403 2021-07-01 2021-09-30 0001358403 2020-07-01 2020-09-30 0001358403 2020-01-01 2020-09-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2020-12-31 0001358403 us-gaap:CommonStockMember 2020-12-31 0001358403 us-gaap:TreasuryStockMember 2020-12-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001358403 us-gaap:RetainedEarningsMember 2020-12-31 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001358403 2021-01-01 2021-03-31 0001358403 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001358403 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2021-03-31 0001358403 us-gaap:CommonStockMember 2021-03-31 0001358403 us-gaap:TreasuryStockMember 2021-03-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001358403 us-gaap:RetainedEarningsMember 2021-03-31 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001358403 2021-03-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001358403 2021-04-01 2021-06-30 0001358403 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001358403 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2021-06-30 0001358403 us-gaap:CommonStockMember 2021-06-30 0001358403 us-gaap:TreasuryStockMember 2021-06-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001358403 us-gaap:RetainedEarningsMember 2021-06-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001358403 2021-06-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001358403 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2021-09-30 0001358403 us-gaap:CommonStockMember 2021-09-30 0001358403 us-gaap:TreasuryStockMember 2021-09-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001358403 us-gaap:RetainedEarningsMember 2021-09-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001358403 us-gaap:CommonStockMember 2019-12-31 0001358403 us-gaap:TreasuryStockMember 2019-12-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001358403 us-gaap:RetainedEarningsMember 2019-12-31 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001358403 2019-12-31 0001358403 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001358403 2020-01-01 2020-03-31 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001358403 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2020-03-31 0001358403 us-gaap:CommonStockMember 2020-03-31 0001358403 us-gaap:TreasuryStockMember 2020-03-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001358403 us-gaap:RetainedEarningsMember 2020-03-31 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001358403 2020-03-31 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001358403 2020-04-01 2020-06-30 0001358403 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001358403 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2020-06-30 0001358403 us-gaap:CommonStockMember 2020-06-30 0001358403 us-gaap:TreasuryStockMember 2020-06-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001358403 us-gaap:RetainedEarningsMember 2020-06-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001358403 2020-06-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001358403 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember 2020-09-30 0001358403 us-gaap:CommonStockMember 2020-09-30 0001358403 us-gaap:TreasuryStockMember 2020-09-30 0001358403 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001358403 us-gaap:RetainedEarningsMember 2020-09-30 0001358403 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001358403 2020-09-30 0001358403 2020-02-04 0001358403 2020-02-05 0001358403 2020-06-14 0001358403 2020-06-15 0001358403 blcm:A2130W.HolcombeBlvd.Member 2020-04-14 2020-04-14 0001358403 srt:MaximumMember 2020-05-01 2021-09-30 0001358403 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember blcm:ResearchAndDevelopmentFacilityMember 2020-12-31 0001358403 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember blcm:ResearchAndDevelopmentFacilityMember 2020-10-01 2020-12-31 0001358403 blcm:ReedRoadHoustonTXMember 2021-02-26 0001358403 blcm:SanFranciscoOfficeSpaceMember 2021-03-15 2021-03-15 0001358403 blcm:SanFranciscoOfficeSpaceMember 2021-06-01 2021-06-30 0001358403 blcm:SanFranciscoOfficeSpaceMember 2021-03-26 0001358403 blcm:SanFranciscoOfficeSpaceMember us-gaap:EquipmentMember 2021-03-26 0001358403 blcm:SanFranciscoOfficeSpaceMember 2021-01-01 2021-03-31 0001358403 us-gaap:ScenarioAdjustmentMember 2020-09-30 0001358403 us-gaap:RedeemablePreferredStockMember 2021-01-01 2021-09-30 0001358403 us-gaap:RedeemablePreferredStockMember 2020-01-01 2020-09-30 0001358403 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001358403 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001358403 us-gaap:PrivatePlacementMember 2021-01-01 2021-09-30 0001358403 us-gaap:PrivatePlacementMember 2020-01-01 2020-09-30 0001358403 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001358403 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001358403 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001358403 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001358403 2020-02-05 2020-02-05 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001358403 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001358403 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001358403 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001358403 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001358403 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001358403 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001358403 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001358403 blcm:WarrantDerivativeLiabilityMember 2021-01-01 2021-09-30 0001358403 blcm:WarrantDerivativeLiabilityMember 2020-01-01 2020-12-31 0001358403 blcm:PrivatePlacementOptionDerivativeLiabilityMember 2021-01-01 2021-09-30 0001358403 blcm:PrivatePlacementOptionDerivativeLiabilityMember 2020-01-01 2020-12-31 0001358403 srt:MinimumMember 2021-09-30 0001358403 srt:MaximumMember 2021-09-30 0001358403 2020-11-30 0001358403 2020-11-01 2020-11-30 0001358403 srt:MaximumMember 2020-11-01 2020-11-30 0001358403 srt:MinimumMember 2020-11-01 2020-11-30 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember blcm:PublicStockOfferingMember 2019-08-16 2019-08-16 0001358403 blcm:PublicStockOfferingMember 2019-08-16 0001358403 us-gaap:CommonStockMember blcm:PublicStockOfferingMember 2019-08-16 0001358403 2019-08-21 2019-08-21 0001358403 us-gaap:RedeemableConvertiblePreferredStockMember blcm:PublicStockOfferingMember 2019-08-16 0001358403 srt:MinimumMember us-gaap:CommonStockMember blcm:PublicStockOfferingMember 2019-08-16 0001358403 srt:MaximumMember us-gaap:CommonStockMember blcm:PublicStockOfferingMember 2019-08-16 0001358403 blcm:Series2PreferredStockMember us-gaap:PrivatePlacementMember 2019-08-16 2019-08-16 0001358403 blcm:Series2PreferredStockMember us-gaap:PrivatePlacementMember 2019-08-16 0001358403 blcm:Series3PreferredStockMember us-gaap:PrivatePlacementMember 2019-08-16 2019-08-16 0001358403 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2019-08-16 0001358403 blcm:PublicWarrantsPrivateWarrantsAndStockOptionsMember 2021-01-01 2021-09-30 0001358403 blcm:WarrantDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001358403 blcm:PrivatePlacementOptionDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001358403 blcm:WarrantDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001358403 blcm:PrivatePlacementOptionDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001358403 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30 0001358403 blcm:WarrantDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001358403 blcm:PrivatePlacementOptionDerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001358403 blcm:Series2PreferredStockMember 2021-01-01 2021-09-30 0001358403 blcm:Series2PreferredStockMember us-gaap:PrivatePlacementMember 2021-01-01 2021-09-30 0001358403 blcm:Series3PreferredStockMember us-gaap:PrivatePlacementMember 2021-01-01 2021-09-30 0001358403 blcm:Series2PreferredStockMember 2021-09-30 0001358403 blcm:Series3PreferredStockMember 2021-09-30 0001358403 blcm:Series1and2PreferredStockMember 2021-09-30 0001358403 blcm:Series1and2PreferredStockMember 2021-01-01 2021-09-30 0001358403 blcm:Series3PreferredStockMember 2021-01-01 2021-09-30 0001358403 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001358403 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001358403 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001358403 blcm:A2019EquityIncentivePlanMember 2021-09-30 0001358403 blcm:A2019EquityIncentivePlanMember 2020-01-01 2020-01-31 0001358403 blcm:A2019EquityIncentivePlanMember 2020-06-01 2020-06-30 0001358403 blcm:A2019EquityIncentivePlanMember 2021-06-01 2021-06-30 0001358403 srt:MaximumMember blcm:A2019EquityIncentivePlanMember 2021-09-30 0001358403 blcm:EmployeeStockOptionsAndInducementOptionAwardsMember 2020-12-31 0001358403 blcm:EmployeeStockOptionsAndInducementOptionAwardsMember 2021-01-01 2021-09-30 0001358403 blcm:EmployeeStockOptionsAndInducementOptionAwardsMember 2021-09-30 0001358403 blcm:RestrictedStockandRestrictedStockUnitsMember 2020-12-31 0001358403 blcm:RestrictedStockandRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001358403 blcm:RestrictedStockandRestrictedStockUnitsMember 2021-09-30 0001358403 us-gaap:EmployeeStockMember blcm:A2014EmployeeStockPurchasePlanMember 2021-09-30 0001358403 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001358403 us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0001358403 us-gaap:EmployeeStockMember 2021-09-30 0001358403 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001358403 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001358403 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001358403 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001358403 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001358403 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001358403 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001358403 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001358403 blcm:BaylorMember us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0001358403 blcm:BaylorMember us-gaap:LicensingAgreementsMember 2021-04-01 2021-06-30 0001358403 blcm:BaylorMember us-gaap:LicensingAgreementsMember 2021-07-01 2021-09-30 0001358403 blcm:AgensysInc.Member us-gaap:LicensingAgreementsMember 2015-12-10 2015-12-10 0001358403 blcm:BioVecPharmaIncMember us-gaap:LicensingAgreementsMember 2015-06-10 2015-06-10 0001358403 blcm:TakedaMember 2021-01-01 2021-09-30 0001358403 blcm:MDAndersonMember 2021-07-01 2021-09-30 shares iso4217:USD iso4217:USD shares blcm:subsidiary blcm:segment pure blcm:plan blcm:product 0001358403 --12-31 2021 Q3 false 0.1 P2Y6M P2Y P10D P10D 10-Q true 2021-09-30 false 001-36783 BELLICUM PHARMACEUTICALS, INC. DE 20-1450200 3730 Kirby Drive Suite 1200 Houston TX 77098 832 384-1100 Common Stock, par value $0.01 per share BLCM NASDAQ Yes Yes Non-accelerated Filer true false false 8397803 19266000 35495000 1501000 1501000 556000 2000 1019000 802000 0 1643000 22342000 39443000 0 645000 27000 189000 4000 307000 22373000 40584000 521000 891000 5339000 4165000 7842000 10345000 2800000 7803000 0 825000 0 672000 16502000 24701000 0 344000 16502000 25045000 0.01 0.01 10000000 10000000 0.01 0.01 1517500 1517500 452000 452000 452000 452000 18036000 18036000 0.01 0.01 80000000 80000000 8465549 8397803 8385650 8317904 84000 84000 67746 67746 5056000 5056000 546138000 543561000 -348000 -339000 -552983000 -540747000 -12165000 -2497000 22373000 40584000 0 0 700000 0 5000000 0 5000000 0 5000000 0 5700000 0 6348000 8140000 19531000 30346000 1681000 4163000 5458000 12095000 8029000 12303000 24989000 42441000 -14000 0 -478000 3761000 -3043000 -12303000 -19767000 -38680000 6000 10000 24000 392000 0 725000 4000 2473000 -4264000 -12131000 -7506000 -14256000 6000 0 5000 0 4276000 11416000 7531000 12175000 1233000 -887000 -12236000 -26505000 469000 0 0 0 764000 -887000 -12236000 -26505000 0.08 -0.18 -1.21 -5.25 0.07 -0.18 -1.21 -5.25 10108388 5059779 10086246 5050603 10194668 5059779 10086246 5050603 1233000 -887000 -12236000 -26505000 -9000 36000 -9000 -26000 1224000 -851000 -12245000 -26531000 452000 18036000 8385650 84000 67746 -5056000 543561000 -540747000 -339000 -2497000 903000 903000 369 0 -11267000 -11267000 452000 18036000 8386019 84000 67746 -5056000 544464000 -552014000 -339000 -12861000 821000 821000 79530 0 -2202000 -2202000 452000 18036000 8465549 84000 67746 -5056000 545285000 -554216000 -339000 -14242000 853000 853000 1233000 -9000 1224000 452000 18036000 8465549 84000 67746 -5056000 546138000 -552983000 -348000 -12165000 538000 21468000 5076593 507000 67746 -5056000 511684000 -533025000 -327000 -26217000 457000 -457000 0 1323000 1323000 1045 -4000 -160000 40000 1000 159000 160000 17576000 -13000 17563000 534000 21308000 5117638 51000 67746 -5056000 513623000 -515449000 -340000 -7171000 1564000 1564000 9526 0 65000 65000 361 -43194000 -49000 -43243000 534000 21308000 5127525 51000 67746 -5056000 515252000 -558643000 -389000 -48785000 1606000 1606000 -887000 36000 -851000 534000 21308000 5127525 51000 67746 -5056000 516858000 -559530000 -353000 -48030000 -12236000 -26505000 2577000 4493000 90000 1229000 -7506000 -14256000 -478000 3761000 33000 297000 23000 371000 0 550000 181000 -178000 216000 -103000 -370000 -1345000 230000 -4629000 -17078000 -43275000 900000 14909000 7000 807000 893000 14102000 0 10000000 0 65000 35000 56000 -35000 -9991000 -9000 -26000 -16229000 -39190000 36996000 93816000 20767000 54626000 0 1973000 0 859000 0 113000 0 160000 0 199000 ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bellicum Pharmaceuticals, Inc. (“Bellicum”) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer. Bellicum is devoting substantially all of its present efforts to developing next-generation CAR-T product candidates in cellular immunotherapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bellicum has two wholly-owned subsidiaries, Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom, and Bellicum Pharma GmbH, a private limited liability company organized under German law. Both were formed for the purpose of developing product candidates in Europe. Bellicum, Bellicum Pharma Limited and Bellicum Pharma GmbH are collectively referred to herein as the “Company”. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company’s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2020, the Company filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to (i) effect a reverse stock split of all issued and outstanding shares of the Company’s common stock at a ratio of 1-for-10 and (ii) reduce the number of authorized shares of the Company’s common stock from 200,000,000 to 40,000,000. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, the Company filed with the Secretary of State of the State of Delaware a Second Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 40,000,000 shares to 80,000,000 shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. However, as of September 30, 2021, and December 31, 2020, the Company had an accumulated deficit of $553.0 million and $540.7 million, respectively, and at September 30, 2021, the Company had cash, cash equivalents and restricted cash of approximately $20.8 million. Based on the Company’s current business plan, management believes that existing cash and cash equivalents, revenues and other cash inflows will be insufficient to fund its operations for one year from the date these financial statements are issued, and therefore, substantial doubt about the entity’s ability to continue as a going concern exists. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has recorded losses from operations since its inception and if the Company does not successfully obtain regulatory approval and commercialize any of its product candidates, the Company will not be able to achieve profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there is substantial doubt that its current capital resources, which consist of cash and cash equivalents are sufficient to fund operations through at least the next twelve months from the date the accompanying interim financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of additional equity, incurrence of debt, the entry into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals. Moreover, if the Company does not obtain such additional funds, there could be substantial doubt about its ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to the Company's stockholders and other security holders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s sources of revenue during the nine months ended September 30, 2021 are from its supply agreement with Takeda Development Center Americas, Inc. (“Takeda”) and from its licensing agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply of Product</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised product in supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised services in license agreement with MD Anderson consists of certain option and license rights to the Company’s intellectual property. If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement and when management believes the license to its intellectual property and products has stand-alone value, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone Payments</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Royalty Revenues</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the nine months ended September 30, 2021 as compared to the significant accounting policies described in Note 1 of the “Notes to Consolidated Financial Statements” in the Company’s audited financial statements included in its Annual Report for the fiscal year ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all short-term, highly liquid investments with maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:61.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,767 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the Asset Purchase Agreement with M.D. Anderson on April 14, 2020, $1.5 million of the cash proceeds received are subject to certain escrow provisions and recorded as restricted cash. The funds are required to be held for a period of 18 months subsequent to the April 14, 2020 closing date or until any outstanding claims against the escrow are resolved, and are listed as Restricted cash at September 30, 2021, and December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disposition of Assets and Liabilities Held for Sale and Held for Use</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, in connection with the Company's restructuring plan, Management elected to seek an exit to its leased manufacturing facility in Houston, Texas. As a result of this decision, the Company reclassified the assets and liabilities associated with the leased facility as held for sale. The reclassified assets and liabilities included a right-of-use asset of $0.5 million, property and equipment of $2.3 million and the related lease liability of $0.7 million. Based on the cost to exit the lease and the net realizable value of the related assets the Company recognized an impairment charge of $1.3 million in the fourth quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposal of the assets and liabilities associated with the Houston facility was completed on February 26, 2021. Under the terms of the agreement a third party assumed the lease for the facility. In addition, the third party paid $1.1 million to the Company for substantially all of the property, and equipment associated with the location. The consideration included $0.9 million in cash and an unsecured promissory note for $0.2 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2021 the Company entered an agreement to terminate its sub-lease of the South San Francisco office space contingent upon consent of the prime lessor. Under the terms of the agreement, the company agreed to pay a lease termination fee of $0.9 million while the security deposit of $0.2 million was returned to the Company in June 2021. The decision to exit this lease reflects the ability of the Company to carry on administrative function remotely. On March 26, 2021, the Company met all of the conditions of the agreement and disposed of substantially all of the assets and liabilities associated with the lease including the right-of-use asset of $0.6 million, leased equipment with net book value less than $0.1 million, and the related lease liability of $1 million. The Company recognized a loss on termination of $0.5 million during the first quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued patient treatment costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical research costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the 2021 presentation. Expenses related to clinical studies totaling $1.2 million were reclassified from Accrued Other to Accrued Clinical Research Costs. Another $0.1 million for expenses related to drug manufacture and professional consulting services were reclassified from Accrued Other to Accrued Manufacturing Costs and Accrued Professional Services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Derivatives</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding warrants are classified as liabilities in the accompanying condensed consolidated balance sheets as they are exercisable for multiple underlying instruments that are potentially redeemable. The Company accounts for these warrants at fair value on the date of issuance and are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.</span></div><div style="margin-top:12pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">rivate Placement Option</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a security purchase agreement that contains a call option on preferred shares that are puttable outside the control of the Company. The Company recorded the option as a liability and measured the fair value of the option at the time of issuance. The Company will re-measure the option to fair value at each balance sheet date and record changes in fair value in other income (expense) in the accompanying condensed consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of these liabilities using a binomial lattice model, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.</span></div><div style="margin-top:12pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying condensed consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified within mezzanine equity in the accompanying condensed consolidated balance sheets. At all other times, preferred shares are classified within stockholders’ deficit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company’s obligation to make lease payments arising from the lease, and a corresponding right-of-use (“ROU”) asset which represents the Company’s right to use an underlying asset during the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company's incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards include disclosure requirements around fair values used for certain financial instruments and establish a fair value hierarchy. The three-tier hierarchy defines a three-tiered valuation hierarchy for disclosures that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market, as described further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inputs are classified into the following hierarchy:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 Inputs - unobservable inputs for the assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuance Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity issuance costs represent costs paid to third parties in order to obtain equity financing. The costs related to preferred and common stock have been netted against the proceeds of the equity issuances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) and Net Income (Loss) per Share of Common Stock Attributable to Common Stockholders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic and diluted net income (loss) per share attributable to common stockholders is based on the more dilutive method of either the two-class method or the treasury stock method. Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. Diluted net income (loss) per share gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period, assuming the exercise of all “in-the-money” common stock equivalents based on the average market price during the period. For periods of a net loss position, since the participating securities are not contractually obligated to share losses with the common stockholders, the diluted loss per share is calculated similarly to basic loss per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share - basic:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net income (loss) per share </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 4pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,194,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of common stock equivalents were excluded from the computations of diluted net income (loss) per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Equivalents:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible series 1 preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,520,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,340,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,675,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,675,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,965,337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,089,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Requirements and Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which modifies fair value disclosures and removes some disclosure requirements for both public and private companies. In addition, public companies are subject to some new disclosure requirements which requires to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standards Update No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.</span></div> 2 1 1 200000000 40000000 40000000 80000000 Basis of PresentationThe accompanying unaudited condensed financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). -553000000 -540700000 20800000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s sources of revenue during the nine months ended September 30, 2021 are from its supply agreement with Takeda Development Center Americas, Inc. (“Takeda”) and from its licensing agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply of Product</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised product in supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised services in license agreement with MD Anderson consists of certain option and license rights to the Company’s intellectual property. If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement and when management believes the license to its intellectual property and products has stand-alone value, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone Payments</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Royalty Revenues</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all short-term, highly liquid investments with maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:61.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,767 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:61.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,767 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19266000 35495000 1501000 1501000 20767000 36996000 1500000 P18M 500000 2300000 700000 1300000 1100000 900000 200000 900000 -200000 600000 100000 1000000 -500000 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued patient treatment costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical research costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 278000 1071000 2507000 899000 1658000 1562000 252000 41000 289000 279000 355000 313000 5339000 4165000 1200000 100000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Derivatives</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding warrants are classified as liabilities in the accompanying condensed consolidated balance sheets as they are exercisable for multiple underlying instruments that are potentially redeemable. The Company accounts for these warrants at fair value on the date of issuance and are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.</span></div> <div style="margin-top:12pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">rivate Placement Option</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a security purchase agreement that contains a call option on preferred shares that are puttable outside the control of the Company. The Company recorded the option as a liability and measured the fair value of the option at the time of issuance. The Company will re-measure the option to fair value at each balance sheet date and record changes in fair value in other income (expense) in the accompanying condensed consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of these liabilities using a binomial lattice model, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.</span></div> <div style="margin-top:12pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying condensed consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally </span></div>redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified within mezzanine equity in the accompanying condensed consolidated balance sheets. At all other times, preferred shares are classified within stockholders’ deficit. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company’s obligation to make lease payments arising from the lease, and a corresponding right-of-use (“ROU”) asset which represents the Company’s right to use an underlying asset during the lease term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company's incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards include disclosure requirements around fair values used for certain financial instruments and establish a fair value hierarchy. The three-tier hierarchy defines a three-tiered valuation hierarchy for disclosures that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market, as described further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inputs are classified into the following hierarchy:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 Inputs - unobservable inputs for the assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of these instruments.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuance Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity issuance costs represent costs paid to third parties in order to obtain equity financing. The costs related to preferred and common stock have been netted against the proceeds of the equity issuances.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) and Net Income (Loss) per Share of Common Stock Attributable to Common Stockholders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic and diluted net income (loss) per share attributable to common stockholders is based on the more dilutive method of either the two-class method or the treasury stock method. Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. Diluted net income (loss) per share gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period, assuming the exercise of all “in-the-money” common stock equivalents based on the average market price during the period. For periods of a net loss position, since the participating securities are not contractually obligated to share losses with the common stockholders, the diluted loss per share is calculated similarly to basic loss per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share - basic:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: undistributed earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic net income (loss) per share </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 4pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,108,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,194,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,050,603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of common stock equivalents were excluded from the computations of diluted net income (loss) per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Equivalents:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible series 1 preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,520,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,340,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,616,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,675,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,675,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,965,337 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,089,697 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1233000 -887000 -12236000 -26505000 469000 0 0 0 764000 -887000 -12236000 -26505000 10108388 5059779 10086246 5050603 0.08 -0.18 -1.21 -5.25 764000 -887000 -12236000 -26505000 10108388 5059779 10086246 5050603 86280 0 0 0 10194668 5059779 10086246 5050603 0.07 -0.18 -1.21 -5.25 4520000 5340000 11616080 5750000 9675000 9675000 1985277 1142470 168980 182227 27965337 22089697 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Requirements and Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which modifies fair value disclosures and removes some disclosure requirements for both public and private companies. In addition, public companies are subject to some new disclosure requirements which requires to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standards Update No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.</span></div> FAI<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> VALU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> MEASUREMENTS AND INVESTMENT SECURITIES</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, $1.5 million of restricted cash on the Company's balance sheet is held in a money market fund.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds, U.S. Treasury, U.S. government agency-backed securities, corporate debt securities and municipal bonds are valued based on various observable inputs such as benchmark yields, reported trades, broker/dealer quotes, benchmark securities and bids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Derivative Liability and Private Placement Option Liability </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial liabilities recorded at fair value on a recurring basis include the fair values of the warrant derivative liability and the private placement option liability. As of September 30, 2021, the fair values of the warrant derivative liability and the private placement option liability are classified as current liabilities in the accompanying condensed consolidated balance sheets. These liabilities will be shown as current liabilities on the balance sheet when it is deemed more probable than not by management to be exercised within one year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs used to determine estimated fair value (Level 3) of the warrants include the fair value of the underlying stock relative to the warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the warrants, and risk-free interest rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs used to determine estimated fair value (Level 3) of the private placement option include the fair value of the underlying stock relative to the preferred share conversion price and warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the call option on the preferred shares and expected term of the warrants, and risk-free interest rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:27.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ending balance of the Level 3 financial instruments presented above represents the Company's best estimate of valuation and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds and treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,463 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table> 12481000 0 0 27463000 0 0 12481000 0 0 27463000 0 0 1500000 1500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:27.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at September 30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value at December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private placement option liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Derivative Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Option Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.0095 0.0046 0.9500 0.9000 P4Y10M20D P5Y7M20D 0.0133 0.0077 0.9500 0.9000 P7Y P7Y 0 0 7842000 0 0 10345000 0 0 2800000 0 0 7803000 0 0 10642000 0 0 18148000 LEASES <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company determines whether an arrangement is a lease at its inception. Operating leases relate primarily to office space and manufacturing facilities with remaining lease terms of one year to seven years, some of which include options to extend the lease term for up to five years. Management considered the options in determining the lease term used to establish the Company's ROU assets and lease liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate based on the information available at lease commencement date was used to determine the present value of lease payments. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased asset</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P1Y P7Y P5Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of lease cost are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased asset</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 18000 16000 54000 0 5000 5000 17000 1000 169000 56000 668000 0 235000 53000 476000 1000 427000 130000 1215000 PUBLIC OFFERING AND PRIVATE PLACEMENT<div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">November 2020 Underwritten Offering</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company closed an underwritten offering of 1,040,000 shares of its common stock, pre-funded warrants to purchase 3,109,378 shares of its common stock, and accompanying common warrants to purchase up to an aggregate of 4,149,378 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $6.025 and $6.024 for each pre-funded warrant. The pre-funded warrants were immediately exercisable at a price of $0.001 per share of common stock. The common warrants were immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance, or November 3, 2025. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company were approximately $25.0 million before deducting underwriting discounts and commissions and other offering expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Public Offering</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 575,000 shares of the Series 1 Redeemable Convertible Non-Voting Preferred Stock of the Company (the “Series 1 Preferred Stock”) and warrants (the “Public Warrants”) to purchase up to 5,750,000 shares of its common stock. Each share of Series 1 Preferred Stock was sold together with a warrant to purchase 10 shares of common stock at a combined price to the public of $100.00. Under certain circumstances, each warrant to purchase 10 shares of common stock will be exercisable, at the irrevocable election of the holder, for one share of Series 1 Preferred Stock. The offering closed on August 21, 2019, and the net proceeds to the Company from the Offering was approximately $53.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding any proceeds that the Company may receive upon exercise of the Public Warrants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Public Warrants sold in the Offering have an exercise price of $13.00 per share of common stock or, in certain circumstances, for $130.00 per share of Series 1 Preferred Stock, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Public Warrants will be immediately exercisable upon issuance, provided that the holder will be prohibited, subject to certain exceptions, from exercising a warrant for shares of common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 19.99% upon 61 days’ notice to the Company. The Public Warrants will expire on August 21, 2026, unless exercised prior to that date. No Public Warrants have been exercised as of the balance sheet date.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Placement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue in a private placement (i) 350,000 shares of its Series 2 Redeemable Convertible Non-Voting Preferred Stock (the “Series 2 Preferred Stock”), at a purchase price of $100.00 per share, and related warrants (the “Private Warrants”) to purchase up to 2,800,000 shares of common stock at an exercise price of $10.00 per share, and (ii) 250,000 shares of its Series 3 Redeemable Convertible Non-Voting Preferred Stock (the “Series 3 Preferred Stock” and, together with the Series 1 Preferred Stock and Series 2 Preferred Stock, the “Preferred Stock”), at a purchase price of $140.00 per share, and related warrants (also, “Private Warrants”) to purchase up to 875,000 shares of common stock at an exercise price of $14.00 per share. The purchase and sale of the securities issuable under the private placement agreement may occur in two or more separate closings, each to be conducted at the Purchasers’ discretion within five days’ notice to the Company. The purchase and sale were subject to the Company’s obtaining stockholder approval for additional authorized shares of Common Stock or a reverse stock split (the “Required Stockholder Approval”), which occurred in the first quarter of 2020. The right of the Purchasers to purchase such securities will expire two and a half years after the Required Stockholder Approval, on June 15, 2022, with respect to the Series 2 Preferred Stock, and three years after such stockholder approval, on January 15, 2023, with respect to the Series 3 Preferred Stock, if not exercised prior to that date. No shares have been exercised as of the balance sheet date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $11.2 million in option proceeds, net of offering costs, upon the execution of the Securities Purchase Agreement. Total offering costs incurred by the Company related to the Public Warrants, Private Warrants and options amounted to $3.0 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in the Company's common stock price and the time to expiration of both warrant derivative and private placement option had the most impact on the fair value. The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant Derivative Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Option Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,803 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,642 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1040000 3109378 4149378 1 1 6.025 6.024 0.001 6.50 P5Y 25000000 575000 5750000 10 100.00 10 53800000 13.00 130.00 0.0999 0.1999 P61D 0 350000 100.00 2800000 10.00 250000 140.00 875000 14.00 11200000 3000000 10345000 7803000 18148000 -2503000 -5003000 -7506000 7842000 2800000 10642000 REDEEMABLE CONVERTIBLE PREFERRED STOCK<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company sold Series 1 Preferred Stock pursuant to the Offering. The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.01, of which the Company has designated 1,517,500 shares as Series 1 redeemable convertible non-voting preferred stock, 350,000 shares as Series 2 redeemable convertible non-voting preferred stock and 250,000 shares as Series 3 redeemable convertible non-voting preferred stock. There were 452,000 shares of Series 1 preferred stock issued and outstanding as of September 30, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no shares of Series 2 or 3 preferred stock issued and outstanding as of September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company classified the Series 1 Preferred Stock as mezzanine equity, as the Series 1 preferred stock will be redeemable at the option of the holders upon passage of time, which is outside of the Company’s control to prevent.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series 1 Preferred Stock is not currently redeemable and is only redeemable upon the fifth (5th) anniversary of the initial issue date or upon a fundamental change in a redemption price. The Company does not believe a fundamental change is considered probable until it occurs. Subsequent adjustment of the amount presented in mezzanine equity to its redemption amount is unnecessary if it is not probable that the instrument will become redeemable. As of September 30, 2021, the Company did not accrete the Series 1 Preferred Stock to its redemption amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Optional Conversion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Preferred Stock is initially convertible into 10 shares of Common Stock. The conversion price at which Preferred Stock may be converted into shares of common stock, is subject to adjustment in connection with certain specified events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the applicable Transition Date (defined below), at any time on or after the date that is the fifth (5th) anniversary of the initial issue date of the applicable series of preferred stock, all or any portion of the preferred stock is redeemable at the option of the holder at a redemption price of $100.00 per share (for Series 1 and Series 2 Preferred Stock) and $140.00 per share (for Series 3 Preferred Stock).  The “Transition Date” means:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to the Series 1 preferred stock, the first date following August 21, 2021, on which each of the Conditions (as defined below) is met (the “Series 1 Transition Date”);</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to the Series 2 preferred stock, the first date following the six-month anniversary of the Series 1 Transition Date on which each of the Conditions is met (the “Series 2 Transition Date”); and</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to the Series 3 preferred stock, the first date following the six-month anniversary of the Series 2 Transition Date on which each of the Conditions is met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The “Conditions” mean: (1) the closing price of the Company’s common stock has been equal to or exceeded $25.00 per share for 180 calendar days (for determining if the Conditions are met for the Series 1 preferred stock and Series 2 preferred stock) and $35.00 per share (for the Series 3 preferred stock) for 180 calendar days; (2) the 50-day average trading volume of the Company’s common stock on the Nasdaq stock market is greater than 50,000 shares; and (3) a Phase 3 or Phase 2 pivotal clinical trial for one of the Company’s CAR T product candidates has been initiated, meaning that at least one clinical trial site has been activated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Preferred Stock will be entitled to receive dividends equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the applicable Transition Date, in the event of a liquidation, dissolution, winding up or deemed liquidation, holders of the Preferred Stock will receive a payment equal to the applicable per share purchase price of their Preferred Stock before any proceeds are distributed to the holders of Common Stock. The liquidation preferences, protective voting provisions and redemption rights of the Preferred Stock will terminate upon the occurrence of certain events.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of Preferred Stock will generally have no voting rights, except to the extent expressly provided in the Company’s certificate of incorporation or as otherwise required by law.</span></div> 10000000 0.01 1517500 350000 250000 452000 452000 0 0 0 0 10 100.00 140.00 25.00 P180D 35.00 P180D P50D 50000 SHARE-BASED COMPENSATION PLANS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Plans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has five share-based compensation plans, including the 2019 Equity Incentive Plan (the "2019 Plan"), which was adopted in June 2019. Each plan authorizes the granting of shares of common stock and options to purchase common stock to employees and directors of the Company, as well as non-employee consultants, and allows the holder of the option to purchase common stock at a stated exercise price. The only plan under which the Company may currently grant equity awards is the 2019 Plan although there remain outstanding awards under the other four plans. Options vest according to the terms of the grant, which may be immediately or based on the passage of time, generally over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMzcxMzZmN2ViOTQ1Mzg5YjYzMzRlY2FlYTc4NzE5L3NlYzo0ZTM3MTM2ZjdlYjk0NTM4OWI2MzM0ZWNhZWE3ODcxOV81Mi9mcmFnOmE1MzZhZjA1ZDg4ZjQ1M2RiNzI3NmNmYTNhNDRmOGFjL3RleHRyZWdpb246YTUzNmFmMDVkODhmNDUzZGI3Mjc2Y2ZhM2E0NGY4YWNfOTM0NTg0ODg0MTA1NQ_03837108-c015-42c1-ab40-72d8e2a44fa5">two</span> to four years, and have a term of up to 10 years. Unexercised stock options terminate on the expiration date of the grant. The Company recognizes the share-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019 Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2019 Plan, is designed to secure and retain the services of the Company’s employees and directors. The 2019 Plan is successor to and continuation of the 2014 Equity Incentive Plan, as amended, the (“2014 Plan”), and no additional awards may be issued from the 2014 Plan. Subject to adjustment for certain changes in the Company’s capitalization, the aggregate number of shares of common stock that may be issued under the 2019 Plan (the “Share Reserve”) will not exceed the sum of (i) 250,000 new shares, (ii) an additional 600,000 shares that were approved at the Company’s Special Meeting of Stockholders in January 2020, (iii) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2020, (iv) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2021 and plus (v) the Prior Plans’ Returning Shares, as defined in the 2019 Plan documents, in an amount not to exceed 600,540 shares, including any stock award granted under the 2014 Plan, 2011 Stock Option Plan, as amended, or 2006 Stock Option Plan, as amended, that were outstanding as of the date the 2019 Plan were approved by the Company's stockholders, as such shares become available from time to time.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following shares of common stock (the “2019 Plan Returning Shares”) will also become available again for issuance under the 2019 Plan: (i) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award is settled in cash; and (iii) any shares issued pursuant to a stock award granted under the 2019 Plan that are forfeited back to or repurchased by the Company because of a failure to vest.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock awards.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for all stock plans during the nine months ended September 30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and Inducement Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,587 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock award activity for all stock plans during the nine months ended September 30, 2021: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Awards and Units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,980 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2014 Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2014 Employee Stock Purchase Plan (the “ESPP”) provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase the Company's common stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to 55,000 shares of the Company’s common stock to participating employees and allows eligible employees to purchase shares of common stock at a 15% discount from the lesser of the grant date or purchase date fair market value. During the nine-month periods ended September 30, 2020, there were 9,526 shares purchased by employees under the ESPP. The ESPP has been suspended since December 2020, resulting in the inactivity during the first, second, and third quarter of 2021. As of September 30, 2021, there were 18,488 shares available for issuance under the ESPP.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity within the ESPP follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions from employees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of option grants is determined using the Black-Scholes option-pricing model and has been estimated with the following weighted-average assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by classification for the three and nine months ended September 30, 2021 and 2020 are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>At September 30, 2021, total compensation cost not yet recognized was $4.0 million and the weighted-average period over which this amount is expected to be recognized is 1.6 years. 5 P4Y P10Y 250000 600000 500000 500000 600540 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity for all stock plans during the nine months ended September 30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options and Inducement Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,968 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,587 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1510968 823000 0 348691 1985277 466587 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock award activity for all stock plans during the nine months ended September 30, 2021: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Awards and Units</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,980 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 129861 136626 95001 2506 168980 55000 0.15 9526 18488 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity within the ESPP follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions from employees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 116000 0 70000 0 113000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of option grants is determined using the Black-Scholes option-pricing model and has been estimated with the following weighted-average assumptions: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.0084 0.0118 0.9035 0.8178 P5Y7M17D P6Y10D 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by classification for the three and nine months ended September 30, 2021 and 2020 are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 296000 668000 829000 1877000 557000 938000 1748000 2616000 853000 1606000 2577000 4493000 4000000 P1Y7M6D COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development and Co-Commercialization Agreement - Adaptimmune Therapeutics plc</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 16, 2016, the Company entered into a Co-Development and Co-Commercialization Agreement with and Adaptimmune Therapeutics plc (“Adaptimmune”) in order to facilitate a staged collaboration to evaluate, develop and commercialize next generation T cell therapies. Under the Agreement, the parties agreed to evaluate the Company’s GoTCR technology (inducible MyD88/CD40 co-stimulation, or “iMC”) with Adaptimmune’s affinity-optimized SPEAR® T cells for the potential to create enhanced TCR product candidates. Depending on results of the preclinical proof-of-concept phase, the parties expect to progress to a two-target co-development and co-commercialization phase. To the extent necessary, and in furtherance of the parties’ proof-of-concept and co-development efforts, the parties granted each other a royalty-free, non-transferable, non-exclusive license covering their respective technologies for purposes of facilitating such proof-of-concept and co-development efforts. In addition, as to covered therapies developed under the agreement, the parties granted each other a reciprocal exclusive license for the commercialization of such therapies. With respect to any joint commercialization of a covered therapy, the parties agreed to negotiate in good faith the commercially reasonable terms of a co-commercialization agreement. The parties also agreed that any such agreement shall provide for, among other things, equal sharing of the costs of any such joint commercialization and the calculation of profit shares as set forth in the Agreement. The Agreement will expire on a country-by-country basis once the parties cease commercialization of the T cell therapies covered by the Agreement, unless earlier terminated by either party for material breach, non-performance or cessation of development, bankruptcy/insolvency, or failure to progress to co-development phase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements - Baylor</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2008, 2010, 2014 and 2016, the Company and Baylor College of Medicine (“BCM”) entered into license agreements pursuant to which the Company obtained exclusive rights to certain technologies and patent rights owned by BCM. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2014 license agreement, the Company is required to pay BCM a low annual maintenance fee on each anniversary of the agreement date. The Company is also required to make royalty payments in the low single digits, subject to certain annual minimums, on net sales of products covered by the license, and, to the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is also required to pay BCM a percentage in the low double-digits on all non-royalty income received from sublicensing revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company determined that $0.6 million of sublicense expense was incurred in 2019 through 2020 related to the Company's obligation to pay BCM a percentage of sublicense revenue earned by the Company under the 2014 license agreement. Management evaluated the impact of the adjustment and determined that the amount was immaterial to the consolidated financial statements for the current year and prior years. As such, the entire amount of $0.6 million was recorded during the second quarter in 2021. During the third quarter of 2021, the Company earned additional sublicense revenue and therefore recorded an obligation to pay the sublicense expense of $0.5 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - Agensys, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2015, the Company and Agensys, Inc. (“Agensys”), entered into a license agreement (the “Agensys Agreement”), pursuant to which (i) Agensys granted the Company, within the field of cell and gene therapy of diseases in humans, an exclusive, worldwide license and sublicense to its patent rights directed to prostate stem cell antigen 1 (“PSCA”) and related antibodies, and (ii) the Company granted Agensys a non-exclusive, fully paid license to the Company’s patents directed to inventions that were made by the Company in the course of developing the Company’s licensed products, solely for use with Agensys therapeutic products containing a soluble antibody that binds to PSCA or, to the extent not based upon the Company’s other proprietary technology, to non-therapeutic applications of antibodies not used within the field. As consideration for the rights granted to the Company under the Agreement, the Company agreed to pay to Agensys a non-refundable upfront fee of $3.0 million, which was included in license fee expense. The Company is also required to make aggregate milestone payments to Agensys of up to (i) $5.0 million upon the first achievement of certain specified clinical milestones for its licensed products, (ii) $50.0 million upon the achievement of certain specified clinical milestones for each licensed product, and (iii) $75.0 million upon the achievement of certain sales milestones for each licensed product. The Agreement additionally provides that the Company will pay to Agensys a royalty that ranges from the mid to high single digits based on the level of annual net sales of licensed products by the Company, its affiliates or permitted sublicensees. The royalty payments are subject to reduction under specified circumstances. These milestone and royalty payments will be expensed as incurred. Under the Agreement, Agensys also was granted the option to obtain an exclusive license, on a product-by-product basis, from the Company to commercialize in Japan each licensed product developed under the Agensys Agreement that has completed a phase 2 clinical trial. As to each such licensed product, if Agensys or its affiliate, Astellas Pharma, Inc., exercises the option, the Agensys Agreement provides that the Company will be paid an option exercise fee of $5.0 million. In addition, the Agensys Agreement provides that the Company will be paid a royalty that ranges from the mid to high single digits based on the level of annual net sales in Japan of each such licensed product. If the option is exercised, the aggregate milestone payments payable by the Company to Agensys, described above with respect to each licensed product, would be reduced by up to an aggregate of $65.0 million upon the achievement of certain specified clinical and sales milestones. The Agensys Agreement will terminate upon the expiration of the last royalty term for the products covered by the Agensys Agreement, which is the earlier of (i) the date of expiration or abandonment of the last valid claim within the licensed patent rights covering any licensed products under the Agreement, (ii) the expiration of regulatory exclusivity as to a licensed product, and (iii) 10 years after the first commercial sale of a licensed product. Either party may terminate the Agensys Agreement upon a material breach by the other party that remains uncured following 60 days after the date of written notice of such breach (or 30 days if such material breach is related to failure to make payment of amounts due under the Agensys Agreement) or upon certain insolvency events. In addition, Agensys may terminate the Agensys Agreement immediately upon written notice to the Company if the Company or any of its affiliates or permitted sublicensees commences an interference proceeding or challenges the validity or enforceability of any of Agensys’ patent rights.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement - BioVec</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2015, the Company and BioVec Pharma, Inc. (“BioVec”) entered into a license agreement (the “BioVec Agreement”) pursuant to which BioVec agreed to supply the Company with certain proprietary cell lines and granted to the Company a non-exclusive, worldwide license to certain of its patent rights and related know-how related to such proprietary cell lines. As consideration for the products supplied and rights granted to the Company under the BioVec Agreement, the Company agreed to pay to BioVec an upfront fee of $100,000 within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMzcxMzZmN2ViOTQ1Mzg5YjYzMzRlY2FlYTc4NzE5L3NlYzo0ZTM3MTM2ZjdlYjk0NTM4OWI2MzM0ZWNhZWE3ODcxOV81NS9mcmFnOjYwZmNjMmMyMTIwOTRhNDliZmEwMDUwY2Y1YmFlNDM0L3RleHRyZWdpb246NjBmY2MyYzIxMjA5NGE0OWJmYTAwNTBjZjViYWU0MzRfNzc2Nw_81fe2a57-7391-4bc8-aa90-9ed4e6c1951a">ten</span> business days of the effective date of the BioVec Agreement and a fee of $300,000 within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlMzcxMzZmN2ViOTQ1Mzg5YjYzMzRlY2FlYTc4NzE5L3NlYzo0ZTM3MTM2ZjdlYjk0NTM4OWI2MzM0ZWNhZWE3ODcxOV81NS9mcmFnOjYwZmNjMmMyMTIwOTRhNDliZmEwMDUwY2Y1YmFlNDM0L3RleHRyZWdpb246NjBmY2MyYzIxMjA5NGE0OWJmYTAwNTBjZjViYWU0MzRfNzg1Mw_578ce42f-a2f6-45c6-b334-cab6890ebe36">ten</span> business days of its receipt of the first release of GMP lot of the products licensed under the BioVec Agreement. In addition, the Company agreed to pay to BioVec an annual fee of $150,000, commencing 30 days following the first filing of an Investigational New Drug Application or its foreign equivalent, for a product covered by the license; with such annual fees being creditable against any royalties payable by the Company to BioVec under the BioVec Agreement. The Company also is required to make a $250,000 milestone payment to BioVec for each of the first three licensed products to enter into a clinical phase trial and one-time milestone payments of $2.0 million upon receipt of a registration granted by the Federal Drug Administration or European Medicines Agency on each of the Company’s first three licensed products. The BioVec Agreement additionally provides that the Company will pay to BioVec a royalty in the low single digits on net sales of products covered by the BioVec Agreement. The Company may also grant sublicensees under the licensed patent rights and know-how to third parties for limited purposes related to the use, sale and other exploitation of the products licensed under the BioVec Agreement. The BioVec Agreement will continue until terminated. The BioVec Agreement may be terminated by the Company, in its sole discretion, at any time upon 90 days written notice to BioVec. Either party may terminate the BioVec Agreement in the event of a breach by the other party of any material provision of the BioVec Agreement that remains uncured on the date that is 60 days after written notice of such failure or upon certain insolvency events that remain uncured following the date that is 30 days after the date of written notice to a party regarding such insolvency event.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Supply Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, the Company entered a multi-year supply agreement with Takeda Development Center Americas, Inc. (Takeda). The Company will supply Takeda with rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The Company generated revenue of $0.7 million for the nine months ended September 30, 2021, with the possibility of additional revenue from future sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MD Anderson License Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2019, the Company entered into a licensing and commercialization agreement with MD Anderson (the "2019 MD Anderson License Agreement"). Under the 2019 MD Anderson License Agreement, the Company granted MD Anderson non-exclusive rights in certain Caspase-9 and related technologies and use of a small molecule known as rimiducid in a certain cell therapy program. During the fourth quarter of 2019, and under the terms of the 2019 MD Anderson License Agreement, MD Anderson exercised an option to grant a non-exclusive sublicense of the rights licensed by the Company to MD Anderson. MD Anderson, as a result of this exercise, granted a sublicense that entitled the Company to receive as consideration an upfront license fee as well as additional future annual maintenance fees, milestone payments related to the achievement of pre-specified development, regulatory, and commercialization events, and royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2021, the Company entered into a second licensing and commercialization agreement with MD Anderson (the “2021 MD Anderson Option and License Agreement”). Under the 2021 MD Anderson Option and License Agreement, MD Anderson has certain rights to the use of CaspaCIDe and rimiducid in product candidates nominated under the agreement, and receives an option to a non-exclusive license to the technology in these candidates. Upon exercise of an option and sublicense of a product candidate to a third party, the Company is entitled to a sublicense execution fee, a percentage of certain consideration received by MD Anderson for the sublicense, an annual maintenance fee, and a percentage royalty on net sales of licensed products. During the third quarter of 2021, the Company received an upfront payment of $5.0 million upon execution of the agreement and granted licenses for two nominated programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2019, Bellicum was served with a second amended complaint indicating that the Company had been added as an additional defendant in an ongoing civil tort lawsuit, captioned Kelly v. Children’s Hospital of Los Angeles et al., filed in the Los Angeles County Superior Court, Case No. BC681477. On July 10, 2019 plaintiffs filed a third amended complaint seeking unspecified monetary damages including punitive damages and alleging claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability - failure to warn, breach of express warranty and products liability design or manufacturing defect. Bellicum filed a demurrer and motion to strike plaintiffs’ third amended complaint, which were granted in part on August 5, 2020 with the Court dismissing (without prejudice) all claims against Bellicum with the exception of the breach of express warranty and products liability design or manufacturing defect causes of action. The Court also granted Bellicum’s motion to strike plaintiffs’ claim for punitive damages. On September 15, 2020, plaintiffs filed a fourth amended complaint alleging the same causes of action and damages against Bellicum as were pled in the third amended complaint. On November 3, 2020 Bellicum filed a demurrer and motion to strike the fourth amended complaint, which currently is set for hearing on November 23, 2021. A trial date has not been set in the case.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with NASDAQ Listing Rules</span></div>On May 5, 2021, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”), that the Company was in breach of Listing Rule 5450(b)(2)(A) (the “Market Value Rule”), for continued listing on The Nasdaq Capital Market because the market value of the Company's listed securities for 30 consecutive business days had been less than $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a grace period until November 1, 2021, to regain compliance with the Market Value Rule by maintaining a market value of listed securities $35 million or more for a minimum of 10 consecutive business days any time prior to November 1, 2021. 600000 600000 500000 3000000 5000000 50000000 75000000 5000000 65000000 P10Y P60D P30D 100000 300000 150000 P30D 250000 3 2000000 3 P90D P60D P30D 700000 5000000 XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
9 Months Ended
Sep. 30, 2021
Oct. 27, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-36783  
Entity Registrant Name BELLICUM PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-1450200  
Entity Address, Address Line One 3730 Kirby Drive  
Entity Address, Address Line Two Suite 1200  
Entity Address, City or Town Houston  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 77098  
City Area Code 832  
Local Phone Number 384-1100  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol BLCM  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Shares Outstanding (in shares)   8,397,803
Entity Central Index Key 0001358403  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Security Exchange Name NASDAQ  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 19,266 $ 35,495
Restricted cash 1,501 1,501
Accounts receivable, interest and other receivables 556 2
Prepaid expenses and other current assets 1,019 802
Assets held for sale 0 1,643
Total current assets 22,342 39,443
Operating lease right-of-use assets 0 645
Property and equipment, net 27 189
Other assets 4 307
Total assets 22,373 40,584
Current liabilities:    
Accounts payable 521 891
Accrued expenses and other current liabilities 5,339 4,165
Warrant derivative liability 7,842 10,345
Private placement option liability 2,800 7,803
Current portion of lease liabilities 0 825
Liabilities held for sale 0 672
Total current liabilities 16,502 24,701
Long-term lease liabilities 0 344
Total liabilities 16,502 25,045
Commitments and contingencies
Redeemable preferred stock: $0.01 par value; 10,000,000 shares authorized, Series 1 redeemable convertible preferred stock, $0.01 par value, 1,517,500 shares authorized at September 30, 2021 and December 31, 2020; 452,000 shares issued and outstanding at September 30, 2021 and December 31, 2020 18,036 18,036
Stockholders’ deficit:    
Common stock, $0.01 par value; 80,000,000 shares authorized at September 30, 2021 and December 31, 2020; 8,465,549 shares issued and 8,397,803 shares outstanding at September 30, 2021; 8,385,650 shares issued and 8,317,904 shares outstanding at December 31, 2020 84 84
Treasury stock: 67,746 shares held at September 30, 2021 and December 31, 2020 (5,056) (5,056)
Additional paid-in capital 546,138 543,561
Accumulated other comprehensive loss (348) (339)
Accumulated deficit (552,983) (540,747)
Total stockholders’ deficit (12,165) (2,497)
Total liabilities, redeemable preferred stock and stockholders' deficit $ 22,373 $ 40,584
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 80,000,000 80,000,000
Common stock, issued (in shares) 8,465,549 8,385,650
Common stock, outstanding (in shares) 8,397,803 8,317,904
Treasury stock, shares (in shares) 67,746 67,746
Convertible Preferred Stock    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 1,517,500 1,517,500
Preferred stock, shares issued (in shares) 452,000 452,000
Preferred stock, outstanding (in shares) 452,000 452,000
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues        
Revenues $ 5,000 $ 0 $ 5,700 $ 0
Operating expenses        
Research and development 6,348 8,140 19,531 30,346
General and administrative 1,681 4,163 5,458 12,095
Total operating expenses 8,029 12,303 24,989 42,441
(Gain) loss on dispositions, net 14 0 478 (3,761)
Loss from operations (3,043) (12,303) (19,767) (38,680)
Other income (expense):        
Interest income 6 10 24 392
Interest expense 0 (725) (4) (2,473)
Change in fair value of warrant and private placement option liabilities 4,264 12,131 7,506 14,256
Other income 6 0 5 0
Total other income (expense) 4,276 11,416 7,531 12,175
Net income (loss) 1,233 (887) (12,236) (26,505)
Less: undistributed earnings to participating securities (469) 0 0 0
Net income (loss) attributable to common shareholders $ 764 $ (887) $ (12,236) $ (26,505)
Net income (loss) per common share attributable to common shareholders, basic (in dollars per share) $ 0.08 $ (0.18) $ (1.21) $ (5.25)
Net income (loss) per common share attributable to common shareholders, diluted (in dollars per shares) $ 0.07 $ (0.18) $ (1.21) $ (5.25)
Weighted-average shares outstanding, basic (in shares) 10,108,388 5,059,779 10,086,246 5,050,603
Weighted-average shares outstanding, diluted (in shares) 10,194,668 5,059,779 10,086,246 5,050,603
Other comprehensive loss:        
Foreign currency translation adjustment $ (9) $ 36 $ (9) $ (26)
Net comprehensive income (loss) 1,224 (851) (12,245) (26,531)
Supply agreement        
Revenues        
Revenues 0 0 700 0
License revenue        
Revenues        
Revenues $ 5,000 $ 0 $ 5,000 $ 0
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Series 1 Preferred
Preferred stock, beginning balance (in shares) at Dec. 31, 2019             538,000
Preferred stock, beginning balance at Dec. 31, 2019             $ 21,468
Increase (Decrease) in Temporary Equity [Roll Forward]              
Conversion of redeemable preferred stock into common stock (in shares)   40,000         (4,000)
Conversion of redeemable convertible preferred stock into common stock $ 160 $ 1   $ 159     $ (160)
Preferred stock, ending balance (in shares) at Mar. 31, 2020             534,000
Preferred stock, ending balance at Mar. 31, 2020             $ 21,308
Balance, beginning of period (in shares) at Dec. 31, 2019   5,076,593 67,746        
Balance, beginning of period at Dec. 31, 2019 (26,217) $ 507 $ (5,056) 511,684 $ (533,025) $ (327)  
Increase (Decrease) in Stockholders' Equity              
1-for-10 Reverse Stock Split 0 $ (457)   457      
Share-based compensation 1,323     1,323      
Issuance of common stock upon vesting of restricted stock units (in shares)   1,045          
Conversion of redeemable preferred stock into common stock (in shares)   40,000         (4,000)
Conversion of redeemable convertible preferred stock into common stock 160 $ 1   159     $ (160)
Comprehensive income (loss) 17,563       17,576 (13)  
Balance, end of period (in shares) at Mar. 31, 2020   5,117,638 67,746        
Balance, end of period at Mar. 31, 2020 (7,171) $ 51 $ (5,056) 513,623 (515,449) (340)  
Preferred stock, beginning balance (in shares) at Dec. 31, 2019             538,000
Preferred stock, beginning balance at Dec. 31, 2019             $ 21,468
Preferred stock, ending balance (in shares) at Sep. 30, 2020             534,000
Preferred stock, ending balance at Sep. 30, 2020             $ 21,308
Balance, beginning of period (in shares) at Dec. 31, 2019   5,076,593 67,746        
Balance, beginning of period at Dec. 31, 2019 (26,217) $ 507 $ (5,056) 511,684 (533,025) (327)  
Increase (Decrease) in Stockholders' Equity              
Comprehensive income (loss) (26,531)            
Balance, end of period (in shares) at Sep. 30, 2020   5,127,525 67,746        
Balance, end of period at Sep. 30, 2020 (48,030) $ 51 $ (5,056) 516,858 (559,530) (353)  
Preferred stock, beginning balance (in shares) at Mar. 31, 2020             534,000
Preferred stock, beginning balance at Mar. 31, 2020             $ 21,308
Preferred stock, ending balance (in shares) at Jun. 30, 2020             534,000
Preferred stock, ending balance at Jun. 30, 2020             $ 21,308
Balance, beginning of period (in shares) at Mar. 31, 2020   5,117,638 67,746        
Balance, beginning of period at Mar. 31, 2020 (7,171) $ 51 $ (5,056) 513,623 (515,449) (340)  
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 1,564     1,564      
Issuance of common stock - Employee Stock Purchase Plan (in shares)   9,526          
Issuance of common stock - Employee Stock Purchase Plan 65 $ 0   65      
Issuance of common stock upon vesting of restricted stock units (in shares)   361          
Comprehensive income (loss) (43,243)       (43,194) (49)  
Balance, end of period (in shares) at Jun. 30, 2020   5,127,525 67,746        
Balance, end of period at Jun. 30, 2020 (48,785) $ 51 $ (5,056) 515,252 (558,643) (389)  
Preferred stock, ending balance (in shares) at Sep. 30, 2020             534,000
Preferred stock, ending balance at Sep. 30, 2020             $ 21,308
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 1,606     1,606      
Comprehensive income (loss) (851)       (887) 36  
Balance, end of period (in shares) at Sep. 30, 2020   5,127,525 67,746        
Balance, end of period at Sep. 30, 2020 (48,030) $ 51 $ (5,056) 516,858 (559,530) (353)  
Preferred stock, beginning balance (in shares) at Dec. 31, 2020             452,000
Preferred stock, beginning balance at Dec. 31, 2020 18,036           $ 18,036
Preferred stock, ending balance (in shares) at Mar. 31, 2021             452,000
Preferred stock, ending balance at Mar. 31, 2021             $ 18,036
Balance, beginning of period (in shares) at Dec. 31, 2020   8,385,650 67,746        
Balance, beginning of period at Dec. 31, 2020 (2,497) $ 84 $ (5,056) 543,561 (540,747) (339)  
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 903     903      
Exercise of restricted stock unit awards (in shares)   369          
Exercise of restricted stock unit awards 0            
Comprehensive income (loss) (11,267)       (11,267)    
Balance, end of period (in shares) at Mar. 31, 2021   8,386,019 67,746        
Balance, end of period at Mar. 31, 2021 (12,861) $ 84 $ (5,056) 544,464 (552,014) (339)  
Preferred stock, beginning balance (in shares) at Dec. 31, 2020             452,000
Preferred stock, beginning balance at Dec. 31, 2020 18,036           $ 18,036
Preferred stock, ending balance (in shares) at Sep. 30, 2021             452,000
Preferred stock, ending balance at Sep. 30, 2021 18,036           $ 18,036
Balance, beginning of period (in shares) at Dec. 31, 2020   8,385,650 67,746        
Balance, beginning of period at Dec. 31, 2020 (2,497) $ 84 $ (5,056) 543,561 (540,747) (339)  
Increase (Decrease) in Stockholders' Equity              
Comprehensive income (loss) (12,245)            
Balance, end of period (in shares) at Sep. 30, 2021   8,465,549 67,746        
Balance, end of period at Sep. 30, 2021 (12,165) $ 84 $ (5,056) 546,138 (552,983) (348)  
Preferred stock, beginning balance (in shares) at Mar. 31, 2021             452,000
Preferred stock, beginning balance at Mar. 31, 2021             $ 18,036
Preferred stock, ending balance (in shares) at Jun. 30, 2021             452,000
Preferred stock, ending balance at Jun. 30, 2021             $ 18,036
Balance, beginning of period (in shares) at Mar. 31, 2021   8,386,019 67,746        
Balance, beginning of period at Mar. 31, 2021 (12,861) $ 84 $ (5,056) 544,464 (552,014) (339)  
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 821     821      
Exercise of restricted stock unit awards (in shares)   79,530          
Exercise of restricted stock unit awards 0            
Comprehensive income (loss) (2,202)       (2,202)    
Balance, end of period (in shares) at Jun. 30, 2021   8,465,549 67,746        
Balance, end of period at Jun. 30, 2021 (14,242) $ 84 $ (5,056) 545,285 (554,216) (339)  
Preferred stock, ending balance (in shares) at Sep. 30, 2021             452,000
Preferred stock, ending balance at Sep. 30, 2021 18,036           $ 18,036
Increase (Decrease) in Stockholders' Equity              
Share-based compensation 853     853      
Comprehensive income (loss) 1,224       1,233 (9)  
Balance, end of period (in shares) at Sep. 30, 2021   8,465,549 67,746        
Balance, end of period at Sep. 30, 2021 $ (12,165) $ 84 $ (5,056) $ 546,138 $ (552,983) $ (348)  
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (12,236) $ (26,505)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 2,577 4,493
Depreciation and amortization expense 90 1,229
Change in fair value of warrant and private placement option liabilities (7,506) (14,256)
(Gain) loss on dispositions, net 478 (3,761)
Amortization of right-of-use assets 33 297
Accretion of lease liability 23 371
Amortization of deferred issuance costs 0 550
Changes in operating assets and liabilities:    
Accounts receivable, interest and other receivables (181) 178
Prepaid expenses and other assets (216) 103
Accounts payable (370) (1,345)
Accrued liabilities and other 230 (4,629)
Net cash used in operating activities (17,078) (43,275)
Cash flows from investing activities:    
Proceeds from sale of property and equipment, net 900 14,909
Purchases of property and equipment (7) (807)
Net cash provided by investing activities 893 14,102
Cash flows from financing activities:    
Payment on debt 0 (10,000)
Proceeds from issuance of stock from employee stock purchase plan 0 65
Payment on financing lease obligations (35) (56)
Net cash used in financing activities (35) (9,991)
Effect of exchange rate changes on cash (9) (26)
Net change in cash, cash equivalents, and restricted cash (16,229) (39,190)
Cash, cash equivalents and restricted cash at beginning of period 36,996 93,816
Cash, cash equivalents and restricted cash at end of period 20,767 54,626
Supplemental cash flow information:    
Cash paid during the period for interest 0 1,973
Non-cash investing and financing activities:    
Purchases of property and equipment in accounts payables and accrued liabilities 0 859
Leasehold improvements paid by landlord 0 113
Conversion of redeemable preferred stock into common stock 0 160
Reclassification of property and equipment, net to assets held for sale $ 0 $ 199
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Bellicum Pharmaceuticals, Inc. (“Bellicum”) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer. Bellicum is devoting substantially all of its present efforts to developing next-generation CAR-T product candidates in cellular immunotherapy.

Bellicum has two wholly-owned subsidiaries, Bellicum Pharma Limited, a private limited company organized under the laws of the United Kingdom, and Bellicum Pharma GmbH, a private limited liability company organized under German law. Both were formed for the purpose of developing product candidates in Europe. Bellicum, Bellicum Pharma Limited and Bellicum Pharma GmbH are collectively referred to herein as the “Company”. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation.

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company’s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.
Reverse Stock Split
On February 5, 2020, the Company filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to (i) effect a reverse stock split of all issued and outstanding shares of the Company’s common stock at a ratio of 1-for-10 and (ii) reduce the number of authorized shares of the Company’s common stock from 200,000,000 to 40,000,000. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented.

On June 15, 2020, the Company filed with the Secretary of State of the State of Delaware a Second Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 40,000,000 shares to 80,000,000 shares.
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2020, as filed with the SEC on March 31, 2021.
The accompanying interim condensed financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. However, as of September 30, 2021, and December 31, 2020, the Company had an accumulated deficit of $553.0 million and $540.7 million, respectively, and at September 30, 2021, the Company had cash, cash equivalents and restricted cash of approximately $20.8 million. Based on the Company’s current business plan, management believes that existing cash and cash equivalents, revenues and other cash inflows will be insufficient to fund its operations for one year from the date these financial statements are issued, and therefore, substantial doubt about the entity’s ability to continue as a going concern exists. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has recorded losses from operations since its inception and if the Company does not successfully obtain regulatory approval and commercialize any of its product candidates, the Company will not be able to achieve profitability.

The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry.

The Company believes that there is substantial doubt that its current capital resources, which consist of cash and cash equivalents are sufficient to fund operations through at least the next twelve months from the date the accompanying interim financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of additional equity, incurrence of debt, the entry into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals. Moreover, if the Company does not obtain such additional funds, there could be substantial doubt about its ability to continue as a going concern and increased risk of insolvency, which could result in a total loss of investment to the Company's stockholders and other security holders.
Use of Estimates
The preparation of the interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.
Revenue Recognition
The Company’s sources of revenue during the nine months ended September 30, 2021 are from its supply agreement with Takeda Development Center Americas, Inc. (“Takeda”) and from its licensing agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”).
Supply of Product
The promised product in supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.
Licenses of Intellectual Property
The promised services in license agreement with MD Anderson consists of certain option and license rights to the Company’s intellectual property. If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement and when management believes the license to its intellectual property and products has stand-alone value, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the
Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments
At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.
Significant Accounting Policies
There have been no significant changes to the accounting policies during the nine months ended September 30, 2021 as compared to the significant accounting policies described in Note 1 of the “Notes to Consolidated Financial Statements” in the Company’s audited financial statements included in its Annual Report for the fiscal year ended December 31, 2020.
Cash, Cash Equivalents and Restricted Cash
The Company considers all short-term, highly liquid investments with maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.
(in thousands)September 30, 2021December 31, 2020
Cash and cash equivalents$19,266 $35,495 
Restricted cash1,501 1,501 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$20,767 $36,996 
In connection with the closing of the Asset Purchase Agreement with M.D. Anderson on April 14, 2020, $1.5 million of the cash proceeds received are subject to certain escrow provisions and recorded as restricted cash. The funds are required to be held for a period of 18 months subsequent to the April 14, 2020 closing date or until any outstanding claims against the escrow are resolved, and are listed as Restricted cash at September 30, 2021, and December 31, 2020.
Disposition of Assets and Liabilities Held for Sale and Held for Use
In the fourth quarter of 2020, in connection with the Company's restructuring plan, Management elected to seek an exit to its leased manufacturing facility in Houston, Texas. As a result of this decision, the Company reclassified the assets and liabilities associated with the leased facility as held for sale. The reclassified assets and liabilities included a right-of-use asset of $0.5 million, property and equipment of $2.3 million and the related lease liability of $0.7 million. Based on the cost to exit the lease and the net realizable value of the related assets the Company recognized an impairment charge of $1.3 million in the fourth quarter of 2020.

The disposal of the assets and liabilities associated with the Houston facility was completed on February 26, 2021. Under the terms of the agreement a third party assumed the lease for the facility. In addition, the third party paid $1.1 million to the Company for substantially all of the property, and equipment associated with the location. The consideration included $0.9 million in cash and an unsecured promissory note for $0.2 million.
On March 15, 2021 the Company entered an agreement to terminate its sub-lease of the South San Francisco office space contingent upon consent of the prime lessor. Under the terms of the agreement, the company agreed to pay a lease termination fee of $0.9 million while the security deposit of $0.2 million was returned to the Company in June 2021. The decision to exit this lease reflects the ability of the Company to carry on administrative function remotely. On March 26, 2021, the Company met all of the conditions of the agreement and disposed of substantially all of the assets and liabilities associated with the lease including the right-of-use asset of $0.6 million, leased equipment with net book value less than $0.1 million, and the related lease liability of $1 million. The Company recognized a loss on termination of $0.5 million during the first quarter of 2021.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other liabilities consist of the following:
(in thousands)September 30, 2021December 31, 2020
Accrued payroll$278 $1,071 
Accrued patient treatment costs2,507 899 
Accrued clinical research costs1,658 1,562 
Accrued manufacturing costs252 41 
Accrued professional services289 279 
Accrued other355 313 
Total accrued expenses and other current liabilities $5,339 $4,165 

Certain prior year amounts have been reclassified to conform to the 2021 presentation. Expenses related to clinical studies totaling $1.2 million were reclassified from Accrued Other to Accrued Clinical Research Costs. Another $0.1 million for expenses related to drug manufacture and professional consulting services were reclassified from Accrued Other to Accrued Manufacturing Costs and Accrued Professional Services.
Warrant Derivatives
Freestanding warrants are classified as liabilities in the accompanying condensed consolidated balance sheets as they are exercisable for multiple underlying instruments that are potentially redeemable. The Company accounts for these warrants at fair value on the date of issuance and are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit.

The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Private Placement Option
The Company has entered into a security purchase agreement that contains a call option on preferred shares that are puttable outside the control of the Company. The Company recorded the option as a liability and measured the fair value of the option at the time of issuance. The Company will re-measure the option to fair value at each balance sheet date and record changes in fair value in other income (expense) in the accompanying condensed consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.

The Company estimates the fair value of these liabilities using a binomial lattice model, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Preferred Stock
Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying condensed consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally
redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified within mezzanine equity in the accompanying condensed consolidated balance sheets. At all other times, preferred shares are classified within stockholders’ deficit.
Operating Leases
At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company’s obligation to make lease payments arising from the lease, and a corresponding right-of-use (“ROU”) asset which represents the Company’s right to use an underlying asset during the lease term.

Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company's incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.
Fair Value of Financial Instruments
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.

Accounting standards include disclosure requirements around fair values used for certain financial instruments and establish a fair value hierarchy. The three-tier hierarchy defines a three-tiered valuation hierarchy for disclosures that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market, as described further in Note 2.
Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.
These inputs are classified into the following hierarchy:
Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;
Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and
Level 3 Inputs - unobservable inputs for the assets.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of these instruments.
Financial Instruments and Credit Risks
Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.
Equity Issuance Costs
Equity issuance costs represent costs paid to third parties in order to obtain equity financing. The costs related to preferred and common stock have been netted against the proceeds of the equity issuances.
Net Income (Loss) and Net Income (Loss) per Share of Common Stock Attributable to Common Stockholders

Basic and diluted net income (loss) per share attributable to common stockholders is based on the more dilutive method of either the two-class method or the treasury stock method. Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. Diluted net income (loss) per share gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period, assuming the exercise of all “in-the-money” common stock equivalents based on the average market price during the period. For periods of a net loss position, since the participating securities are not contractually obligated to share losses with the common stockholders, the diluted loss per share is calculated similarly to basic loss per share.

For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

The following table sets forth the computation of basic and diluted earnings per share:

Three Months EndedNine Months Ended
(in thousands, except share and per share amounts)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Net income (loss) per share - basic:
Net income (loss)
$1,233 $(887)$(12,236)$(26,505)
Less: undistributed earnings to participating securities(469)— — — 
Net income (loss) attributable to common shareholders$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Basic net income (loss) per share $0.08 $(0.18)$(1.21)$(5.25)
Net income (loss) per share - diluted:
Net income (loss) attributable to common shareholders, basic$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Effect of dilutive securities:
Stock options and restricted stock units86,280 — — — 
Weighted-average shares outstanding, diluted
10,194,668 5,059,779 10,086,246 5,050,603 
Diluted net income (loss) per share$0.07 $(0.18)$(1.21)$(5.25)
The following outstanding shares of common stock equivalents were excluded from the computations of diluted net income (loss) per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.
September 30, 2021September 30, 2020
Common Stock Equivalents:Number of Shares
Redeemable convertible series 1 preferred stock4,520,000 5,340,000 
Warrants to purchase common stock11,616,080 5,750,000 
Private placement option9,675,000 9,675,000 
Options to purchase common stock1,985,277 1,142,470 
Unvested shares of restricted stock units168,980 182,227 
Total common stock equivalents27,965,337 22,089,697 

New Accounting Requirements and Disclosures

Fair Value Measurement

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies fair value disclosures and removes some disclosure requirements for both public and private companies. In addition, public companies are subject to some new disclosure requirements which requires to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.

Financial Instruments – Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.
Investments

In January 2020, the FASB issued Accounting Standards Update No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES
 
Investment Securities

The following table presents the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)
Level 1
Level 2
 Level 3
Level 1Level 2 Level 3
Cash equivalents:
Money market funds and treasury bills$12,481 $— $— $27,463 $— $— 
Total cash equivalents$12,481 $— $— $27,463 $— $— 
As of September 30, 2021 and December 31, 2020, $1.5 million of restricted cash on the Company's balance sheet is held in a money market fund.

Money market funds, U.S. Treasury, U.S. government agency-backed securities, corporate debt securities and municipal bonds are valued based on various observable inputs such as benchmark yields, reported trades, broker/dealer quotes, benchmark securities and bids.

Warrant Derivative Liability and Private Placement Option Liability

The Company's financial liabilities recorded at fair value on a recurring basis include the fair values of the warrant derivative liability and the private placement option liability. As of September 30, 2021, the fair values of the warrant derivative liability and the private placement option liability are classified as current liabilities in the accompanying condensed consolidated balance sheets. These liabilities will be shown as current liabilities on the balance sheet when it is deemed more probable than not by management to be exercised within one year.

Inputs used to determine estimated fair value (Level 3) of the warrants include the fair value of the underlying stock relative to the warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the warrants, and risk-free interest rates.

The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:

September 30, 2021December 31, 2020
Risk-free interest rate
0.95%0.46%
Volatility
95.00%90.00%
Expected term (years)
4.895.64

Inputs used to determine estimated fair value (Level 3) of the private placement option include the fair value of the underlying stock relative to the preferred share conversion price and warrant exercise price at the valuation measurement date, volatility of the price of the underlying stock, the expected term of the call option on the preferred shares and expected term of the warrants, and risk-free interest rates.
The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:
September 30, 2021December 31, 2020
Risk-free interest rate1.33 %0.77 %
Volatility95.00 %90.00 %
Expected term (years)7.007.00

The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Warrant derivative liability$— $— $7,842 $— $— $10,345 
Private placement option liability— — 2,800 — — 7,803 
Total fair value$— $— $10,642 $— $— $18,148 

The ending balance of the Level 3 financial instruments presented above represents the Company's best estimate of valuation and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.21.2
LEASES
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
LEASES LEASES
The Company determines whether an arrangement is a lease at its inception. Operating leases relate primarily to office space and manufacturing facilities with remaining lease terms of one year to seven years, some of which include options to extend the lease term for up to five years. Management considered the options in determining the lease term used to establish the Company's ROU assets and lease liabilities.

As most of the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate based on the information available at lease commencement date was used to determine the present value of lease payments.

Components of lease cost are as follows:
Three Months EndedNine Months Ended
(in thousands)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Finance lease cost:
Amortization of leased asset$— $18 $16 $54 
Interest on lease liabilities— 17 
Operating lease cost169 56 668 
Short-term lease cost— 235 53 476 
Total lease cost$$427 $130 $1,215 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.21.2
PUBLIC OFFERING AND PRIVATE PLACEMENT
9 Months Ended
Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]  
PUBLIC OFFERING AND PRIVATE PLACEMENT PUBLIC OFFERING AND PRIVATE PLACEMENT
November 2020 Underwritten Offering
In November 2020, the Company closed an underwritten offering of 1,040,000 shares of its common stock, pre-funded warrants to purchase 3,109,378 shares of its common stock, and accompanying common warrants to purchase up to an aggregate of 4,149,378 shares of its common stock. Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $6.025 and $6.024 for each pre-funded warrant. The pre-funded warrants were immediately exercisable at a price of $0.001 per share of common stock. The common warrants were immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance, or November 3, 2025. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company were approximately $25.0 million before deducting underwriting discounts and commissions and other offering expenses.
August 2019 Public Offering
On August 16, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 575,000 shares of the Series 1 Redeemable Convertible Non-Voting Preferred Stock of the Company (the “Series 1 Preferred Stock”) and warrants (the “Public Warrants”) to purchase up to 5,750,000 shares of its common stock. Each share of Series 1 Preferred Stock was sold together with a warrant to purchase 10 shares of common stock at a combined price to the public of $100.00. Under certain circumstances, each warrant to purchase 10 shares of common stock will be exercisable, at the irrevocable election of the holder, for one share of Series 1 Preferred Stock. The offering closed on August 21, 2019, and the net proceeds to the Company from the Offering was approximately $53.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding any proceeds that the Company may receive upon exercise of the Public Warrants.

All of the Public Warrants sold in the Offering have an exercise price of $13.00 per share of common stock or, in certain circumstances, for $130.00 per share of Series 1 Preferred Stock, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Public Warrants will be immediately exercisable upon issuance, provided that the holder will be prohibited, subject to certain exceptions, from exercising a warrant for shares of common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 19.99% upon 61 days’ notice to the Company. The Public Warrants will expire on August 21, 2026, unless exercised prior to that date. No Public Warrants have been exercised as of the balance sheet date.

Private Placement

On August 16, 2019, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue in a private placement (i) 350,000 shares of its Series 2 Redeemable Convertible Non-Voting Preferred Stock (the “Series 2 Preferred Stock”), at a purchase price of $100.00 per share, and related warrants (the “Private Warrants”) to purchase up to 2,800,000 shares of common stock at an exercise price of $10.00 per share, and (ii) 250,000 shares of its Series 3 Redeemable Convertible Non-Voting Preferred Stock (the “Series 3 Preferred Stock” and, together with the Series 1 Preferred Stock and Series 2 Preferred Stock, the “Preferred Stock”), at a purchase price of $140.00 per share, and related warrants (also, “Private Warrants”) to purchase up to 875,000 shares of common stock at an exercise price of $14.00 per share. The purchase and sale of the securities issuable under the private placement agreement may occur in two or more separate closings, each to be conducted at the Purchasers’ discretion within five days’ notice to the Company. The purchase and sale were subject to the Company’s obtaining stockholder approval for additional authorized shares of Common Stock or a reverse stock split (the “Required Stockholder Approval”), which occurred in the first quarter of 2020. The right of the Purchasers to purchase such securities will expire two and a half years after the Required Stockholder Approval, on June 15, 2022, with respect to the Series 2 Preferred Stock, and three years after such stockholder approval, on January 15, 2023, with respect to the Series 3 Preferred Stock, if not exercised prior to that date. No shares have been exercised as of the balance sheet date.

The Company received $11.2 million in option proceeds, net of offering costs, upon the execution of the Securities Purchase Agreement. Total offering costs incurred by the Company related to the Public Warrants, Private Warrants and options amounted to $3.0 million.

Decrease in the Company's common stock price and the time to expiration of both warrant derivative and private placement option had the most impact on the fair value. The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:
(in thousands)Warrant Derivative LiabilityPrivate Placement Option LiabilityTotal
Balance, December 31, 2020
$10,345 $7,803 $18,148 
Change in fair value(2,503)(5,003)(7,506)
Balance, September 30, 2021
$7,842 $2,800 $10,642 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.21.2
REDEEMABLE CONVERTIBLE PREFERRED STOCK
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
REDEEMABLE CONVERTIBLE PREFERRED STOCK REDEEMABLE CONVERTIBLE PREFERRED STOCK
In August 2019, the Company sold Series 1 Preferred Stock pursuant to the Offering. The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.01, of which the Company has designated 1,517,500 shares as Series 1 redeemable convertible non-voting preferred stock, 350,000 shares as Series 2 redeemable convertible non-voting preferred stock and 250,000 shares as Series 3 redeemable convertible non-voting preferred stock. There were 452,000 shares of Series 1 preferred stock issued and outstanding as of September 30, 2021. There were no shares of Series 2 or 3 preferred stock issued and outstanding as of September 30, 2021.

As of September 30, 2021, the Company classified the Series 1 Preferred Stock as mezzanine equity, as the Series 1 preferred stock will be redeemable at the option of the holders upon passage of time, which is outside of the Company’s control to prevent.

The Series 1 Preferred Stock is not currently redeemable and is only redeemable upon the fifth (5th) anniversary of the initial issue date or upon a fundamental change in a redemption price. The Company does not believe a fundamental change is considered probable until it occurs. Subsequent adjustment of the amount presented in mezzanine equity to its redemption amount is unnecessary if it is not probable that the instrument will become redeemable. As of September 30, 2021, the Company did not accrete the Series 1 Preferred Stock to its redemption amount.

Optional Conversion

Each share of Preferred Stock is initially convertible into 10 shares of Common Stock. The conversion price at which Preferred Stock may be converted into shares of common stock, is subject to adjustment in connection with certain specified events.

Redemption

Until the applicable Transition Date (defined below), at any time on or after the date that is the fifth (5th) anniversary of the initial issue date of the applicable series of preferred stock, all or any portion of the preferred stock is redeemable at the option of the holder at a redemption price of $100.00 per share (for Series 1 and Series 2 Preferred Stock) and $140.00 per share (for Series 3 Preferred Stock).  The “Transition Date” means:

With respect to the Series 1 preferred stock, the first date following August 21, 2021, on which each of the Conditions (as defined below) is met (the “Series 1 Transition Date”);

With respect to the Series 2 preferred stock, the first date following the six-month anniversary of the Series 1 Transition Date on which each of the Conditions is met (the “Series 2 Transition Date”); and

With respect to the Series 3 preferred stock, the first date following the six-month anniversary of the Series 2 Transition Date on which each of the Conditions is met.

The “Conditions” mean: (1) the closing price of the Company’s common stock has been equal to or exceeded $25.00 per share for 180 calendar days (for determining if the Conditions are met for the Series 1 preferred stock and Series 2 preferred stock) and $35.00 per share (for the Series 3 preferred stock) for 180 calendar days; (2) the 50-day average trading volume of the Company’s common stock on the Nasdaq stock market is greater than 50,000 shares; and (3) a Phase 3 or Phase 2 pivotal clinical trial for one of the Company’s CAR T product candidates has been initiated, meaning that at least one clinical trial site has been activated.

Dividends

Shares of Preferred Stock will be entitled to receive dividends equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.

Liquidation

Until the applicable Transition Date, in the event of a liquidation, dissolution, winding up or deemed liquidation, holders of the Preferred Stock will receive a payment equal to the applicable per share purchase price of their Preferred Stock before any proceeds are distributed to the holders of Common Stock. The liquidation preferences, protective voting provisions and redemption rights of the Preferred Stock will terminate upon the occurrence of certain events.
Voting

Shares of Preferred Stock will generally have no voting rights, except to the extent expressly provided in the Company’s certificate of incorporation or as otherwise required by law.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION PLANS SHARE-BASED COMPENSATION PLANS
Share-Based Compensation Plans

The Company has five share-based compensation plans, including the 2019 Equity Incentive Plan (the "2019 Plan"), which was adopted in June 2019. Each plan authorizes the granting of shares of common stock and options to purchase common stock to employees and directors of the Company, as well as non-employee consultants, and allows the holder of the option to purchase common stock at a stated exercise price. The only plan under which the Company may currently grant equity awards is the 2019 Plan although there remain outstanding awards under the other four plans. Options vest according to the terms of the grant, which may be immediately or based on the passage of time, generally over two to four years, and have a term of up to 10 years. Unexercised stock options terminate on the expiration date of the grant. The Company recognizes the share-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period.

2019 Equity Incentive Plan

The 2019 Plan, is designed to secure and retain the services of the Company’s employees and directors. The 2019 Plan is successor to and continuation of the 2014 Equity Incentive Plan, as amended, the (“2014 Plan”), and no additional awards may be issued from the 2014 Plan. Subject to adjustment for certain changes in the Company’s capitalization, the aggregate number of shares of common stock that may be issued under the 2019 Plan (the “Share Reserve”) will not exceed the sum of (i) 250,000 new shares, (ii) an additional 600,000 shares that were approved at the Company’s Special Meeting of Stockholders in January 2020, (iii) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2020, (iv) an additional 500,000 shares that were approved at the Company's Annual Meeting of Stockholders in June 2021 and plus (v) the Prior Plans’ Returning Shares, as defined in the 2019 Plan documents, in an amount not to exceed 600,540 shares, including any stock award granted under the 2014 Plan, 2011 Stock Option Plan, as amended, or 2006 Stock Option Plan, as amended, that were outstanding as of the date the 2019 Plan were approved by the Company's stockholders, as such shares become available from time to time.

The following shares of common stock (the “2019 Plan Returning Shares”) will also become available again for issuance under the 2019 Plan: (i) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii) any shares subject to a stock award granted under the 2019 Plan that are not issued because such stock award is settled in cash; and (iii) any shares issued pursuant to a stock award granted under the 2019 Plan that are forfeited back to or repurchased by the Company because of a failure to vest.

The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other stock awards.
The following table summarizes the stock option activity for all stock plans during the nine months ended September 30, 2021:
Options and Inducement Awards
Outstanding at December 31, 2020
1,510,968 
Granted
823,000 
Exercised
— 
Forfeited
(348,691)
Outstanding at September 30, 2021
1,985,277 
Exercisable at September 30, 2021
466,587 

The following table summarizes the stock award activity for all stock plans during the nine months ended September 30, 2021:
Restricted Stock Awards and Units
Outstanding at December 31, 2020
129,861 
Granted
136,626 
Vested
(95,001)
Forfeited
(2,506)
Outstanding at September 30, 2021
168,980 

2014 Employee Stock Purchase Plan

The 2014 Employee Stock Purchase Plan (the “ESPP”) provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase the Company's common stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to 55,000 shares of the Company’s common stock to participating employees and allows eligible employees to purchase shares of common stock at a 15% discount from the lesser of the grant date or purchase date fair market value. During the nine-month periods ended September 30, 2020, there were 9,526 shares purchased by employees under the ESPP. The ESPP has been suspended since December 2020, resulting in the inactivity during the first, second, and third quarter of 2021. As of September 30, 2021, there were 18,488 shares available for issuance under the ESPP.

A summary of activity within the ESPP follows:
Nine Months Ended
(in thousands)September 30, 2021September 30, 2020
Deductions from employees$— $116 
Share-based compensation expense recognized— 70 
Remaining share-based compensation expense— 113 


Share-Based Compensation Expense

The fair value of option grants is determined using the Black-Scholes option-pricing model and has been estimated with the following weighted-average assumptions:
Nine Months Ended
September 30, 2021September 30, 2020
Risk-free interest rate
0.84 %1.18 %
Volatility
90.35 %81.78 %
Expected life (years)
5.636.03
Expected dividend yield
— — 
Share-based compensation expense by classification for the three and nine months ended September 30, 2021 and 2020 are as follows:
Three Months Ended
Nine Months Ended
(in thousands)
September 30, 2021
September 30, 2020
September 30, 2021
September 30, 2020
Research and development$296 $668 $829 $1,877 
General and administrative557 938 1,748 2,616 
     Total$853 $1,606 $2,577 $4,493 
At September 30, 2021, total compensation cost not yet recognized was $4.0 million and the weighted-average period over which this amount is expected to be recognized is 1.6 years.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Co-Development and Co-Commercialization Agreement - Adaptimmune Therapeutics plc

On December 16, 2016, the Company entered into a Co-Development and Co-Commercialization Agreement with and Adaptimmune Therapeutics plc (“Adaptimmune”) in order to facilitate a staged collaboration to evaluate, develop and commercialize next generation T cell therapies. Under the Agreement, the parties agreed to evaluate the Company’s GoTCR technology (inducible MyD88/CD40 co-stimulation, or “iMC”) with Adaptimmune’s affinity-optimized SPEAR® T cells for the potential to create enhanced TCR product candidates. Depending on results of the preclinical proof-of-concept phase, the parties expect to progress to a two-target co-development and co-commercialization phase. To the extent necessary, and in furtherance of the parties’ proof-of-concept and co-development efforts, the parties granted each other a royalty-free, non-transferable, non-exclusive license covering their respective technologies for purposes of facilitating such proof-of-concept and co-development efforts. In addition, as to covered therapies developed under the agreement, the parties granted each other a reciprocal exclusive license for the commercialization of such therapies. With respect to any joint commercialization of a covered therapy, the parties agreed to negotiate in good faith the commercially reasonable terms of a co-commercialization agreement. The parties also agreed that any such agreement shall provide for, among other things, equal sharing of the costs of any such joint commercialization and the calculation of profit shares as set forth in the Agreement. The Agreement will expire on a country-by-country basis once the parties cease commercialization of the T cell therapies covered by the Agreement, unless earlier terminated by either party for material breach, non-performance or cessation of development, bankruptcy/insolvency, or failure to progress to co-development phase.

License Agreements - Baylor

In 2008, 2010, 2014 and 2016, the Company and Baylor College of Medicine (“BCM”) entered into license agreements pursuant to which the Company obtained exclusive rights to certain technologies and patent rights owned by BCM.

Under the 2014 license agreement, the Company is required to pay BCM a low annual maintenance fee on each anniversary of the agreement date. The Company is also required to make royalty payments in the low single digits, subject to certain annual minimums, on net sales of products covered by the license, and, to the extent the Company enters into a sublicensing agreement relating to a licensed product, the Company is also required to pay BCM a percentage in the low double-digits on all non-royalty income received from sublicensing revenue.

During the second quarter of 2021, the Company determined that $0.6 million of sublicense expense was incurred in 2019 through 2020 related to the Company's obligation to pay BCM a percentage of sublicense revenue earned by the Company under the 2014 license agreement. Management evaluated the impact of the adjustment and determined that the amount was immaterial to the consolidated financial statements for the current year and prior years. As such, the entire amount of $0.6 million was recorded during the second quarter in 2021. During the third quarter of 2021, the Company earned additional sublicense revenue and therefore recorded an obligation to pay the sublicense expense of $0.5 million.
License Agreement - Agensys, Inc.

On December 10, 2015, the Company and Agensys, Inc. (“Agensys”), entered into a license agreement (the “Agensys Agreement”), pursuant to which (i) Agensys granted the Company, within the field of cell and gene therapy of diseases in humans, an exclusive, worldwide license and sublicense to its patent rights directed to prostate stem cell antigen 1 (“PSCA”) and related antibodies, and (ii) the Company granted Agensys a non-exclusive, fully paid license to the Company’s patents directed to inventions that were made by the Company in the course of developing the Company’s licensed products, solely for use with Agensys therapeutic products containing a soluble antibody that binds to PSCA or, to the extent not based upon the Company’s other proprietary technology, to non-therapeutic applications of antibodies not used within the field. As consideration for the rights granted to the Company under the Agreement, the Company agreed to pay to Agensys a non-refundable upfront fee of $3.0 million, which was included in license fee expense. The Company is also required to make aggregate milestone payments to Agensys of up to (i) $5.0 million upon the first achievement of certain specified clinical milestones for its licensed products, (ii) $50.0 million upon the achievement of certain specified clinical milestones for each licensed product, and (iii) $75.0 million upon the achievement of certain sales milestones for each licensed product. The Agreement additionally provides that the Company will pay to Agensys a royalty that ranges from the mid to high single digits based on the level of annual net sales of licensed products by the Company, its affiliates or permitted sublicensees. The royalty payments are subject to reduction under specified circumstances. These milestone and royalty payments will be expensed as incurred. Under the Agreement, Agensys also was granted the option to obtain an exclusive license, on a product-by-product basis, from the Company to commercialize in Japan each licensed product developed under the Agensys Agreement that has completed a phase 2 clinical trial. As to each such licensed product, if Agensys or its affiliate, Astellas Pharma, Inc., exercises the option, the Agensys Agreement provides that the Company will be paid an option exercise fee of $5.0 million. In addition, the Agensys Agreement provides that the Company will be paid a royalty that ranges from the mid to high single digits based on the level of annual net sales in Japan of each such licensed product. If the option is exercised, the aggregate milestone payments payable by the Company to Agensys, described above with respect to each licensed product, would be reduced by up to an aggregate of $65.0 million upon the achievement of certain specified clinical and sales milestones. The Agensys Agreement will terminate upon the expiration of the last royalty term for the products covered by the Agensys Agreement, which is the earlier of (i) the date of expiration or abandonment of the last valid claim within the licensed patent rights covering any licensed products under the Agreement, (ii) the expiration of regulatory exclusivity as to a licensed product, and (iii) 10 years after the first commercial sale of a licensed product. Either party may terminate the Agensys Agreement upon a material breach by the other party that remains uncured following 60 days after the date of written notice of such breach (or 30 days if such material breach is related to failure to make payment of amounts due under the Agensys Agreement) or upon certain insolvency events. In addition, Agensys may terminate the Agensys Agreement immediately upon written notice to the Company if the Company or any of its affiliates or permitted sublicensees commences an interference proceeding or challenges the validity or enforceability of any of Agensys’ patent rights.

License Agreement - BioVec

On June 10, 2015, the Company and BioVec Pharma, Inc. (“BioVec”) entered into a license agreement (the “BioVec Agreement”) pursuant to which BioVec agreed to supply the Company with certain proprietary cell lines and granted to the Company a non-exclusive, worldwide license to certain of its patent rights and related know-how related to such proprietary cell lines. As consideration for the products supplied and rights granted to the Company under the BioVec Agreement, the Company agreed to pay to BioVec an upfront fee of $100,000 within ten business days of the effective date of the BioVec Agreement and a fee of $300,000 within ten business days of its receipt of the first release of GMP lot of the products licensed under the BioVec Agreement. In addition, the Company agreed to pay to BioVec an annual fee of $150,000, commencing 30 days following the first filing of an Investigational New Drug Application or its foreign equivalent, for a product covered by the license; with such annual fees being creditable against any royalties payable by the Company to BioVec under the BioVec Agreement. The Company also is required to make a $250,000 milestone payment to BioVec for each of the first three licensed products to enter into a clinical phase trial and one-time milestone payments of $2.0 million upon receipt of a registration granted by the Federal Drug Administration or European Medicines Agency on each of the Company’s first three licensed products. The BioVec Agreement additionally provides that the Company will pay to BioVec a royalty in the low single digits on net sales of products covered by the BioVec Agreement. The Company may also grant sublicensees under the licensed patent rights and know-how to third parties for limited purposes related to the use, sale and other exploitation of the products licensed under the BioVec Agreement. The BioVec Agreement will continue until terminated. The BioVec Agreement may be terminated by the Company, in its sole discretion, at any time upon 90 days written notice to BioVec. Either party may terminate the BioVec Agreement in the event of a breach by the other party of any material provision of the BioVec Agreement that remains uncured on the date that is 60 days after written notice of such failure or upon certain insolvency events that remain uncured following the date that is 30 days after the date of written notice to a party regarding such insolvency event.
Takeda Supply Agreement

On May 4, 2021, the Company entered a multi-year supply agreement with Takeda Development Center Americas, Inc. (Takeda). The Company will supply Takeda with rimiducid for potential use in clinical trials of TAK-007 (CD19 CAR-NK cell therapy). The Company generated revenue of $0.7 million for the nine months ended September 30, 2021, with the possibility of additional revenue from future sales.
MD Anderson License Agreements

On January 22, 2019, the Company entered into a licensing and commercialization agreement with MD Anderson (the "2019 MD Anderson License Agreement"). Under the 2019 MD Anderson License Agreement, the Company granted MD Anderson non-exclusive rights in certain Caspase-9 and related technologies and use of a small molecule known as rimiducid in a certain cell therapy program. During the fourth quarter of 2019, and under the terms of the 2019 MD Anderson License Agreement, MD Anderson exercised an option to grant a non-exclusive sublicense of the rights licensed by the Company to MD Anderson. MD Anderson, as a result of this exercise, granted a sublicense that entitled the Company to receive as consideration an upfront license fee as well as additional future annual maintenance fees, milestone payments related to the achievement of pre-specified development, regulatory, and commercialization events, and royalties on net sales of licensed products.

On August 31, 2021, the Company entered into a second licensing and commercialization agreement with MD Anderson (the “2021 MD Anderson Option and License Agreement”). Under the 2021 MD Anderson Option and License Agreement, MD Anderson has certain rights to the use of CaspaCIDe and rimiducid in product candidates nominated under the agreement, and receives an option to a non-exclusive license to the technology in these candidates. Upon exercise of an option and sublicense of a product candidate to a third party, the Company is entitled to a sublicense execution fee, a percentage of certain consideration received by MD Anderson for the sublicense, an annual maintenance fee, and a percentage royalty on net sales of licensed products. During the third quarter of 2021, the Company received an upfront payment of $5.0 million upon execution of the agreement and granted licenses for two nominated programs.
Litigation

On May 29, 2019, Bellicum was served with a second amended complaint indicating that the Company had been added as an additional defendant in an ongoing civil tort lawsuit, captioned Kelly v. Children’s Hospital of Los Angeles et al., filed in the Los Angeles County Superior Court, Case No. BC681477. On July 10, 2019 plaintiffs filed a third amended complaint seeking unspecified monetary damages including punitive damages and alleging claims for wrongful death, negligence, breach of fiduciary duty, fraud, medical battery on decedent, medical battery on individual plaintiffs, products liability - failure to warn, breach of express warranty and products liability design or manufacturing defect. Bellicum filed a demurrer and motion to strike plaintiffs’ third amended complaint, which were granted in part on August 5, 2020 with the Court dismissing (without prejudice) all claims against Bellicum with the exception of the breach of express warranty and products liability design or manufacturing defect causes of action. The Court also granted Bellicum’s motion to strike plaintiffs’ claim for punitive damages. On September 15, 2020, plaintiffs filed a fourth amended complaint alleging the same causes of action and damages against Bellicum as were pled in the third amended complaint. On November 3, 2020 Bellicum filed a demurrer and motion to strike the fourth amended complaint, which currently is set for hearing on November 23, 2021. A trial date has not been set in the case.
Compliance with NASDAQ Listing Rules
On May 5, 2021, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”), that the Company was in breach of Listing Rule 5450(b)(2)(A) (the “Market Value Rule”), for continued listing on The Nasdaq Capital Market because the market value of the Company's listed securities for 30 consecutive business days had been less than $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a grace period until November 1, 2021, to regain compliance with the Market Value Rule by maintaining a market value of listed securities $35 million or more for a minimum of 10 consecutive business days any time prior to November 1, 2021.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying unaudited condensed financial statements have been prepared in conformity with the authoritative U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC").
Use of Estimates
Use of Estimates
The preparation of the interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.
Revenue Recognition
Revenue Recognition
The Company’s sources of revenue during the nine months ended September 30, 2021 are from its supply agreement with Takeda Development Center Americas, Inc. (“Takeda”) and from its licensing agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”).
Supply of Product
The promised product in supply agreement with Takeda consists of rimiducid including any components, drug substance, raw materials and/or excipients to be supplied by the Company. Revenue is generally recognized upon the transfer of control of promised goods to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods.
Licenses of Intellectual Property
The promised services in license agreement with MD Anderson consists of certain option and license rights to the Company’s intellectual property. If the license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement and when management believes the license to its intellectual property and products has stand-alone value, revenue is recognized from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over a period of time or at a point in time. If over a period of time, the
Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Milestone Payments
At the inception of each arrangement that includes developmental, regulatory or commercial milestone payments, we evaluate whether achieving the milestones is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. Revenue is recognized from the satisfaction of performance obligations in the amount billable to the customer.
Royalty Revenues
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, no royalties have been received.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
The Company considers all short-term, highly liquid investments with maturity of three months or less from the date of purchase and that can be liquidated without prior notice or penalty, to be cash equivalents.
Warrant Derivatives
Warrant Derivatives
Freestanding warrants are classified as liabilities in the accompanying condensed consolidated balance sheets as they are exercisable for multiple underlying instruments that are potentially redeemable. The Company accounts for these warrants at fair value on the date of issuance and are subject to re-measurement to fair value at each balance sheet date. Any change in fair value is recognized as a component of other income (expense) on the accompanying condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants or a change in control, as defined. The warrants are freely exercisable at any time from the issuance date until the expiration date, provided exercise does not cause a warrant holder to exceed a pre-determined beneficial ownership limit.

The Company estimates the fair value of these liabilities using the Black-Scholes valuation technique, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Private Placement Option
Private Placement Option
The Company has entered into a security purchase agreement that contains a call option on preferred shares that are puttable outside the control of the Company. The Company recorded the option as a liability and measured the fair value of the option at the time of issuance. The Company will re-measure the option to fair value at each balance sheet date and record changes in fair value in other income (expense) in the accompanying condensed consolidated statement of operations and comprehensive loss at each reporting period. Offering expenses arising from the issuance of the private placement option were expensed as incurred.

The Company estimates the fair value of these liabilities using a binomial lattice model, which utilizes assumptions including (i) the fair value of the underlying stock at the valuation measurement date, (ii) volatility of the price of the underlying stock, (iii) the expected term, and (iv) risk-free interest rates.
Preferred Stock
Preferred Stock
Preferred shares issued by the Company that are subject to mandatory redemption are classified as liability instruments in the accompanying condensed consolidated balance sheets and are measured at fair value at the date of issuance. Conditionally
redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified within mezzanine equity in the accompanying condensed consolidated balance sheets. At all other times, preferred shares are classified within stockholders’ deficit.
Operating Leases
Operating Leases
At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company’s obligation to make lease payments arising from the lease, and a corresponding right-of-use (“ROU”) asset which represents the Company’s right to use an underlying asset during the lease term.

Operating leases are recognized as ROU assets and operating lease liabilities on the balance sheet based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company's incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Any lease incentives received are deferred and recorded as a reduction of the ROU asset and amortized over the term of the lease. Rent expense, comprised of amortization of the ROU asset and the implicit interest accreted on the operating lease liability, is recognized on a straight-line basis over the lease term. The Company determines the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Leases with a term of 12 months or less are not recognized on the balance sheets.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.

Accounting standards include disclosure requirements around fair values used for certain financial instruments and establish a fair value hierarchy. The three-tier hierarchy defines a three-tiered valuation hierarchy for disclosures that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market, as described further in Note 2.
Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.
These inputs are classified into the following hierarchy:
Level 1 Inputs - quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;
Level 2 Inputs - inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and
Level 3 Inputs - unobservable inputs for the assets.
The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of these instruments.
Financial Instruments and Credit Risks
Financial Instruments and Credit Risks
Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and accounts receivable. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation and Security Investor Protection Corporation. Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.
Equity Issuance Costs
Equity Issuance Costs
Equity issuance costs represent costs paid to third parties in order to obtain equity financing. The costs related to preferred and common stock have been netted against the proceeds of the equity issuances.
Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders
Net Income (Loss) and Net Income (Loss) per Share of Common Stock Attributable to Common Stockholders

Basic and diluted net income (loss) per share attributable to common stockholders is based on the more dilutive method of either the two-class method or the treasury stock method. Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. Diluted net income (loss) per share gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period, assuming the exercise of all “in-the-money” common stock equivalents based on the average market price during the period. For periods of a net loss position, since the participating securities are not contractually obligated to share losses with the common stockholders, the diluted loss per share is calculated similarly to basic loss per share.

For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.
New Accounting Requirements and Disclosures
New Accounting Requirements and Disclosures

Fair Value Measurement

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies fair value disclosures and removes some disclosure requirements for both public and private companies. In addition, public companies are subject to some new disclosure requirements which requires to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.

Financial Instruments – Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no material effect on its financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.

Income Taxes

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2019. The Company adopted the standard effective January 1, 2020 with no impact on its financial statements.
Investments

In January 2020, the FASB issued Accounting Standards Update No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)—Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force), which clarifies the interaction of the accounting for equity securities, investments accounted for under the equity method, and certain forward contracts and purchased options. This update is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted the standard effective January 1, 2021 with no impact on its consolidated financial statements.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash, Cash Equivalents and Restricted Cash, Reconciliation
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.
(in thousands)September 30, 2021December 31, 2020
Cash and cash equivalents$19,266 $35,495 
Restricted cash1,501 1,501 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$20,767 $36,996 
Schedule of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.
(in thousands)September 30, 2021December 31, 2020
Cash and cash equivalents$19,266 $35,495 
Restricted cash1,501 1,501 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$20,767 $36,996 
Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consist of the following:
(in thousands)September 30, 2021December 31, 2020
Accrued payroll$278 $1,071 
Accrued patient treatment costs2,507 899 
Accrued clinical research costs1,658 1,562 
Accrued manufacturing costs252 41 
Accrued professional services289 279 
Accrued other355 313 
Total accrued expenses and other current liabilities $5,339 $4,165 
Earnings Per Share, Potentially Dilutive Securities
The following table sets forth the computation of basic and diluted earnings per share:

Three Months EndedNine Months Ended
(in thousands, except share and per share amounts)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Net income (loss) per share - basic:
Net income (loss)
$1,233 $(887)$(12,236)$(26,505)
Less: undistributed earnings to participating securities(469)— — — 
Net income (loss) attributable to common shareholders$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Basic net income (loss) per share $0.08 $(0.18)$(1.21)$(5.25)
Net income (loss) per share - diluted:
Net income (loss) attributable to common shareholders, basic$764 $(887)$(12,236)$(26,505)
Weighted-average shares outstanding, basic
10,108,388 5,059,779 10,086,246 5,050,603 
Effect of dilutive securities:
Stock options and restricted stock units86,280 — — — 
Weighted-average shares outstanding, diluted
10,194,668 5,059,779 10,086,246 5,050,603 
Diluted net income (loss) per share$0.07 $(0.18)$(1.21)$(5.25)
The following outstanding shares of common stock equivalents were excluded from the computations of diluted net income (loss) per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.
September 30, 2021September 30, 2020
Common Stock Equivalents:Number of Shares
Redeemable convertible series 1 preferred stock4,520,000 5,340,000 
Warrants to purchase common stock11,616,080 5,750,000 
Private placement option9,675,000 9,675,000 
Options to purchase common stock1,985,277 1,142,470 
Unvested shares of restricted stock units168,980 182,227 
Total common stock equivalents27,965,337 22,089,697 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Summary of Assets Measured at Fair Value on a Recurring Basis The following table presents the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)
Level 1
Level 2
 Level 3
Level 1Level 2 Level 3
Cash equivalents:
Money market funds and treasury bills$12,481 $— $— $27,463 $— $— 
Total cash equivalents$12,481 $— $— $27,463 $— $— 
Schedule of Derivative Liabilities at Fair Value
The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:

September 30, 2021December 31, 2020
Risk-free interest rate
0.95%0.46%
Volatility
95.00%90.00%
Expected term (years)
4.895.64
The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:
September 30, 2021December 31, 2020
Risk-free interest rate1.33 %0.77 %
Volatility95.00 %90.00 %
Expected term (years)7.007.00

The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Warrant derivative liability$— $— $7,842 $— $— $10,345 
Private placement option liability— — 2,800 — — 7,803 
Total fair value$— $— $10,642 $— $— $18,148 
The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:
(in thousands)Warrant Derivative LiabilityPrivate Placement Option LiabilityTotal
Balance, December 31, 2020
$10,345 $7,803 $18,148 
Change in fair value(2,503)(5,003)(7,506)
Balance, September 30, 2021
$7,842 $2,800 $10,642 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.21.2
LEASES (Tables)
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Components of Lease Cost Components of lease cost are as follows:
Three Months EndedNine Months Ended
(in thousands)September 30, 2021September 30, 2020September 30, 2021September 30, 2020
Finance lease cost:
Amortization of leased asset$— $18 $16 $54 
Interest on lease liabilities— 17 
Operating lease cost169 56 668 
Short-term lease cost— 235 53 476 
Total lease cost$$427 $130 $1,215 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.21.2
PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables)
9 Months Ended
Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]  
Schedule of Derivative Liabilities at Fair Value
The fair value of the warrants has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:

September 30, 2021December 31, 2020
Risk-free interest rate
0.95%0.46%
Volatility
95.00%90.00%
Expected term (years)
4.895.64
The fair value of the private placement option has been estimated with the following weighted-average assumptions, including the most sensitive input, volatility:
September 30, 2021December 31, 2020
Risk-free interest rate1.33 %0.77 %
Volatility95.00 %90.00 %
Expected term (years)7.007.00

The following table provides the warrant derivative and private placement option reported at fair value and measured on a recurring basis:
Fair Value at September 30, 2021
Fair Value at December 31, 2020
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Warrant derivative liability$— $— $7,842 $— $— $10,345 
Private placement option liability— — 2,800 — — 7,803 
Total fair value$— $— $10,642 $— $— $18,148 
The following table reflects the fair value roll forward reconciliation of the warrant derivative and private placement option liabilities for the period ended September 30, 2021:
(in thousands)Warrant Derivative LiabilityPrivate Placement Option LiabilityTotal
Balance, December 31, 2020
$10,345 $7,803 $18,148 
Change in fair value(2,503)(5,003)(7,506)
Balance, September 30, 2021
$7,842 $2,800 $10,642 
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock Option Activity
The following table summarizes the stock option activity for all stock plans during the nine months ended September 30, 2021:
Options and Inducement Awards
Outstanding at December 31, 2020
1,510,968 
Granted
823,000 
Exercised
— 
Forfeited
(348,691)
Outstanding at September 30, 2021
1,985,277 
Exercisable at September 30, 2021
466,587 
Stock Award Activity for All Stock Plans
The following table summarizes the stock award activity for all stock plans during the nine months ended September 30, 2021:
Restricted Stock Awards and Units
Outstanding at December 31, 2020
129,861 
Granted
136,626 
Vested
(95,001)
Forfeited
(2,506)
Outstanding at September 30, 2021
168,980 
ESPP Activity A summary of activity within the ESPP follows:
Nine Months Ended
(in thousands)September 30, 2021September 30, 2020
Deductions from employees$— $116 
Share-based compensation expense recognized— 70 
Remaining share-based compensation expense— 113 
Valuation Assumptions The fair value of option grants is determined using the Black-Scholes option-pricing model and has been estimated with the following weighted-average assumptions:
Nine Months Ended
September 30, 2021September 30, 2020
Risk-free interest rate
0.84 %1.18 %
Volatility
90.35 %81.78 %
Expected life (years)
5.636.03
Expected dividend yield
— — 
Share-Based Compensation Expense by Classification
Share-based compensation expense by classification for the three and nine months ended September 30, 2021 and 2020 are as follows:
Three Months Ended
Nine Months Ended
(in thousands)
September 30, 2021
September 30, 2020
September 30, 2021
September 30, 2020
Research and development$296 $668 $829 $1,877 
General and administrative557 938 1,748 2,616 
     Total$853 $1,606 $2,577 $4,493 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 17 Months Ended
Mar. 15, 2021
USD ($)
Apr. 14, 2020
USD ($)
Feb. 05, 2020
shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
shares
Sep. 30, 2021
USD ($)
segment
subsidiary
shares
Sep. 30, 2021
USD ($)
shares
Mar. 26, 2021
USD ($)
Feb. 26, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 15, 2020
shares
Jun. 14, 2020
shares
Feb. 04, 2020
shares
Dec. 31, 2019
USD ($)
Class of Stock [Line Items]                              
Number of wholly-owned subsidiaries formed | subsidiary             2                
Number of operating segments | segment             1                
Number of reportable segments | segment             1                
Reverse stock split ratio     0.1                        
Common stock, authorized (in shares) | shares     40,000,000     80,000,000 80,000,000 80,000,000       80,000,000 40,000,000 200,000,000  
Accumulated deficit           $ (540,747) $ (552,983) $ (552,983)              
Cash equivalents, restricted cash           36,996 20,767 20,767     $ 54,626       $ 93,816
Operating lease right-of-use assets           645 0 0              
Property and equipment, net           189 27 27              
Accrued clinical research costs           1,562 $ 1,658 $ 1,658              
Scenario, Adjustment                              
Class of Stock [Line Items]                              
Accrued clinical research costs                     1,200        
Accrued manufacturing costs and accrued professional fees, current                     $ 100        
Maximum                              
Class of Stock [Line Items]                              
Escrow deposits related to property sales, period up to               18 months              
2130 W. Holcombe Blvd.                              
Class of Stock [Line Items]                              
Escrow deposits cash proceeds received   $ 1,500                          
Research And Development Facility | Disposal Group, Held-for-sale, Not Discontinued Operations                              
Class of Stock [Line Items]                              
Operating lease right-of-use assets           500                  
Property and equipment, net           2,300                  
Operating lease, liability           700                  
Impairment charges           $ 1,300                  
Reed Road, Houston, TX                              
Class of Stock [Line Items]                              
Amount paid upon closing of asset sale                   $ 1,100          
Discontinued operation, consideration, cash                   900          
Discontinued operation, consideration, note receivable                   $ 200          
San Francisco Office Space                              
Class of Stock [Line Items]                              
Operating lease right-of-use assets                 $ 600            
Operating lease, liability                 1,000            
Lease termination fee $ 900                            
Security deposit returned       $ 200                      
Loss on termination of lease         $ 500                    
San Francisco Office Space | Equipment                              
Class of Stock [Line Items]                              
Operating lease right-of-use assets                 $ 100            
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 19,266 $ 35,495    
Restricted cash 1,501 1,501    
Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 20,767 $ 36,996 $ 54,626 $ 93,816
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued payroll $ 278 $ 1,071
Accrued patient treatment costs 2,507 899
Accrued clinical research costs 1,658 1,562
Accrued manufacturing costs 252 41
Accrued professional services 289 279
Accrued other 355 313
Total accrued expenses and other current liabilities $ 5,339 $ 4,165
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net income (loss) per share - basic:        
Net income (loss) $ 1,233 $ (887) $ (12,236) $ (26,505)
Less: undistributed earnings to participating securities (469) 0 0 0
Net income (loss) attributable to common shareholders $ 764 $ (887) $ (12,236) $ (26,505)
Weighted-average shares outstanding, basic (in shares) 10,108,388 5,059,779 10,086,246 5,050,603
Basic net income (loss) per share (in dollars per share) $ 0.08 $ (0.18) $ (1.21) $ (5.25)
Net income (loss) per share - diluted:        
Net income (loss) attributable to common shareholders, basic $ 764 $ (887) $ (12,236) $ (26,505)
Weighted-average shares outstanding, basic (in shares) 10,108,388 5,059,779 10,086,246 5,050,603
Effect of dilutive securities:        
Stock options and restricted stock units (in shares) 86,280 0 0 0
Weighted-average shares outstanding, diluted (in shares) 10,194,668 5,059,779 10,086,246 5,050,603
Diluted net income (loss) per share (in dollars per shares) $ 0.07 $ (0.18) $ (1.21) $ (5.25)
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details) - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 27,965,337 22,089,697
Redeemable convertible series 1 preferred stock    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 4,520,000 5,340,000
Warrants to purchase common stock    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 11,616,080 5,750,000
Private placement option    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 9,675,000 9,675,000
Options to purchase common stock    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 1,985,277 1,142,470
Unvested shares of restricted stock units    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Total common stock equivalents (in shares) 168,980 182,227
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Restricted cash $ 1,501 $ 1,501
Level 1    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents 12,481 27,463
Level 1 | Money market funds and treasury bills    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents 12,481 27,463
Level 2    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents 0 0
Level 2 | Money market funds and treasury bills    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents 0 0
 Level 3    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents 0 0
 Level 3 | Money market funds and treasury bills    
Fair Value Inputs, Assets, Quantitative Information [Line Items]    
Total cash equivalents $ 0 $ 0
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Derivative [Line Items]      
Risk-free interest rate 0.84% 1.18%  
Volatility 90.35% 81.78%  
Expected life (years) 5 years 7 months 17 days 6 years 10 days  
Warrant Derivative Liability      
Derivative [Line Items]      
Risk-free interest rate 0.95%   0.46%
Volatility 95.00%   90.00%
Expected life (years) 4 years 10 months 20 days   5 years 7 months 20 days
Private Placement Option Liability      
Derivative [Line Items]      
Risk-free interest rate 1.33%   0.77%
Volatility 95.00%   90.00%
Expected life (years) 7 years   7 years
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant derivative liability $ 7,842 $ 10,345
Private placement option liability 2,800 7,803
Level 1    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant derivative liability 0 0
Private placement option liability 0 0
Total fair value 0 0
Level 2    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant derivative liability 0 0
Private placement option liability 0 0
Total fair value 0 0
 Level 3    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrant derivative liability 7,842 10,345
Private placement option liability 2,800 7,803
Total fair value $ 10,642 $ 18,148
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.21.2
LEASES - Narrative (Details)
Sep. 30, 2021
Lessee, Lease, Description [Line Items]  
Leas term option to extend 5 years
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease term 7 years
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.21.2
LEASES - Components of Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Finance lease cost:        
Amortization of leased asset $ 0 $ 18 $ 16 $ 54
Interest on lease liabilities 0 5 5 17
Operating lease cost 1 169 56 668
Short-term lease cost 0 235 53 476
Total lease cost $ 1 $ 427 $ 130 $ 1,215
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.21.2
PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended
Aug. 21, 2019
Aug. 16, 2019
Nov. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Class of Stock [Line Items]          
Common stock, issued (in shares)     1,040,000 8,465,549 8,385,650
Shares issuable per warrants (in shares)     3,109,378    
Warrants to purchase aggregate shares of common stock (in shares)     4,149,378    
Shares purchased by selling common stock and pre-funded warrant (in shares)     1    
Common stock, par value (in dollars per share)     $ 0.001 $ 0.01 $ 0.01
Warrant exercise price (in dollars per share)     $ 6.50    
Expiration period     5 years    
Proceeds from issuance of stock     $ 25.0    
Proceeds from issuance of redeemable convertible preferred stock in a public offering, net $ 53.8        
Proceeds upon entering into private placement agreement       $ 11.2  
Maximum          
Class of Stock [Line Items]          
Price of each share of common stock and accompanying common warrant (in dollars per share)     $ 6.025    
Minimum          
Class of Stock [Line Items]          
Price of each share of common stock and accompanying common warrant (in dollars per share)     $ 6.024    
Series 1 redeemable convertible non-voting preferred stock          
Class of Stock [Line Items]          
Shares issuable per warrants (in shares)       10  
Series 2 Preferred Stock          
Class of Stock [Line Items]          
Expiration period       2 years 6 months  
Public Warrants, Private Warrants And Stock Options          
Class of Stock [Line Items]          
Total offering costs related to warrants and options       $ 3.0  
Public Offering          
Class of Stock [Line Items]          
Shares issuable under warrants (in shares)   5,750,000      
Price per share (in dollars per share)   $ 100.00      
Public Offering | Series 1 redeemable convertible non-voting preferred stock          
Class of Stock [Line Items]          
Number of shares of common stock sold in offering (in shares)   575,000      
Warrants exercise price (in dollars per share)   $ 130.00      
Public Offering | Common Stock          
Class of Stock [Line Items]          
Shares issuable per warrants (in shares)   10      
Shares issuable under warrants (in shares)   0      
Warrants exercise price (in dollars per share)   $ 13.00      
Notice period for percentage change   61 days      
Public Offering | Common Stock | Maximum          
Class of Stock [Line Items]          
Warrants, limitations on ownership after exercise   19.99%      
Public Offering | Common Stock | Minimum          
Class of Stock [Line Items]          
Warrants, limitations on ownership after exercise   9.99%      
Private Placement | Series 2 Preferred Stock          
Class of Stock [Line Items]          
Number of shares of common stock sold in offering (in shares)   350,000   350,000  
Shares issuable under warrants (in shares)   2,800,000      
Price per share (in dollars per share)   $ 100.00      
Warrants exercise price (in dollars per share)   $ 10.00      
Private Placement | Series 3 Preferred Stock          
Class of Stock [Line Items]          
Number of shares of common stock sold in offering (in shares)   250,000   250,000  
Private Placement | Preferred Stock          
Class of Stock [Line Items]          
Shares issuable under warrants (in shares)   875,000      
Price per share (in dollars per share)   $ 140.00      
Warrants exercise price (in dollars per share)   $ 14.00      
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.21.2
PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Derivative Liability Rollforward [Roll Forward]        
Change in fair value $ (4,264) $ (12,131) $ (7,506) $ (14,256)
 Level 3        
Derivative Liability Rollforward [Roll Forward]        
Balance, December 31, 2020     18,148  
Change in fair value     (7,506)  
Balance, September 30, 2021 10,642   10,642  
Warrant Derivative Liability |  Level 3        
Derivative Liability Rollforward [Roll Forward]        
Balance, December 31, 2020     10,345  
Change in fair value     (2,503)  
Balance, September 30, 2021 7,842   7,842  
Private Placement Option Liability |  Level 3        
Derivative Liability Rollforward [Roll Forward]        
Balance, December 31, 2020     7,803  
Change in fair value     (5,003)  
Balance, September 30, 2021 $ 2,800   $ 2,800  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.21.2
REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) - $ / shares
9 Months Ended
Aug. 16, 2019
Sep. 30, 2021
Nov. 30, 2020
Class of Stock [Line Items]      
Preferred stock, authorized (in shares)   10,000,000  
Preferred stock, par value (in dollars per share)   $ 0.01  
Shares issuable per warrants (in shares)     3,109,378
50-day trading volume on Nasdaq stock market (in shares)   50,000  
Average trading volume period   50 days  
Series 1 redeemable convertible non-voting preferred stock      
Class of Stock [Line Items]      
Preferred stock, authorized (in shares)   1,517,500  
Preferred stock, outstanding (in shares)   452,000  
Preferred stock, issued (in shares)   452,000  
Shares issuable per warrants (in shares)   10  
Series 2 Preferred Stock      
Class of Stock [Line Items]      
Preferred stock, outstanding (in shares)   0  
Preferred stock, issued (in shares)   0  
Series 2 Preferred Stock | Private Placement      
Class of Stock [Line Items]      
Number of shares of common stock sold in offering (in shares) 350,000 350,000  
Price per share (in dollars per share) $ 100.00    
Series 3 Preferred Stock      
Class of Stock [Line Items]      
Preferred stock, outstanding (in shares)   0  
Preferred stock, issued (in shares)   0  
Closing price of common stock (in dollars per share)   $ 35.00  
Closing price of common stock threshold period   180 days  
Series 3 Preferred Stock | Private Placement      
Class of Stock [Line Items]      
Number of shares of common stock sold in offering (in shares) 250,000 250,000  
Series 1 and 2 Preferred Stock      
Class of Stock [Line Items]      
Price per share (in dollars per share)   $ 100.00  
Closing price of common stock (in dollars per share)   $ 25.00  
Closing price of common stock threshold period   180 days  
Preferred Stock | Private Placement      
Class of Stock [Line Items]      
Price per share (in dollars per share) $ 140.00    
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS - Narrative (Details)
$ in Millions
1 Months Ended 9 Months Ended
Jun. 30, 2021
shares
Nov. 30, 2020
Jun. 30, 2020
shares
Jan. 31, 2020
shares
Sep. 30, 2021
USD ($)
plan
shares
Sep. 30, 2020
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of share-based compensation plans | plan         5  
Expiration period   5 years        
Compensation cost not yet recognized | $         $ 4.0  
Period for recognition         1 year 7 months 6 days  
2019 Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares authorized (in shares)         250,000  
Additional authorized shares approved (in shares) 500,000   500,000 600,000    
2019 Equity Incentive Plan | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares authorized (in shares)         600,540  
Options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Expiration period         10 years  
Options | Minimum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period         2 years  
Options | Maximum            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period         4 years  
ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Discount rate from grant date fair market value         15.00%  
Issuance of common stock ESPP (in shares)           9,526
Shares available for issuance under ESPP (in shares)         18,488  
ESPP | 2014 Employee Stock Purchase Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares authorized (in shares)         55,000  
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details) - Employee Stock Options And Inducement Option Awards
9 Months Ended
Sep. 30, 2021
shares
Options and Inducement Awards  
Outstanding at beginning of period (in shares) 1,510,968
Granted (in shares) 823,000
Exercised (in shares) 0
Forfeited (in shares) (348,691)
Outstanding at end of period (in shares) 1,985,277
Options and inducement awards, exercisable (in shares) 466,587
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details) - Restricted Stock Awards and Units
9 Months Ended
Sep. 30, 2021
shares
Restricted Stock Awards and Units  
Beginning balance (in shares) 129,861
Granted (in shares) 136,626
Vested (in shares) (95,001)
Forfeited (in shares) (2,506)
Ending balance (in shares) 168,980
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense recognized $ 853 $ 1,606 $ 2,577 $ 4,493
Remaining share-based compensation expense     2,577 4,493
ESPP        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Deductions from employees     0 116
Share-based compensation expense recognized     0 70
Remaining share-based compensation expense     $ 0 $ 113
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]    
Risk-free interest rate 0.84% 1.18%
Volatility 90.35% 81.78%
Expected life (years) 5 years 7 months 17 days 6 years 10 days
Expected dividend yield 0.00% 0.00%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.21.2
SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense recognized $ 853 $ 1,606 $ 2,577 $ 4,493
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense recognized 296 668 829 1,877
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense recognized $ 557 $ 938 $ 1,748 $ 2,616
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 10, 2015
USD ($)
Jun. 10, 2015
USD ($)
product
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
Takeda            
Loss Contingencies [Line Items]            
Additional revenue from sales         $ 700,000  
Baylor | Licensing Agreements            
Loss Contingencies [Line Items]            
Sublicense expense     $ 500,000 $ 600,000   $ 600,000
Agensys, Inc. | Licensing Agreements            
Loss Contingencies [Line Items]            
Nonrefundable upfront fee $ 3,000,000          
Milestone payments upon first achievement of specified clinical milestones 5,000,000          
Milestone payments upon achievement of specified clinical milestones for each licensed product 50,000,000          
Milestone payments upon achievement of sales milestones 75,000,000          
Option exercise fee 5,000,000          
Milestone payments reduced upon exercise of option $ 65,000,000          
Termination period, number of years after first commercial sale of licensed product 10 years          
Termination period, notice of failure on uncured items 60 days          
Period of notice of failure on uncured items, if material breach is related to failure to make payments 30 days          
BioVec Pharma Inc | Licensing Agreements            
Loss Contingencies [Line Items]            
Nonrefundable upfront fee   $ 100,000        
Milestone payments upon first achievement of specified clinical milestones   $ 250,000        
Termination period, notice of failure on uncured items   60 days        
Upfront fee payment period, number of days from effective date   10 days        
License costs due upon first release of product   $ 300,000        
License costs due upon first release of product, period of payment   10 days        
License agreement, annual fee   $ 150,000        
License agreement, annual fee period, from first IND filing   30 days        
Milestone payments, number of initial products | product   3        
License agreement, milestone payments upon receipt of FDA or EMA registration   $ 2,000,000        
Termination notice period for any other breach   90 days        
Termination period, after insolvency event   30 days        
MD Anderson            
Loss Contingencies [Line Items]            
Upfront payment received     $ 5,000,000      
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"HT!8(9;6"$:B"_ A.'Y]E$@)]+:SO M>IQ ]I?OL%4]R-/U&W1JR 6\/')0OI!4*G?)"FW538\^&DZ(@) M.IRCKYXDC^,;[[&JXS?7\EE(>ZB0?V\*C5*^+(M0L.*LQ/(4 _MAX3H]N<22%,/;X]LE<'1QWV,O9!ST%]!S\IDF3VDB?01J@(>S MG)(9R@/4OF\F,V2:%0#I*6%_!C,%=%#8[D6U5JX#4FH/3S77S:'PF2?]ZXS@ 2>AT.JU-/I?L."*>>'.]@O<%W#WO]& M$_7J?V!&>G3E6#S]44"MT/!:L9 P"BEU?5OAL:38D>-2THYY:91 X=O[.-O( MIPQO7U+GT!X2G)MS &G4GP5L?)G( >U+0 B#\F$S[%BAM+?Z\=229X*/&S*0 MP;NG/"1P(29(D#7)UY.2'YVDD JQGESS*JMK.$;VC. 2P?QHXXPQGB^@V0ZD G%!=F@ZD9D/FBZ>/Q3%5Z4[-JA&+#"-J[: MOL*V] Y;/:K9/+S#,O$$CROSU0K!^0'&BCL2@[((G$O'_ 'O1UP*+ZU]3T2P/O1$)EA5TI;,GLNSK7!>!'*/ M*Z.EY9:0:-_:=J1XLHXD,RI?#!25&#E.Z03?R$_HN[^H=.E;H+O29\=O"9%T M< +,E+3![RB)R>(OA_21(6O[M[\9JOQ)._+O)L\$VSA(H;.[#5JR2;?1. Y& MW&PJH.O)LOC&BE\PP![O%S&\4\,=4%'1NY^F\*Y$,VC1X;&Q=>)H?G$O'4'D MX(<&*@ZM>-D>;1*\^? H-J82G)T'FL<_M9;&FY5FB M;$M(\L6<6# G2C-(%($ 1''>JNJ/Z)FE:J2ZV6^PT"N#>N9&CE1@OF[=K8=_Q2QF1R/0JLH2I MP*RT1H_E;]I=I^E>?9F6Q68=K%.QZY&R!^0D0RD3F-U+]';J32]FA;3.P([@ M.#?@>9=>*$MGB3$;2TR/]W/I2!!$.X4J\88H,&MMR8U//E$?!E)[#?>LX>&$"HE[[\NZXR>??5A(57M9:J*Z MGO*QQM-K-A^V/FA/5Q][6X(%,[Y%7^$O*DJAO>0B\D[>]I(+$B4KZKP"9C>- MMG,7#M,+K_*9?4TXU[[4R8.HUH-BHZW=IN M/>A5RV:5O/'=&P&CTBD)C."PC!1[;"L'X@!1H@1MU-FRUV*>PW\C)&BHY*9? MVSSRK<.K"$N 7UPRRJBZEAS[,,B5$%(V'+-R0PWULC7#4W&M)*K8JL@HVKA3 MKYXKU<$+Q9;8!:8F2;K$G6*:2.9%VZ&66/&D(([;HN9@8.*1M)B>,5:MR4>- MZ T@IY$C&&7HB?2'$Q'Q75GMG'',, KO1!&0WC4A@P?NFR P;@?R]'@-(HS] M@3,0,!J[E_S652VEV2EM^Z(K.2%F\Y=\TH=J3PP#IQ[9#<*TLJ\TF_C4#D6= M?&YA9?K%+CK=2X=L33LJ"=\(?/, GVQ2/%@L^/0A]B52<5MU@][YC["M-6 " M/-6P( >)RO 4'=U9HW]]P]T:--M^ &>,>KUI)=^(/8@W>'.0"=[PF##&<<*8 M #GE?Q^" $W1COE&3P*"MXM=ZU'GG_)!D(0(WSN/X-I@R$6KR&'N45T2]Z8^ M<-^"3UZ#4\0'%\@)D.1^KY(8[HE 8 #T6,'EG7=P0J]>_U "8:';[+#J.#R MYZ"UP A&@:,M3T;$_U=L/'#PN\X 1-E+L<5'S&K=3 M8S&:=1I$H;T!J-9M+D>4\((*5+YYM<8$3$;0N[;SS@'YI-2H"[!ATP.\3R:8 M>]@Y#1P? '[+A##[M\;UNZZPQ3D[\ 3OBTX/93\#V3 MZY5H? K4.:!#F3' M,\;[U1G=P $ M]_RY&28Z%@&'4YQ/KIO[ZH],HC^:WE>D_J[%X3JD0Z&^>\ M9Q2^+P:O*[FQHU?1]7@E;H&,XF:)*[3) MN)^OD-O(PB2]_N)/)1ZF(XBQ;&3J$H_%]P^<>0]82L'A>C;.55+*12O!$49( MQW'HPC=5^&^>@"3LM7RIAS*?L MQ>G#4#+D*RPE@>+*/?AV#^:W>BGM[O5ZLJ'\H1$)13=;4/#Y/+VVC:]D@[>I MHJ!-JZG<%T.C'B*K'-W1+!]YPY1BDL92PK[HX-#;O$U&UN*J-!@63[V^;#5@ M!PI#T5A%(7@V>)\WZ$GI/<%^@J(7XOV^_*JTH@EHXN?MV(,_'H_@I(/+'G82 M;Z3LP!*O/N?6"4$VH4V?P7J3]7A<4UK4+1DS9.]-=$F4]?&6C_[6^C3%:CJ_U3]YC>JKWI-<:EA*;;%JU;V4>6SONGB:'A^?XL/IR5$Z/SBBA]/T:+K_!#_F>3*= M3+&W[\5T,CMAX";S&7TXG,P!L(?))$PX1J@G8$9W]'^&H#=L_E5'DPQ[7G@M M7J[F50='?%B2NQ(#89SX9+J3;9X$N\HS0G]ZD!X=/0K]4]P<(O#Q0P3NZZ#Q MF[)W.AO2"2 )%Z]Y(Z75Q!;P(4B'RSS%'=YYXZQ/!GL"AZ0$9; CD??)8>QN MWE-&F#Q1C?4"HNB<(8B$]\FO&9%7H:A-54900:SP\<<>DEE[6CE.TZ/C0WHE?/H0"@D[ MEDA/3P[3^?$Q?)H=S-.#XRF$ QCQV_C2\QW",CLZ@?'39'8"4CX_UG-UNUAL M?IR>'F$C[G$RG\.V ,[38] W=W&._*J7!L<36%&*.2HIO(O2BQ=EC;O=E^NFN>%Q^K#6B=D_GTY>MH73SZL+;X MHTBB!L[[!WVC-WO0(T^/KZ0],.LJQ\1N$SM!<4J=%14Z30V?D-Y5+\"EJ/2\ MZ7+#Y?XR7&;9D_S>L>%PTV!HCA*E@Z/"#=.:RAU/A\HI,J.WK/KJV]@5'/P% M.:?462 *W[OP&)A'>=BQG#%YP.$"QL>@FPSY$SU55G=T-D1.Q5O]X1%\$!V; MEM*#7O>E"M3GGJO&#EY?V!M74CANEGBDP9\;X(-#L]-)\H9B,).+;G'DDZY= MVPX[P^@52>MI>2L"_D^FI,->>B"!CWM4=$XM\W=NCM^//I[<)1&$J%D2O+\P M$UWXTSJ@,!^2_R.6_]U3SX=3BU+8GQ^!4HBU!>;0>F_BZ;;1B=,M41G41R1) M$*Z%Y'DC"0DHDLI,=/:FQA LI)K[[!YXG-H0?$YAY3"K2[4>7!8,%UVUY6_? M] >*4M%"4EYFL<"[MF!:K;S8S#0#1CX:9>1_--_^'5A3+QKS'L=#/'J]=90Y M;KU$='B>&V-*%OA3_"FT/%PQ?+'&Y+U>(5(EG@%W,>[>@!'E,FA<(?1^<\#- M/EUMPZ\\J#*\P7L*J'A0]@''1#3>7"_Y?/UA#KG=M&SYV@8ZZF)JM^067\=[ MX!:,<#[+MR;@EK8+? 1=C_<5*B8MX<\4316=(2_N1\3\=&]Z\ >QJK8^QFS: M.XS"A[KS&VI7%==A=OB2^7J<4OK:P?REUPJYR_\0A9(%YGL)]WSFVK1!D\A% MV'H_CQQRVN#O&55=@[V,-6IUS$@L_8V+>G0W+MQVVOY6Z2W9H0=3.JW06GOH"02J M68ER?/1FT8E6HCZ:+VRN/9X1QP^:[-.]V3Q-KJG=:WFO,$4A ^Z_-[U(V?'! M]&4RX!K_6VU-N/WBB_2U-NI54F,3F4S_^W(T+__RC;\L)M5;C>0>Z-JH&UGH MP6^I$4L6E%XC.'D^O!FGSZ*BN3VXI.O\+6S^,7DUXL+R]3]C8DF] M3$%V_TEV_BDNZ$5T,Q"ZF#)5^*6.'LL&CKSVC5Z?-N1V,2O/IWO361K/*D9& M"M+1KQYYKW/V\H$![[@&BDC]$UU5^!=XAR)'/W[_I5YD\JCA4HO'9EP%#2\8 MK?5'$;4OSD.7^H_[O(Z?+GEAY#* IO.UZS=K6].R6)''&[5,\QDK.ID-]E!- MF?2SAN7].?6^Z$L]/.2!TMZ-3O*V-,^%1+X,XP2^W'FOG755?8=,I,4OQIAF M4/+0-$G"VC&)'[1'C_$T_8C.UWG#9"S_(6':;(>,/*[EQWZ0]U7TF\I(??KE M:+K N6SYYY7]TT1_G/J,?Y,YO,Z_;/W.(//@G0M+&#J='!\^X]YR_0/<2OJ% MYD75MM6:/J[ =;4UO@#?+ZNJU3]P ?^3W=__+U!+ P04 " !Q@&13W)V( M6(0& !9$P & 'AL+W=ON[6 Z[L3)TT"N(F+!6BZ($[2AV$/E'0<$:%$E:3L>+]^YU"R?(F5=2B* M;2^61/+2)$M7N=3H'[43(M'%VXM>NS=F)SIV2*5X;L'F2"+/\@$HO3AO=QFKA M1C[$CA?:9R>9>, INKOLVM!7N^(2R013*W4*!F>GC7'W^,. S_L#]Q(7=N,= MV)) ZT?^N(Q.&QU6"!6&CCD(>LSQ')5B1J3&UY)GHQ+)A)OO*^X?O>UD2R L MGFOU148N/FV,&A#A3.3*W>C%KUC:,V1^H5;6_\*B.#OL-"#,K=-)24P:)#(M MGN*I],,&P:B.H%<2]+S>A2"OY85PXNS$Z 48/DW<^,6;ZJE).9ER4*;.T*XD M.G?V<7QY _?C3W<3N)J,IW2N!=89@\\<+,@:5C(&7 M,?B1?OY;$5#(@&\5 I?I'*VC)',PQ3 WTDFR_#9&F&E%"2O3!W B4 B4\I:. M67"T>:Z33*3+GW\:];J'[RW(-1N[9O-&IJ'*(^+1!#D#D65*ALRL24RT10B5 ML%;.)$9 ";J/<2"42$.$HD )"Z&P,>#77,Z%8G7>$IF@'8.0H.# 14#?,P[I MW(>44Y_*!VEEV!I*86F9DYZ1R9G#)$!3H0E$&L$%AN5JUZ]VCF$#(L+MH]L^ M\(P#^X*-SBT)(*4_X1P5=,MGKWSV:]?/=\P^YIS")54"\TB.F>7$U>ONC/?" M$@*IE(57T.TU!Z,NO7B?]MYOO?4.FX.#_M[-6^V$>N;N[V X_D(\)&46 .]":$VF3;"(36$8"L'V+@D3V4H,W)GH'V< M"*P>FY%O*![\6D@PCJ09)*/N# MJE3$:@1&/Z)I1TC!,O UU\ZO5H0[>@4RLBWX(HP1*6/64)2Y1\(G*0@^TBW] ML6N_CG"M! 6)'?%;YCOJ^MCM5B!F,J5 2+)7E2=8(J6@-M&WI6=1.- '>'W6 M XB7%J7*T5IEM:4R'\I*M;-*;5VH71UMU6*R^8,E>PAL5#\N;.0 /KKI,EE M7(1AX5MV4$@0HIF(LT"G5BL9">>!M %^BBI%Q.(6LP6E$F&!3NA%6B>Q3*KM M5%K$F(+T*14A&42(UH;-U($'*E7@%%+M(."$2BE-O-%.LSA\0A-*UG-G=Z$N69./J"EL(*T1G*! M*GS*T%]F MOT70:1T-7]/OX. UW*^]>31L=3JOX:CC'Y,MC[UA\% +';1&1S!L'0R^%T>U MZ?J=N**):8:&!Q(;^WS7-"49_V^F1!B%^K\ OE!092AM+@O CNY%O_@!R*WU M_?\.R=U6OP\,Y<-#>(YE*,$,=6@^Y$W_LW_XUG-)+;ZN!['K:UU9C0G;C==/ M)JN1>5\7_O>GWB\O==O] ^AAQU.\W^8%C-,R^TYQ7-ZMEKCB@RNZLD MJ],O!^4-Q]8*/ZC7;-3L#D8^])A&102*#ESFR?VL\(C-<5QG%O-<%QL-!+(L^3IT_IS^_Y'M93!=+\",(I3<7"$W2 M(\R0)Q%7SM"^1'#.\0BPY!&]&(QSFL%+GC18*_DG^IE<)C1','-*2>=4&8?" MV W36OO^>KRK-05-Q_5:G5O-"ZN2];'BTNG*V$>2!PHG!$I M)>^P037,7^04'TYG_O(DT,[IQ+_&2-.VX0.T/],T9)GBHE':+I/2^GJ6IRTNLA.N9 M&C6]V1I;"4]3NTM=;5$4 52I-.OW)VDEI$Z6\[!V9Y=STW@E-=Y9<$U5"7N\ M0F4.BV20G!;NY:[TO) NY[78X1K]A_K.TBSM6 I9H7;2:+"X722KP>QJQ/;! MX$^)!W>7O]^LUC?K>>J)BU?2O,5=15SV#.XUW!KM2P %OF'GV##P#9]S#"E7#CZM-LY;ROWG%SA''>Q'%CS5PMEPC7IJJ%/E(U>;249-)]*-&7:$%0X5HK M] ZI$SQ(!P(4NP:"9MZ!U#G67. ]>%>C%5[J7;1PU#1*>(3:2FHXJ8[@#9CM M5N8(00ZQ%U1,NME2@!K+2!I));UD"=*71,&=W7$""W1$ D8C'%%8YG2X1QUF M[@*F\V"CIRF#0QOL'!_?O/H!P#BF0'(N(5%)L MVB#T8.6@,LZS1X^A;8P+ ]IXBK'9DSK.EZQJ)7/I@9*!%T]0% \;_!$*-L92 M ;)JM@R'2T%Q#0BIXX$;3JZ]D(KDAYQ'B;FIB"2/D2D8?1"N\[:KHT 52H[, M]D(U(3.1HA9'1I.+K([22>.O;W/V65C:TE%J%)W=;D:U:A$?-3[\P;L\6OE1 ML@>F<110]Q-07WNL-E3*I^;^=JG_'ZW>2"W(Z3.),UA5QGKY=XS427X1DPK? MPZOOIMD@^X5&@RD_)O08C^"MI@@AIU5_F_0.-*;/X/)I7\78#(CK-8PG,)E, M85V2B)]#Q9V9G&BR(1$-870Y@?>&$W]F0Y+H.\HN>33L\_,B&XSAWTZK].R8 MK]#NPF7FB*?1/I[XW6IW7Z[B-?'5/%ZVM\+NI.8BWA*TW[L<)V#C!18GWM3A MTM@83U=0&)9TYZ-E WJ_-<:?)KQ!]R]B^0]02P,$% @ <8!D4_MHBNGL M"0 JQT !D !X;"]W;W)K&ULK5G9(NSPIWUEM45?GLZ,@E"Y5+US>E*O!D9FPN*US: M^9$KK9(I;\JSHV$<'Q_E4A>]\Q=\[]J>OS!UE>E"75OAZCR7]OZERLSRK#?H M-3<^ZOFBHAM'YR]*.5I&>]F Q2F4HJDB#Q[U9=JBPC03#C>Y#9:U72QN[O1OIK M]AV^3*53ER;[JM-J<=8[[8E4S62=51_-\M\J^#,A>8G)'/\52[]V/.F)I':5 MR<-F6)#KPO^7=R$.G0VG\9X-P[!AR'9[16SE*UG)\Q?6+(6EU9!&/]A5W@WC M=$%)N:DLGFKLJ\ZO/[]\^^92?'C]^NKCF_=_B(OWK\3UQS=?+CY=B>NW%Y=7 M[Z[>?WIQ5$$5;3A*@MB77NQPC]BGXITIJH435T6JTO7]1S"QM7/8V/ER>%#@ MC2K[8A1'8A@/!P?DC5J_1RQOM$]>)2N%XJJ$F8F;RB3?%B9+E76_B:OOM:[N MQ7\NIJZRJ)K_'E W;M6-6=WX[P[S0;'4L<]<*1-UUD-+.F5O5>]ANL1[%.L+XM$M5#BTN2E+.Y%DAFG4B$+47=W MFV8W CN(XG$* M^N)*)@N_@)YWG[$-V]ZL:3:%VK-Y*9UP*$(LGRL$V@(*JH60&XX\3%I??$*J MRGJ:Z625DM+JA)>JPSXBX'P\GO)1_C@7&@Q>Z[7XP94>2EPKZ=9ZK M5",#V;U0=\HFVLEIIH2LX'IK\*.X'\<#42(J!_S=3/D/%13-'=51==R?Q/LU ML==+G6786FH\GV&LB'LEK1,S:W+ND314E':NED6B(H'XM+TT8AB;>)M7I?: M4G*^SDG%H5J/@N?0CKU.E=)Z_]GVS:#XYQ22NH20QF9OWMP:YV")291*N8FZ M&,"R9(G'=SKWTA[!L1BC*LMHZDX5*@/Q4&F-^0M+6ZR@BU2[Q-24*3*,G(!R M;//7AIN@+5Z$&V1 N;ZXJ.>8C(CAX*FX]B7>8M:'HGD\.(YXR3IJ ?)AW2K=WPD?!Y$Q.ZTIHHMK[!J,G)9 /!:<.-=W8@/JH4\>#J MN30%;*\T_7YOBM^_&+;A&CQ+68HYS]E&0I.0KOY6ZL:>UAZNWZ:[NSM#&7P- MS]H-VZ _B4XF/YI)FR"_SZ[]F+T+K ?QWF:O/,Q/,=_3@$2AT]ITB4>#F$"P M[X>U2!!JD&Z1:)O4N:NH95%>#,(_IYW!;*JZX!B12:1>P]E;DW!^6RH=,N@9 M4\38OS:(]H7+(TI;>8% F+9CAX.F8QN0*W LV8<]+=BVO4_9V "CR:A_VH*1 MG*%-?@V+E*M89KJ-1Z*4]QR?Z7W7/N^$NDNR.F5L@C+]"W5 Z.H:^P&'GJ1[4UR94;-"I6\7 M67&*<.TTTBRMW^!\J6T&IJGT?91@;?X1,36W.F7D#>GR)=_*P8*%G@)\TS6? MFD A^:ID R-?K4$7ET/;I!2_/9T9*E[=510$MJ)K.C*(O5B$O[ZVY_J62Q-) M]Z:X&G#0I#Q::]MUR**HRME,9R2[.W]E55D]K;GQP1/\$%N:&B5FEH7(:;S# MLD(\[3]]^L^F)"M3(9]%S7R'LK?'P84J&IK"*NN*ZHH:!DH6F@@E;*/ M$@A% ^\:5\?Q .3NW@5UM+ #UJ&;#Q1?X(R;F#<$5ZF+3(%J-D67W]@XL9K9C4O$()LLM')K*4C;M77 M/"]Y>C(O9=*ZU4FKDQ6!N$FPFR?\DH<7#Y'FF,J\$/ENR"Q\(M W!=&V%>RO M-SUA,3$XJQC[*<$0ST?S!\+UMJM\N.V,][/D06'J%O2*537S7BHP)12?[W:E&V>37 M1YA)V2R\$_'$A"0>-#NBF?AGC6/$8,(3<1CY-D64RDX"]C>E/S.@S-84>WMW MY,8KE 4"<=_H'!W4N04N8,4SI@H_G-DAVS\_JC]UAE8X'Z3HU4%_V)YJD%=3 M>GH6CA<1GYL@=774,H[>"C&#\8P2&>R>Y0[.:9C!=&Y='!2'REH_^+18%J*W MP5*70WV14*.:C[;?WH'A"M.4 RSV,F MAPJ5C<=34-N6?Z,HR!Y]J\)+MTWL"M%=2"\RA_.@X:5$@81PSJ2V C55AXS- M3 ;BR2]@&!E1-L1*W<9B8;&., *FT @ QB5,P#N)^5DKL7T*&9Q)0A^&8^PU M.(ORF\0;'$G":\CP.>49YC/Y86H'T>Y)DQA$O-7Y-HB]WT4>O>;5$E\M+WTY M1Y2XH-!SW5@\$H,X&HTG^'$"IC&B&Z?18'PJ+IG;4XH[87H\C";QZ(EX3).- M_I_@^OC)2L.V3U[R>(C_S&6\RF/>$_P*V6^\^8[Z2=@\&*3,VP->Z?3'H>5YN+RI3\.0XU6)FF!P J14 !D !X;"]W M;W)K&ULK5AI;]PX$OTK1.]@80/M/MV3PP?@.#V8 M8"<3P_9D/BSV UMBMSB12(6DW'9^_;XJJM7JR^/L!O A4635JZI7AW2^M.Z+ MSY0*XK'(C;_H9"&4;_M]GV2JD+YG2V7P9&Y=(0-NW:+O2Z=DRH>*O#\:#'[N M%U*;SN4YK]VXRW-;A5P;=>.$KXI"NJ=W*K?+B\ZPLUJXU8LLT$+_\KR4"W6G MPA_EC<-=OY&2ZD(9KZT13LTO.E?#M^].:3]O^*S5TK>N!5DRL_8+W7Q(+SH# M J1RE022(/'O05VK/"=!@/&UEMEI5-+!]O5*^B]L.VR92:^N;?ZG3D-VT7G= M$:F:RRH/MW;YJZKMF9"\Q.:>_XIEW#M^TQ%)Y8,MZL- 4&@3_\O'V@^M Z\' M!PZ,Z@,CQAT5,7PM%N2*,+-I5/ YPV%)2[X/!4XURXO)V^GTX_ M7KW[;2JN/_W^>7I[_X&N;VZGOTQO\5#@GM=QW4>[H@-PW MXJ,U(?-B:E*5;I[O V,#=+0"^F[TK, [5?;$>- 5H\%H^(R\<6/XF.6-#\B; M?JUT>!+_OIKYX,"-_SPC\[21>#,4-J*^<4U@*-ODBRLKY2IH@@N53G^9XK,VB)^Y;,C*) MLX/N8,"_0E8ALTY_@Q2?20?!=B[*1K)GR4L=,B%%*9UXD'FE:,]/@]Y@V*6K M9::3; ,GZ4B5UPLC X0,NY/AJ^X$VFH5>-Q8 2T*)6J6*Y%8\Z!](&WV_-"%-*D:'!(Z_7R![VRFQI#^GDU%;,)S5V+V-0WM? MX8;@H.SZ@ N2+NM395#%3+DF>3;4&+NK820L=O__:JX./-ED9I)+[_5<0S0M M'^0H]!3JVS=ID!Q"RGE1E5@K M 0@-B9^A 75KFFK/=NM4K4[5)OSS'Z]'PU=GGL(<'$HXL@A 'I0),8$.V@21 MQ@;4>:R9D#]MX(2?2:797&:$I'RNYTBMHTG(CK'7H+:JP>//5(* G*@$9 ^-ZG"#*^U:HPW4#-M%!%@+ MR+MKZDV]WSR[A!))"' 5+X4B6Q%'#V@"6W:__\P0QB=I1EKA..XKV3X!H_?T\Z$G >$D.1P5C /M/]?O/;JU]8:.$& M!]=/V_1[*XZ&QWPZR:V/,88.4[QHY[,#SD86;SVLLW@\ MV9/$SX7O>#_N,W$TBGZ;#$ZP("1"1W,2WI]X$GRP>56\S(_U#/.[]*G\6J\5 MTGU17(H73LE8HZ41&P-VY.31&*:)&P1# 3VPQDLX0&.RIE$$;U HQPB0HWI- MYEAS$-GUU:VXI\$@K<#MA.9:8JU?1SL6?K2\+C,H$IDJ;Q"YDF Y2=]2"NZJ MM03^^D 2>N*]?L!P9%*\*C2M<[O5KN96-$$=^(WC;D,GGMIL^ZN0'"S)WE2Y&L9A,'CO;6*-R@?S+*J%)P^JH!; M-K:OAO@ZS'M]NG(BO9(^\3C2.'$+[#IA\':<,,':=4*['04S!4>JV-Z=I9H0 M$QEF@!*S*L0XMM\W]DYD+:/JU%0&LVR7I ;%G[%$\P9I'[2/)0/Q:\T!CCY' M/>^+6("HMC8O%3RBOVB\ C2<W43;,D?XV8V!%OP9:8DN$ ;\'QN$>+ZAA0T7V&ULO5G;NLA//3*8VB%.^VM MO2]?'1VY9*URZ?JF5 7>+(W-I<='NSIRI54RY4UY=C2,X^E1+G71.WO-WUW9 ML]>F\IDNU)45KLIS:;<7*C.;T]Z@UWQQK5=K3U\%WS6:N,ZSX(\N3'F"WUXEY[V8C)(92KQ)$'B MWZUZH[*,!,&,K[7,7JN2-G:?&^D_L^_PY48Z]<9D_]*I7Y_V9CV1JJ6L,G]M M-K^JVI\)R4M,YOBOV(2UXU%/))7S)J\WPX)<%^&__%;CT-DPBQ_9,*PW#-GN MH(BM?"N]/'MMS4986@UI],"N\FX8IPL*RL);O-78Y\\6OYY?7QY>G"\NWXHW M']]?77Y8G']Z]_&#N/KG^8?%ZR,/';3R**GE701YPT?DS<5[4_BU$Y=%JM+] M_4>PK35PV!AX,7Q2X$*5?3&*(S&,AX,GY(U:AT7%NK2Q6BI__?7[CO$6R_.<)9>-6V9B5C7\8ND_*HPI]Y4J9J-,>2M I>ZMZ MWU$B@L,7[/ ;DZ.:G>2"N,IDX<2GM>*O9;$5:^G$$D4B7 >DI+NGI#V1T$62 M5:DN5L)C^S >S,7EUTK[K7A7)$"19)!X<4#O>[R /O=>1F*SULE:;*!*IJ;T MT* +\5M5!#E]<2GQFO0(6?FUL?I/Y5C-"D'RI-,L@X&.GF!>#L-0*,D7(8M4 M0"8LQ18CRLHF\$GM+\(+E9>9V2I(H!VIMN (8UF>W^$1"1BY 6'0_\(4A\TV MR"LAUC 09;$$4U@)V+&60A K!D!MI4R>TVX6)HR(S %NM6(Y5X%9B M;P'*AB$%A[7>&72R'[14+$UE0P[TQ<<:YUOEX$.2&!L2PO!ZKVS>XLE&-9$G M>V^4T'FN4@V_8;0)S(K8%;R^E,ZA(_!V=(!(K%2A+##&TELR:&.>2KI/76B+177S!WQ@(],_T&B8_=#E1:(LPX)L!2DZ M42-T%Y%$EMK+3/_)C@53Y6IEU0I!%465WX0J>*14_1JIOV_F+MMV@#*!U P MDXGKP'L-".B7*-#"(.F_)8I"3-&LC;+76P MF)7?TS[Y'[7_PXGS D*?5ALX->B\_4M5#C@SRZQRX@":2NMH_1)IJ@M*AY M!0;)RJD:IHX@]:W4[+H-_6U#S9W=E[5SJ"^B;BY;2XO%5)O7_ ^V,QB":# M.)I/9^*7.C=FPQ%WD\MZA$V9.0;#$_%SFQ@'H_$LFLX'+^\JN&\A-,QGDVAX M?-Q(#$3RX-KQ=!I-9L?/AS2D]8]%]'J7'Z$?U%@2PK\C59Z#ZG >S::#%M/! M:!I-AU/Q&:()OOD$$ .]#J+#:!)/GX7G= 9$XWKN;(XQP=*KYF#2'9Z_LZK; M'"X75U=M&]BK597IE:8P-%7?3M%[K;ZF!I(3$0=@(ERAIKG)F[(TUE.Q;?<. M4?L=\?Z1*M4NH?& ^J_ELTXIMQ;9 :W(]YH)B.";N->2J8,2CKE,T:9*2&W, M;'53QZY+F&R^>TYMFQP(JBK)ZLFD.VH]T8MI?4ZT:7D86O__%$?-UM\ M=V^[&#UV2"9\!I.?6HQVYX,,!Y?=V370+,\G".:>^T39%AC9+\J+6YE5F"K> M[M?,(=<,4:,VZ:.E$T?U(91GGGDT0<+7=N_UCIV'NS9$X'?"0+<7W'1=Y7-9RGVR,9*RMC:='0^DYUZ)#T15 MW?LW='M:9RH'\]W+AYCA?D2 5U,A(3-VV+]H:?V%& RF8O'8/1$F*SS3U4)B M5@5*8]<0CF.0)5TXM+/G4P*:78/!Z/&;K,MZ,7< 2DS.2,*L[IZ0[J$82(PJ+E.3V5%[+O-%_2S623YI]8SAZ( M/RCSGQD+Y8 >YFV^"E*W*C,EST\OQ' ^Q=\I)J,7F(GF5";1#%/,+^$"*Y!W MBOS3=,G,D^MD?C,=BB)B,6,0T)K'H]A#U0HRC\7PD M'KJ>/NK\$) KN^*?.ZBU@.7#;P+MM^TO*N?AAX3=\O!SS'MI5QH,D*DEML;] MXTDO3,G-!V]*_EGAQGAO^;2"RD1 !W,P &0 'AL+W=OEU-71NS?\V'EV>_?'J@M;S@K]KM;7)[X(D61KSF?[XD+\]FA-#JE!92R=( M_'A0"U44=!#8^)<_\RB2I(WI[^'T/['LD&4IK5J8XA\Z;S=OCUX=B5RM9%>T MG\SV+\K+\YS.RTQA^5^Q=6N?GQ^)K+.M*?UF<%#JROV47[P>D@VOY@^6_Q\<_/A_N;] M[?V=N+R]%HN?;^\_W/[Y_>WBP_N[-ZW9(7E.6NH57 MM5;(*A<+L*NKM:HRK:RXUC8KC.T:)?[WH7D2J%TSUXK^EY=]P M'$0ZOE8/"+>:Q/12'I/@JLFT+/2_)0?$Y;I1BI<D"GHWW:C<&Y9RVHG<(AJ5"YTU1HA_P,.MKK= M\+I'&7GR^]^].C^?_Y@LXD_.?GP*TL(T.3@$!RN9Z4*WLE5@QK8 EUP@4 JY M-(VCC$7J018=ELP0Q,PKT\\2)I6HU)=6P#F4WW8O,N 'B0[&X# GXI>*:4(7 M41BGFEHV+;F4I(_SE&"J.6+_[.6/5OS9W"\^B59EF\H49KT33W25=YE>%DK< M[*Y?O3I=7%_,P=ZQA>1=P?S,(++P.M$WBZ@+UN9(24Q%KE:ZTNWNV- C2)B+ MNX_O+S_]_G=G+R]^].)9 :QW,I@6\D 7Q'X&S ?SJMK(*L-&XK=N#)AL10;5 MZ1R/H9%KA821(Z8$P[8%/%IA5N[ 1F5P9IWA2.PUJV/\EQF<5[>BW@!=A\I3 M7VJ@-U'':BC26L$.UF[-<2N;-9(6-)*/? T?91-?X]-/Q+UA K KK:[@UM8B M&"5.^?8D4R[4"BIL[5"8-4YMH3@ELXTP1 62-&8G M"QAD!2^9B8I2EMH++'.Z.&3@CU>J*%-9'R M1K8L \L9-PB[ 3$RY(/.64.P36DH_%BC[0;&AB>J?W50*1:SWWC7SHQUP1G/ M/:0@\@O>(8O,HP_M ]F59AX:8M<*BY D=]F0<@:PZ"1+(;\@$]<:R98(@&A7 MM+D[]K]2O:7!'P5C:HL,BCW@!+1LC-+1L,O=&*F[JB!04;(I-"D+9M*5 M;-U:I5F#1'7'KHHWH: MU)KA[D;E.D.Q$3/MU>(F9I5!D@\1*7LN@#2V0T03Z]N- M=L$8"9IEBQ:!HCU&=4,5LY-4-?1TB%[$8BT9I_U*LZV<9-64$Y@$OFS[$JL 7L5 MPLW*PL&[S\83?_>:X1PWHQ.3##BIXFPHXL"!VTAXT8O;J,+E#U[DC\X#[8G. M)XKH%8_ P6:JSE(]Y 9TU;'3 P,#0IGB+"A/5PA\17E"P2@ W\:40V8;!$W5 MP2C774B2P"5DN%P !!L(2=JBAF+(;JY<_ >P_6%^\@+J+HJ88);!R:@PH9]; M2?K*NL8%!GGB:VQN3+?>$(6YTY<3/:'U!XB&P]:Q&MVKEB%-+Q:!5=4;-S#? M?24:3L2-K'"H2^F^%'68KG$"7"UX=OXKVLY83(V5PDM*PFB-$QYC8&.XI49E" M%:X\Z@@0N?7T8K5] Y\FIXK2&6<5VDUP'S2V<_PNT?MR74 :%E31#I-695H> MQ:''J$VUEU-7_((H,$6UE+C[WIJ/XU8KX4_6-:233FM<$0<;,KF.J(W=E$&* M\ ZNYB<$ =N\3T5O-P? ^G)_M=)W&PP89N0I@!DI-]A*-Q89)MMHN!S#"\>\*W6H9]-0,7K1,"Z(!%W^H/#=XXT<:3\\G^^C M^!_3XAIP6NGXR":"+_>*>(@@UVO?0F/<,O4IB,#!=7RV3\O!?-Q93?PFU$^\ M'&ZY)LI4.]'64K.1-_#:827JX\Q+5! \N.C@6G10?D[,,4*;&1N-1E %=<^6 M.I^::HN6(J1'9^K=2>Y)M8P>,ZV+X9B=&^V[<$H,J9L,%7)+A;P[S*8>RU ] M/IR5MHP!D8NDLCLPYHNZI5BA($MS&TW87,IWG<\@1?4E.7>^7F'4^8:)&G>^ ML]Y P;;<%J8C2IS\5UG+:K\'[1W'3'*W\PFTEW1V72C.8:[?%.=]6+14YC'F MT323R/'(8!H9>M4C03.T.K2&E%H4H/5Q(]$VNZH$U<<7DLFR/P?MS0ZP^Q77 M7RJ7.:GX43.)U--?Z;13_GZ,L&AL/#QL $JU2']0V*B"?^>[U$1S' M+YQ91K5"#R8T,;=9HY?D)DOTFB[K)Z.V XBY-1UJNZ5RH>MZ&)#@UF"S!;=O>Q-C1C\H/]-X3:B$I:^?H M8?($ D]\D9A[':3DT1\M(9*I@NB1&W1RFN26NDSKDU[Y@QHW#H[)HE/ WEN7 MQ.IUJ \8BP:!!J55P#4-K4A[:#+0Y\NSN6OR NMI^?*@1[:V'AN8#IU[_?I M8*Z4N\1X^\.732K'\[M@(Y.S&&>7R"$^=:: MP/D&)70""YK3-2L$&HWJZ+H U3+/M1N1T3Q<,? 218X/'FVR],DUT_7>5G^P>L7VO _;F3 M_GM/^^V7]CV%[=#L[$9I# @>_"1MF[CWI0MH-Y ]T-!,&MAI"YY,,KW9A]"4 M-M"?*[,]WM =>Q\0X;YJ#V>/]&$1VEAFSS?>,H[R6 LZYH]3%/S[Q%99+38$]_ M?'H7O^#MXA(PBSP99T)NY=-A&\AYT9_LCW*)7J.0Z3*=NPO&>$E,_3^$&]:+ MW!K<7_YT/)^_%$\6UV>OQ>+RT_'M3^DES6Y$V5^YJSS.U]QP[&4L"8)]*[JM M*-T[)XK>.1%WJF[=1"R\-N+F2\X=C+4Z"?]^IA<(<;&VZEK"7BX@3L3-M;@D ME["@N^?VA3! HE"#2YZ?,PR\?O3MB&2J/GKA8'07Z-A.J3, '/&0^5&FCIZ. MKD>^LG[(;PB+=,OP'MK'C^Y3RT+:&C7L\>M!'$_NF4".NV/ .U:09HV=-;C&Y#1O5\W:CCOI8? M7)[VU>;L0-BXBF:6=/?D=.,[LDG-RT/TRV[=H?Q\=O88X(9[,7>I\%NCV*=Q M(C=X^',=[]LG_AAR_#"XO^. H4-SP^\#K+^+I4-]F')0+SY<^Y%)&IK3-W\0 M .'N?.^;'PX7V._L,(+&L3.:>".?JG3#I^+NG#X:.S/R#/A MW+]2Q!=!W 1,+C'[,#+#( /5K'/U!KV^,[Z\B^@UB+%XB@#*TOW7\V0$VYM9V&NV>271#'_*1H M7/MP(A8;7>1H6>(EQ5^,K74K>=;S-X/N"ET+&0W6D\7)#$UQX2;VQ&2Z8$$- MX([J1L57I@O*?C.*5R5NS8FX6KQX=7;Q\N6):U! WCHE'K@J[6,GBU[X7I934&&R;544RN&MGE2"KTB@HUS1(M8L/>GL,_ M<\:8/0_)W@\XBMXXC*+/^KX ?:>O!X_3GGLKFRKE1GVI^;4N_/WU9-# M-=#5WTAP BG$=>D!I_AGL_<6PFQ(&;/H2O54EO.9D_HD>EHY*E^A6$S]91? MP?#VDVN:C+1)Z(63@-^J3H/^OZT\A%3G7V24//V10B=L9JY FN(\1X1 M#K@"\WMK'GP3Y"W^G8Z7U-0'?[IM!- MS:C^X*M<@ES:'ZZC^3TW F6X!N4[]K';R[OKR_]!/K ,WI_0-MA]K^:?)E^& M0$VVYJ]\6/=VH?M>1/PT?JODTGV9HE_NOI)R(YLUS0$+M<)6M)_/CURA%/YH M3?=_4$L#!!0 ( '& 9%/& M])S'BA@ $Q. 9 >&PO=V]R:W-H965TFIRU:JE&YDUJJ" M;Q;&EK*&/^WRU*VMDCEM*HO3R=G9D]-2ZNKHS2MZ=FW?O#)-7>A*75OAFK*4 M=OM6%6;S^FA\%![G;UZMY5+-5/UE?6WAK],()=>EJIPVE;!J\?IH M.G[Q=OP$-]"*7[7:N.2SP*O,C?F*?USFKX_.$"-5J*Q&$!+^NU47JB@0$N#Q MNP=Z%,_$C>GG /T#71XN,Y=.79CBGSJO5Z^/GAV)7"UD4]0W9O-WY2_T&.%E MIG#TK]CXM6='(FM<;4J_&3 H=<7_RSM/B(=LF/@-$\*;#R(LW\E:OGEES498 M7 W0\ -=E78#_^73ST_3J\K^FGR\_70W$V^GL_"=^-[O\Z>KRP^7%].JSF%YF7RXO+]S-Q?&T*G6GE3EZ=UH B'G2:>73>,CJ3/>@\%Q]-5:^<>%_E*N_N M/X6KQ?M-POW>3@X"G*GU2)R?#<3D;#(^ .\\TNN:R?^>SIWM06!_)\#&#V* M&#TBC![MP>BM=-KA4>G1?93_$V ^KQ3H36;*M:RVNEJ*II)-KFN5B\P ARH' MGQ;QBJZ]XDK>*C%7JA)@+-;2PCI=X28T)+K>@IC7*U$C_*9>&:OQ0-CR930; MB:6JE)5%L<7#U1J/0RR:JD8M".7'\[__V;#(Y>_G3='I-'\WV4K62T5"$19:DNUG #Y?JX^WT0!'*6.1-%%>\5Z-9R-XLBOH_5NB+NV!R^4LQ7Y ?8 M[-\;#<($YJH" X^+D=BE_*I$IFP-+D.HB!"2\;B5K(1<+L-V$%V!J M+,E!B6) @BJ=4[4;B$++N2Z(&0,"H^[6B+L;B6E6-X L( %&VL%=FB(7N0:X M5BRL*0&V -WPV$6';!JHBR/G[Z MT@EG&ILI(H?U6W(03- 2I%H%4$7)!E6A006Y!6TJYW#]8!,%Z";30@.%7+-> MH]HMK6*&$3L_ \MR*=[!"859T_,+A9(BIB6(2R:!\)=5-HKZR!NB1B)3XA'@ M&]"I XJ[IP#&7RHP M:A@8 K?59WTHF/[\04D+<.:'"!,F;#Z>&X9$4X .1&Z;)4 $ X^H#H25&X&R94%K2,I/P3RI.S!@FB7=@)ED%#2@-=\2YSR? M1R(( MCFUBI:EHH_8'T#!],.\">50[D&/ 'GVD(H 1_C?9?&Y'0:!Q5 +%+< MRFL4:QQ$1!@N.8)(-P>JLH& G9N5SMAF ^;((E2T+-Z!'A9LZ%4PB&B,6@+#EJEU&I?*3<"C;&K*/1 M#Q LQFJ$=]VC5#I%:^W1&HE+-I$!1G?SW_9L0\;E"M@/L1M(.=(VX5FVI+3M!;)2T3 BVU6X&D3.SM7($VW MRNUBK.M]>))/9)U [^W0PE?Y4!8@V.)6%@W*U&8C#R(IUI B?!.'P#H(,FV71YDEK#L/(#U>" N;% TX/LY MZ,E")\3UL$?HY\,?P<6 \9L#TBBV)$R>$2Q^H,X)B_$ %WT4GH@>R#&-*UDW M5@4W"@9A3OSNYRCNC4*!-*!#'[(1KNO@DR-9,+=($5RJ34Y'0[XDX(YX,;$V MP&B2%WA*TMN[OGM%A9PF?XQ/2R6=OQ50!+0.+JLDV !VQQ2,,3"@^T#HA:@4 MZ*J#] X\G.1>R"RK"I*+(%JV=7@C\5%#D%>C %[++0<&T]K'*1@7 M^L"%4$HU@EC+)EJA^D6W)0L48@KHC-TBJ8#@($84TI3QM+4_;2 V*I(D\@E. M ]T*/C;NL$.D"F1H7SS) MT$)_5>BM&$@).)F.9" -7!#B(QW 2 MOM<6^";!' XBEGT$ 0*M-"XQMA=)(KSK./I= MVTK;2.L]@7?TJ.,JJE3$("XN@GE,S28<9[:R +/OCW5D&Q,= B:\Y/3";7(=I.M0XO(T M)BY/#^8<%]*M!@+_%>\A7:0@/\DW:PA![, %DLEO56 [P8B/@!Q*-1#+=[P K9<60'>V5=&F6 M'8U,6AG:4S&8RX+TABJ4#@'!SBW!5W?H>!W9)TP32LC1L:P#QA187A!478%P M-#O.8VUJC(=]*H1F V&,.I+CZT7.)R *8\UX.8@-I;;!T54=.= .RT(^.L'3 M()?[C0G(,N<$ 'MDDU=:X^.KTTF$1L. M1\',HHDY]H6-DX#S0QB0%&H0WMKG;C8%$*XUR7BAOP'^2<-9I2 MC'C;H"X(Q)9(S+=S.]<+;A&8+2UD)#;81\][TAZXE>Y6H2*GT*@FA(MA@D1O MLN0_%QU/S(:6)]@FJ+#]M>=.<:8YV(=6[@JA0= M2,HZ @)B98H<0WF#&;!"EJ(7&R89(&U:J)$Q"X>^#2+H\%5QHP.B#K MC[)[K&]/()%W7X?(<*Y< M&$_58A[WDTN<\/6LMK,I*0>P!%^2Z?UONJ>=^ M)/: ZG < P.J:U%4C9MXEWBK4/]E&@$1 %D]V@\,,G151V]SFT6TF; MYKOK!B)G"F.;&KUK*/:$DE&G_I0BB);*HAY0Q<)75?#HUA0@8SSW\SWB$S:R MT'#*VIK='OO36MUT_T.-K\\R$?,]1@ISD'XS^QU^+IK9!UG9B.]N(CT2G[ X MC0]"%1MXIDF[[QNN5HM(NM91NCR--LJJ (>\"]RP09GX<5,C(;>H(#@',P9* M38%0:7)5_+^W+N.SMO-Z]@W[$C1TA@CU-DL/0L"._0NW!J:_/EICU\[>JJ-= ML.)ZUQ"@^-RK-+?F(8EW(.7)N5*"85;I%7=O:+CMA&L_$"3ZR"L:DF[ Y@5B M-V ;83)1TQ\<'>?2)-1E0_P60Z8^YOQ-$;PE+L@&67)1-\O!N M>2[&$6ZG:LA[4W=0X&'(9"Y24G3?;K$4>D*"DY26J9\6JLF]L&_5EFT$U<^I MF>#=!FF8B\IV#^IN2Z#;6^@M3%)-:PZ6663@ K%_XH6B'G#7@V](!;PJZR$6 M&_V6%JV8LHD"V\NM;M?;!>AF^M2U9#BQP''/,-/W;#^0H:!T;FTXLR**#ISQ3LU;0PE:0$RRB@UX%JB)!8LB;X^E:0?@)'O MJ](M3'='QP_X'*3K<3LU'W^)KGU?-%0H!R'695/NDI0DH8NWH#"G93(K/D0[ M6"1D?/&VR-/^)7&!1*C%$^",4_"EJ M0KKXQ70LU@^!--[7#SCDH 8:&A<&(//12\A M<,*%A!X-(@J&[F5O-Q1)#-RN%/@^BZF&&0J<+VPF-B.NIR!4;F/QTOCP@[*R M6E5O.)@=]T0?THK\&=6QGDRY;O]WKX7X8JOC0J7GX MY#TP-;H&CMB(T-R:F"<%=/0;V*\FJ>7/ZD[7?M-::FX7ACZX[,0EN!I5#O2\ MTZN8JWJCJ'=JOP)8JL)F>BW#8$N8-L+^$"_Q[-F-0G'8)(XH44%-HO,),IAK MET'DWY#%I;F8X$-@3YZ$-QA@^\L&P4N'F%J*^K82B*AV*&-)A+32H*B0,/K\ MC0J@PQK++_$;SP)';8_P-9S;AMGM4L2EQ=]GDE0#U37%^.TF74%VZ3A]Y;HK M%?YWF@&DA75;0/>[Z.(Z!/CD69.H#_N']]=,D\\04A!X'"'&G76)_/ MB2L#"CX!UY?NI,/\J$.TYV:.M*85P$[IYU6JMH'D1VW8O3>5V0NQSV5[V4F2 M(6*-BYMWHFI/0 R6BH*=5^3'"S NV$P9@X+1WJ'XO3$U-:AH5.*XJ;A.I_(3 MGLZBT3K&@2NB'*!E&&NRMX_&K>OPF+7[^ MDL9'E:"+78QC-]'W!,,%8U*24-L7=!GQ@5":@.:@45E=4$\7N.;_>DG,8FCG M+3I]W.N ]650;-@L011\X*J%CM=C$%;4X=PC:<\*#R! M* 'SR30VI!;H7>QX ^JI@.\5Y7(^UHQ/P[3D%O([3L;T.>HW ^; ;*4A.>FQ$)11MCKNHDQ%87RU'(%W$9( M@\92Y,+3"%PZ!V=@FB5W;C\P;/&.<4AV7!@+UJ<=TIV%^N[T&%D"9L$?+W#TMM.>8\/SV=CVQ0)$6I_%\;M"=;^!!SAG\;*8D9/8Q[J M_XXQ5AR4\-U BJSP&_:B)(K8&&*)KY;>G'J@D4YMC=J722$X]E6_ML5=J9H& M?Y=8V*A]8FF0BRYVD[K8'Z9X.W0]/CPS?04.^QD^_2&\!$[_9P09@J$&Z5U1 MU89/*.()5$+$T9L.Q)1S :+>B?D@!U4,G&(1&ENBX2T=2TWUQ@PI!HI?^^>6 M/-[6BT88>6*<_P(\DUK"' )C#18K3E#?@_X0F+ZTNJ%7@E0^!%FV$M*;JJ'1 M:YR"X5(LS>HF4H\=F="+3XHX/LD-XP?=XMG"3[%%(.GD@?A2X; I88P-3&DK M +HSD!F3'LY=DE<;N!Q,];\XZ-E2A#P'Y]&X,?GF 40:B7-@VKQ;H:PK=#@*^V MOJRW_[R.;@3Y"$DH);3WL.#Y5?[L)]:0=-1/(D]#KR0Y+$#QKD-L]:-MH>1, M"1#5.UDDF/K>L\57=7K8R+XQ&(TB6$C>W]4M!]ZUD)2 &ZH'93OK^8*1E3'X M[U;+.EG]G^LP,-(!-1_:[[E#?(L%T1F$N#5DL/N8U]-T8HT/:<:]"5H.3%Q7 MP#K .C(>ZJM-FU6#0'HXBF#'#IXH.O"GQ5&\T5]10SSP/@,TT'XE:JV!&C M=&A#P\UU; M7^D-$OXRZ"*IUGU,,O?+2DR;)0[W3,[&SUA#/DQG;T.[<#K[(J[,B+X=CL\' M^^ N<#)XG>08U-P-WZ,[]6-GX_$>_)U,O?#&)I,+R28 M]>[\!2WQ26FH'"?(_RRK1H)1&M,+>V?LCBN##1OLRR+H3F&GG?@;[2G&DPI" M=.++$[^P$(%@_]Q4"K%_8^RVTEB3H#(J M'FNUHE?^J"Y 2;.?1_#B%7M*K!;XSA^ #45-E4FW(\A/>@7Y7RVW?X%HAA<> M0^1^4$9G#6C_[TWBV=,!)R1'E+D^H62%?XXOX^=D44C;+DLL/857&8R( KA/ M<(<[@HAT -+C">VT)P:A&P9%YZ/_P ML&#=)KOP'W7>1QMBOU(O-+]VCEAUY']@!6SEN@G"V?H+54F M?+'M4?/GP[-'/TC5X.M3R@XZX^=XS[^K?$E#83YT&#\^8;GNYU18]FAR$JU" MKO,?XI"88UY-M-?*S_]'2X+YQRUJM_/=="Z"6W6K3>. =AN+5AVSB$5\ 3VK MX[LLZ==N%?J:NV]0M8T#7ZQD([&*KVB%B>(?.9]%H"7"#]J6AQH5@NUCI3G. M:]";A-X9#_!FW@Z[$FRXLHG%32*O@PYUBKGAONW;09?YU+G'5Y8[ET^KO$GV MO= 6HN+?P=#Y5XC U)UWS:2.XVY4FG3Q]PE"RV :M:0Q@59W M_X_\_$-"T,ODW2P,,3THA-,CLJU$SN(,Q9H#C"AZ/W7A0-/RA \L3)RZ. MG$3L!O'C.9\3P8ECEA+(VYK8[7A?*DO'8@\'?\I%NJ]8.KNK[#DI;)!QTWJGSJ_U<2ELP\=NX4,*XQZ$58SC9X^/N*!TO 'A)7TF MI(\K"%V5Q07P_<*8.OR!!\0?D'OSOU!+ P04 " !Q@&139J$*IXP& !1 M$P &0 'AL+W=O9,S.'PQ%/UE)]T4O.#7S+LT*?MI;&K(X['9TL>[YC)N[U43A5Z>1DHJ<%UK( A1?G+8&WO%Y1//MA%\$7^N= M-I E'K@0]YEI$@A/&UEMEJ5-+"W?9&^I6U'6V9 M,\V',OLL4K,\;<4M2/F"E9F9RO7/O+8G('F)S+1]PKJ>Z[8@*;61>;T8$>2B MJ-[L6^V'MRSPZP6^Q5TILB@OF&%G)TJN0=%LE$8-:ZI=C>!$04&9&86C M>9 MLYOIQ\%X]-O@=G0S=N!\,!O-X.8*)M/+V>7XUG;#8'P!L[OKZ\'T5QJ;C3Z. M1U>CX6!\"X/A\.9N?#L:?X3)S:?1<'0Y@Z-;-L^X?G_2,0B0U'22&LQY!<;? M Z8/U[(P2PV71@ZAG$?7V(!HRO40D^(3+KZ5X8)G506"F'-6(Q/ 4JEE3GDA$ MDPF+[Z7P'-1%^>%8KUC"3ULK,E0]\-;9[9+#0F:XN45Q#X9"#RLE'T3*$0;N MVUV=Y)/$8J$G\">(U1:Q'5=\)15]K859B@(,ZIJS#%W*P5)>8Q6R)"UZ*=<%U*+T-B8U+EB@';H-1W:&+#6BTN\!:803 MYUPU7((+GM0]GNUQJQB0%<],>P=>W_'#$!O=P.GU@]W0V-F>$[A>_;RU%OP- M+[W))M3MNTX41@0B=/K]$ ZP+VC8%QQDWPS/B+3$B*.NQOZG9'R): ?%_D^T M_PS1PH9HX4&B#9)$E8CC\AM6(YI7^&X0AX)/@LTQ[$;P%YEV4.[+3-LHX[O* MI%66;94!\DT+;38<:+AY_(^BNE&Z8M\52B(W1C%%U'$C;V<451<&#!9@AKR/ M*#2&P,>(1A#W^\W,!$T5"0:8S&(*J5G-])PPB(D!H=_,S5E1+O! *A5MK5IB MX$-O1[&2"ZZI%$.1Y">1H O\N(\PMTHK)W6# .WJU@1C^[V9E$J1#;M>?0>! MT^WV\=USO# X1)ZH(4]TD#R73!5HF(8)ZIPMF>(.3*1!S7@R9]_A0F0EU888 M*$2TETD'E;P]9VG*)EA-FZ6E32+S5;FM&+#"%(EU44JHR&\;]"M$KPG],=PN M%>>/BB48(Y['/8]8Z*#_$^1A)<$J:.1MDM:+3'W6Y;YQUAC_*$2!YG$XRJ1& MZ5N%'RH[CU^81(SWNUU\'\5Q1-]'GH\]H6WZ(1(]> ^?D(O'4!:IH!0U?^PH MS- KIHQ(!&T7=+QNX@I'O;#_'G[\(?8]_Z=G[^=PF*GDV]"A8!S+,5+6C*7, M4JZ(LE'8>P7P9_M[P-,/[($K_-NI)&#N+ UF4K2CN'?JX'NNX[FQTXUCW IN MT'L6K 8X.!?AQ#MJ!U*!<-+&S)N^6 6N. M.C!S9"5EE(62^=.DI1OOOH+TJ9I]_*'!S<["-&GUH10A4TR!U?\5:F+:#O F MP*@605JSJ [;V?)K668IS"GI&?%A0X3V&]/8L()5466GJL4M4=J9J'M6.7+* M4\YS:P_6!D@%(ZJ$KPB&1^@7'$^\#;=Z3H"EDNNZ=.3UJM9GIA0CSU,2*_'8 M9IH_]IN')[@7(EUH6114RR8*<1ET5(8GD*T+*E9#WPFCP$[9MFYJPN]7X?3C MP/&C"%M>SW=ZD0MW:)"V^Z)AS9[-XH4QKG?!BW&7^]&FSMQ',3]R^B&=^1'X M/IJ%./O1B\=^9^>:(^?JWE[F4!V&AU=UX]'T-O=%@^J:9#N]NFRZ9NI>H LR MOL"E;CO"'Q)57>!4'T:N[*7)7!HC<]M<9M!9. MG+6=EO[W-W;2M$#:EWLXW4O\.;^9^7EF[%RLI7K52T0#;XE(]65C:4QVWFKI M<(D)TTV984HKL50),S14BY;.%++("26B%?A^OY4PGC9&%V[N48TN9&X$3_%1 M@-:[_7!>C*7\M4.;J/+AF\-0H&AL0B,FA5>HQ 6B,SX56(V M*I56<+^_1?_A?"=?YDSCM10_>626EXUA R*,62[,5*[_P-(?9V HA79?6!=[ M^T$#PEP;F93"9$'"TZ)E;R4/>P)#_X! 4 H$SNY"D;/RAADVNE!R#0+WD_'L>3JYGSP\S6#\< .W#R^3 MV9,=PVQR_3R]?;J=S.#DB!'[2/X'4J,CH.KW.(#,85O#"1(]QP'0JI MB5BXIQ0G>U&.18V,.=":/@" M[<#K#MO4<9P&W]_U@H'7[7=J%Y^D8>(3W?\"\$AN]*K52&T3B6XVYQ]/L]QX ML)*"_"4_-^=U$?@YYJ9X!!1 [OH/O7%5*YXA'H_D.BM4$6TS>2#5"K,I#*?ZIR5 MJ4I@7='[[ZO8S\^>BC)W-P<*RL ;=H,#:VW?ZW1[\'B(J!WV5F;;!MZ03N;C M+.GR.V7AVR/VH/+^8!U_,[IW#2\WS7#FC&WL2NNZ2?$%1V ZW'4IKMP"JH?FM&_P!02P,$% @ <8!D M4]LJK[.K @ X@4 !D !X;"]W;W)K&ULC91M M;],P$,>_RBD@-*2Q/#1]6&DKM643DQA,ZX 7B!=N MAZ;2R'+O5(HPB:)>6#(N@\G(S]WHR4AMK. 2;S2835DR_7.&0FW'01SL)V[Y MNK!N(IR,*K;&!=K/U8VF4=A0#JWP<1$X0"LRL(S#Z/. F1Y@SE59 M*8G2&E K\#O 7!G[W/$=);F<&YJ*93@.**D,Z@<,_L(+C\\(#TPC, ,K)2B9 MS!#N"HWXY +@(VWP=.:$2["%VA@F<_,:Z'PMEDO4S2'_.Q7]I]4EETQFV)(X MA&FIM.6_F$^ZO?R<9!LJ,2_AU8M!$B=OJ1F)^_"I0DU\N6Z?34RL<^CVH-<;P*(@$6\(6;9-]IBD0Z .I/T> MW"G+1-N&)-&;)GW7ZT2N/4WB+CSWUX2MO"M1KWUU,<392%NG8#/;%+!IG;=_ MS.OJ=\WTFDM#2E;D&IWUJ5[HNJ+4 ZLJG\5+9:DF^&Y!11BU,Z#UE5)V/W ; M-&5]\AM02P,$% @ <8!D4ZU74EGN P Q0D !D !X;"]W;W)K&ULU5;?<^(V$/Y7=MQ+F\QP8(Q)( 5F("%M9I(SO!(U\EQ@I:HT'.5OB$YGL^4S1KU5YBGF*FN>;Q-"@9&Q'A@-:[Q"(:PC2N-G MY=.K0UK#_?^=]QN'G; LF,8K*7[PV"1#K^=!C$M6"/,H-W]CA:=K_452:/>% M3:D;]CV("FUD6AE3!BG/RI&]5CSL&?3\(P9!91"XO,M +LMK9MAHH.0&E-4F M;_;'0776E!S/[*8\&46KG.S,:/9]9231,LQCC]_8MRK5. M.-@E/ D^=?B$>1,Z?@,"/VA_XJ]3$]!Q_CK'_!EFD*K,@%S"DY'12R)%C$K_ M =.?!3=;^&>\T$91^?S[2;BP#A>Z<.&Q<-15<2'01KM&Q=?,5B7<<;;@@AN. M&IB!&\85/#-1X"'&/XU@N_A2YRS"H4=MJE&MT1O-$X2E=;JV3FUP0Y(-4XIE M1D/"-"P0,T!M.)4ZQE2&)G%*2RFHAX]G>6$:L):"\!+.[2701A+Q"U3U;A(A425I.XD/CUR_ M?%TJM!X,$AP#BM(#O]GOGM W/#^!Y]HI]+M-WS^!ON^&Z6M.O4]8R#*%TRTR MI<\@;/;ZT&V>AW"8E-QM"HV"."P+PT'\_Y'4;G8Z8%FZN("/-$'%$QPCZL(N MNL_\'4)CSP*B2:YY3.6Z5TAT'-85S;+X.)4*W<(7^/VW7M ._GSW=]'HA<&1M;;?Z(1=F!TCZLWWSF8W!HT>[ T!#)(C/E+5M+ZS?*N+R:W]3+!\X]4RN>:1"X)%/JRJX'JGPT ME!,C+B"1J)!W'^_4[4K+L MKHX:8/VB-_*>(^]Y[GBZV@KYI%)$#2]Y5JCK3JIU>=GOJSC%G*F>*+&@D960 M.=/T*M=]54IDB37*L[[G.$$_9[SH3*[LM[F<7(F-SGB!UU MQ^WL/]SS=:K-A_[DJF1K7*#^4LXEO?4;E(3G6"@N"I"XNNY$[N4T-//MA$>. M6W7T#&8G2R&>S,NGY+KCF 5AAK$V"(QNSWB#66: :!E_UYB=QJ4Q/'[>H_]F M]TY[63*%-R+[@RZ$'4APQ3:9OA?;CUCOQS=XL5'=V4L=AR.#T'G%P*L-/+ONRI%=Y7NFV>1*BBU(,YO0S(/=JK6FQ?'" MD++0DD8YV>G)XF-T/[N81HO9>[BY^SR?W2ZBAT]WMS#_/;I=P/D#6V:HWEWU M-3DS)OVX!IY6P-XKP&/X+ J=*I@5"29?V_=IDX#6\E$F\,(PF,&<[$IJ&2$I6K-$^_QDME9:DFK]:G T;9T/K M;/B:,RWB)[@KK1(CHT2N=Z>"V@IC,O12E2S&ZPZEH$+YC)W)0XJP$AFE%R_6 MH UA=8[Q?U"!IF%EW8ORD CDGHPDL"RK1\N,%0J2C;0H9%20<\@K$M&0"$2! MQGR)LN'ALMZ3 E8D\*E(-G$5O6C+9*+@;J.5IB&#R32\Q[BV=ZV] V[7=YWN M. CA X5>DY/0&W0=QX'9"\J8&W9^^2GT7.]7H#1<(3=SS@?#L!N,W7?_=?#M M"LG#./2[WFBT1[0!.CUW& 1=/QQ!"^-^P[C_!L9M&!K";<0CBG@U.#<1/R6" M5N3_*0)F5_1C-7"/E"D\-LP<;;O2Q)>"Z[?HP!MWP\!M5. .@F[@!?!(T(;P ML4^B(+Z/-.!U?2=XDP*"D#3@M+$:-*P&K:S.%O-Y:_ZVFI^F+MJ?B"!6!V*V M7*>\L"18IQ6YZA)N#27'M17.[3RQ410%]>Y4!+[YY! %E*M5ZJZDR 'S,A,[ M)*V<-0EW!JX;P'&AC$5.[8!BMI#@BWE&.IMCL2Y(9X=4'3DD"M,3&%;4]P#V M5JX[:"-IU) T:B7ID66;RD&D*+15@3I%5BM,2YXQ+N&9G*!AK*ZJ:R-4U#H!.^SSE$#>IHA[KIXN5A(1.*4@[5B#I!6 TPN' M\#.X/3>DVZ/(*+:9D>C8Z0U\^A2ZO9$9FA&=M@AD?(5POD,F28Y^+QA T',& MA_&$))Y0.8$=Q^P@FOV]10)A(X&PO?I:R4VMY&Z.)3>K);?,K'MN1 M4_IH]7%:']]-%G(C,EM4? M0/6B16F[[J70U,/;QY1^FE":"32^$D+O7XR#YC=L\B]02P,$% @ <8!D M4]]!9@V.!P 6B$ !D !X;"]W;W)K&ULM5I; M<^*X$OXK*FH?9JI(L&1C8"M)%0.Y,)L !9F=/>?4>5","#YC6ZPD)Y.M_?'; M,L8&7X1GZB0/B2_=K;Y^W9)S\VOG8[T-BRD\IQO M601OUER$5,&M>.[(K6!TE3"%08=8EML)J1^UKBZ29W-Q=<%C%?@1FPLDXS"D MXNT3"_CK90NW]@\6_O-&Z0>=JXLM?69+IKYLYP+N.IF4E1^R2/H\0H*M+UM# M_.O/#57ZG-9:O?0BNVIG&@%OSUCJ4&=;4\CP4UJKA;Q8*AZFS*!!Z$>[O_1[ZH@#!H)K&$C*0)HRV"F#762H4\E)&9RF M*W13AFY3!C=E<(L,O1J&7LK0*S X3@U#/V7H-UUAD#(,FMJ K7WDK,8L6; ; M1QOOPXU+\:[-J'W <>.(XWW(<2GFM2S[H./&4H'\B/Z!?D1>MSP6-)H)2\Z"I37*G2\5-%/.T5) MC:(/5)PCW&TC8A'\93E&'W[Y6"%E9)8RW&HI3B+%JIN(>\IUOS7(A=-2[IO;9$D%F3"CDE9-XX*_&@TBD=0+L,\D@&>201:]>('0542L37:*FX]PW]YQ[> MHXEBH?RO0;J=2;<3Z4Z-]&D!"\G?'7B*U0EOH^DT@/@O#L[_SI M6U6=[1;J)@OIR?#EBEQT7BIT%5GV(GJ M'ZQNG=>LW\O6[QG7'_$PA.$Z6;Z-:*PV7/A_08)\@):Y*YZ/VB5U933NE3SB M6+N?3+%=%R@3]BL)[YH23IH2/C0EG#8U9E8F)%:1\B@>_2P>?6,\AIX7AW% M%80 -B>^YU?EX>U.B'NP_EG7L7I.K^#+*KHN&?3M@BM/TQU9,\BL&9BSB\H- M8G_&_@L-='&UH>*D$KZGS?/@995M@Y)O;7/6&8-Q.PK_5>-I&$:M,YE3:$:KV M!T53RD2D&&TSS;$Q>!OD<5D3&U(VJ.N2HD6D ME%#8[?:+-IV@.K8JGQ2P>518>BR"@8"WT7#U/]CLE1O>L>"\S6/G'28/QZ.>US1M4D=4..\, 0IZL1#5$\9]NNA1O&MUS;L\-K?Y!_K=#^/0%(&\0^'^>T0X[QG8W#2N MI:=Y5C";21]\*=BN'2JN7;D#%@G]!/P(-SY?H7@++RLW=.:5APD3?0I>5N&)F.%IL2_J(132&&;D@"<]!-U0SX<9^0UF MTK$O05VHJ5O!XVT;W;%@=0;;FS.='&TTY4J3>!!@/])UF#9:'AG#G0,=>0^@ M(SG0$3/0_>1<0,I@5Q^/'.N(&>M^L*.GTHX:L5VK18YBQ(QB!9>T4>#3IR0= M*I4H#^F]6AUR]"/F 7T2;JDODEST8%/T7+DKNB7E@1K7.R"'1F(&K 74(UIP MNH)LY_J(-FJCQS],)PMG6>YQ,Y!!FFV?"8$3;P/39 ;P: \%?Y;?4NY3>[/.,-:I4Z M., QXUY#I2*N6 K+^O"B4C^[Y+7:F:K6&#RM!R M2SUF2I(<\^SN>R1A#F.V&<9^#E,_V^69S*WU98YF]O\1S3[;933#M:<-=@YG MMAG.[A,_*"9"/TJ22T^H55]([#*BU>=[#FBV&="6#$9AW<[3T0.2&N;HJ'+6 MN+;+._#:E'9RX'/,8]L]URD7'?D ,C")2=4WD52YQ!.SF&.68,^\DB<\J 54;YSL'71OU?!P_0@?U(PDIKX++. M>U ?8OC^#;Y /G$E>)A&ULC55;;]HP&/TK5K2'5NJ:&TE+!4@IER[2&A"!3=NT!Y,88C6QJ6V@ MVZ^?[:0I]_&2^'+.Y_-]QY?6AK(7GB$DP%N1$]XV,B&6#Z;)DPP5D-_2)2)R M9DY9 87LLH7)EPS!5).*W'0LRS<+B(G1:>FQ$>NTZ$KDF* 1 WQ5%)#]>40Y MW;0-VW@?&.-%)M2 V6DMX0+%2$R7(R9[9ATEQ04B'%,"&)JWC_2! MSEWF,H,<=6G^':%ZT$!.RU& M-X IM(RF&KKZFBWKA8G:)[%@3:CB(>B">/C\'XQ]J,@Z?HG 0=H-H H)N=SB-)F'T!$;#KV$W[,?@,QBC MA)($YQCJW4#GH MY=J._H/^ZPFN8(R(X@"258"X83@1*R_FK'A(0Y_Q:!IK& M/7#UZ1I\ IB 24977#)XRQ0R=96 F51I/I9I.B?2C-'R%KC6#7 LQSY"[YZG M]U BZ;:F6T?HO;5VOSSFJ;4"$=2O0YVR^CKBW;%0]X1C=$G2N1 M(< _G)6.Z_FY?$..&N =E-:Q[OR[O1P/4:[?;.[9U#M$>0W?V4/U#U%-]][V M]PIF;EV#ZI%[AFR!"0=7LGP[#RX2@[@B[US3BC0MZSNIG)MQ8Q!9#S MT==MO7KW?D'4$L#!!0 ( '& 9%,EW+DE20, /8( 9 >&PO M=V]R:W-H965T^9 M1(0QXP@P?E<^K?J11K@_?O-^6\0.L2RP(I%@W^A29P.K:Z$E6>$MTS.Q^T*J M> +C+Q5,%;]H5]DZ%DJW2HN\$@-!3GGYCU^J/.P)W-8)@5<)O',%?B7PBT!+ MLB*L$=9XV)=BAZ2Q!F]F4.2F4$,TE)M33+2$70HZ/9S,[L)Q_"./;. K'1Q/(_'=V@Z MN8^C^"9!GU"8IG)+ENCF!:I-$84P7Z*)SHA$]Q0O**.:PNJ'$=&8,O41)(_) M"'VX^(@N$.5HGHFM HWJVQJ"-*AV6@5T70;DG0@H(9LKY#N7R',\MT$>O2\? MD13D;B%W_I?;D-HZOUZ=7Z_PYY_*KUQC3O]@4[.7*!)<"4:7N"QA2,I4$D6X M+A?$"MU2CGE*,4,)+!)X7[1"/\.%TA(J_M<[1'Y-Y!=$K1-$;V>SP:]2,-:4 MX=)!NW!@KH'GH=?I]NWG_30>V[A.QZV-_D-KU6BM,]&@/+A&&NXE;5* 4J%T M8S&4#H-]U,#I'+ >&W5[O6;4H$8-SD)-88.F<%SF'+%,L].HP1&%VPX.T]I@ M%+2]9M9VS=H^BS7'?+N"*MI*RM>G.=L-*?4.,(]M6B?.OE-#=LX[>RE61)DF M 4E51#[3E#1B=HXQN[T#S :;SHF#[]:C57[UVNN="0,%S1D?V+MT"%9B*E>978OPNX";]W]%X'OG^8UV.C%M3R00#V M7EE]]:?.\"]02P,$% @ <8!D4^6N]S6Q! OA$ !D !X;"]W;W)K M&ULO5A=;^(X%/TK%IJ'CM22+PA0420^TB[2%%#3 M[FCWS20&K"9QUG;*[+]?VPD!$I,R.ZOM0TGLWAL&"W8HAJQ-4I2(G@VA,>3BE6X-EE($0V441X9MFJX10YRT1D/5 MMJ*C(>U94&"O$[1GMV\@QD*&M"WN7+/'QHF7)&*$(!ERZ@ M^/E 4Q1%TI.8QU^%TU8YIC0\?3YX?U3!BV#6D*$IB;[CD.\>6OT6"-$&9A%_ M(?O?4!&0FF! (J;^@WV!-5L@R!@G<6$L9A#C)/^%/PHB3@R$'[V!71C858/. M!0.G,'"N':%3&'2N':%;&*C0C3QV1=P,+.SX:/GR-%[,_QR_SI>+6S 9^W,?+!_!ZL7SO<6K:@;CQ0SX;\_/XY<_ M9)\_?UK,'^?3\>(5C*?3Y=OB=;YX JOEM_ET[OG@#DQ)G&8<*B60#9A A@, MDQ#,<)1Q% (/T@0G6P96B )_!RD"-S/$(8[85V'_YL_ S9>OX LP ).]#. $ MO"68LUO1*)Y?=R1CPB,;&ERP(&,Q@B+B21ZQ?2%B!SR3A.\8\)(0A1K[6;/] MH,'>$.R72V ?EF!B-SKT4=H&CGD+;-.V-/.97F]NZL+YM=&]?SWZ&1E.J4=' M^7,N^%N(O1$G 8F%(B+"A!Q2(1$E B&,M532?<,PG7*8CAJF<^TP.AWE+ESE M0FZX'R/+=IRA\7&Z.'707;_?.P?--"#+MAWW'.9I8+;;-;LE["S6;AEKMS'6 M;XBQ>Y E(6:P0]$145PV&=%+<&XV%B%%&[S M= ,WN"!%GR6]VDI9IF7VG7Z_0DH=**(8]'H5^JS&@=FJ[IZ*GI ME]3T&ZG)CZND82.2C(0DBB!EQU8M.?E(O5,9M\TJ,770G=FV*JB9!F6UY99] MQHD&U6W;%\0R*!D9_,*F'.:'>M.V;)G'IM-N+^(4M. MI4EQ SDYSAKU>2Q/+*=Q#7Q.@G= 4EG;,E73"HZ%0 -YJC+5F7'AK&Z8E?:)];]U-*TS^3'"77_/;K/OVP\ M0[K%(C,CM!%#F>V>F#'-/Q;D+YRDZC:\)ESD# "$#@ &0 'AL+W=O$&K9I>D:"2-H:]/*U&1_T M6"8I2?&,@\B2!/'W$:9LUV]9K8^%.5FMI5XP!KT-6N$0RY?-C*N94:'$),&I M("P%CI?]UM#Z-K9\[9!;_$'P3NR-08?RRMB;G@1QOV5J1ICB2&H(I!Y;/,:4 M:B3%XT<)VJKVU([[XP_TASQX%**?92+V'!3.>0>[=+"/'=H7')S2P$K2E8#?GI@07V"&.81KQ/$-S)C$J22(TG>X(S33*D*( MHXP32;#RN,,2$:J\GA0N!Q(GXIX%5NV+5 MSEFU+[!:,(DH1,7NZH\;O0'^D9$MHDIP)2Q)2T&_G%.TP'9S;%U[M@.[XWNN MXW1ZQG8_U6<,;;/K>WYM>$#?K>B[C?3G.,:J1+Y2K&)(MYA+HL<"<_VWM$!5 MR27F',=%; T)\ZH=O4\D8Z=BU;FBC)T3==JN.E),\TC%4SO7:1_8'9#O5N2[ MC>2_(\Z1IBD9;#(>K56%/XBE(4%^M8?_B62SS+J2FU<4K@3?5\2R/,LSN\?2 MG;%T.^YE[:R]L\AJC&#&%5N)84-1A-5=00+;Z,.^*3UV#6Y_)MGJ6FXYUY3- M.1'#]W(UCE7[=\/# .JR;S77_6FNT?_ZY*RZ.%ON9U*O+N&6=TWUO-./SN^Z M=N?XT#MG:+7M=N>2>G6UMYK+_8LZZH34IUI.$]A2W9LC%+TLE<6E MM5JM6JEAWD *D@S=N.(L6+EJ>82+;)NX97 M)E4/D@_7JDW$7!NH]TNF+O+E1&]0-9Z#7U!+ P04 " !Q@&130'?Y0' # M @#@ &0 'AL+W=OFAZ(&1QS$12E1)RFZ _?%+2HIDMXGB@P%? M)%*:&;UY3WP@>ULA']4:4<.OB,>J[ZRU3BY<5X5KC*@Z$PG&YLU*R(AJ,Y4/ MKDHDTF66%''7][RV&U$6.X->]NQ6#GHBU9S%>"M!I5%$Y=-7Y&+;=XCS_&#& M'M;:/G 'O80^8(!ZD=Q*,W/+*DL68:R8B$'BJN\,R<7(SQ*RB#N&6[4S!MO* MO1"/=C)=]AW/(D*.H;8EJ+EM<(2!):YHRO5,;/_&HJ&6K1<*KK(K;(M8SX$P55I$1;)!$+$XO]-? M!1$[":3Y2H)?)/B')C2*A$;6:(XL:VM,-1WTI-B"M-&FFAUDW&39IAL66QD# M+8J&@R35ZC,,E4)[_S>EL6::VO_2O,R7F/U5OU^9(C#5 M&*D?-1 :)81&!J'Y"H2985ZR4.,20JK6+U&:%VAG!>Q"W@Q(RS/L;7:)>R-H M#UNSQ-:LQ7:%&^1 :KILE95:IR*Z74)HUS8S%YKRC&/ GRG;4&[^]Q=_X;Q. M:Y=*O]G]G? _H_Q.L]UXF?%.";)S"./P'UR+&)^,-\A'X_ZKU*PV,$L.M'%W ME -GY-PV3'I\FI M6">5^1'_2+P7A78I]7XCO39D'V!EC:3>&PO&C[ :2&5YI'DR92JW)*UC*=-Z M6YFZD'V E9>26C.UV]$+E= 0^X[9;RJ4&W0&']Z1MO17CNE[IU+.KZS6)T=2KBC4KE&N M-B0'Z.YLW^W9Z9K*!Q8KX+@R.=Y9Q\@N\^-(/M$BR7;T]T*;\T$V7)LC'$H; M8-ZOA-#/$WM(* ^%@_\!4$L#!!0 ( '& 9%-0(I'+?@, .T- 9 M>&PO=V]R:W-H965TYR]F]/1?/ M.Y;LN) M*4NL02^;FXI!C^]4Q!*<"I"[.*;B]1HCON];Q'J;F+'U1J43SJ"WI6N.24E9#$FDO$$!*[ZUI!>J,01C[ZS4&WZ5L>"$%=T M%ZD9WW_%PJ%FREOR2&:_L"^>=2U8[J3B<2'6%L0LR?_I2Q&((X'7.B/P"H'W M3D#."?Q"X+]?H7E&T"@$C2PRN2M9',94T4%/\#V(]&E-2R^R8&9J[3Y+TO<^ M5T+?95JG!C?#R0P6P]O' +[=P%TPG#_.@KO@_F$.P_LQ3.X7P?PA'<,\&#W. M)@^38 Y?X(8R 0L:[1#X"KY3(6BB)'P0G/M&8ESW-K@NY_!^.6+]C.>?Y8GV&^:%AG\N-7W8*(PEC\-Y$9);F3DQAGR MC,GG+RN!""Q1*% J$%1A50J80:[=:7RH"K191FS2^6#PHUGZT31R%CS2\8F8 M>JTRW:SMNK;?K+3=K.L0NVTTOE4:WS*"@I>M_I)B"!%;(7Q\12JJJ]",:4*F MA#;$>3&1-H3T559Y9B:U"A)Q*P G+K9+%]M&8O&5@:-,OF7TJ>*-G> [);YS MX0+IEN3NI0K$#'+M;F62C>MDC98IQXA[:!;N/Y1(C;C;M%VWTOPZH?NG\-2! MHVY'+E,F-9S&(;N+0O&J\KQPS\SZH^8J4:<.>P>'/2-\FB4UPC2B2]3[-07? MMMF&ZV]*AQR:"[ET=R&']D(NUE]J2,3V_>H$K&M,[;8Q_PXMAOQ+CZD1&PJH MMCO5%-"AS9 +]9D:3CM/^DIG_H4+"DN\2E>_[RMGRS#+, M=NKOYJ_)U2@_>1PP^4'HCHHU2R1$N-)(G1@Z\B(_6^0#Q;?9;ON)*[UWSRXW M^CR&(GU WU]QKMX&Z0+E"6_P'U!+ P04 " !Q@&1372052(H# "#@ M&0 'AL+W=ON[WE=-R8T<89]\^R6#_LLDQ%-X)8CD<4QX3\_0\3V P<[CP_F]&$K]0-W MV$_) X0@E^DM5S.WC+*F,22"L@1QV R<$;X8XW/M8"SN*.S%P1CI5.X9^Z8G ML_7 \3011+"2.@117SL80Q3I2(KC>Q'4*7]3.QZ.'Z-?FN15,O=$P)A%7^A: M;@=.X* U;$@6R3G;_PU%0AT=;\4B83[1OK#U'+3*A&1QX:P(8IKDW^1'48@# M!]P^X> 7#OYS'5J%0\LDFI.9M"9$DF&?LSWBVEI%TP-3&^.MLJ&)7L90(IJ@Q99E@B1KT7>E2D8CN:L"_',.[I\ #R$]0RWO+^1[/FYP']O= M)[!2[MBX>W5W5Y6PK*-?UM$W\5JGZEAE>PU$9!Q4KTLT2]),"J12-"^):=T% MK+8)_9ZI@OU[I>*@F818?+50M$J*EJ%HGZ#X0C@GZF?7U?)$Q?+\;"IQ'JUK MHND__&[8"]I^W]T=%O+8"'NM=J>TJI&V2]*VE?36 )*([+*2\524QPK;QZS M)>P0XBA"U+U"TC=5^Q47HE1>]%&Z5W5-.G M5;=9U!"#$C'X QT2_!+49E$#/2]!SZV@"R9)A#9Z77=Z79NPSG^)9;.H86&O MDG;O&4WK6]H%'VP3^!7;%E\15 KK,VD M#EM),;9K\7,:&!^KZA&:S:2.5LDNMNJN/L1>B%35<."H4ZH O@-G^.X-[GJ? M3'?GPY:MM2IAQJ^IS+B29ORRVHR/I;=A%V^PLFSCN%)I_"=D&A^K<,-.WF!U M>BO'E5[C_R_818CZJ:=[7-4&LP"W@R>([L$!7=^.K@E_H(E $6R4GW?64RGR M_,*13R1+S9G]GDEU S##K;JD =<&ZOV&,?DXT=> \MHW_ ]02P,$% @ M<8!D4QU4WKLL @ 8 8 !D !X;"]W;W)K&UL MM55=;]HP%/TK5IXVB>$0H$ 5(I72:97HA$#;'J8]F.1"K/HCL\U"_WUM)UA, M*MG+^I+XVO>><^Y)=)W64CWK$L"@$V="SZ/2F.H68YV7P(GNRPJ$/=E+Q8FQ MH3I@72D@A2_B#"=Q?(,YH2+*4K^W5EDJCX91 6N%])%SHEX6P&0]CP;1>6-# M#Z5Q&SA+*W* +9AOU5K9" >4@G(0FDJ!%.SGT=W@=C%S^3[A.X5:7ZR1ZV0G MY;,+'HMY%#M!P" W#H'8UQ^X!\8JC8=Q#29P,_B[' M5EA0EP1UB<<;7E,'6@/TT JL\3VT!)TK6OG/^7-E<]&C :Y_=3 - ]/0,XVN M,A&-#"B.9(-O)(*3 5&\Y4(WUAB] %&Z0]4HJ!IU(CU10?F1=R"- ]+XG9V\ M"4PWG9HWX&8!%0?$')GV%BKN3^S/I)IYU@1&5GZ&[*2Q$\DO2WL% M@'()]GPOI3D';BR%2R5[!5!+ P04 " !Q@&13"U2JU6E79[-L00JXF=V:9T^_6[=D(&20C5]@*V<\ZY/MQ&C MRJAC#P))+=IBL6O"4GX;F@YUG[AF6YBI1?LT2##&[(@ZC5[$C"S M2Y6(IH1)RAD29#VTQDY_WM-X _A.R4X>C)%VLN3\34_NHZ'5T1LB"5DIK8#A M[YU,29)H(=C&ST+3*D-JXN%XKWYGO(.7)99DRI,?-%+QT.I9*")KO$W4,]]] M)86?0.NM>"+-+]KEV/#60JNM5#PMR+"#E++\'W\4>3@@@$XSP2T(;I7@GR!X M!<'[; 2_(/B?C1 4!&/=SKV;Q,VPPJ.!X#LD-!K4],!DW[ A7Y3I.EDH 4\I M\-3H83Y>S!?H&DUYFG%&F)*(K]$#@>3#FE3H.5.Q1',6D:B!/VOGW[;P;'TCB&S!DAX#)G7(8%?0HZPX3B)4VH MHJ3Q9?)-@>ETN0OK$>N^&M MA+<5AW5,4#W+.B0,>\T>NZ7';JO'10QE>PT'FIXQV3U[B'6$ZU6/L8X)O(K) M.L3OALTF>Z7)7JO)%ZYP9HW8%PGJ#BT#^Z\ ME(B-:38D['[+5/ZI*U?+?F9LKO'*^L3I3YV&]1GT/WF[\E<^;YX>L=A0)B%? M:PC5N>G"68B\(W&<;0PQ&A ?!\S;G:3W2 LBL<_0%02P,$ M% @ <8!D4Z!_]Q@C!P SR0 !D !X;"]W;W)K&ULO5IM;]LV$/XKA+$!+9#:>J-L%TF U$FV $UJQ$W[8=@'1J)MH9*H M4;2= /OQ.TJ**$<2)3?U^J&1;-[QX?'NN8>R3G>,_TC7E KT%(5Q>C98"Y%\ M'(U2;TTCD@Y90F/X9LEX1 3<\M4H33@E?F84A2/+,-Q11()X<'Z:?3;GYZ=L M(\(@IG..TDT4$?[\B89L=S8P!R\?W >KM9 ?C,Y/$[*B"RH>DCF'NU'IQ0\B M&JOWB_3I;/"SFD:1TQL+O@2_69X/) /ET23:AN&>[ M/VFQ("S]>2Q,L__1KAAK#)"W206+"F- $ 5Q_I<\%8&H&)A.BX%5&%A]#>S" MP.YKX!0&SFN#<8L!+@QPWQG)R-'B3%]EV9=80 MX""6F;40'+X-P$Z(,LPIPWFLQ[FIMMJ?JDW MOV/;(;(-:6X9#>97>O,%34ISL\'\6F]^23TP-YMF'\$&E[MLE;ML9?[L%G^S MD*0I8DNT$,S[@?[Z#-^C&T&C]&^-=[OT;F?>G3;O+(J )%+I^P0%:;JA/GH' MFY^GQ/NFZ.<><>91LM_VW#0< _Z=CK;5,-?'31P78V>Z/^ZZ89P]P2Y6_O:6 MYI1+<[1+6Q1)#6LBCR%%">5H)TLA%FG7$IT:)-LTIO9XT@P)EY"P%M+WE^D% M0\F&>VO@5416*TY71-"7,H2]]BK;TH45U[ ZIM..U2VQNGW"]P+31X_/"+H* M#%OMPR.QCZ S?EAN8A^&%2'N0NW6DZ@9[[C$.SX@DQ/"T9:$&YKA\%D8$IYF M*9!A:H24^Y]6(!E#PS!?974^:KP_ZM6@ZXY!>PN1)\H]P)(G(0' MWB'KF]1 N4/A<8/5/ KN$RTU -T=#Z MFG/F4>JG:,E9E%=^#"&"@LK2HK&5Y![=2E2LEJ"8E<9L_B0.3GT*^E+RD4BR+@)-!GE\&514["G!$KO,0P\L(*OH.I.4$Q%8R\N9()160.VARWU;ZK& M8UK]5K%)8']I+#(8@$VR%P^VDK*2D'@4U*H &N,TNVKLN%8=HFD.K1:(JGN9 M^O9U2YZ":!/IDD>U"],Y0J,U%?>;>O*?9^4*_BGQUGF9UJA>*NB"O&-L?'B+@B3%//F/]SQ">-$7=: M(JXHUM03Y +*#AJQV<8=,8L_;)F0V%_1B$Y]*DZUC"-LDJ6XTM)SY1MDVE7A M>E^*-L?;JNAM/>T5\;;0O(SFHBN:BK L^QC15"1FZ45OGX9\U>'#RCLR!1E\243]W[L^K^,IRCQ%PQ6&6 M7G9^98*$98^&PDQA*9R&L#1?ROPRE271L*:%%7LRKND0NR63%?]9'?R7Q_Q+ M 4ZW7L5&UO08QU%%-[9>PKVF WFHZ$T(L\)YE1#P&.^=3?=Q*9JRNR2=["5E M!^C?%V:%8W>/I-KP*):R.\39_MZB?]%1^H1=>9!P#&:S%;/9>E:ZVT2/$&>I MY9N/R2D+?2FU-UNQH7T,16/^^ >7("!5&"EHS+2P^.BV0%-+4F\8HV8M%[ M=4WDDV>=4G 4HSJ',FJU/."V^[#I*+9TCL&63N79IYXME'&-G%+?B8\I17)>C$\V)R%64[';]+O.S1.$V M:%&G#8\B5%=/J&\G"K?A4/_Z2>^H\FJ'?-7GEO!5 $H@I$LP,H9C"#3/WY[) M;P1+LK<]'ID0+,HNUY3 #LH!\/V2,?%R(U\@*=]A.O\/4$L#!!0 ( '& M9%/G)O<2Q@, +L. 9 >&PO=V]R:W-H965T?2AZ(/M#VVA4JBEZ3M%MB/7Y)2 M=$DD)9L:>;%):N:*?O!MP "_8S"F/>,K1"[<]/DRRU$A)_1'<3R MR9JRB @Y91N3[QB0E7:*0M.VK)89D2 V^EV]-F/]+MV+,(AAQA#?1Q%AOX80 MTF//P,;#PCS8;(5:,/O='=G #8B[W8S)F9FAK(((8A[0&#%8]XP!/I_@CG+0 M%O>" M1JFSC" *XN2?_$P+47"0.-4.=NI@/W9P:QR2N M"S#VPF:70Y&DZO)]2WZC*8D8.B>A'M =(W&P((#4:\8709D$82! M^(4^C$&0(.0?I?G=S1A]>/\1O4=!C&ZW=,])O.)=4\B0%;&Y3,,;)N'9->$Y MZ(K&8LO1)%[!JL)_W.S?:? W9:FR>MD/]1K:C8 WL#M#CO4)V9:-*^(9O=S= MJDKG]]@GKV8O%& M<;0E\0:4J-9*D H$W4B>VLR@'G;1,W]LW^3,L%T"R4O5,> M; 7ZLM,GT]=K-6^D^*TZ*!!17R8J&' M6WF[!*8,Y/,UI>)AH@BR^VK_/U!+ P04 " !Q@&13/LE+1,($ ?%P M&0 'AL+W=OOG:0Q%.*$=ME>E'R=X]?' MYSP^27?'Q:-<4:K SY@ELM=8*;5^[WEROJ(QD==\31-]9\%%3)0^%4M/K@4E M86H4,P_Y?LN+290T^MWTVECTNWRC6)30L0!R$\=$_+JCC.]Z#=AXNC")EBME M+GC][IHLZ92JK^NQT&=>X26,8IK(B"= T$6O<0O?#W''&*1/?(OH3NX= S.5 M&>>/YN0^[#5\HX@R.E?&!=$_6SJ@C!E/6L>/W&FC&-,8[A\_>?^03EY/9D8D M'7#V/0K5JM?H-$!(%V3#U(3O?J?YA +C;\Z93/^#7?9L"S7 ?",5CW-CK2". MDNR7_,P#L6< FR4&*#= =0UP;H#K&C1S@V8:F6PJ:1R&1)%^5_ =$.9I['(\GHP^CB;X) MIE\^#_X ;X94D8C)M^ *_ 8\(%=$4-GUE)9@''GS?+B[;#A4,MSM9GD-8.L= M0#Z\.6$^<)M/Z?H:8-^8(WC"?.@V?^#;PMP_-/=TW(K@H2)X*/6'2_P-&)$2 M\ 68*CY_!']^U/?!O:*Q_,OA'1?><>J]6>)]K"N "D%#((W[=X!LU(J+Z&]] MY4V4Y&OP]E04,\=!ZMA4_K8/_>ROZVU/2&H6DIKG25H3 ;:$;6BJ*.2,$2'! MFHI,W4EQV1#M/7'^M0]/"PL*88%3V#2-!8BDW) 9HZF"'1&")$I6!&L8' 4+ M0_\&MSNG);4*22VGI,"_"LDOH 0)HV0)MIQM8@HTZAZ(#,F/+(*ZE,6CIGO% M>K:.) ;EB]DN!+:= F^W5&BT/U>H0Q?Q\)0*M[O !WJ^TI'XG4)8Q[V86H%> M3*CWE9#J;O8,P GB)RB2 +8^BF<5XG"-A(32NJ %J@PN 2=6#I"-UX?%7*'?.P M+)@6AM"-KY=F6[NV%(L_6(M_1^L*_M%7HBU1%(P9F5/=?BO76ECDP4LP#UGF M(3?S'C;Q3!>+'B"+I#F:\SC6FV&V"TK.0J #S1=ZOM4)<(>.28@/=\1L=:J? M.YR1!2:J F8TI[;/J=_]W.6.6X>]68F>O4;4S49*,A=UZ@_9-&'W,WD"U& CAO),BF6DLA-R0'C,NMS3+X]+YOZ/7<^3.N@ M$$K$660B-S+=XM1*!VIE"KN\HZP8 '8J>TIDJ8IJ4?6H1,ZD*K)419>@*K94 MQ?\S5?$Q+=$IJE8_=S@C2U7LIFK1^.O:/ZNMP1:4^"*O['OO[%4O[2_<& :Y MXUH; [9LQ6ZV_E< R8=I':QYB3@+6NP&[>L!4C% #8!@RV)PQ2IN M7R)%+0BQ&X0O[UURQPHM[>QTCSZ?@3$19?!/O_PM02P,$% @ <8!D M4_1Y74GW! X14 !D !X;"]W;W)K&ULS5A= M;^(X%/TK%NI*K;1M8H?P45$D/CM=35M4=F8?5OM@P$#4),[8#I35_/BUG9"$ M-CATYX4^E,3)/??XWNMS'7>VE+WR-2$"O 5^R.]J:R&B6\OB\S4),+^A$0GE MDR5E 1;REJTL'C&"%]HH\"UDVPTKP%Y8ZW;TV(1U.S06OA>2"0,\#@+,=GWB MT^U=#=;V R_>:BW4@-7M1'A%ID1\BR9,WED9RL(+2,@]&@)&EG>U'KR]=[2! M?N.[1[:\< W45&:4OJJ;A\5=S5:,B$_F0D%@^;,A ^+["DGR^)&"UC*?RK!X MO4'X"DZ^]IRFX!D^8,:S*!5P. MB<">SZ_ !?!"\.CYOBPFWK&$Y*'0K'GJLY_X1$=\0O!(0['F8!0NR*+$?FRV M;QOL+3G_+ AH'X0^,@+^$8G<["/ M*6D#G+F9(7K:%3G&*H" MNE8JM #&DAIYEB+6T_6:[@B4BX%F.U \;T)WNGAWA:S!?C[JX0$#X($_!\# MH7I&J*X)U8_E/PYFA &Z!+S@%:TRUV8:]A&V:+\MFB_UEQ*MB]\*J8L^5%IZ)U*)<:I%9:K\3+KQP90A[!0"J MC#K*-1:9-;80]4J)0;F6(70F4<]5#SF_&G4S0+TZZKG>(;/>C::3B0DH%RGD MGDF@V/9O)K*Y"B*S@CUP'F/9;%7KD=\*E LA,@OA-&V!&_FUCV<^T;MD;T\TEA_=[!1ZX]1-D1YLU5NM(_QR247M MRN*5>B'W*W4P"B*?[@@!4QVU2&ULE55;4Z,P%/XK&9YT1H720L%IF:':W75FU8[L MY3F%0\D("9L$J_]^DT"QW5YT7R"7<[Y++B>3->//H@"0Z+4JJ9A:A93UM6V+ MM( *BRM6 U4S.>,5EJK+5[:H.>#,)%6E[3J.;U>84"N:F+$%CR:LD26AL.!( M-%6%^=L,2K:>6@-K,_!$5H74 W8TJ?$*$I _ZP57/;M'R4@%5!!&$8=\:L6# MZUFHXTW +P)KL=5&VLF2L6?=NLNUK%0 MV@C)JBY9*:@(;?_XM5N'K03W6(+;);A&=TMD5-YBB:,)9VO$=;1"TPUCU60K M<83J34DD5[-$Y/]XOY0Q+_N'M\0(OO\4."+E$B6?J, M'FNSAK%>0R+?T-DM2$Q*<:XBYE5=LC> G5"!8IJA.YHU*:@]E#W"&O-,3&RI MM&L%=MKIG+4ZW2,Z0W3/J"P$FM,,LMU\6WGNC;L;XS/W)& "]14:.A?(==R! M*# '<0)UV"_GT* .CZ!NS.-=\X=<[^"/>OR1P1\=PV^DD J>OP%,B/J;W]^B/,(][YO%)9E498[X< MC@(_'!SF#WK^X'_. ZAC]^F3$.R?A##PW/'XL*2PEQ2>EK1U!FQ@N4LH;*MA#VH_TS$K?5\SV\?8/N M,5<72J 2MN1K#:U=,FDJLRF6:BG$+@.4/,Y8W+3T03]XQK] M!5!+ P04 " !Q@&13F3W2-(X" "K!@ &0 'AL+W=O(&RZ>9 F@T$M%F9PZI5+UA>O*O(0*RS-> M ],G*RXJK'0HUJZL!>#"%E74]3TO="M,F)/$=F\ADIAO%"4,%@+)355A\3H# MRINI,W2V&TNR+I79<).XQFO(0-W7"Z$CMT-WA^GTE*9P=[U%_VJ] M:R^/6,(EI[](H4+7DS35T?@*#EW,J[2]JNES/0?E&*EYUQ5I! M15C[Q"]='W8*_$,%?E?@6]TMD55YA15.8L$;)$RV1C,+:]56:W&$F9>2*:%/ MB:Y327:=+N>#69K-K]#EW01U MU+=S9%%'!U _Z?P-QWG/<6XYS@]PS&!-&"-LK:^C;GT.Z(0PU%HX?:^S+5Q@ MX;!//@I#/WR?/.S)PZ/D#[K/ M'W.'>]R#2>!Y!XR/>^[Q46Y]^U= _H-^O$_O!]X!YU'/'AUEU_?_$Z\^VN]^ M&$TB[Q\-[LX J4"L[9B4*.<;IMI9TN_VDSAM!]#?]':,WV"AKZ=$%%:ZU#L; M:W+1CL8V4+RVX^B1*SW<[++47Q,0)D&?KSA7V\ 0]-^GY ]02P,$% @ M<8!D4Y&Y/(4E P B H !D !X;"]W;W)K&UL MS59;;YLP%/XK%NI#*ZWE$G*KDD@D9&JE7E!HMX=I#TXX":B F>TTS7[];$-H M+H1&FRKM);'-^;[SG0]CG]Z*T!<6 G#TEL0IZVLAY]FUKK-9" EF5R2#5#R9 M$YI@+J9TH;., @X4*(EURS!:>H*C5!OTU)I'!SVRY'&4@D<16R8)INLAQ&35 MUTQMLS")%B&7"_J@E^$%^,"?,X^*F5ZR!%$"*8M(BBC,^YIC7H]-0P)4Q+<( M5FQKC&0I4T)>Y.0VZ&N&5 0QS+BDP.+O%480QY))Z/A5D&IE3@G<'F_8OZKB M13%3S&!$XN]1P,.^UM%0 '.\C/F$K&Z@**@I^68D9NH7K8I80T.S)>,D*:H!5 *Q]@'T$T"@ C5,SV 7 /C5#LP"HTO6\=F6 M]"A9(2JC!9L<*/<56O@5I7*C^)R*IY' \8%_XTS&ET/''[MH]'COC1]\Y^GV M\0%Y=\Z#CR[1V/<\Y,C7&?$U.G>!XRAF%^+)L^^B\[,+=(:B%#V%9,EP&K"> MSH4L2:[/"@G#7()U1$(#W9.4APR-TP"""KQ;C^_6X'5A1^F)M?%D:-42^I!= MH8;Q!5F&95;H&9T.-ZK*^;?LX[_.OF-&H]P@#<77.,878@J7\EL,T(@DXH!B M6'WB#J4X78 X-#B:KM%VG(?7:ME981J@'W>"$MUR2-C/&D%V*DQ-*/]7C(^<9<7Y*T:T14AIKF_Q_6MFS4! MNE M#1,REBG/S]!RM6R;'-4L[*T/S>N16;'NRC9+W>3O]'F/=H_I(A*;*H:Y M2&5<&%!.'=]UATZ.26%-QV9NR:=CMI.4%+#D2.SR'//##"C; M3RS/.DZLR#:3>L*9CDN\A1CDCW+)UW$2(^UDS=B+'MPE$\O5@H#"1FH&K%ZO, =*-9&2\:?FM)J4&G@:']F_&>_* MRQH+F#/ZDR0RFU@C"R60XAV5*[:_A=K/0/-M&!7FB?;5VN' 0IN=D"ROP4I! M3HKJC=_J?3@!^.< ?@WP/P"\X1E 4 ,"8[129FS=8(FG8\[VB.O5BDT'9F\, M6KDAA3[%6'+UE2B"774I0X%NKP!B0D57\:.5"HTE[.I,\ZJC/Z9C%?H@14R$VA1))"\QSM* M?6/!/UJ8^9V$,90V"MROR'=]KT7/_/-PMT-.T.QH8/B"I?M&U>-\RSO=%%AX]!XV/0R?/,J+IDE,A#F_1N[)5K!X-6[=VXD6>' MG>*'C?AA)]'BK51%21TW)2F@RP-@WOYC=-,,D$&B$.75#^*%*,$'T>:LFVE8 M,WEN"\$[BV%C,?R1:[MNZUG]-ZSRX9R4OASXUG0$ M@39L5\BJA#2S3=.)3*W],#]3S:CJ'?]HJD[V@/F6J)I'(564KAVJ:\6K[E - M)"M-@5TSJI[RI@\#G2"ID5/_P)02P,$% @ <8!D4VE@ M##T] P V H !D !X;"]W;W)K&ULS59=;^(X M%/TK5C0/,]*V^0Y0 1*$[$ZEMH-*._.PV@,_Y=Y 2/94%%1,KEW)[8=LBS:'$XIQM@:HW:\9++-62 M;VRQY8 S0RH+VW.0\'V$\NU7C9N MR2:7>L.>CK=X RN0]]LE5RN[4)ZVB"07PEL!>M9Z1# M>6#LNUY<9A/+T1Y! :G4$EC]/4(,1:&5E!__UJ)68U,3V\\OZG^:X%4P#UA MS(IO))/YQ!I:*(,UWA7RENT_0QU0J/525@CSB_8UUK%0NA.2E359>5 26OWC MISH1+8+2Z2=X-<'K$H(W"'Y-\-]K(:@)P7LMA#7!A&Y7L9O$+;#$TS%G>\0U M6JGI!Y-]PU;Y(E0WRDIR]98HGIRN/L]ND[/Y;)4L4/SE>IG MX5#:=@CJKN60L@TE/WI[:5Z)1T9@Q3'("P># M0U!R# J"T:NY@P2$30+"DPFX!0&8ISE2QTW=CX_JXM_J=)_(;=1(1[]'L0>- M0X-?6>Q*/&S7:-2I8WR,B:)AI];'F*$WZI3Z&.,.6_UP$/ZP"7]X,OR_@ +' MA:DTSM2G@ C)L?[,GLCMJ!$?_1[%=IW7#Y/S*\M=J[>/6QAVCF3< QKYW8+W M@-Q!T$$E/2@OW6E[H$OC$CDE#Q[:BL[N%FMQG#9F;XZ.S/W8O8[=E? MZ+'-3 :O\M7,=XWYAE"!"E@K4\[Y0+4GK\:H:B'9ULP)#TRJJ<,\YFKT!*X! MZOV:,?FRT ::87;Z$U!+ P04 " !Q@&13:ES/!+L% ;&0 &0 'AL M+W=O1-/_)<[&VUR%^)A6/"V%$$+,D_Z0OA2,.!%RG M0< M!-R?!2X:!+Q"P#MUAWXAT#]58% (#$X5&!8"PU,%1H7 R 0K]ZX)S9PJ M.AD+_DR$7HW:](6)KY'&B+!$I^)*"?R6H9R:S#[?WR\>[V^6CRLR7<[)[//R M<;&\O5G.%C9+ZJ43:W*UM!>DX\H\QUFB'=G "I7X*3 M/<>XY[)62Q?SH4P*MTP*UZCM-ZA]I-\AH!9%7JG(,XJ\!D5W7$HRXXEBR082 MGX$D?][A&K)0$,N_+#OTRQWZ5JC3(&"ZI]$(&^,3)!F04/"82!J!K M+KFYH MU.D^_309]?3?N/M4 V-0PAA885S37<0%^8?<,5_WZ61#IAL!@$U;28N9PU+_ M\)T<.2IW&%DM6&7KR& ' B^I_JPKL-&1]P8_>B^OH.-EPYIEMZW+?K#DHK3D MPIX2Z"&YDV=DD6!UO#HDE^4VE^\4$J=7->>>U90E3Y"9LR2@ZPA(EF)J)XJ$ M4!>;ZT+7H3N]GL6?S@%'.%88]PR+27&T+:4[XS_$@G-$R(14.$UL&9:>?DYX M2&0*/@L9!,1'/5UL/CA*JB;<51MS['VL"?=K$!,<]PB@!"G* M(R#-!'1= *JQI](Y0CN\NK=NS8^_'GU$R8\ +"9]A+ MFG*U_\J85XW8L7?B&C<)P'!AW(R[2F3H*V[ UN(;'+E(!@/SDB2Q6L0&M(.J)"$A@IO\_+R>1QKR)B5.K9ZT4F9:$?A]/*M;&VJ MH@['SAVU)G&%*#7:$"?(3.!E0K+$QZN ,-TB:U';-QKV2$!W5M 52SAVFG@P M0#7 =JAGA(4X=6-0=!C6PO0#IC,KPHB1+?B(M?.1:^AQ%FAZ[",'4L1NP<# M\G]CEC=AQ%FQ^2%L=V"!77&(:^>0-RO46 M+A_](0S!''#@,U6?%O8-G7;P%1VY=CJZ*V9JGTO,D2"#PSS!]@$TIZ+F3CYS MC[G(LR5QQ42NG0->B>VL\+IYE,>A%FXK\;0YM^(=UTX'>P/HOHV=$9HD&=97 M4S\X?N-P;(55D8EK;]E6)&6VFO3,W;M8SO$*U6QJ]:K.,6SOP+5>#9N:+X"?&"I:;F?YE."<_O- M_12?;IA4@C:,>C/O^+7)M4UZ7D55GIVJ#KMMT66+"M+O%#39$:ZVZ.=\GJC% M9M_@LC4/O(K1O)8SGQIJR,=0ED@>/2&?[X@^8:F-?(OR]H3U#HZ46MZ#YF2: M!"#DS^'\45]%+U[_G886KV(!S\X">PK;TY?)U"<(ZHY8O.-V7__FT3TX]=4_ M&]Q3L<%8D0A"E.R=CU"1R$_B\QO%4W,0O.9*\=A<;H&B*_4"_#[D7.UO]-ER M^7O(Y%]02P,$% @ <8!D4[*L!>@D P :!( T !X;"]S='EL97,N M>&ULW5AM;]HP$/XKD3M-K30U0$9*5D#:D"I-6J=*[8=]JPQQP))C9X[IH+]^ MOC@)+_4AU@];61"-?8_ON<=WESIB6)JU8/<+QDRPRH4L1V1A3/$I#,O9@N6T MO%0%DQ;)E,ZIL5,]#\M",YJ6X)2+L-?IQ&%.N23CH5SF-[DI@YE:2C,B_=84 MN-O7=$2Z\4<2.+J)2MF(/)Z__[E4YOI=X.YG'\[..H\7U_OV\PJX(*&7M'\$ MZ64'Y[481AWO4M?++5/CB3E>':?IH"B4?' 4^0'JBCBL2S8>9DIN*A<19["1 M::KKN] M/MDX5#<;9*ITRG0;IDL:TW@H6 9R-)\OX&Y4$0)HC,KM(.5TKB2M-#0>]<#2 MSI@0]_"H_NAHW 3XM]D<]S;MZWB#@C\I\V5IMR.K M.?0*N],LXZMJOLI: 1A[%V>G12'6GP6?RYRYS1\=<#RDC5^P4)H_VVC0*C-K M8)H$3TP;/MNV_-*T>& KT[33*L,U]TY0\]_-\YQ)IJG8%FU[_RUG^=6*HZM_ M);GZK[(OV*NQ/C_?NLC^*8B,3T'D2?3DX$V*#.NS<>L WCE^6VL KSDC\AU> MJ,0F:#!=)$!ZC- ?9R7#YE4'RR.WR>QEW^G21)% M<8QE=#+Q*IA@>8MC^/K9,&W@@<6!2'^6:[S:>(<<[@.LIH!GO+[1!%4%=.&/<$XDB08 KWH[]$X1K(3 MP\=?'^PIB:(D\2. ^15$$8; TX@CF +0@"%15)V#>^=1V)Q3X>:WI?%O4$L# M!!0 ( '& 9%.7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 204 322 1 false 53 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.bellicum.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Deficit Sheet http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Deficit Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 2109102 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES Sheet http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIES FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES Notes 8 false false R9.htm 2114103 - Disclosure - LEASES Sheet http://www.bellicum.com/role/LEASES LEASES Notes 9 false false R10.htm 2118104 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT Sheet http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENT PUBLIC OFFERING AND PRIVATE PLACEMENT Notes 10 false false R11.htm 2122105 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK Sheet http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCK REDEEMABLE CONVERTIBLE PREFERRED STOCK Notes 11 false false R12.htm 2124106 - Disclosure - SHARE-BASED COMPENSATION PLANS Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANS SHARE-BASED COMPENSATION PLANS Notes 12 false false R13.htm 2132107 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 15 false false R16.htm 2310302 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables) Sheet http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIESTables FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables) Tables http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIES 16 false false R17.htm 2315303 - Disclosure - LEASES (Tables) Sheet http://www.bellicum.com/role/LEASESTables LEASES (Tables) Tables http://www.bellicum.com/role/LEASES 17 false false R18.htm 2319304 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables) Sheet http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTTables PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables) Tables http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENT 18 false false R19.htm 2325305 - Disclosure - SHARE-BASED COMPENSATION PLANS (Tables) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables SHARE-BASED COMPENSATION PLANS (Tables) Tables http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANS 19 false false R20.htm 2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 20 false false R21.htm 2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 21 false false R22.htm 2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details) Details 22 false false R23.htm 2407404 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details) Details 23 false false R24.htm 2408405 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details) Sheet http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details) Details 24 false false R25.htm 2411406 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details) Sheet http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details) Details 25 false false R26.htm 2412407 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details) Sheet http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details) Details 26 false false R27.htm 2413408 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details) Sheet http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details) Details 27 false false R28.htm 2416409 - Disclosure - LEASES - Narrative (Details) Sheet http://www.bellicum.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 28 false false R29.htm 2417410 - Disclosure - LEASES - Components of Lease Cost (Details) Sheet http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails LEASES - Components of Lease Cost (Details) Details 29 false false R30.htm 2420411 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details) Sheet http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details) Details 30 false false R31.htm 2421412 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details) Sheet http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details) Details 31 false false R32.htm 2423413 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) Sheet http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details) Details http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCK 32 false false R33.htm 2426414 - Disclosure - SHARE-BASED COMPENSATION PLANS - Narrative (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails SHARE-BASED COMPENSATION PLANS - Narrative (Details) Details 33 false false R34.htm 2427415 - Disclosure - SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details) Details 34 false false R35.htm 2428416 - Disclosure - SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details) Details 35 false false R36.htm 2429417 - Disclosure - SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details) Details 36 false false R37.htm 2430418 - Disclosure - SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details) Details 37 false false R38.htm 2431419 - Disclosure - SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details) Sheet http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details) Details 38 false false R39.htm 2433420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIES 39 false false All Reports Book All Reports blcm-20210930.htm a2021q3exhibit311.htm a2021q3exhibit321.htm blcm-20210930.xsd blcm-20210930_cal.xml blcm-20210930_def.xml blcm-20210930_lab.xml blcm-20210930_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blcm-20210930.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 204, "dts": { "calculationLink": { "local": [ "blcm-20210930_cal.xml" ] }, "definitionLink": { "local": [ "blcm-20210930_def.xml" ] }, "inline": { "local": [ "blcm-20210930.htm" ] }, "labelLink": { "local": [ "blcm-20210930_lab.xml" ] }, "presentationLink": { "local": [ "blcm-20210930_pre.xml" ] }, "schema": { "local": [ "blcm-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 398, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://www.bellicum.com/20210930": 2, "http://xbrl.sec.gov/dei/2021": 5, "total": 10 }, "keyCustom": 50, "keyStandard": 272, "memberCustom": 22, "memberStandard": 27, "nsprefix": "blcm", "nsuri": "http://www.bellicum.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.bellicum.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118104 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT", "role": "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENT", "shortName": "PUBLIC OFFERING AND PRIVATE PLACEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "blcm:ConvertibleRedeemablePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122105 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK", "role": "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCK", "shortName": "REDEEMABLE CONVERTIBLE PREFERRED STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "blcm:ConvertibleRedeemablePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124106 - Disclosure - SHARE-BASED COMPENSATION PLANS", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANS", "shortName": "SHARE-BASED COMPENSATION PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132107 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables)", "role": "http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIESTables", "shortName": "FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - LEASES (Tables)", "role": "http://www.bellicum.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables)", "role": "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTTables", "shortName": "PUBLIC OFFERING AND PRIVATE PLACEMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - SHARE-BASED COMPENSATION PLANS (Tables)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables", "shortName": "SHARE-BASED COMPENSATION PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "blcm:NumberOfWhollyOwnedSubsidiariesFormed", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "blcm:NumberOfWhollyOwnedSubsidiariesFormed", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accrued Expenses and Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "0", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details)", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings (Loss) Per Share, Potentially Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details)", "role": "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails", "shortName": "FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Investment Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "ic6378b5dd08f45b39dbd2fbfbe3e6c6e_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details)", "role": "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "shortName": "FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Fair Value of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i54826d1e49b040d38afb27127df2bcc5_D20210101-20210930", "decimals": "4", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413408 - Disclosure - FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details)", "role": "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "shortName": "FAIR VALUE OF MEASUREMENTS AND INVESTMENT SECURITIES - Derivative Liabilities Reported at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "ic6378b5dd08f45b39dbd2fbfbe3e6c6e_I20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.bellicum.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417410 - Disclosure - LEASES - Components of Lease Cost (Details)", "role": "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails", "shortName": "LEASES - Components of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "ia3dbae56fc49451eb7f94202e83eede1_I20201130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details)", "role": "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "shortName": "PUBLIC OFFERING AND PRIVATE PLACEMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "ia3dbae56fc49451eb7f94202e83eede1_I20201130", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421412 - Disclosure - PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details)", "role": "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails", "shortName": "PUBLIC OFFERING AND PRIVATE PLACEMENT - Fair Value of Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i53663e4a08a6425882d80bf052dd7df8_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details)", "role": "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails", "shortName": "REDEEMABLE CONVERTIBLE PREFERRED STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if5ed32a4ec874b049f69464fed808942_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "blcm:NumberofSharebasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - SHARE-BASED COMPENSATION PLANS - Narrative (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails", "shortName": "SHARE-BASED COMPENSATION PLANS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "blcm:NumberofSharebasedCompensationPlans", "reportCount": 1, "unique": true, "unitRef": "plan", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i6c7993dc582241df892527e9a46cf8ca_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427415 - Disclosure - SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails", "shortName": "SHARE-BASED COMPENSATION PLANS - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i6c7993dc582241df892527e9a46cf8ca_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i1b95d20a5ce54474bd08384d41ae2d06_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails", "shortName": "SHARE-BASED COMPENSATION PLANS- Stock Award Activity For All Stock Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i1b95d20a5ce54474bd08384d41ae2d06_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "shortName": "SHARE-BASED COMPENSATION PLANS - ESPP Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if9656ca2e7da4530b34ef0440b74907a_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "blcm:EmployeeStockPurchasePlanCashContributions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails", "shortName": "SHARE-BASED COMPENSATION PLANS - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431419 - Disclosure - SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details)", "role": "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails", "shortName": "SHARE-BASED COMPENSATION PLANS - Expense by Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i7ccd92d135bb485c930747ae74024707_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if8fb9ec2d4494cc09260fb390fe74f24_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "if8fb9ec2d4494cc09260fb390fe74f24_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i56e47411c7ac4d30be7522c85b478818_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "iffd388f92c194ceaa45124c533324c6f_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Deficit", "role": "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i9c74d88fa8644fb7b84b79a7137b1bdf_D20200101-20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109102 - Disclosure - FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES", "role": "http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIES", "shortName": "FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114103 - Disclosure - LEASES", "role": "http://www.bellicum.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "blcm-20210930.htm", "contextRef": "i64ef03d661bf4e9ead057c81918a71c3_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "blcm_A2014EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2014 Employee Stock Purchase Plan [Member]", "label": "2014 Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "localname": "A2014EmployeeStockPurchasePlanMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_A2019EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Equity Incentive Plan [Member]", "label": "2019 Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "A2019EquityIncentivePlanMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_A2130W.HolcombeBlvd.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2130 W. Holcombe Blvd. [Member]", "label": "2130 W. Holcombe Blvd. [Member]", "terseLabel": "2130 W. Holcombe Blvd." } } }, "localname": "A2130W.HolcombeBlvd.Member", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_AccruedClinicalResearchCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Research Costs, Current", "label": "Accrued Clinical Research Costs, Current", "terseLabel": "Accrued clinical research costs" } } }, "localname": "AccruedClinicalResearchCostsCurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_AccruedManufacturingCostsAndAccruedProfessionalFeesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Manufacturing Costs And Accrued Professional Fees, Current", "label": "Accrued Manufacturing Costs And Accrued Professional Fees, Current", "terseLabel": "Accrued manufacturing costs and accrued professional fees, current" } } }, "localname": "AccruedManufacturingCostsAndAccruedProfessionalFeesCurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_AccruedManufacturingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Manufacturing Costs Current", "label": "Accrued Manufacturing Costs Current", "terseLabel": "Accrued manufacturing costs" } } }, "localname": "AccruedManufacturingCostsCurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blcm_AgensysInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agensys, Inc. [Member]", "label": "Agensys, Inc. [Member]", "terseLabel": "Agensys, Inc." } } }, "localname": "AgensysInc.Member", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "blcm_AmortizationofLeaseLiability": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Lease Liability", "label": "Amortization of Lease Liability", "terseLabel": "Accretion of lease liability" } } }, "localname": "AmortizationofLeaseLiability", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blcm_BaylorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baylor [Member]", "label": "Baylor [Member]", "terseLabel": "Baylor" } } }, "localname": "BaylorMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "blcm_BioVecPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioVec Pharma Inc [Member]", "label": "BioVec Pharma Inc [Member]", "terseLabel": "BioVec Pharma Inc" } } }, "localname": "BioVecPharmaIncMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "blcm_ClassOfWarrantOrRightNoticePeriodForPercentageChange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Notice Period For Percentage Change", "label": "Class Of Warrant Or Right, Notice Period For Percentage Change", "terseLabel": "Notice period for percentage change" } } }, "localname": "ClassOfWarrantOrRightNoticePeriodForPercentageChange", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "durationItemType" }, "blcm_ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Number of Securities Purchased, Called by Each Warrant or Right", "label": "Class of Warrant or Right, Number of Securities Purchased, Called by Each Warrant or Right", "terseLabel": "Shares purchased by selling common stock and pre-funded warrant (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesPurchasedCalledByEachWarrantOrRight", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blcm_ClassofWarrantsorRightsLimitationsonOwnershipAfterExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrants or Rights, Limitations on Ownership After Exercise", "label": "Class of Warrants or Rights, Limitations on Ownership After Exercise", "terseLabel": "Warrants, limitations on ownership after exercise" } } }, "localname": "ClassofWarrantsorRightsLimitationsonOwnershipAfterExercise", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "percentItemType" }, "blcm_CommonStockRedemption50DayAverageTradingVolumeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Redemption, 50 Day Average Trading Volume, Shares", "label": "Common Stock Redemption, 50 Day Average Trading Volume, Shares", "terseLabel": "50-day trading volume on Nasdaq stock market (in shares)" } } }, "localname": "CommonStockRedemption50DayAverageTradingVolumeShares", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "blcm_CommonStockRedemptionAverageTradingVolumePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Redemption, Average Trading Volume Period", "label": "Common Stock Redemption, Average Trading Volume Period", "terseLabel": "Average trading volume period" } } }, "localname": "CommonStockRedemptionAverageTradingVolumePeriod", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "durationItemType" }, "blcm_CommonStockRedemptionRequirementClosingPriceMinimumPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Redemption Requirement, Closing Price Minimum, Per Share", "label": "Common Stock Redemption Requirement, Closing Price Minimum, Per Share", "terseLabel": "Closing price of common stock (in dollars per share)" } } }, "localname": "CommonStockRedemptionRequirementClosingPriceMinimumPerShare", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "blcm_CommonStockRedemptionRequirementClosingPriceThresholdPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Redemption Requirement, Closing Price, Threshold Period", "label": "Common Stock Redemption Requirement, Closing Price, Threshold Period", "terseLabel": "Closing price of common stock threshold period" } } }, "localname": "CommonStockRedemptionRequirementClosingPriceThresholdPeriod", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "durationItemType" }, "blcm_ConvertibleRedeemablePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Redeemable Preferred Stock", "label": "Convertible Redeemable Preferred Stock [Text Block]", "terseLabel": "REDEEMABLE CONVERTIBLE PREFERRED STOCK" } } }, "localname": "ConvertibleRedeemablePreferredStockTextBlock", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCK" ], "xbrltype": "textBlockItemType" }, "blcm_DerivativeLiabilityPrivatePlacementOption": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Liability, Private Placement Option", "label": "Derivative Liability, Private Placement Option", "terseLabel": "Private placement option liability", "verboseLabel": "Private placement option liability" } } }, "localname": "DerivativeLiabilityPrivatePlacementOption", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "blcm_DerivativeLiabilityRollforwardRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liability Rollforward", "label": "Derivative Liability Rollforward [Roll Forward]", "terseLabel": "Derivative Liability Rollforward [Roll Forward]" } } }, "localname": "DerivativeLiabilityRollforwardRollForward", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "blcm_DisposalGroupIncludingDiscontinuedOperationConsiderationCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Cash", "label": "Disposal Group, Including Discontinued Operation, Consideration, Cash", "terseLabel": "Discontinued operation, consideration, cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationCash", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable", "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable", "terseLabel": "Discontinued operation, consideration, note receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_EmployeeStockOptionsAndInducementOptionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Options And Inducement Option Awards [Member]", "label": "Employee Stock Options And Inducement Option Awards [Member]", "terseLabel": "Employee Stock Options And Inducement Option Awards" } } }, "localname": "EmployeeStockOptionsAndInducementOptionAwardsMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "blcm_EmployeeStockPurchasePlanCashContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan Cash Contributions", "label": "Employee Stock Purchase Plan Cash Contributions", "verboseLabel": "Deductions from employees" } } }, "localname": "EmployeeStockPurchasePlanCashContributions", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails" ], "xbrltype": "monetaryItemType" }, "blcm_EscrowDepositsRelatedToPropertySalesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Deposits Related to Property Sales, Term", "label": "Escrow Deposits Related to Property Sales, Term", "terseLabel": "Escrow deposits related to property sales, period up to" } } }, "localname": "EscrowDepositsRelatedToPropertySalesTerm", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "durationItemType" }, "blcm_LeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability, Current", "label": "Lease Liability, Current", "terseLabel": "Current portion of lease liabilities" } } }, "localname": "LeaseLiabilityCurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "blcm_LeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability, Noncurrent", "label": "Lease Liability, Noncurrent", "terseLabel": "Long-term lease liabilities" } } }, "localname": "LeaseLiabilityNoncurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "blcm_LesseeOperatingSubleaseTerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Sublease, Termination Fee", "label": "Lessee, Operating Sublease, Termination Fee", "terseLabel": "Lease termination fee" } } }, "localname": "LesseeOperatingSubleaseTerminationFee", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities Held-for-sale, Not Part of Disposal Group, Current", "label": "Liabilities Held-For-Sale, Not Part Of Disposal Group, Current", "terseLabel": "Liabilities held for sale" } } }, "localname": "LiabilitiesHeldForSaleNotPartOfDisposalGroupCurrent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseAgreementAnnualFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Annual Fee", "label": "License Agreement, Annual Fee", "terseLabel": "License agreement, annual fee" } } }, "localname": "LicenseAgreementAnnualFee", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseAgreementAnnualFeePeriodFromFirstINDFiling": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Annual Fee Period, From First IND Filing", "label": "License Agreement, Annual Fee Period, From First IND Filing", "terseLabel": "License agreement, annual fee period, from first IND filing" } } }, "localname": "LicenseAgreementAnnualFeePeriodFromFirstINDFiling", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementExclusiveLicenseOptionExerciseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Exclusive License Option Exercise Fee", "label": "License Agreement, Exclusive License Option Exercise Fee", "terseLabel": "Option exercise fee" } } }, "localname": "LicenseAgreementExclusiveLicenseOptionExerciseFee", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseAgreementExclusiveLicenseOptionExercisedMaximumReductionInAggregateMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Exclusive License Option Exercised, Maximum Reduction In Aggregate Milestone Payments", "label": "License Agreement, Exclusive License Option Exercised, Maximum Reduction In Aggregate Milestone Payments", "terseLabel": "Milestone payments reduced upon exercise of option" } } }, "localname": "LicenseAgreementExclusiveLicenseOptionExercisedMaximumReductionInAggregateMilestonePayments", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseAgreementFirstReleaseFeePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, First Release Fee Period", "label": "License Agreement, First Release Fee Period", "terseLabel": "License costs due upon first release of product, period of payment" } } }, "localname": "LicenseAgreementFirstReleaseFeePeriod", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementMilestonePaymentsuponRegistrationwithFDA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Milestone Payments upon Registration with FDA", "label": "License Agreement, Milestone Payments upon Registration with FDA", "terseLabel": "License agreement, milestone payments upon receipt of FDA or EMA registration" } } }, "localname": "LicenseAgreementMilestonePaymentsuponRegistrationwithFDA", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseAgreementPeriodOfNoticeOfFailureOnUncuredItemsFailureToMakePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Period Of Notice Of Failure On Uncured Items, Failure To Make Payments", "label": "License Agreement, Period Of Notice Of Failure On Uncured Items, Failure To Make Payments", "terseLabel": "Period of notice of failure on uncured items, if material breach is related to failure to make payments" } } }, "localname": "LicenseAgreementPeriodOfNoticeOfFailureOnUncuredItemsFailureToMakePayments", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementPeriodafterInsolvencyEvent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement Period after Insolvency Event", "label": "License Agreement Period after Insolvency Event", "terseLabel": "Termination period, after insolvency event" } } }, "localname": "LicenseAgreementPeriodafterInsolvencyEvent", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementPeriodofNoticeofFailureonUncuredItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement Period of Notice of Failure on Uncured Items", "label": "License Agreement Period of Notice of Failure on Uncured Items", "terseLabel": "Termination period, notice of failure on uncured items" } } }, "localname": "LicenseAgreementPeriodofNoticeofFailureonUncuredItems", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementTerminationNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement Termination Notice", "label": "License Agreement Termination Notice", "terseLabel": "Termination notice period for any other breach" } } }, "localname": "LicenseAgreementTerminationNotice", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementTerminationPeriodAfterFirstCommercialSaleOfLicensedProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Termination Period After First Commercial Sale Of Licensed Product", "label": "License Agreement, Termination Period After First Commercial Sale Of Licensed Product", "terseLabel": "Termination period, number of years after first commercial sale of licensed product" } } }, "localname": "LicenseAgreementTerminationPeriodAfterFirstCommercialSaleOfLicensedProduct", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseAgreementUpfrontFeePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement Upfront Fee Period", "label": "License Agreement Upfront Fee Period", "terseLabel": "Upfront fee payment period, number of days from effective date" } } }, "localname": "LicenseAgreementUpfrontFeePeriod", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "blcm_LicenseCostsDueUponFirstReleaseofProduct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Costs, Due Upon First Release of Product", "label": "License Costs, Due Upon First Release of Product", "terseLabel": "License costs due upon first release of product" } } }, "localname": "LicenseCostsDueUponFirstReleaseofProduct", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseCostsforRightsGrantedUnderAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Costs for Rights Granted Under Agreement", "label": "License Costs for Rights Granted Under Agreement", "terseLabel": "Nonrefundable upfront fee" } } }, "localname": "LicenseCostsforRightsGrantedUnderAgreement", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_LicenseRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Revenue [Member]", "label": "License Revenue [Member]", "terseLabel": "License revenue" } } }, "localname": "LicenseRevenueMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "blcm_MDAndersonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MD Anderson [Member]", "label": "MD Anderson [Member]", "terseLabel": "MD Anderson" } } }, "localname": "MDAndersonMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "blcm_MilestonePaymentsForEachLicensedProductAchievementOfClinicalMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments For Each Licensed Product, Achievement Of Clinical Milestones", "label": "Milestone Payments For Each Licensed Product, Achievement Of Clinical Milestones", "terseLabel": "Milestone payments upon achievement of specified clinical milestones for each licensed product" } } }, "localname": "MilestonePaymentsForEachLicensedProductAchievementOfClinicalMilestones", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_MilestonePaymentsForEachLicensedProductAchievementOfSalesMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments For Each Licensed Product, Achievement Of Sales Milestones", "label": "Milestone Payments For Each Licensed Product, Achievement Of Sales Milestones", "terseLabel": "Milestone payments upon achievement of sales milestones" } } }, "localname": "MilestonePaymentsForEachLicensedProductAchievementOfSalesMilestones", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_MilestonePaymentsNumberOfInitialProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payments, Number Of Initial Products", "label": "Milestone Payments, Number Of Initial Products", "terseLabel": "Milestone payments, number of initial products" } } }, "localname": "MilestonePaymentsNumberOfInitialProducts", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "blcm_MilestonePaymentsforFirstLicensedProducts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments for First Licensed Products", "label": "Milestone Payments for First Licensed Products", "terseLabel": "Milestone payments upon first achievement of specified clinical milestones" } } }, "localname": "MilestonePaymentsforFirstLicensedProducts", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_NumberOfWhollyOwnedSubsidiariesFormed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Wholly-Owned Subsidiaries Formed", "label": "Number Of Wholly-Owned Subsidiaries Formed", "terseLabel": "Number of wholly-owned subsidiaries formed" } } }, "localname": "NumberOfWhollyOwnedSubsidiariesFormed", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "blcm_NumberofSharebasedCompensationPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Share-based Compensation Plans", "label": "Number of Share-based Compensation Plans", "terseLabel": "Number of share-based compensation plans" } } }, "localname": "NumberofSharebasedCompensationPlans", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "blcm_OperatingLeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-Of-Use Asset, Amortization", "label": "Operating Lease, Right-Of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortization", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blcm_OtherSignificantNoncashTransactionConsiderationPaidByThirdParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Significant Noncash Transaction, Consideration Paid By Third-Party", "label": "Other Significant Noncash Transaction, Consideration Paid By Third-Party", "terseLabel": "Leasehold improvements paid by landlord" } } }, "localname": "OtherSignificantNoncashTransactionConsiderationPaidByThirdParty", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blcm_PatientTreatmentCosts": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Patient Treatment Costs", "label": "Patient Treatment Costs", "terseLabel": "Accrued patient treatment costs" } } }, "localname": "PatientTreatmentCosts", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blcm_PrivatePlacementOptionDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Option, Derivative Liability [Member]", "label": "Private Placement Option, Derivative Liability [Member]", "terseLabel": "Private Placement Option Liability" } } }, "localname": "PrivatePlacementOptionDerivativeLiabilityMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "blcm_PrivatePlacementOptionPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Option Policy [Policy Text Block]", "label": "Private Placement Option Policy [Policy Text Block]", "terseLabel": "Private Placement Option" } } }, "localname": "PrivatePlacementOptionPolicyPolicyTextBlock", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "blcm_ProceedsFromPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Public Offering", "label": "Proceeds From Public Offering", "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock in a public offering, net" } } }, "localname": "ProceedsFromPublicOffering", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blcm_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering [Member]", "label": "Public Stock Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_PublicWarrantsPrivateWarrantsAndStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrants, Private Warrants And Stock Options", "label": "Public Warrants, Private Warrants And Stock Options [Member]", "terseLabel": "Public Warrants, Private Warrants And Stock Options" } } }, "localname": "PublicWarrantsPrivateWarrantsAndStockOptionsMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_ReedRoadHoustonTXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reed Road, Houston, TX", "label": "Reed Road, Houston, TX [Member]", "terseLabel": "Reed Road, Houston, TX" } } }, "localname": "ReedRoadHoustonTXMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_ResearchAndDevelopmentFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Facility", "label": "Research And Development Facility [Member]", "terseLabel": "Research And Development Facility" } } }, "localname": "ResearchAndDevelopmentFacilityMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_RestrictedStockandRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock and Restricted Stock Units [Member]", "label": "Restricted Stock and Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Awards and Units" } } }, "localname": "RestrictedStockandRestrictedStockUnitsMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "domainItemType" }, "blcm_SanFranciscoOfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Francisco Office Space", "label": "San Francisco Office Space [Member]", "terseLabel": "San Francisco Office Space" } } }, "localname": "SanFranciscoOfficeSpaceMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "blcm_Series1and2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series 1 and 2 Preferred Stock [Member]", "label": "Series 1 and 2 Preferred Stock [Member]", "terseLabel": "Series 1 and 2 Preferred Stock" } } }, "localname": "Series1and2PreferredStockMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "blcm_Series2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series 2 Preferred Stock [Member]", "label": "Series 2 Preferred Stock [Member]", "terseLabel": "Series 2 Preferred Stock" } } }, "localname": "Series2PreferredStockMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "blcm_Series3PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series 3 Preferred Stock [Member]", "label": "Series 3 Preferred Stock [Member]", "terseLabel": "Series 3 Preferred Stock" } } }, "localname": "Series3PreferredStockMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "blcm_SublicenseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublicense Expense", "label": "Sublicense Expense", "terseLabel": "Sublicense expense" } } }, "localname": "SublicenseExpense", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_SupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply Agreement", "label": "Supply Agreement [Member]", "terseLabel": "Supply agreement" } } }, "localname": "SupplyAgreementMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "blcm_TakedaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Takeda", "label": "Takeda [Member]", "terseLabel": "Takeda" } } }, "localname": "TakedaMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "blcm_TemporaryEquityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity", "label": "Temporary Equity [Policy Text Block]", "terseLabel": "Preferred Stock" } } }, "localname": "TemporaryEquityPolicyTextBlock", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "blcm_TransferOfPropertyAndEquipmentToHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfer Of Property And Equipment To Held-For Sale", "label": "Transfer Of Property And Equipment To Held-For Sale", "terseLabel": "Reclassification of property and equipment, net to assets held for sale" } } }, "localname": "TransferOfPropertyAndEquipmentToHeldForSale", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "blcm_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront Payment Received", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "blcm_WarrantDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Derivative Liability [Member]", "label": "Warrant Derivative Liability [Member]", "terseLabel": "Warrant Derivative Liability" } } }, "localname": "WarrantDerivativeLiabilityMember", "nsuri": "http://www.bellicum.com/20210930", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bellicum.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r44", "r46", "r92", "r93", "r206", "r220" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r205", "r219", "r269", "r272", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r421", "r423", "r431", "r432" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r205", "r219", "r269", "r272", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r421", "r423", "r431", "r432" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r161", "r255", "r257", "r394", "r420", "r422" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r161", "r255", "r257", "r394", "r420", "r422" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r205", "r219", "r259", "r269", "r272", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r421", "r423", "r431", "r432" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r205", "r219", "r259", "r269", "r272", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r421", "r423", "r431", "r432" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r45", "r46", "r92", "r93", "r206", "r220" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r104", "r109", "r270" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r104", "r109", "r184", "r270", "r382" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Accounts receivable, interest and other receivables" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r400", "r416" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r7", "r8", "r33" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued payroll" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r49", "r50", "r51", "r411", "r428", "r429" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r48", "r51", "r57", "r58", "r59", "r96", "r97", "r98", "r320", "r424", "r425", "r441" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r303", "r304", "r305", "r341" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r273", "r275", "r309", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "auth_ref": [ "r233", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.", "label": "Adjustments to Additional Paid in Capital, Stock Split", "negatedLabel": "1-for-10 Reverse Stock Split" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r275", "r300", "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation expense recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDeferredChargesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortization of Deferred Charges [Abstract]", "terseLabel": "Finance lease cost:" } } }, "localname": "AmortizationOfDeferredChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r66", "r79", "r209", "r363" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total common stock equivalents (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r150", "r153", "r159", "r165", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r318", "r321", "r351", "r379", "r381", "r398", "r409" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r41", "r91", "r165", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r318", "r321", "r351", "r379", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "auth_ref": [ "r173", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.", "label": "Assets Held-for-sale, Not Part of Disposal Group, Current", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r276", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r268", "r271", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r27", "r81" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r11", "r82", "r397" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r75", "r81", "r87" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Cash equivalents, restricted cash", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r75", "r354" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r89", "r91", "r114", "r118", "r119", "r123", "r127", "r133", "r134", "r135", "r165", "r194", "r198", "r199", "r200", "r203", "r204", "r217", "r218", "r222", "r226", "r351", "r439" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r244", "r274" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Shares issuable per warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Shares issuable under warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r183", "r401", "r415" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "auth_ref": [ "r182", "r190", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments, contingencies, and guarantees.", "label": "Commitments Contingencies and Guarantees [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for issuance under ESPP (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97", "r341" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 80,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020; 8,465,549 shares issued and 8,397,803 shares outstanding at September\u00a030, 2021; 8,385,650 shares issued and 8,317,904 shares outstanding at December\u00a031, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56", "r62", "r403", "r418" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss)", "totalLabel": "Net comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r138", "r408" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Financial Instruments and Credit Risks" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Additional revenue from sales" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Conversion of redeemable preferred stock into common stock" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r217", "r218", "r222" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79", "r149" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r46", "r330", "r331", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r42", "r43", "r46", "r350" ], "calculation": { "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "totalLabel": "Total fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Warrant derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328", "r332", "r333", "r335", "r337", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r94", "r324", "r325", "r327", "r328", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Warrant Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r1", "r175", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Amount paid upon closing of asset sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r63", "r101", "r102", "r103", "r104", "r105", "r111", "r114", "r123", "r126", "r127", "r130", "r131", "r342", "r343", "r404", "r419" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per common share attributable to common shareholders, basic (in dollars per share)", "verboseLabel": "Basic net income (loss) per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net income (loss) per share - basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r63", "r101", "r102", "r103", "r104", "r105", "r114", "r123", "r126", "r127", "r130", "r131", "r342", "r343", "r404", "r419" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per common share attributable to common shareholders, diluted (in dollars per shares)", "verboseLabel": "Diluted net income (loss) per share (in dollars per shares)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Net income (loss) per share - diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r354" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r57", "r58", "r59", "r96", "r97", "r98", "r100", "r106", "r108", "r132", "r167", "r233", "r240", "r303", "r304", "r305", "r313", "r314", "r341", "r356", "r357", "r358", "r359", "r360", "r361", "r424", "r425", "r426", "r441" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsIssuancesPolicy": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income statement treatment of issuances of stock by an equity method investee.", "label": "Equity Method Investments Issuances, Policy [Policy Text Block]", "terseLabel": "Equity Issuance Costs" } } }, "localname": "EquityMethodInvestmentsIssuancesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EscrowDepositsRelatedToPropertySales": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Escrow deposits related to property sales in noncash investing and financing activities.", "label": "Escrow Deposits Related to Property Sales", "terseLabel": "Escrow deposits cash proceeds received" } } }, "localname": "EscrowDepositsRelatedToPropertySales", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r79", "r212" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant and private placement option liabilities", "terseLabel": "Change in fair value of warrant and private placement option liabilities", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "verboseLabel": "Fair Value Inputs, Assets, Quantitative Information [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r207", "r210", "r211", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r345", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS AND INVESTMENT SECURITIES" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r207", "r260", "r261", "r266", "r267", "r345", "r383" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r207", "r210", "r211", "r260", "r261", "r266", "r267", "r345", "r384" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r207", "r210", "r211", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r345", "r385" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r207", "r210", "r211", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESDerivativeLiabilitiesReportedatFairValueDetails", "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r329", "r332", "r338" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r367", "r372", "r377" ], "calculation": { "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r368", "r375" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payment on financing lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r367", "r372", "r377" ], "calculation": { "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of leased asset" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r168", "r169", "r171", "r172", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r168", "r170" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r79" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "(Gain) loss on dispositions, net" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Loss on termination of lease" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentChargeOnReclassifiedAssets": { "auth_ref": [ "r174", "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For the asset that is reclassified back to held and used from held-for-sale, the amount of impairment charge that is recognized on the reclassification date.", "label": "Impairment Charge on Reclassified Assets", "terseLabel": "Impairment charges" } } }, "localname": "ImpairmentChargeOnReclassifiedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r179", "r181" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r78" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r78" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedTerseLabel": "Accounts receivable, interest and other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r78" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in security deposits.", "label": "Increase (Decrease) in Security Deposits", "negatedTerseLabel": "Security deposit returned" } } }, "localname": "IncreaseDecreaseInSecurityDeposits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r115", "r116", "r117", "r127" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r60", "r148", "r362", "r363", "r406" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDomesticDeposits": { "auth_ref": [ "r405" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on deposits in United States money market accounts and other United States interest earning accounts.", "label": "Interest Income, Domestic Deposits", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeDomesticDeposits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r74", "r76", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Components of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Leas term option to extend" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r91", "r154", "r165", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r319", "r321", "r322", "r351", "r379", "r380" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r91", "r165", "r351", "r381", "r399", "r413" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable preferred stock and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r91", "r165", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r319", "r321", "r322", "r351", "r379", "r380", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds and treasury bills" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r75" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r75" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r75", "r77", "r80" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r52", "r54", "r59", "r61", "r80", "r91", "r99", "r101", "r102", "r103", "r104", "r107", "r108", "r120", "r150", "r152", "r155", "r158", "r160", "r165", "r194", "r195", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r343", "r351", "r402", "r417" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r101", "r102", "r103", "r104", "r111", "r112", "r122", "r127", "r150", "r152", "r155", "r158", "r160" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss) attributable to common shareholders", "verboseLabel": "Net income (loss) attributable to common shareholders, basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Requirements and Disclosures" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r84", "r85", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Purchases of property and equipment in accounts payables and accrued liabilities" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r152", "r155", "r158", "r160" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r373", "r377" ], "calculation": { "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r365" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r110", "r144", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r33" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAccruedExpensesandOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r47", "r49", "r352", "r353", "r355" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Total offering costs related to warrants and options" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r65" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r276", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r217" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r217" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r25", "r26" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement", "verboseLabel": "Private placement option" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds upon entering into private placement agreement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment, net" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r72" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of stock from employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r28", "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r178", "r381", "r407", "r414" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r177" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series 1 Preferred", "verboseLabel": "Series 1 redeemable convertible non-voting preferred stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [ "r10", "r91", "r165", "r194", "r198", "r199", "r200", "r203", "r204", "r214", "r351" ], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.", "label": "Redeemable Preferred Stock [Member]", "terseLabel": "Redeemable convertible series 1 preferred stock" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r73" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedNetLabel": "Payment on debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r312", "r393", "r433" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r11", "r87" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r14", "r87", "r430" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESInvestmentSecuritiesDetails", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested shares of restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r240", "r306", "r381", "r412", "r427", "r429" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r96", "r97", "r98", "r100", "r106", "r108", "r167", "r303", "r304", "r305", "r313", "r314", "r341", "r424", "r426" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r151", "r156", "r157", "r161", "r162", "r163", "r254", "r255", "r394" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r88", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares of common stock sold in offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScenarioAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.", "label": "Scenario, Adjustment [Member]", "terseLabel": "Scenario, Adjustment" } } }, "localname": "ScenarioAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Share-Based Compensation Expense by Classification" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Liabilities at Fair Value" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEMEASUREMENTSANDINVESTMENTSECURITIESTables", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings Per Share, Potentially Dilutive Securities" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r114", "r118", "r123", "r127", "r131" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r11", "r87", "r397", "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash, Reconciliation" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r276", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "ESPP Activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]", "terseLabel": "Stock Award Activity for All Stock Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r281", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r36", "r89", "r133", "r134", "r213", "r215", "r216", "r217", "r218", "r219", "r220", "r222", "r226", "r231", "r234", "r235", "r236", "r237", "r238", "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Remaining share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Discount rate from grant date fair market value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Warrants to purchase aggregate shares of common stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Price of each share of common stock and accompanying common warrant (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility", "verboseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSExpensebyClassificationDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r282", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Restricted Stock Awards and Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional authorized shares approved (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options and inducement awards, exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Warrant exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r283", "r302" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r274", "r280" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSESPPActivityDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockAwardActivityForAllStockPlansDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r294", "r307" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/FAIRVALUEOFMEASUREMENTSANDINVESTMENTSECURITIESFairValueofWarrantsDetails", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options and Inducement Awards" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, end of period (in shares)", "periodStartLabel": "Balance, beginning of period (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r374", "r377" ], "calculation": { "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/LEASESComponentsofLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r89", "r91", "r114", "r118", "r119", "r123", "r127", "r133", "r134", "r135", "r165", "r194", "r198", "r199", "r200", "r203", "r204", "r217", "r218", "r222", "r226", "r233", "r351", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r40", "r57", "r58", "r59", "r96", "r97", "r98", "r100", "r106", "r108", "r132", "r167", "r233", "r240", "r303", "r304", "r305", "r313", "r314", "r341", "r356", "r357", "r358", "r359", "r360", "r361", "r424", "r425", "r426", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r132", "r394" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r39", "r208", "r233", "r234", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable preferred stock into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r233", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock - Employee Stock Purchase Plan (in shares)", "verboseLabel": "Issuance of common stock ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r233", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r233", "r240", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of restricted stock unit awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://www.bellicum.com/role/SHAREBASEDCOMPENSATIONPLANSStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r40", "r233", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r17", "r18", "r233", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock - Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r40", "r233", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of restricted stock unit awards" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Options to purchase common stock" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r91", "r164", "r165", "r351", "r381" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r90", "r218", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "PUBLIC OFFERING AND PRIVATE PLACEMENT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTNarrativeDetails", "http://www.bellicum.com/role/REDEEMABLECONVERTIBLEPREFERREDSTOCKDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r194", "r198", "r199", "r200", "r203", "r204" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Preferred stock, ending balance", "periodStartLabel": "Preferred stock, beginning balance", "terseLabel": "Redeemable preferred stock: $0.01 par value; 10,000,000 shares authorized, Series 1 redeemable convertible preferred stock, $0.01 par value, 1,517,500 shares authorized at September\u00a030, 2021 and December\u00a031, 2020; 452,000 shares issued and outstanding at September\u00a030, 2021 and December\u00a031, 2020" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r10", "r214" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Preferred stock, ending balance (in shares)", "periodStartLabel": "Preferred stock, beginning balance (in shares)", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r38", "r242" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r38", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r38", "r242", "r243" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock: 67,746 shares held at September\u00a030, 2021 and December\u00a031, 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r121", "r124", "r125" ], "calculation": { "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Less: undistributed earnings to participating securities", "negatedTerseLabel": "Less: undistributed earnings to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r136", "r137", "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEarningsLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "periodEndLabel": "Balance, September\u00a030, 2021", "periodStartLabel": "Balance, December\u00a031, 2020" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/PUBLICOFFERINGANDPRIVATEPLACEMENTFairValueofDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r113", "r127" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding, diluted (in shares)", "totalLabel": "Weighted-average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r111", "r127" ], "calculation": { "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bellicum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.bellicum.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2459-110228" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r436": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r437": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r438": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r439": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r440": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 56 0001628280-21-021750-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-021750-xbrl.zip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

;F3N[U\_6_RLG:)HY""2W8X\'\=7HAS_ /X_]0$7(,!EZG(?=XB3+.L=3<&AZ>@?2I>_<\R5[ .&N,G'8&R M,!?/]/Z:H?9;- L+6?U^,=K/^[__+T/ZB94U+O#,W^VY\L'A&)U47-F@F;2L M:CA,&;D'U^.]\F^W1)MD[?WNP!^-I MG7O^]>CCT=?#;P2B4OSU:(_OT7].9^D_FV\^'C9W [S%OX?-+V\/6^\^L];Y MP='7=U^/=MY\%O YW./@\.N;/U/S$_XY1?])!,4F*HY4R#T79'#()N*1(EQ8 MCTG@MJBZ6&?\MOR?]U:2Y9(97PO=BUB.:["KP6YT2(UK+YWD/C'%)<=:2LZ8 M#8E0+'TP-=BM&-B=3X%=E%YX[#'B3!L .T8S 2)%P6)OP&))C?':IEK7F-58 M5V/=R\8ZP:1DD5NL;4YZ:TV#SNUK! U!A:1KK%LQK"/3O.X&1\4$1K[H.A&4 M1291B3#U6$HJC6$>'#N]3OCE3D0K"G:W#LY3\9\[!^=/H:'E8>6\BW*Q0[ P M14-O]^YSP7GU0.JWVX2?F@5#L)+P'TXB-59BQZB2. 6:J+]N9S1+#[PP_'0K MW'H+:U-0*6V-^ZM<%)+5P'4;X&K/1*1:&QI(,@@G%G-U(D6&*8.2$BQB,$C1 MV'Q21,QQTB[EM6^)# _J@LT\Q MM@E)>,'!/&LFD]L50")G2FC*,=!()14%T M9%)+4:93!):KH=0O;W-O09G/O7;WJDH;!HL0>B>Y;F?T0G66:&D3M-JX?QM? M+A#LE6)!*--)O)6+>A-SG MEB'CA4<1)X%-,('D-)):!].^W"S2$I3H>>34:SBMX?0V^:[,34IM#HAY\ED! M13X9R4(0B;$:3E<-3J?C8(>3<3AB)*Q)B(,'C9PQ&CQHI82)RH= JS8H-9S6 M<%K#Z0/#*2#+<&\I"#:(.Z6"9H%P7U:OR5_(/2VR&/\I#K_,HYZ^@I+Z1B?*7AY?M5S,5YV' M6ZCEM23*W*S5)->_",GUTYZO5'.EM+6SN]T0#71EF_4[G7:?[*M^T0/KHC/6 MN&=!T;)@%Q[V9P=^>&)[M?.ILE>'?[;WONR)O2_-L]:;CP=?#_^!:S^V]P[A MYZ-MUJ+Y?F!7WOQU.'L&N/GN+[B^ _;J/6Z]>WL$W^]\??=7._\,8V-[,/;F MER9N'K5R;Q3:_&=?)TVHL@D1G##B@6%DP(U'7BC-DK:8FDNG12.7TD;G#1&! M1\(,U3C@"+=27G)GUAH1G(#C+&W]$]"OC]MOMK>;6W_^O=UXO=/Z=_OC[OO\ M\X>/VV^W/\*'C4^[.Z__O]DN[C?M-SVDP7A%Z+Z'>F6CI/4GZ575%&]SBP@UNVTTHP MAXQ:P#&MN,-%4WLN>8I!YT0 G>^>WK:=UK2"EQT(M\:-9E:F&])C:WQS]S/> M-TGQ(!U!T0J-.*4<.:4%A.[.8&,SKP N/$R\J''IW)8]QV,!&C%5%BS(QW9T M)OR.C;/N(3!7R<0'V]_I?QKFQA?%7NK*]>Q[=-DXW,;[.#@? TA$LIR#+1#@ MZSF5D"MY@2\W?\\($6+>YBYZC-P2+#0\-W) 9^*X M<=9J<(81)#(Z 6A 2,F5 +!8 M%R1OBB]NK6<'%Z:F?]&AU%]X9PWX&OI1-">=Q9+U6XJ- 6?1IJ0 Y10W3$,\ M+1+#+E#!N=?RFKJ,%]'S]M&EZ?P]V]=$DQ@]129*,#TB&F2]QBA*JU(4/E(F MKB<$N) E>GM9*IJ,W$Z<0'8<$1[^"_(#CK+%#*0+*YH"\=J36IR>(G;9.M^G M3'J5'%@K'1/B.JA,3 R.#2$4E@S;B-/U#93M1//D6XO31B/[P_VJ,>)SL6ZE M)+U@X?G&][&441+/4*24@!NL,+*2ZQSV&L%98-:J*Q+O*[:B\_+O+W)9(]4> M:Y\[FB67R.R_S%J4^;2551/+!>5J M%R3BDVF!A:6"C]B<\FY8IA*/R6D.49D!%RL"]*J(94P050:A;QK6+R:HJX5^ MD=##>,Z_G38/FV<[NTV2:5L!N837!'EC+(3UN=DQF$-$8PK8)'"VHK\MLG$I MB+!<*^T]SX<9/.?*@/?C26 II =9WQ=OIBXM+0=]4CR)') SQ D!!QKP#N%@ ML%.8.YF>Q]+6JCMW?7,_09J/N!H9(LJY+N1P2,ARA94RT1#);[N^3P+-M>K. M+FTR(4KI$HI,@NJR()%6)',2)Z>(U=&EN+;9O4P+>H<_7/9::.ZBSI;CNORZ M'5^WKGKOZ=T3GVD8VJE=LF0NWD>!J3R*Y^>V"P]KY&;OP[/U_,>I+UW.G7F+7MC=8>=L:I9!$?*$=:?_/.[# MG=II>-#X30P/?H=KN^W,29![Y5U8+G-'>KSVI7?-LV$KCU-A_6 M@@O\^$B\+9YS-&H(WO9Q>H9'[1@-;DDLL )=4$M*X>.*2*.L=!C +\^<(6$[,YP4%BP+P!SUK=0, M='0R25?0)3]:ON9>]$WY#:>O?;&>4G-W[WPG.[XX4AP%HIIAQ#GVX/,RCXBB MAB:;G-"9H.=*[J9)TI@21/U8)49=VH>559R5JLS X\9)WQ'Y]GQ>J/4L@Q,< M.!-("H@)MP 4'#/NC)FV,WM*Z2\4)G;P3.'FXQ@VGSG*?"YL8V'WCH_AW0O[ M5&RM%,6>C3?9>O\68H)OAFQ]>Z<5_2 8G*++?_;#^A-W!7;R'- MCFA0FK'+!18P%K";>0 PGN->?](OO.SFW]"5+.D59SV2NY9N$.^)2#PW1#!< M2FFQ"-8R1@77C"5W8WA=>8+%IRC6:)[N.RZQ(L(CQD)"7%B*K'<>&4<@QJ?, MQ+*4YQJ"Q<9OF5!A[#!=1=+Y>_%IS;:Y6L+P_K2UM4^(,#*W8!M:VHUV9 Q3ASZ^6GBRHSAN@ M?'KIE>#31YJJ.Y5_:G<#&-I7B.CBU-53&)EB+N0?\_9Z'F<(?TQ-%^$;(L_% ME\6$;I>2$>L3#'F%C;K@@!F5EI)13)9]GL*]*D@*Q^F&;DGVERE;]J,6 MR+=))^!5XS?R M>^DVY FHJ&PO0HOY.>D)AK5<0UPRA/[WQ!9Y:O!0XL_,G7@==^9#12;5V:(\ MR,(ON@B+*T;7G YX7;YIX:4V(=H[.CFJG548#T0N*EF)@T]()J<@KUJ*TH7#FOW5JXZ0>47@KE)JB#>XET;3A)GT(5BC=1+S M>R].;'V"8OA7X:0?[-F=EW_W ( HQ]@?"LJZE[;HY^_%SIO/Y[E"JW7N3YO_ M[&,>@L,I("9AV7EBQ4XH0X8'$XS!P4:6FSGCV4-AC:PWW6#[!8EU&:V$.(S] MHY)SNGT)9K.,9#L_8@U]14UUMQ3[+9XSBV#HJLH)5+& M,,05(T@[1Q&)RC!"H@N$YJKSF\3%5_D0OU^+1)1A3+S,9VD$=\):RP//_PD> M_E_/;QA9(]$#(M'./_N.2$%YT@B$A"!N$X:?,$>!!!VXQSKR= ,D^J/Q&[WP M6'\',E\MLR]EM#,OI;?PHYO=&KFU55]"R@V#_6_WM MR/:_QV(3X5L_VG)W =SZ53IGNUC2!'YCS^:)VZ=JE"_6%KUGS:U]$[5D4>4S M*MR5K> U]0P%;L )*>%SUVCKSRQ4N0@&K^Q"FULXT-!_\YR5%3^"-Y+^T=! M >\A7LMM5T V\U93-E"][D+1?+WUL;&;JS7""83,/E>#Y6!X<]SKJBFP,X)?=F+;>=Y*1W MV^Y,W3?YD@42H,Q$$K5)R8[RZV]5 9PT>$@\R#;/T.V6*! H5#VH&33ZTDO! M));-"+@6O+]3W-, Z$%VF@F _?*>F^WOZ]CV M0"NJU3>V^$X^T8Q8_;LTL]2L0^GF+#<5YJFO">34GS$OLQ*CJA-17;)> KX0 M M&'L,H)1B7+0>O-P$%SROZ8\DP@@JX/T]]3_OHS [5-\$<281]4^TY)$;B% MW!@U%,!M+ZGI$OW'6:;R4^=3@ZP^4&Y%]_$J(U(#W%K6KG@9FQ,L*&VCYN6E MR3;*_W1>) 2M;:]55JR\(); NU+%Y(L O.O*Q+STZQ4EBZ(3"MX3YVWSJ>%LIO165GG.%*N(+V. M)$JGKZQ-6EG;DNOQ=MT*-G?=ZAMHW?\&6E=L,72YED';0:@"R@'%%*9UK A618?#=\R(+D<+A;1"UKK*BF6'J:@I MG!TJDRN; '=.-8-2IA9,#7Y7G&4EICJ3>T88\<(8\;-+(>OE^O9YSI,UFP16 MY1! A9HX.G6H\([2]L]I".??7$.X*H/H("LQ"#4OY'&*>R@G)5<>LQ$:)OMY M.2N)E7Z'$U_\I92$5J'SKOLB.P-(_& M1V"!'IV 13H^?OUJQ7+]].'CCZ/QJ_'AP=_?C@].P'+]^./S:[!0OR;.)^?S MR:'S$BS:3^S3/U16;1^>?6$NBX#H#ABMCF>RE'MF:(O03%@HP]!-TS1ARUW3 M8M^)$E>R, @$"P(P;\- 2E]Z/$Q9XEG+;>+>_\_>NY?F[WOO7QX8^\>'?[T\ M>K_WX<83SEPO=,.8QW%L"S9[U\B% M.YF/S_)"E'+2<:ZIXH%+ZZ%T)OG&R5!2 M>4F]]D";DD6258:T,G:IW(ZH05K\FBYR6)[1%.P1D:J"-'[&07JJE/MZ&V"V M0-CYD,8I4-T:HQG;J7)5OU3OI'7@HR"@\T(QP:YQK.E\*DNJ+@-!)8Y0"B(: MSS4]:5+5UNMRDFP\E@+=I3!IT/\4LVDS>Z53)B]E9K@\EHRD-6Z]4"A<&B1V?69S9=A"!-NW%,;-=SKS BBX;C%M"\CIE MO58FVR"^AP5@0PK0_KY8T3?WD#OI'W\#\V'TEN)U]J/#^J7-'WY)>.+Z 6-F M!$:/R1BSS8C'B1DGB?"M2 C7]@'Z48P7DA?ELMZHT(Q,0$XRC#(XGP*/7!RU MC3S; _V/@PD?,M^-8^%+;G'AIWXH9+2^M> :1L&)K>62E:-^E4OB92YY^7V: M*2MS&V*ZMV^@_/CF?0$=W?)EF)J@?+LF\V*\B=62)E[HZ$F;)XZ=M@L(ZR ^ MLD8A4/0:TVOE>@:5D=/:VY55J6:F*2%OFX>2T.0?T.UE3I8A2\BFNH!@KE1I<>GQ)_ M_M#Q)0H0#8>%'*+D3\A(.T=7I]AX=YJ-NMD0M%.!0/&F=Q+WJBX[4/Y+;'&@ MTI[5;L[IY-K)GEXQ-X0%OI,$?AA9<(J*R ' #7W'">W49C;G['K:%/ZTTM/M M>KI]G9AO_8 [_/#1/G[[)7!<)Q \P1:5C@D;%YJ1XPF3N=QBDH$*X@;GM#N= M .XH=A@ SV28T-J6J:NQD&_[09JDKF V8SYSPB1T@L#U[2A(9.PQTH.L2@^" M/US[3GEIKUYHSU4-5WF'9U\X$V!(<=^T7"\&7G+!E+)M;EIADH(I!0HU)F+[ MF^X"T,!'0$=](_D4PR385&JV%E'?8Q\$X+=#*2M'!X5HJG X>DHX'"3% HL* M+>+57V16QEWNAX$-_^. 3AA&B0TZNQ?XL'0),*B9U:^8U;]CX.N9=0VS)F?' M>U_T(L) \C1U*'WN%YGUOTMC;S*97\"ERI^G M6/3TUS@T"N,T#," $99@$6>1#29F;$LKL((X=2NSTJ_,RIY#MY!#A]^!0Z5G M.ZD3>*87I2%PJ,3FC5%B@K*56LRW/9;8M\VAJJ7#=#0OC1U@5)4,E&&V*'HY M-3*#RCF;%Y31^5YK":UJ;:T>-RJKR!-JWT6>'[,4A'U>NF6L?S7O<7A\ NW$F%',3?=5#"3Q9%G MQB*"OVR1^H[/>< 2I4%X;"/+MP,N=#N5BAP@W;6+8\ET8MJ0A#]MG>2AO/5K M#$Q@=3S6+WJLD;K59IBM!C]M,>C*:+Q8DM&R)9'T+K";3RHAUSWO^"G/1I2& MI"Q8;"V$ 0;X]STN#:Y]%$TA]08;N6W\-H1=1J.N)0R"GZ_2CP_1HD?K'FUM MCAF,:ZSM9V0Q$X^I";5;>5W,=WI^*NN]D 1XVK2'"?%Y*?4FMP8BCR$NO6@E M -5^Q9(:A0'+J8Y.:>,KQ&*14ZF3A%9&/>&G2!^5ET\S>%X9=K>X-G0&R1GE MB:,[A9"&KP..R#-;SILSB%#@% MW6+P*_2(WF/QJO,9&A+I[+2RKG-585*5B*9];QW/]H#BO1B7G<_R8K'\I=X: MP#8TV%H)Q0-LJC KLF365,Z20V[-%WC@U]].94'G- IF]W<4TZ;H:_OSR^3$ M]1< KTU%#F\[%7G=#IR7''M1PM12@I4MG1W!R MU$W1;RIG\'UR(L6<.H^MU1])M=#I GN8GY_-%I1<_(C3!JVCLR\>DY:+<=K4 M\5R364ELABP49B ='OJA2"U++J\R9#IXV2JI@-PQN( MN7AZJV\I>\00\Z)*'Z(.RM1 IC1(V=S4UWBU7]K=$**^GD;3H$)$N@@>)C'B MTU(^J_YX+K(2UKQXEDUH*/K1 M?[U+7RU=;*^^"ZU=._0W?@W?;OSNO&'M8->WV:6&I5OL];2!,DB___,$D*S; MTNF99=B4?EV-=\ZCSO0[/OQ\Y5A9IJ0BXNT?-E;3@5K%#-],Q#PA*]H@F[E) M&;T$A5:O/TH2*=/T^3GTP(Y/*WR53[O'&!#HE!47:N:,@E1:@%BLH5]-]=RR=?!I_ M'QU__>,K?,\./WRRC__YY!S"W(Z^OCHY/C@\^_SZU3?0(1:?OYZ,X5UV]1MX MU_RS\]$_',,4,_OWCZ.M+[TL8P+^(G+T+'71NANB(JK@>? MVP&^FU >MP_X7E9IJ[^N)/;0=T7HVWPG'KF#U"5X!^0&4/"E8AEM7U&]?3VH M7074%DN@YEFA]!B FG2X9;+0"LW(9Q9L(Y>.':5AZL2J4;'M/+\F5:_7YFY, MK%]549Y'J<_M/&B%3N_M'&\)K0M6>NR[-/8=[2]AGVU3EQ% O#A*3"8\O#36 M2Q %HRBQ[,3% G27A0,_LE>P[^D#UN7JE]Z%'WV=>V^#U[_W[_VB?R\(6>"Y MS.PD\=P(_7M1Z V<(.C]>UL&C=KRJ:ZDNWYHU(31.Z;#D"YLB\CG^-)J MB:TM7?-M#YY; 9XM;NG!\^K@N>P$C!,_DBZ/3$]@-R^,O0>?V"^$O@^ANE)[2SRMI-I2YJ]'?7.49[K80\NCJX5)TB^IPC ME7-TN/>%)5[H6[YK1]P/(WX/'RX^?3@9+RNW1Q_>PAS>PIQ&(YSG MT<$GZ_#KM\7QZS]./OWSYOOG@S_&GW[\<7+\^O-JYD\L_#B,0LM,'3\!Y=9F M9FQ;S+0"QQ'Y;I*C/^[FTG2^<-+)""P!1,.[Q MB(%E$MMNPFS7]A)K6\)$FV%2[W4/CEP6*HM M?V"Q\UM"PY6\(9L)B;0A'^QAO)38](2+4706FK$38:E,G *7Q& R M@ZWL##QK51GL4X<>4.K0I<)RC]"IZ(B415PX(0M2QATGCH)4@J'D6O#_823O MNBE5[U2\&:!<*2=,+3MP(M_T;>FBW6R;,8\#TW:%C)/0]FS7 [O9#P=1^,ME M,]*I3',3B4U)LRG MT[R8(<@O.E?4=#NUK5Y8([(RP9:&V!>NH)MDIGQ1Y*,1O!7OQU9=DK!U5Q6" MUR-C9S<\M,=% M:3,W< 3\KQ5B[U#OW-:A&UK[+]\.->6(^MF44_/0;N-_?=%3+7O-MVWYV70] M%DVL>:"%_E61 MCP]Y\4W._L)[JBKHPBNK:RXUG4?'IM\61WM?1(#PXD>FZWF>R9ACFV$8I&:< MV#)R19!RR4$3\E98]+]J3&TN:QC)LFQN$E,MZ]2M*D47+K%Y7P&8BGMBG/+1 M7.X:!]UT)Y/2G?0E)^=G/5D#?2\8-?"\8K-FL)0CU[;=P,?.]SR2KA2 M('K M.U'@IX? &%\$OL'H:VRSDGG!B+ED R)MX2> QYH%Z!\J??SV*Q#Z='\3"^^J^ M%<7<^A(4\2HO7LW1U_=&ZT6/F+??6,=[7VP_30/8%S..!3=9E *7)[$+V@+G M<6JY 1R>V 1RP,+5OC85<[?Z#J_OF$O,?6UFRETG3V]$RCYS6F=. V/YL<># M- E,Z5O,9!Y+S"BV4C.07@J Z86I3%P-&EO-Q'F/]_J/+_7Z(JLB92<$FZ7948=^Z;4S%10H)\#J.*E[L: L3\VLUT%@)$OW*XB]1P/!@*6C=12W#G9+@H/9Q*EN]MGZN+3'Z MXM#AUA'E7S>T^'L:+YV7XGH]>:9[47^M>)2,GVU4Y?=Y>;(/\RFR>$Z\6QN* M[OW4YW7(,_EQ]/JC=^B\/3M^_=(Z_/'6^?1!9)\//KF?G(]GA^.W/SZ-/W\] M>OURI4CX".?RX=N/SP=[[-.'MS^.#CZ?'#E_?#OZ*KY^_K"W^'QPE'T>'UJ? M/JSI%.BXJ2_L*#"MU)4FL@3!.4L3WF79<[&#&OQ[9;P+8?'6SC2>BF+$G,F&,75"OU =8"V*(DB2T1I9'K MA$]>V/8OET#<"J[==M.8.U'*T:T'VX7N^*3EV,/;M>!O:10RR8<3#"1OM'<> M9O;O-BEHE3MV;S3*$SZ38H,W5NU9CV%7P;#EX@49"<^/L%I!)@SS!;C))1< M9%[ A2_MR FN33^[QA3>GP2IC0Z(1R_5UZ:"]-)[D]*[HH%(3UBA&8:84!JY M8%VY\)^!=#W'3QAGL?OD1? (6[#?<5N3,<\F]7VEYR@7XAO3 M*GIIO0YI[6H1;LQBH+QC)D)Z)O-MUXQC&9G,L86=^A[S?4S&M-TMDM1N4N9H E),TW]D'N!%P:^NQ695=2.$E.M M*<<:TZOT7;>4FXW7N /&J[OK\:[VLDI6_7T$D&$"J^0CK J@WYA38$/B-&-96"?Z4(MN8H^S::@1?@7:$:JYLJ;BXYZ]@R]_H'7_W M$ H%M65[]/7SZW7F85N3WK''#5>1 M<&+FI#$3?L1"*^"V:P-N.780QI:,G0N\9SU<;3U<=1UQB16$J>.[IN"I!+CB MJ1F[3)B^'_@\"GS/LH(G+^Q=>SMNFM]RN-J*+H?;I5;^G8] Y$?9;/$H6QP^ M(&41G;QX;T:SHSW^7AE_EY.A8D>&L9<(DWF>;3(_DB9/@M1T6&1Q*XVEZV.] MO[7KKC:FN*&,BBW'V#X-ZY%I?3WN7 ON=/4^/[0LUXDCTX\]UV39;CF+E0EF<8H2Z6QLY"\:)4LKU?SKDBQ M0'/*?0'R8H>6&H-/9GADS%IM^&',9Q]RV1?SDA;?KNZL9)#?H]GJ,0O=3.DTO=/=" MZ+JZ3)CX<2P8#'J:; MP7R$L5G&KGIR57G1732;_15OK0.]WQ]*ZIVWK;A><5AJPNX'DEDA- M827<9,)US9#9MNEY,A(NAP,)F][UU6Z/ 11^T?"6LU/>%SFH_EL\T^V(#>2-8"M[@-U+L(21Q*^6A:PDO\GSF) Y/L!^%SE[EQ2K@-7!8ZM)A>'I3)U8B(%T8RXF69 MI9GB$.H\C)G_LQ-,E\3Z .SC;HQ5FO-Y#=QM>AH/=P/>BG>!+#=[/:]C<8U6 M]Z:$P/5V 0RN/RN?[=H6NR\E!#W*^N^I@WRU<4N0)")RA.UZ<Z,U>TVS;"]+(C<+ ]+W$-9F?.":/(L\4(I$BCD1D)?&3%TYTXPUI M+U4^<@]Z;??X]F#QS0\8$\RS4NDS@=$_3]I1Y+,DM462)CKZ%_3M+N\4W[J1 M.I&FG"<>,R6/F,GL.#;CR)9FXD0V"YGGBRA]\L+WMZ,\KL>W'M_N#M^8%5IQ M'/IQ[+ P$B&302IMGP?<"N _+]$^L\>WF\A$/;[U^/:X\S0A^3&<#0 :0+ . 2AX>QQRT9 M7Z*QZ!5N%^[![R; S^V 7^#Y*8N2R!2!FX!RQP#\8LLU+<_F?BI%:(=@O-J# M, CN"_P]ABM57LN)++AJS,C%.)MDY:R@++'^!I6-OV33AL0"4+)3.Y8 )V*/2E'3(7K-,G M+SSOE]&ISQO?7LE-8NFZL-66)UPF$C]. ]]/D]2RA&1>E/9NHZV0W!]+;3V\ MV&;2-B5/0;,(;&YR="#Q&'C5=VP1NF!61>ZM%=?WDGO[DBNB5#JF%CG \ MPN04#8: ]8+]@ 7;8HFP RL,N",8\W@<)788)%[('1LVV>X] =LOV%U/@"<" M">*R:+_,",!6Q?Z$<\#D(+CFWGR0MGX/_ZS:K]Q697$DM%W4W__)#/ M^.@GG3"Z!,(%XHM\C@45U6IZY^ZU$>C!8+[G2Q8PVTX"GC#A6K$,/,=)0B]F M01C:8>] N7M87VG'(RW?MX/4-I,@<4S&TM@$(&>F&UL ]SR0PDF>O B]Z[IF MZOH$YWZ$OWH([2'T"C?SL=AV?-\+DY0S#VPIX3DL<85CI8R#"74)3U:O-M\Q MOG;=7)'->,C\T+0EMK"-D\CDD73,*'43RY6>)5R&]K!O77/^9X^P/<+V"+N: MHO!K7:=ZA-T"A.UZ'"/73<+$$Z83 +BR.([-,.2^&01I &:(+U@BT3'A77>* M0H^P/<+V"+OF=NE?:N'5(^P6(&S7]>LZ@>?:(C:]( 4=5H32! /%-87C.X[K M<-<5R9,7;,"BA^,EZ/;QJOMV=;IYK>OC57>;4DUD<()1%_6ZO7PNZ/AUV6%N MNR70^FY8%W>WVIMM:OLS,&;HJ>XV&$KR=R4H>CF>CO*%E.]E<9HE M634UD"7E$OP9*\\\L]M([RV2<),Z^66Z.7?S_1ZQ<::27?C\Z^>(DO M?.DZ9FR#FL<2X9I<.MP,$I=Y?AH$TN: /[O6"OH8P/HCY U,A,1^5"OW3T^! M_W-AY/"?QME)EN"%U5EI\#&@T@SOQ)95@]]9;L2RS83PY5VUM+\Q5ON+R/$J M+_1'^-P][;C]*^W;SH#KN"O3 (X]TTFP43T+NRO'>-W_Y M8##HEH?=U?/!6('Y\\\ HCJ3;F"[P.4RCICGAE'LNRX &9<\" ,[^N)Y3U9& MO+GC(%A['!A'QQ]>&H%A7K]$=!D?^'>=XD;V4 MY;;T'3QZKQGWZZ,/7P_'AXO##F[/C#^^ 44?9Y_%+4+P^GGUR/H%"]VIT M='!H+3/NT=??QY^O[2.__D#F'WO[.C#[U\_@T+WZ9^/ M%LPWA;$71Q_>?K%#WTK#*#*]D(%%#%AIQM)-S,2QA9LFGF_9WG)CRH!Q!N3'/(JY'[DL= -?>.%RH\+]X\/#-Q\.7QY]>&_L'1T8^\=''][ Y([V MW[Q\O[&)_,5\OU:ON'ARW<4PUW5]BT>)[;DL@D/?3V(_L'Q'1H$3.-Z3FQ65 MC4VEU@O/?FX>-&U Z*B"CY#399%D,,@/18J]82&I%2>(V9[@TUDV'L\GTOAP M D?95,Y!F2V-Z2BY3)_$*RFAVZ!UV@Y0ZGAB',A$75IN^Z@WXC_Q7,=SC4\6 M!G6YP;-Y L$B>\A%PNQQ4W6#H_4EKDM*8P!880ZKJH)]] M,!(Y&N'286* ?[O&QPF]$VA1+T:19LK!S($]X/BQ:+^P33GJI!P\+XW7^8?] M=\9,)B<3V-7APMC))F*>9&A]'2X.PO"W_0-FP?2 S;/Q?$3S&<"2#4V3['"_ MI@51IAEH%PLSQZ](G7K_U\N]=V 3!.RY7EY9MQ&=YC-8#] "IY\4 M$B!H(698&,=CL+#=G8*.!>0(4 M$4N\!A\E*[Q&H^\:'W)Z >PK/CT!MBY+7BP&]$/@H71>T.["E.I)J\EH(J[. M6[^R/0LPIO-B5G87,Z1S4AB2@[J;XUM@)46^X"/8$+S??@ V%QB=\%B9PA1@ MZ]4G\GLRFI?9J30 V:CS:X**,Y(81LD*I#+2"9^H.0C?B/LXG1?3O)2T!;5< MX$_+.4SC"HO9-=Z 0@\FON(\3EM!$Y&BD8A*F."S>2T:?+UHK"<(6'DP*^20 MU757C+FZO; Z6E!+-/]!*="D(;8!H/J: T2M_SE?6LQBDQQ/Y# 'H0!9 'X9 MYF#&I!Q?U9W8: 'OYF4^H8ZX (_CLGK+&NZL*;2+J->\=%3F]9M/^(S60.NL M?V"4)_ RW$CL@8\4&J 9A>)'% 6[:C($3I3_F0-)X6'B&\W::.BK:57C;B)0 M9\B:G;U(@+ ;F ?6T;I>F/CQ3)2SRG4 +&PZDCLF&&6D@YC[_J0[#:]FJ2H(R-YV-X!J8W M >PN^4CI"EJU6P%/31E2F-!YW%:G5DR"LK((8 ;JAWCX-,M5EVB@'H,/Z:%% M]>X5FJ\0HB$\H##VVD3?8HL.*GQA*CK0*0/G H)V1;QL J<(N1=?N_%OW3WT=LL/AE\ / \_CTO0I)4[&MAF'H6M:5BI=.V).'-A/7EB[ MFQ+B*I\^:=H5;>N[*# T!,(T+]1QA2@:X344^7QXHJZ5(%E78MMBI_\&L83! MAK59OE:DN^_4(HE:VZ0!IHH_YQ<@^:YQR"=H5 N=3@)2&![L;3@+\MD2_A$+LVIQ!LDUFY,%69W"1 MP5?*H6WLE:2:*RE$>[RH7PPSO8KXN9Y(>1Q8GALXC,=.Z($P1DX2"MN)',_1 MGF!6>8+]GPK,]>+7%;\?;]C1WA@N7UOIT'[CEZ^M66&:WM@*53:-0-2@W7Y&!S8^!7/B6S,7XZ1 MZ/G_+HX$!T]>T+UK"&H8'<6C_7__QE^LV\:U<;8+XV9+<;;(\T5BLR2-7)M9 M01K;//02UPH<":4;<99=0SM9$^K2=2.]]8D!Q0TTJ9S MBG=I(SN3'Q6GCS&PRB].CLVL1!\L.1U.YD##$AT"C:,)ALN+D3A#EW2]"!BG MI0K S- H[[J;!"BW5=K/M,A)5X8-E>-J*K,,IF+8-07_>K^_5[O+\ V5F8&/ MQKG(9*EB.SL9$*"]*Q41*J+P;JQE8*1S=.)/>2:,UIS7!>_4&KJSSR:GJ*N# M#:#,A3/85V/,A5RV5S3-DQRV3+:4Y*DIME#SC;.)($INPODTGZR= MJ0I P$O!G)$S]'WY!CMQ;[V3KXGXD"*;+W$*' \P! '_?)H60%'EYKN:9BL\UW99 MRD4(^A.+G#!*P4RPX]"R[4A8U'O=]FS0:S3\(EAL)[$G3-<",XW%K@5J+O=,EWEI(GP66\)_\L)=D_G8 M47,'&GJU;V0T%\HW4DP14/$1'B%+&?Y1#;^WQ:' A/.I_@! MHOZ6LN-AM0)]Z2WRY*NL*&>:3\5?&JT>,3=^_'YX]L7S)+<2.S8=.Y8F\T/+ MY+83FU(R8=FN#%G(G[SP+N+&!J=3I++!DY,,3AK2*NBH5X$!#)=G@*S"J#,U M:EY3'BL\M=<<0G3 WA=>>Y47+X$ 2ZRVUY#D.-W7RZ]_^Y@9\=-WA,4H8A&S M(M,/?<=D+K9D#]S8#*/0M;DOX6L&C&A=GA-_F@^.$XDXBCUS-B*79/9D0,,:(>F&R=A:'DR8C98Y,$5\' 3%U(H]#*, MMYS:TKA/T8!0F3EE$S6HCGG*@%G1+:O0)#U.]\"7*BR)/QUGI R<@.[6#?)J M75RO:(0FA-*@*RN8/>213(@A,=4P1%F.968H3+%T,<,M>C&@L,<*USW M2B :+Q!OA9Q!@9E7,H@J=TNZLR*9C\'(FR1ZL+*MV9 YMSPX$2VN%2=AM )/ M&](Q:]JB3H7*6-O^Q4Q(Y:Y6Z1(=,[:)=E.&DB889BA5F8^4H31H-JC:6TK? M::>2PLA_<'1/K.6@M6ES*_:]XHD37E*YUDB2G:OR@@RGP4E5-BE%-1?8[H;!MI:WN'+S3((*TK;,$25 M;XIMQ$#G!IUC\L$?Y(!8'(J/BD'_'1*AWU5GU9K)7+7)%9WN\TOQUSSY^^\5V ]<. M/-N,/ $&:1I)L ,8,Q.'NU&8N$)P[\D+_QHTL%4[@)S(2XI9I7XM(P')>YW2 MV[R-DHX[&<-PS,T:/(!?-"40&]+@5MY6.7LR=3!6&<7P@AWM>!9:8-JO+T J M84GYI%IZ/9M3CK7UR8AGX[;/LY'4CM^\+@A \5]5\-;Z.FN/>)<>P/28X)T7 MBUH/RH JO-R4I-<87>=5(?Z4Z%]0E[M6T#_H#8?EJ++:/8R/DF>IJ4!"F^HX M7;*Z'ITT?UR 5<\]/TX2D9@^#P.\RR,QHY!;8%YQX5E@5/$$"VZM]?6V!D6? M6VZE1NLE.54U#ZO'WLMV;OV8+UIRNOY8)^GERRGXE3CFK='4>2XQ_Q8Y'TP# MS+_*1Z/\#"7D-IA4\,6Y/*H8,T^/\AE\DZ>O5 % /OFHIOMF)L?E8V/' YC/ MC^'9X=?#'T<_WEA@ZEL<;P ,):B-' Z:T'-,+@.\!LMUTM07L#<.'#2KK GT M;W-FA;QG!=JP$PPF98FL:X8T*^T &F\/ M-\>\_1+YJ1_*%%C$9Z');$"TF%N6R0(OB&S+ES$+G[QP-W!,IAEB&60HW;_. M7FU5ZU!01FOCA'24EED:8B[/L^.?XL%/@%9I.DU!D(%)=BO5=M40ET'*# !8 MH T_6JB7++']4APT2[M%(P7I$+"8RWJ!%.2C"P=M RQZ*%)0E;#N 0OYI%3% MH(618*6:)#L+WT@:#JH6Z%:;@* DDL=8G[BH*M+RVC]1%U^VM9Z'4@N%I5!9 M_K=<+2&_=YDP?V#=]N8L&+7,CD>IJ7NB[]:7/EV4":/'74F$69,'HQ]M@OOE M?#H=+98?;F2S?)OF9 M>9*?M3&H*MY=,[-S$B)J>X#6G%&6C+ATFL0RD2_(EJ@(/?F5](@T="/I"=L5 M$CM',2Z<(+5C)XI!#XB"5)VYEJ_/7/RC[3!X<_3J1O,CK,=VXOY([*.S+U9B MP69@WB^W$Y.E26I&(O'0;G 38<="V-A=V;(& #BKW:&T.=O!*%2.S.R[>9() M(2?/'A-%':!H:..-7%Y@ E?;V*\ZQ&O9+#.2@DD_L2,/>VT!0NA3P(@!6B98 M)TR*BW8=W*KK2>^3-![,Y4=09,B&?R='F'F8I[71_FAE<6@= MGGU)/JZ5F+$((HJ.QF'L2BOU4./M9?$R%+4QWR8($\FNDLT'[YHPR"5.81VAN!]B7Z]UCV;=#J$]-CD_/MC[<33\XO/42F/?-;D; M,)-%6+[IAK8I7=L/TEC8W))PYGKKY7Q0&6D7>@ &:/@=%/.AL==D7E>I %CG8-[(\-,*RWT)IF&0!48YRPO1"DGY_,, M0$(LB^/T#;:1Y:.>90[>GAWO?7$#*["8B,W(9I[)A T6EHPMTPNYY221+;EC M@U9W EBRRC"K$57,G)BH0FOR3S5M[2@;BU*PR-""G3%GV7AM^L8]TL-6V P] MR^_D,"MGRLF$H/_J8._1YD8UA=NCW5^3HAAL](+R3YZ4:Q&KUR M0XX-HGGMBR%'2)Y8+G5![&:&3\@VP()3K $&;5YW M U5J/!UT!%W;8&.V,H%4+/VQ"3^,C9Z#2 11F B3L]@VF>\GH /YJ9FFKA,' MD#QXIM+DSA6>$N+=L4WU9'VN8<'AT K@/Q!"=E2T161E^; M]:,3_H2:$Y]=='G$;7%FG_^SCEO?+@[/O@@_<&V+23/V4KSUP7/-*'(MG%*U\9'ST$3.!DLB2 M+'*Y*3U,:_0":4:!9*85)5Z2RCB.&=_L2;LP=XR,/H55F"5>B+JE]C(W7:79 MT<_VDGQ\39+LODG2%LSE%ILD7=CT:*E)DL<]AZ>>&_# 90GS8NY;#@S!4LG" MR(XV\O6-YU!=,5WL _\F!3?>JS2E&N\?;C_:XXEQ"-HD&ZSK3ZBSPK@QGH]F MF4D=,W4&%V\9/[,30].M?1')OG+9[1'2\[H9DWKR:==4) -*CZR'4J538./A MQ1Q"W:Y0WY"!C7= 6^@689*I^F'OWZ9E!<;._H$=&?M[[\RC?[<[U"^6WJSO M&Y&B;KAX93]A&D@P[*&ZZ-+GR#U8I?1-L'3^&+3@I03BPP4Q]T:/1W/%X5MU/ 2=]F;62 M;)L^GQ6O405D.I^AHDS>ELV=KUNW9-K.+5^3>440/3PP]O#4*H%TJW<1/&@L M_8/#.5HL#,>AK-SHW)N;6DW:ERY#6KJG1+%4FZR4C_N$^CZ?2^TG3]ME^A<_ MWYUOY?AN_Z1[1X[VUF6-?;?/@?0EZ/^=M-J5BP_FI:Y6*L?8)GZ>MEN^S_H(B"N[WE2P[5JF ?U?O%. MZS^TF_'M7.Q2U,Q.=@@-LJM,&AUM$"F6_9IKSK:'S0P[MZ4 CP2J[$+#,B@LM;ALW42G_+9X MX5+KEC?,QVW:=:CLHKPA0A=B^.K,]3UN=0AEL7+91X,/>1<]X*W)7-4UX)UI MRQ<%U+#< 8_ZA@^ MO9V5'I4,_Z@E2RYA!L#G3K=>F$5N+I8EJ_8B;V>< OV M6I5F5^JZD,2!].-$IM+!Q$'N!8%(@MBV76:[H;C&[ND?U4QU./:=7L,C5OKK M%NH.S.'L"PVA4BXR5(>FI%GN2;W(L?S+!9$>%'J)7LG-**PZ_@Z:3)?,QM;&" M04]U1]SFB 19)#.0.D0A? %^"TKM).Q9"L:?<&SR(BF=7/72XI.V&B4 ,R:" MJ^@=0OQDF%,:9W:* >6\ %V,GY7S#,Z:A!/^PS#_EI@"<+IK[)]D(U'(29U0 M\C]Y.<4=1G[],R\!AX<2$1.@DX]V!YBMJGJDXB3;#^QC8>T"O6"2[D;91YUZ M@(>E-([R7>/W?3^T61#L&E2%"*_758B1HFDIU?-\4!,"SX7H*IBT@X6(_,9G!9TU #T2D$'_)HO M<;]/82@,F]9+'[23"JHR6[-=RWS&BTE[-O+[E"XBA,\11A;Z8IJ5080L,4V8 MKD>M@IX>:92OB"SG&;FWJIIMQ7BDDY:S(L)JZGG)5\[MAL^KN MNMA8NT(Z5)+@4$4R:/72&ZCKAVH7"'$.)B^,LY)4R1W\*I]CYRCY%38VD4_I MGC"]?U6:3JP7M$G15 MO674';%=/B8A:OQ(MJ;A8)TH:>-V599J.2#U"KY?68VZ5JD2G64RDUU7X,0; M1-C "C3?H_Q4N[WTCE^1\5J6^D9>TQ=&B=2WZG:FH.C)F'O&GLZ M%Y247E3^J7$Z0B[^OFK^OO9FSWOH9\-S!;@;]642DZ.]]P=[;\$F*NG\>3<' M++^%>.@V'.!T=?KZ6-;%L2E]\'OK3.,SQ43J= )S!B'AB)>"_\=X/\N3;_#+ MXAOPUI]_[M?%]>K[YGZ(U:P\:J/90K#VEAD>\ZR=^.F.\W1G[VG'E-;O^IN/ MYI*>;=Z!LE''Y #SU'AXBWHSX7VNU $]3"P)(U0'/O71*8W*%5BX?55+L$"6UK M)WFZXS[=V7^ZNCV-UPO^PCX8E)RAT_!JD&@<'SDE$9#1VI4?''B%Q+CI9)G6 M5S@LTVJ5.LLKI2,'K^]2)3WZ'E#\K7T>#>LD/W5#'4Q\>36[JQ+=06>G6K0F M:\W)'3<@)=;,:,L0+Q5U*D2^#'U6B:R\K7KOVW;V?^82;\'F-9#'ZF*S6<.F M_Z.^*8V_^$2..@) G]3])MIOCM8(;WT^M[:F:DLII-XV"L&H-R_="X#."'4K M!V["J)[]^LFKR:+[9#J5&))$UVQUC2&?M6XHZ'C>OF-K2#VM2_.YKP7G*ZZ3^JB9 PO M?'*SR3+KMNWF^_"M ML?H@*Y-Y6586R]Z$CQ9E1H;,J_I:U_U\HKPF],P[BH?1(\=3[8->#3/?#7F[ M&WRGNO-&ZV+]S#^0B5:EX8KNMO#6MH 9U[IQ-^EL3=%L35YOC5&>- V/.=F; M\*NO\XDZ[DC7P$%5V3IL[S177H97>3$&E\HLD+1#GCA3#_S'/R';YOR/PP MR;!)-JG6GEA%7R]'-AG19J1IL\2"V43%E2H1T]Z0L>03W;/@O50"Z 1[E5+Y MOM&<]]1EW7;DNBH/0?EM-&,N/ZI,@'I$^^6:$5]^3TZP$WQK:+9VZ/:#E1:] M=.]%RT@H>8K.GR+."VTJ8".$IL(J+^D"9X*BZAZ,%HN<ELAS(USD"[E)E;D00"D #0?#QB*?5^D%"[U3GRI_8.Y!>-M(N2.Z?$1ZT/%%7U M#W$5S"I-95&7H.']FM7E$*M+PFEM7I-R+6]^UUG&NJG5\*HO33)X]A!6N MUZ( 3(F-FCJ"DM*,XBR?4M/O2/)GK"VD0ZAS/DVP\GD]RE<%:>=)/>9'E<_I;9:4F"*M%2^R-&'YBG$@ M$,JBI4G10PJ4R 0Q9O,Q2!^=$K0P<5+M7NO[L/A" 2O)E4MYT!T0YHV!\:$G&D M-P>#=FX=G"0S)+'J)S,$?I!%-?9RJI]JJP7_1/QH)R\3X./4*LU'W3Y&6TU\ MDD^J=C.(1+3=H&\NZ%YM3$,DYS!,==?X'9W,25Y,J=9+KQ,F74]TL&EVJ /D M=*+$$E,1L!DI$"19Z"M;4HE9]WOB]R6Y M^4_X*49.LK(61F4$)+Q,N%!*,B6?T+5QJ/0-)WRDO>@SF:&!@!M"Z8VEVE6= MJHZE4,0>E.!<,7DMP4J#6QVO+76S(AL.=>(M9D\J=4<)&LX2++;:P[^<*(_8 M "S%Z>9X>';"P63 RJ@I&!V2C_6KE22UY3%#.N M4WJ*J\M1:<"4X#954H?G MH&9D+>0$>", "V6@J4_UKZH55 8FGTQ4WB5045_3CNBUCO,6-%W8-=FZHP]S MZ*C8MYK@,\2KRHI!:T>=V>KK6HEORR<:(Y@U+HWF>3*B1EG:9+P+#!WB/E,[ M_;8 5]-K+5_W7-$ZC'H*V*"ZS2<&DJ=9E8;.V[8IB.8Y4\VHF;G. Y(P8- MP8XJ9<).A.9+I[)GKKTV]4!]EZ'N;/3/M\"8S)"]PZ\+. M^7?HN'_>(9?-=CVD!2K-&9Z)&>HL<#N.UO%-V>%;S"*D9ZL:^KJJ! ,7G0]28$0NIFG0Z0M\3^G6R"3J?8DHT^E)= Q1G!+G5@@ MOY]PY"DM^-GD)(LSDEP-G)B>-&ERH5"S,D#I*'(Y.8\A2X3VM\J3*P ME&JVJC2=3984 A+X&999I O]DF^8,S 98@7$"%.E%,#@1C3T5%8G\!P=<6B/ M3['59X*]/A=T(8K"X@S 8C[+$9E O:3MSS#946TLZE_JG8JV2GEKG92SDX(\ M%R7 2 ;YE@LM3M+FYH)2N?H])PI)7:+,NAHTV^H7ZVGHA=A8$(E9C"HXQF$ M7$Y$14RZY.04TR[E[ PUF*9,0U#CIQRKDN$85S^I@N?-4]U)_Z1JT\/3K\/3 M,>JW5<4-S)&%SG.C[ V/_W7M,&IX7RM*"H;]GB?)88Y0H34TE M-+_!J6F"/3*4L]8S3[4<8-'=J:I8JQD1W=ER7&:(7>,YP6C%F[*HCG_2S;I5 ME!)]/76O)SK>6V7&PURE>%7$^+>=B^4 M<],[>G2Z/G1Z#\;R.?HRGHU5T&/.1Z8"K$J%IV-M@W>@,A4X5AT69NN U5I MJE+2^5!;BHUF,^AH,&WC/M7J@G:B5.6R"6D*RDR)E_T+I-[C\D ;I,&:\L=* MZ7\0#LWU;+?6W4*^NG6.G@'ZB-5.UHZ]37XBU>RA:DZ""O$(3P,=T8/CJ'8P MUCX9BB2,5(QLA#XQBF\2;&.L4EVNS0LNLB&YC2H7(*1"MN=IC">B3Z_:__:_J6?4< 290A MW61"U@/( W(>(9SY84UUL8Y:KO/4$M"LN&@ZZ$C\WG%@US%7)7(4;3$(*,GT MTXA'>N!?[_?WR&>D8];T0FV.5C[I\_T\@^;Q$Q0;;9\UMI*J7R''CKY+<;TQ M2-K;&+%>K@+"FD523*&H:,#K*D!%Y<83:^SA%7ZE-.S?G*6.1U@&2.?([W^9 MENT,5$46J;L:F<:P#4@_;)3(*PO(5&8P%AK6Y-46*]8GP5\X6_H)?=C:#J0W MLH8N37R\\''[BLRZ*-UY\.'>G7ZU#CY:.M/EH(24%;+_NQBRI+>TK4>4%KUX M8E)*3%3W9+="<9>;"7F%N@:FMO4Z4JP,/5V 2&GX(:?8#6$,@CHL\K,9 MMD,EWU45ZC*<#HS]S\MWSGF"WL@Y+0Z;E^ZM"CN.\K^ZT^M%=;M%]5UVFIL) M5KD4\!>PPT@F(SE/,'Z,L23*PZB](;C]GF4_O4O)'I!H7TT+V""N+>]S*Z=* M'Z&UI@RZKHI[3_,,HU@M30#.LTF)^4&ZHWOEK*TUZ/JWRI,S)MY$+[&L]D@5"[EW0$N:)OD!6)3Y506=J.$\5;>0V M0L+7$ZIRCK4J\P"BNJNQ00H_916%L?$)0;RN@9*ENH>J*O;>D)E0I2X@M\#; ML%7,B%2_)E3;U"*KF[4H"P1[?NGVD4VY>:HSR9=Z4]8,-4*G.->UVL#[*-P& M7G*@"A)C72S69,$O7SQ,1E\5@>M:K.CEFQ<)_IGP*:_8JN:;8I:I;+#,9 ?>O&>!A.A3(1EJN&P9QI2+Z=KVP M+MRKL@[I^VLM_;WNRE]DN6NK]S5^L=2WHMA6EOA6B[NYZM[+U?+.FZ36&RKA M/9/GU[Y>2^$N)1E'NMB+>AKK.\92K6HW]X[_? M')AV]"#17:UU4G4.K9S$H/]E$Y7(5.03?IH5\SJ?2[=;J<@R4#T>5 )_AG< M'=1!>0,=.TJ9&X[R&--.IX7.Y,*O];AUD9I=E[+AM__DQ4B@J(U G(^+(9]4 MVJ0 TT$YE+# 7$\$]6@*1%$.)RC9XRS9-3[D1HG7/LW4_4.=S&@9C*6O 1%HJ:'>KRJ<]/JAE"Y49BKKY6. M"A*U]@*Z4J++%B:HW5,>+1(*N_>AP3Q1:LCT9%&2D85"4&S4JJ25:U V1RM!.&5?]T64Y; M!5*MI>B3OML(2=LUJ#YVW0]E-I-5(6/5?M7@V%.+]$Y,3,1;.RK\U+59%4$Q M)866C32A5GJ5DEQM?ZT=:T6&Z),3HTC2U">8FZ-3W2H(ZK!YLP^3[LA]Z+H. M7;/K:&?@VW?9SF!=EZ;;<"JM/P[7%IYO+D1M3=J_,T=8MZQ;70Y=2F6XJM:& M\_$8$5TC1%WKLE3#75F12A4OJ\:'4JRF?VY3$3=--.2_FL^N,Y M8/QTQ!?/L@FMAG[T7(^EQ1&YZ13-6X L+6HD=>KKAM%V+<5LLP+^7U1OUE_O MTE>_S<3J=P[;#8)@X]?6KKWQN_.&M>U=%K@_->SYW[DA>]R3C7:=T78&YNLY_[(:C]GR?NDZ7PQS/+L.FI MZAWUH]'*H\[T.S[\?$4C6 :O<2;$2%[W"1%==$!8ZH HI#0.<[KEY"6ZY6M M7U[A%8@!CQ;YF?K;^7G"*$"_&\+L4X[.=1#C4IR!<:*-?'&;ZN7EJ'.$MME: MKE$:7,\[2[SS"Y!S26ZYF07_3-,2HL$.V:KY'$85Y=-+R)'6"$G)GU9Q]VKF M/TN+VY2G:7FMC^SSHI_K[#> M\V3PHEJY[T%QWISAW-4?7 M_3"TJPNS=6_QC8ZO]7&VM0*Q?5SC#:P+^.;F .E"G]"]INQE3H&>MCW7]I1] M')3M\>"^<^TUA1FV6NGYD,_H.H8+@GW.Q:N^=-SXP?#8KY/BC@V^Q[R]OV2T M]QN\_1OOR"J]R.-W#\\[ MM-V[M&-;@]#V[@3MKLDLO1]JZFMJ'SM2=T2V;BD[O4QBSJ5(<4\XSA[XX57! M^YR-ORE8N*R-]C WB0ULW^TW:;LW:<<9L/ *BFJ_0;?N$V;>56WR?I-N^SQR M!E;D];NTW;NTXP]\-[@3K+M.;VJPY5JJ2I_*5V(I?2)5VXEG.=&61OKZ0.YU MG >N=57=M]_?>[._.VS@!.S*#H]^:[=_:QTVB,(>FA_L_C(P>-E/.O[[_=W^ M_=VQ ["8KQYZNR\)5/?#4[WSFF>3I\8H+^EN#NS)KB] * ?&1/Y<8L7]M3QM MUOL&MGN'?BZWMM^F7I#Z'>KJ5T'OK=[R+=IQ!X%O]S&?K=T@-G#L MWFH%]4_43.F.R.:2HAMQ4-]'_@. L)A[?2;4@[.-[^6F*J=TOZL/:E>C@>-? M=\E8O[%;L+$[=@1:VA6BU?VNWH===<.!'UK]KCZH7;7#061?=[AWFYS.6ZW* M'],]Z]DDRHAW7#_O:W%M31+4!^L@R MG/K\F7NQ33N!%<F( M)W23LI%/,1?*&&4\SD;9+/NUNMU[R*)LX/B]VV'+-\EV!G;?OFW;=VDG&(0_ MD<+2;]"MV1L#S^IC2%N^23:<2%Z_2UN^2SO^(/"NGMC5^UE_(=OGD?E8KXH! MO77;.\'[;>KEZ-YM4.\$W_(-ZH'N7FS3'M?FNOPQ'\L^&4?GNW?WLQ7!9<51OL M]_?>[.\.&_AL"_O1/H;RTR,YJY5^['=XY>RC7RB%WCIB_.N&%K_=XF"<.K7XS1\V[/NUNP:M!MG:N6V?8O*^O9MV??+5@UYE?^;%'*K73OJF91S=HC!EW/WU?I M*M3,W84)BGP>CV1W\I<8Y7Z^\%$L.,$BL:20O*1JL4(ORTCSPIC!E[.30DIC# .=E(:<""F,]W(Z MD^-8%@HV76M@.)9C#X!?QE->P!.SG'Y;\K$TIC"Q7)3&B) DO M&O%9\R@0'3,F##Z$UU$MVEDV.S%P>A\G&0!EF[QAY, MIRCSB;'/)XDLC'V)?1B,'G7%8JZYVPU*XZO6$ MRR5.:I_#=NR_.9#T?3U;F9Q,8&N&F2SQ_<9\FA9 &R,%(LWQ9;2:9A4PXW]Y MNY8!6S?"EZFE)_EP ILD#/HOHO@NK#4K@803X)79? 9;P(TQ_YH7>N$XKGZV MV;%JER:PL9?S+G(QIF8)W LXG?3? 8#9'QDS!6S)<"/>/X9LP(^ M+6E[]_YM6E9@[.P?V)&QO_?.//HW;-AHA",7?+IXNDM,H=^!Y$SGHQ2H"VN& M(>G]0%_8L__,>8'3A5%QY<903JI;22LZXNY8NT&U.[O7)LS;#6!60 !6@C F M)\3?[5U^J:]L-7;>_?]\/'U^\/1>DV6C^A=H^!.R@3^]XOK:VNN&P644G(*$ M\ +690A@1W@>?C9/X*?U!)9PLN0C6:$!K'Z>\F0V+Y"GX2^LV5T,:$,56L!8 M!'%8!IP7"2Z#S^C%V7@Z(F&'H84:H"4Z)WR4:KFQ-# 5LIR/9DK(N/$O=Y?5 MF-9Y#TP0%B0!'&*0MS2;P5^S@@-[J8F5)T :,P9Z"R(4K)(N8*@7FL #0T17 M>BT1">08\($@)2WES(@7. 5[UZZGT#["2E!)-)Q/^8)8FB.8JA54Q-MPX/S. M%\!YQGX.@#(D2A]*D27 .(0[A:09 5CE. 5KUUL[A2ZPP3I+57'-RS)/,K5, M 'J83M:Z(WG7Z 7M*B?98Y"S:#>Z63E33Q,ONVO>1+>DJ)-SM+II*V0=Y6=P MXBZQ/Y N.Z5N J R@8& Z,X#X CIJ ,96IB>E2:3_6F:K(Y:( GDM?[5?.2 M0#" N?OUW/5,D,KR>T;ROFD#J]%'',P:/LN1GO1ZP!F !P,$)9&/12D@J^:U MWFDDPIX8PS:6,]293F5++7A-F[-W_6J!G@KS8/;5E9'/:)-@ L_/,C$[T6Z; M]J^4V^29U?R$QV4^ A5ZXT]:$TQ(I[U]5"1R.UZ7%NU_GA2->3X$209V_V;R M%";[C(_.^*)\\EMG3;!99IN RVO?O /WY]30G'=WZAD9=_!2@G1@-2DVHG]] MPL )D"^D-)> EX#+;HP/5%+.T-"!?Z^<*C6B5N!%$KH./DL-B&$+S.N3[7Q M?�=SV<=4OZR'4S%FOI#=?)6&V&?:R,=45#FVZ;VQG2GWT!(##KJ':H:4Z5_YEGT\8RY,9H/IZ" M=3FNS$KEB6K;?;/++?C2F+*$%:2,M]]!U%M=U/M\#A-^#QO^JN"3)"N3O"-^ MU53Y.)]K'V7+D@7JH:&+QLOD/!K/&G/8&)(_M5HTUL.IF=3PHOUU&_ !-O-P MM^707<6'NW&=7U'257N*-SH?^.5R$>#6AC[.%6*UJ,KN:I@1'1A@'9#7-EOJ M?SQ8Z[/)NM=U*,LSH49U9;=3'0V:SXNZ75W5D6Y1&]V;FM%4/O&@?- 0Q2! ]7O)M-IO-9+03C7$AR7!/T\!(. M1'6<=OOKX2?K)WW.A-'%L"#:@04Z02F%;<] 7G&4= 2G]5Q=4GK.,@"*$+[: M#^.@L:PT# Z3A.%5, %E,"\ EV K1G.,V;4W BE?SO+D&TXZD3=F[ 3Z]%#/"VX;9A/(Z(DK= MN%E&7.]]_#,#E5M4!^8^GZ+F9;R3):PY@=?<.ZU0^51S9(7]'%,45+;!(9_P M(7'C?Y?&7R,^6 )2=%D0X M[M(XX:<2M!/B=:F$3QLT,0>]4D=00&T 0<3A0-D!"5?&1JY?@02M]#U\!#TB M?$;!'*#*C]HF0FU-*QY*CF=9B1J0_KH%!96H3_)B3(&[>5$2KL3S$E9=8@2# ME-.-X =3/N&@+O'R9$#_)#L2\$E6N@^JP""YY+'![]'\V'*N1!@Z:C_*Q4!T]K#^"@J)D2"0[,B@Z$F:(\ M4,:P'4W\70,GJ&:SP/VD'4PTNL%,!TOO[[(\O"F6@VX,KYV25+GGT"#/"F&B MY;5H#.^BG>8A6FD>0.Q3.#_@=W7X:]$9F$QV=3Q6@V$@&W\ !%(Q(J4J%'(X M'ZD!:FOH'?U^U_B= G>Y.LN2>5'@?#9.=(H J=X&C\^R<14S3V9Z M,Y9BMR :PP+-,ZT/T'_S<4G"&4M8TZG4W@L FG(> RRIO"1,9YPIZ,DKIB+C M9UF.:8MB3$-"MTJ&TX27IW,]R8;).O2H]IP^A'-N3C8J#%MH4 0+.=\0'W;N MNY3^0TK8I",YJ/#-$+:)?'E,:7GIG BC3PT4U(GX#41,3H9DWFH6T4/@+'2:&&:( M:&VD;263V^R49Z/*M$R8DDJ64W]HT0BG!:=9$51N'6X:3 MTX(,B@3.EX]J7V*:CP"*R>=1)Q)JO']V;<;9W63A_B.5/@1OEFDJ$R)J>2)! M^@%;-9WS2:,_(7B^ AW%>&^Z]8&?PT\+E?RALU?F4[)HX*6M%%2]YP Q8*0H M^PLZY>X43M#"?EURDK_A^IDT^+*[T<-J=A@RGH3LB8JSL/MGL^'YYT M$FVZ4R*-1W'L.&^/7B?94JK,.M(,C)/\3*)1U$ !*( XQT4^[^J5@."T#B"2 M $;-D:PI/X73D#Z5Q5B?WI6TS_(VE3&HMCIO7I_UU:RKHZ[>L:PMSA73@W+R M9@+KT<&Y-[N_[_I(F>I7I . 2@$_*20,7%2N2**CSGF..0Q#G*-3GM7P1*-= MXTV*2R]X5G;VI3J7VOO2)VG421K^5B5IW U"56+:''!PRE#]$DH*'79M0"$X M.H,SK3S)IK7CO];(R']QDH\PVE-+HLB0'4235T?R1U"BCHKJ2-9V7:&USRE) M _K-M=68T)'*!58-((QQ@E3EFE;Y_7H:\CO@!\IG>SY7DI(,@ 5K#W#$%2(@ M_M!48/KPMC3[#A);I:3F,7!VY=6'!<>2]!'01K_29/.Z3*&R%]5!>RHGZ$5O MZR2-A)<5TK3P2KV\M0Z:)R7]):1Z(B6K;%C4'6EK<D&LK8:2PHY6AU MN]^C54PGG!KYJ3*+UTV2#6P6#=P@7)ID^^>;)^;O>NW7GJ$AV**]\N@N+[.> M!VCG)#038V\^!+8SD)1 4+_&+3V+-;\X O%5FT _\>X[X^^MYM7O'__]YL"T M(P ZT-3&8*,IJ-$ P;]),@%+4.6-#(A3 J&Y4"?&<)3'*"=HN"F(:ER'H%!] MDY7?L F5HO]CAN9S*Q+9QD:1D:%RTK6FT!;7+VG9BY-BV=%2 H9]H>Q=,8 M=>8\@7.##D-]YK>H5@W93 !H0Y]CBL5GY3"1&@W,)1G2P:_[0^%7&A M9"7,J'&T2N7!7YS"B3G6V+BB)#5'K]8P%D:EKVR_[;LQ8+(>5?:KF6U'_ 9] M?Z_0";SMX:<-WO%:5=NK'=[W_-@YVA 4$=)T^!RS+)RVIP?C2 @Q5.@# #DQ:1XJ7R_M!MO/C[// M*$N PNFHUUXJR-Z*S7>3H99JY^KX-KVWG8G44*F)X;7B=1=4"?[+:14&P7(W M%D7AL# CN_WPNB3HK4],W&2@X.'R,#$ K-333"C_65:O\UIPP&HET2^GB*S& M6R^$@34H<+T3KD"@/6\$ "!1(J4H*Z.T)=^57Z>V]5$2ZLSG76R#< D2GTN" MSM3L=F&">J^:VF5G=#\%\%6M\CX\ :P.X5; [AIX>:3R:V%=75QNOT>E[+<] M:6TI74FA6#M!\E2TPR/G\_)*PAI\ &-.*[\:YK*0S?>S3JUN(M;S.]CN]5KP M/GHU,0=@+TFP:@#)^%<^0H^3.I5?PNPP;G1]'7&VCN656=YD+H%ECBM6-?Y: M:=$!_'V5"_7?P)(5X7A#N&F;<'/E_9,5_2HHS+',.2L34-^:WB9Z7+J#*WA> MJN"0;9G_KOF6V%3)UP' O7(W*1>5M8O/8SXA##LORU8T\,JS'*@@%)5NU.EL M_X^]-VURX[JR1?\*HI\[VNY L4E18RONAQ(E2^RV3%Z2ON[WOKQ( D@32 3 MSJ&*\*^_9Z\]G'UR0!5EJEA%(6[RU[K._C#=!*'$+P(Z&Z MJ)QEB8EGFG7@EF^$QOC*BXBSP16??#N[QYL MS>PK?>'+LNP +B0@O953;S^2'VZ5%ZO_]2_%Y_G3KYX\_7+]5;[XYO,OGG[] MS>++IT\_SY=9GGWU]5=/OOG_O_S\7^XK;/-53O6Y9&;JJJPHU05+^$D;!-V1 M B72XDU#%6C KY:2D6^:COI0W/9*!NG1[,]5"*&>V(I_46^R4D",ZDV)YM@;*/HM>GUW>>O/ 8)=$!L=CI*K7/ZBJFI*+7&MHAW MU?Q<)HYEXJ_NNDP\\H;K]:_VANR*A$A=\LW_"20&?2L\4W9OGF6V#>?2__J7 M_^=FB_I5V+_ >82-\XS0PS!5V4,@1^"@GLZS)UQW"=OS?S/=63 UPS/M?U/E MH@EG_ (UGWQ7;9#M>7U-@]!Q"5ENC:W/\L^JAGJ4=E^--0('N;[&/TI#>2!SR_" M>5#1IEBA:D,^M<&@I9(3$5+Z*5)[%PN9G :3D[G)F5.!9I6O]9 "XJ,+D20/ M"F,8 556'#VZI2-Z"W',.\G6A(-]7\"'?=]0[G9[X*O'_W*'$S2^V&%#GCXB MXQ'L0,NI71J%\(>=_MM[ UP?^QGUO]FKHGG;_,K%FI/K:ZHCZ+>ZZ932];91 M:E&NJ=$%,9@E^1AAR='2Y2,%%MYZA5SV5X@"$MH!?0^K]/1??EVO]:."&T]8P<\?P0NLJQV? R\I,[VB)7VVJ,EK#'R5XHDVZ:5Y/^:%//OLX2=CI3K>]O?P\4CBC^$EI:#\"+RTU M_<.[X./ 4K\ #4PM(Z&?QYR4KU>A( "R"VH$6E'-Z?>H\6>8'?C[S KF)V\7I%_CL=N&OK/!CDFIBR' M%TV7#_^@!2BW; M']MX<\F6Q+N*I_OJ'9[97X9(S2*U"A\7W-TZ6^@R\Y,G! MB*#G^>2/[M.PAEB[VW?M%[O.1"*_#<,$$CU;4TQC@ZZ]U1Q83?&@9]*BDS55B?Q21&_2[E]NB_Q* MHN*BGE5(&8?YX[O'*3?\)!4;,V[%Q=S_K5MM\ 5"<,JQ)T$V 28OA ^8NV)I M.JD%@PKJ50AFZ7DF7M?UY<+D#T[4FVWJ:2L]_V=/)8 N.72@N=-# 5C/%9;T M+1\3D"D[T^[U@IZHQD:(U',*.4HNI]'+,B%('+M72A7U)=C=9$P/[T-4+G9ZEGYZ(SHY,7MQV MOD3:RQADZ!) 'ZS#J@Y?5U$+[C7(*'/66'AOO4YDD<*IA--LR26 M)?GF@V1)OOSM94E>7KYZPZOI^?-'LQ=O?OKAU>SYG__XXM7/EV^>O_CS_^M7V6L'61J M;+0_,K;\%AA42AIFL[*#^PNAO>9MPH/EV^N-.RN2$X18/T<'+C4T-G$TK% H M!,'L44M+I^]15"+*6#NGE%_'?B-YVO1$QT>SYWNR !F5\>=L'?1NJRK\".0L MJQ78NAS5#[^.4K6L23' *0?UX*OQ!RY+B80=>?LTO?PR>N>Y%T00 K/!_>;: M?;LFX5]G-[X*&=MJ&B4CJ!2E _^?3+S6M4)04._WGQ9.O[P#Z M,N6DA!?X\MN/9W2^3<;FR>>/H':L[$A@LJ"0,#:U#7CYD!/+P_)"T3BL?R&L MHO^(R&D@EFUJ/S)'_(2<842,(YI4!7WJ@**?)= M+D1IGJE,<^K$]I"0?PH#($A'EL3P0#Z-L;RLLV+GN.=\QWCD;A-*#RQ"HHH* M9A;J84R'YDG5D'\/>30@3*:-,-%?!7P@>;;5/N1K R,I9 M9ZHZ4!KZ>AL.+#!#,0_2- ?2>=W\PG7#ECUL5P(W$TV*$HS0).1E7>UV@#R' M*=5(%O:B;P&2/R9G36P?M&6)0X&J9T)+=LWL8?VU>I[F#S;-ESRXP5-8N;VO MK'!-MLY!74:>O=/=Q28<]PED,C&3="%J_P?M'*KF5]F.@@+J@^N0(FFZAFA\ M0?9*$DOB.@X/DD6X P,L>S><,XK!2*/8.Z O$K" ZTERJ\*#_8HGP#E(C18>M(*Y:& NY=7F[: MK2@9A>>Y8*8I>)KC3H>?9:Q.\SG&S5/$N2?/,.T,G^?_ X8QJYS-0CG!IBA< MBT;"X%T$K(E4T$T\6@Y$Y;=JJJ(A:$T5;ITL%Z5N9/ UDTUO,U)E.LF_>)[_ M7^Y[@%F4(SLF"*A:I1]E\%7>4OXKBHV!UCY?;LOPW)M"PA/.C 4S#ER+V 3Z MH^,L!H5-ZY L8'X44 ,9^_/$?O DE+(UDU9KV&$1)J5;T[>Y ?.E#0%!#+P@C6;HFYVAD_<)C)K%YI4.!I1E5E+ZVJ= M/V?-*ON[R1C]?-Z1'SX]$-E7$K;$ZIH(%OTY&+85U?\IT^,YJ$66@VEBV^07 M">2'4:!IAW^\H;E8]X6=Z#1=PR^N>'V,.M[[LAWVZUYUI!5Q:1PZ8=U<#DMI M*5K&V;]4JU,OG0BK* M4C+<0= MPOL3WIPE%BC,$(2P]AOJ* Z]O[H!L1@ [GQHPYF!EJELZ MIZC]BJ,5/6-/XO4V3T#6B=<\ M^ZL]6##MDEJ@B+VAMPW7^_V__T$>+KF\J+BOZ=3W%8?D2URZZG/,?P#FFCFZ M%APH]N;^9[K)STAWRD6>( TQ>)A?2'GUF\,@/GW\FU*4F#Z&FK!P#+) IOL[ M;[J?EZMPNM3'V\+S/\(A-'BU)U__Z[TN6/_[QQ_,292_#!UC6Z)R/)RV15$= MZ 3+EGG7BA8=FJ6D"3*SP"Q2QH9C@A)@T4Z7E2:_FIA672>E6::?S*"]YF?0 M>X8RL&-S%0;[L\>//XC^8^$@BH+X>C64Q&Q6XM/TAGD MVLVHNW%9@*'_=U]\\31R'6)D1'2P)\O&BVGDK?OK5X\;/&=9**RUOJPA MKTS_8'))OAT3 ,-5BD]R4IRL6L]%ARE_.Y;PQ,/-WSOG>0^:?L;W1B(SPJ3W M EN8R/;:X'"NR- '^I$%BN!AHEX3ON9("]ZYUY+YPPT:B?$B> MVFB(6>79>=R,:Y M@PHKCI/G5*Y'3GRNW8@01PP_E9])'&(Z3FZI];0;3%FQ#NLBK#Y38R75([XQ M"(957/*QJ,/F,A+3T>MM^7=4(=$05Z-;VZ#YY M.;]9Q-:MW:C[V0<0=V^^\/%I?7%EWF3O*QQ:[^AVLI/;/ M:ZWPUG6^!Z;7Q)W]#;(]63P16@X//^*KG7!^N*X_=KWDBZP298XJUO-8/79R M22<2RCE7I*6?LI MK&:(&R6"]449!K#ML-QPAI&+*FLA[)(6P\75>FJ'FJWS%=&^PF>B7;7BL"3\ M]IFRVJK*[KP?>89%:YK;"GG<%@>9R[#],H"-3$D2 M'KEC9L3>%#'>L%A5VI(9.(8"P2;.:TK#%4+:8$JB,B]RD/3[W2[X!CXV&M>A MTSF'%:_#!EB%;9I?D4Z7!/S4@T)J=$=)87-F.BTDA1.S[@[JJHABW4!L;: : M/*DF*N7#Z#T7^T.FJ-8H=!V\Q28O:6SDEF/:;2I R*33[E'IE3E6CBIYLT)& MZJ1HG&2/_O+H]2/U6G>K:T+<\1#1$UG%4X<:KAK2HD2TXE!C1UEU;3PO1Q64B4A.$%/622IJ7_^#=741TZT M%(003OXOSC $@2& HAKIM7#[<$K1EJ&,R!JKR6O7)^THE>4^1@("6X6VA:"# MXS3I21%G3X_D8.;^I)RF^CBOB#M9$74>OA4V:'"[G+!V52:M0SS)R&X+TJM* M(8#5:+RHM9\X]8SHU"2OF)F^B4'D&YR+< 1\&SX[KY![8#,RA_P5-X?3:%VC MM766/+PQ'IF>KOL0H#"WP6V.:$CTPM%70L(%B9Y8,B\]^3299V&MCUA]OH^/ M5]C?X GM?$9FW.$CFBA*6;+_)5++[E)KT.QI/0+RTBUGI%A>*7^7T<^1PSYC M'@SS\.1>81X>WAYZL6PKPO$PAH>V4\F*'2L[%FS9$CTEIX\Z+<>%8*'4@$D) MV.?D !.J29L5$>EGLZ^^^5>WX,EE;D,0->= [\NO:?<]^7Q& +@+@*Q8Z3RG M\I&V8E+Z";FBQQQ:F3]L[NXPFL(WR=_7D\_MSUC$MY+\[SYS"K(H@OKWC?6M M&+&P*%/IK09B"2>9JR'T3Q6U<]*#$KG?OS4(RXM:K4?XS=.8=YR0(M>\]PDE M\D%)Z9,7);]7&^[V%2^C9/KC]Y=)VCX6WKMV6TD 3,=56-\(XV,ZU'V9=F/C MN[UZ5:T/U+YUKP;[_7"[$B.%W8.8G^O"35H8[NV(D;&3.3G"ERJUT(/QVW;A MH4>:?J(F5!28R9!DRZ-:F%)?37'$ M/7<]7F0L)W"Y.[$>TK*L3X+X3!6TP$>R57/_[G5X+1**HBRO#D,8G3UE_L)9 M,_M;V/7-JM#DD#==T79PYE'2>$!?6 +& :]2](AEZH!AI_O,1ID,&%,NGLGLF^YG5M(CX\^C2)E]VS^-$[*@#O@2# ME)\33A\Y>-0SB$/\8 J%BF3$YE%\0OS05L($4!L;^KLJJU>]:^3! 5PVZ'=I MD&!:5*LC'V7(<7--;D35&$/S&-BO\A!4<+E0<_W<6I=9 -V. M+F)MJ9QPJJPZ/F+I&.A#(N.V=OCLG5-1A>O[1 %/];1P!B-TMX:9 I<\B,SR M2L%OY\7UD1<7ES*M&ZFW]ZVQ=D\R@.A_)R<&#?"$9&H8)AY]AZ7+'TF8^MYK M$ M'#LWS^KCOQF?:8"A$+?&(.:03^0S*SK=X(#$1GE#FV^G$WGGN[W+N([29 MKEQUVKAI<%Z#YEX!UB1B GU3(AUY(/ET"X;T?&C:L>VIR3&$/O!#S@O@HR^ M7V2^Q_,R4'DXU'D;>E\,]6 Z8-:K%"Y*?YJ^_ MTZ>3)HZG(\52?C@'EE(?!P"P6:7&(AZHPGWWI\M(7^:NZK['?=*X1Y)YF3&4 MYT3N*OSYAX[81>81SP45%]_$45 M.>BJ7;&4 VQ$!_T7+;X4"Q<5GS):224J).15*7="3#B3K2:,O%E:'UH]D)SL M>Y:/OAOT,(\4.IF2GUH3B)K8<>J#@E[!FJCO ;K,!/ZN8IC#N0ES&NE+? LT ME4 M-;ZZ(3<>":SPLT7.W)1 1SZZ<7/3E'QYQU-R$TX>@Q"&NVK3CB'""<>: MBE?X\EU/CM9-IDP7MF=V>_;\^PCF0JVO):J7N:FCP28;M'NB+T@2GVR_ATYH M C9FYX:AHG6N4&A';XU-/GSD0>.O5"2E6[ZUYKU^XS76C49) [![O^=2ZC\D M?!E7$'];ZGKTR+NP:EBBKU?;"X^U$T E#J3(N/]]L1\/H7.E7*_XVB0 6 !50R!-,[SKB(Q3HTPI_OGIX=5:J/II=.-J^.Z MS;,K(A?0GE0IIQ;EC84HV13N@"C8(&UFB M S4"I'G/D9[":8[[&[.3Y_G]D/-+F$X]F=G0C%,N\X:?@O:.&[,!1H%9F\^B MCA%<^-E]!A>>=]J'W&D,P=&]YD]H"77[.XLVG,6PX@1,3HSC8.CO-Z M^I#KR3OEK@M0>\_.)^M'GA\ \\,.BV%+?N&Q<;ORSQ^WS.UW^7"*LVEB;(+3CZA.R;( MN0<"3XL"C;3+L0S[?-B+>" *#-'H .=AL:TJX&-;X@G;2 R1E]JN<0I+'V_?DQET4AS]6]6ST63"-*?O"NQ&!X[A(]:^\*A/^E80\4FED MA(EVD1\K(X94LF;K8QY!DF*&QTJF85R6X-8D2Y/7Y Z=*N/,'*LAXT^J)M(^ M+Y5'S-<;>LLQV2'4SKR6=D-0*Y=')R(&CC#YL9159BY7/8#/U".EE=-LLH]F M?^0>:ABJWK864:0IGH,DUV+L!L5I]N:YYQP>8S+F]NW^D='/)-%+>9[8])7" M>MQ1^B>/1FY5C=>XIM2;=#M4=5QT:7$,O?#AL*_;G"IY *V#;A^-\;LP!.]:Q>?%"0!CS!MFDCH (87K0K,;NWHV*[+WZ+;\2Z*1I*7SONS;** M*]OL?%4G")V1[8+B:9M?C"H9QU -NAGQ:1[-+JTUD)8RX]RM.CK(.WE"X M><%D:;R>TC$2Q1T\!()ES'IS@Y594!KO6TQUJ0) MFY;HILE2:J,8V@GBB)S,@2_XC[H63C)OC.,6K>_*'1Q.D)&SA:;?YMP]JK<& ML8VJJN/#:PV_;VE=,V?PDA"3%_M]5^*7/EYI9L\??*$CV[?'7QQK4U M+./+C]J0.M<1R&9:*MP=D?X)D>8.= ZC2PYVY$IHXF!BW* B/(4?N;*;TU%' M=QP?:<':.__[DT0JW%_(8*Q>CX1J<]6PNA4-0B*8Z!@>>_Y6W\@MTWT*%X_: MM^J;046Z:*BN;JZ;C,:N/6B$A@B7RT M W4@'!F]I#FS,RE3[S2DU]9!X;. X0'"V]^FC?&\*#[HHO#%<8^P5V@0T=X8 M3WYWH/JJN6,,U1^E)=I$3)/R%ZLLJ'CCXGQ_LM6\^SOG:,%A=E[)ZA&!)!4; M-@*,%Y7W,+G%?D%$K./3I?0>'WALU"H6!9,F^?%&$_TWE3)25.B!Y3V6I[I739^-HUJ?-TRFWA? M-@4 "<]ZN6S*-G/>%YGF-GN+ALB2=5P;+WPF2:A;P"GF RZQ9&:PUUK*4L53Q7S6MLDK7<5A^* MDL^&H%@1D5?"Q/K:FHBDQ:R_!E=5W@@U3R8B+[3QAXLUBA>IA;%2]W29HYZH M<_B5[Y>[JT;+JN=$.R_Z5=X.KH3FN:6:3.NHK7J4 MB=.T L[I8UKK'QKUZ]MK9R MT@8I['IVE=6%'I3,0(SGP:"-YLIC54]/Q97X@,PCC@ >95\)VR\6QPOY3Z[Z M I\T:\B,B*%.:XP77.[K"RV.CPSH)&9PFQ]_6ZW7%^$Q+YIMOEOC;T^^=8@/ MW!<6CBS"0]2C>W[#^?;^UH.U8?H"1A;0]XR!H2[FC.E)3$&V",\A>-I>/GP4 M))$>QE(_U82KK"FF/F)!*<7J_O/PFD_"=?IY!*(W86#MF)NP7H[%V2T"K_:A MPWB3%/O#4A=^":FJ)__QV:A5K4JF)"<#\]W+_[GX\O$3JPLX.!HZH>G\E'I M!B1,2[IF*/DP%[1=XRF-X4\_O/KL@N-0.A2J71%V4+R)- MU_VI8\6.'=BN^T,B\H@,#\A8!MD.#'LI^CT11;=;D\6@)P@Q&+/"TQ]PX_"# M_PJ1&,%56)B3CSKR#!8,26F:CFGS\2X*8Y7[X1%D+(MF%IDUJY'HA'6T*E(L M*S:;O!YEIZ:G8JU[COYNM2\]PX&A?$-TF6(V'">&R\(&M\)Y3X"@DE,5[GXT MMTVIW_2]O=J>G/H3?&%SD0# &%T5;5U)^AYEA/BM\/PZ^?2Y+GBWG-6#NS+L MW EZ3 N>1_%KO05\D[A$E %=,U2POR9M5+"W%5,7-S[11S-:LLX/.;'M&0YH M5<&9(^>.RL2.1]V^/;\=;A07>#$G%T+GJE:!&MX14#1EY/*?D1= Q,7/%8"/S50%!93 M$UQ"M!*FI'(J>IKMCHWR;.P%BRRN-,89Y_@BWQ&*R*E6[ GT8JSA9)L:%1^PM:0I4+16O\QAGJ ,:P#9]QDV)A0+\%$21AV$ M=[K=O>\W8LD9/=7Z!7C44^EV P#4O?#AX01+UIORAL]O(8!AZ/NA,"/-23S) M>SXWJQ\G!X0[CXSZ1UUM[UB8,*UH1#JF\K$C+3H<[HUCX>\#:'P\!*<[= Z(Y>B=(7@JW4I%8*IJR"T2\H%3P[%(<<]/215J?/I:2I:%YA"F.XP7[= MVSCVKW9$Q.20'QQ=KSC)&BT> VN;B(T^R\+3AQ_R2/]8\=GJ90CGZ@6J#-HN MY\(59Z]$P4DJ %)H3'[.:0_0G?E-[(;*D#=&5(I K'%9(?":!5^K?Q5RG M+@F%)!_S5@]8;0P*+N^*)9 URX-VJN%B\$U+J9D'#KF"Y!*2L+K^\ BR N>] M>OZIS@9A'4@W!#.KI?R*B4\;FY+6(/%#KU*OKA(.9V*9HV=N2*B9/5MD< 2) M9PE_8QL-/R#1Z1I93'E*\39S.Q*.TC6'#KFCJ%590HO?C)5GN/-LQ'_P1&"# M>G6O@6VT[#1@Y1H;9$Z!;PMXUPXM<+IY^?"Z?O897&; M=4%6L:5J6QQB)QR1^$H(39SEJUY=[8;:YF\Z:_=7\M^$0&(@G8=/N,TE$D=X MQVS$C56E>M28_<_&;- RJX,+2U)\;&65#YN5_*"+-:X*QA$U['Y^]M-.#KQ%9G=%EW04' MD%<(4WVDTC?B3+V']LUX57[,5WTT>S5^&7D0&0=Z RM]\WD8YB/L4EI*NFUZ M: <,+/;Z(2P6:H'>C9F%WH\*V$GV,!/YI\%L:!G0SX);5^&1_4#/4T &LH.1 M7UDBVS&LPH(,8$Y)O*XT=+TFE=^;C'N9]"EVC6\V/Y&1D)01GSD*(QY-Q-#@ M@9TZ.+*\8VF3SM5"ZX2) 3[YE*L\^(E[*,IM!> RD64:FPH:GMX#D8\ M''8TY-%ZC!.%\/]B4LBJ:VT0N[#/JN^WXO+'GU^J?4SD-Z4EMNQ0(*(EEQ-2 M0?+E3/*K !Q9E_I/WJJ#]3DW&G9\#,O8\VGCUXVD MZ ?&W[NIC/F:8/10=(.71DZZ2V7]DV U8LR5L"].;<3) X3SK_P=1>F2=2!GBCY(DZ"R8T#< MW?.%1J9T+N@C9AEG;^)ZFXL2>7X4DO9$BT4;KB,INSA%6FQVGMI\H'8[( U\ M-'LSLM1H:8:!D9[T$6(Z$VA14!1Y$?Q*,3V#H0Z;-)A1=DN900B0[OP8;Q(M MT@3=!M^M#\)SKE6JY2TQH]1HV/ZK&X,=F&^SW?I7"'NJQ4X$0$]'02N%&5,,.52)@2#E+@J<.3%M>2&*I@ZA+ P^BFL4RN!A686%2W9>'X M-0%GT8MCL!L'P\AKF6L:UO,J1$$GSG?45%94@Y!B!$PSSCY17UA-A(5&_CS! M8C\=+]X@*ST6/%XV:/JF@&,^U#\PB!V'![;L+1-Q@GY&#HM%CI0DBC'8&$3 MTN/;4\%0"&ZAOW7Z(HJ > D0&EZQDUB\ M#:_#AG.R9;;)]XDY75?+KN]",08$6B1AJ78U;AG>E+-,[*@S9UD&CH#XU$=# M6]+LUV][RTNB6:";S71EI4'7J(@M@+5T,<"B< 3<($X:Y<6WD/BA+XW+<#I8 MG'SBB#!A+RMY!&-:>I=?$>O5@#%E AA*,0M,W*C6& +9R$*5]/B')1A.:Z7F M]KUL3KD,8*I:80EC:"V%XNP01M,"=T655=$<.E:Y-_V^6Z>'/HDLZ OO29M) M')*=::@O!2!: .SUSO)#L9^=<*0VWV>"^C/" M./(-T\V5D;@>^\P/>&U#98,>G<(1C4KT;6R']Q._D9S1Z#R>F&93@4NDXN:S M.KN.^&.A@L#\C^1AYK]P+3R\I9 [7J;<4.!<8EC*QC.XT767FR!ZZ]7>2V. M*!=VLQ6]!3NA18KCQOD0*[)EOE'J'CE&Q<#3PCC.R7K6W6&$ZXGC>1P0>H3. MI4MO4Q9MMT).6)8CQ8IL<^<,4:W)<63@*36H4\(,P71X06EY%4A16 3+F)_D M%8#30Q=8V3_WO?MC3RP@UXKPFP1&!* MJ1TUWWI(,MBH% Y^^!,B]A<-P7-;H7MFL=.7D5,3HV MCIIMDYH<)WG33B=GO>CVW,LJN1UU+2DZ#)ET:JO M;>ND;'$25D@G]Z)9XE"EX!B'FC]K*;&9+[N(^P\#0$U[[FCFTWBNU+=A2@#W MKJ2Q%=4._4ZS[=I5=5TV?M&X,T^.2#O2UL[/BM:=%Z=$R'J*&WD,L%AC@KV] MT9!1_4N)R.QU:V!(S5]*%&9OEI)4<):&'M%8O'H% .=)B*['5'W>SC0CTUA$*4DW7,U74,^#G:6>YR4 MN\ -^S&NV]&>O9@I&\U=&$MG5B?D"&$UIV-'R1[KNZ4%1@S!_?(4]41,[3@9 M">*FSH!)QGN.!1+C3-_23V7#.%'E#"LL3'Y?Z:7IZ"#0IA(9N0?HNKV)J] M M/=TDA$9%)SM!E!=UE=DZW>RJ!3M:-*XN[R7'4=?,\F AJCW[8X]F?P716@HM MU6_H11>HH(?_/<[-FJ^Z6O&^SJG3TG-!=16"F+3H\))83Y00PMYM\0H]2#WO M^?!._!+.F^2:<1.1M_#J^\Y\QLP!R^Q V8ZT=)%T1WKOUN'@=L7?NV)%ZV5V M"9QIT^ %M68=+E777(@6KQ?;DZETQJ9+[CVPR3 M];:LKF7.@S61!I2D,4*SQ;7W=WIASAA,R55WFV,3;+I1U\O"Y?V#MK",\@U$ M:_!3=9VC5.WC].5H?W7:4QW/;@-(#?!L$OJDXQM\FHZWZ')746JHGX7OM>;$ MMMKA%/732TUOG$8"OU-,.230T&X]W+1H>[71.$R<6J3%E8ONJ97RU0V:$&Y9 MY<%[+1:$2M\U^357':255'@)7H6?SOZ(#J-&:0D:WN.?1#J7(4FNR5@M,Z.E MZ*1%;?OT83N?]BM<6K!?0#,_];IH1O4R'I1=\TU&KA4_&=#".GA] #3AP*!1 M#BP?.0>44O0%?E[N=%%%WZ$#'LH/-\W+& 1.JN* RY5SI*@1H&[ :8+9@Z"DH9/\GB:2:T MPS[=>4X_ZIP*"#%S\LZQ_A?\8[**GZ3B[_V=(=H\$UD<3?^>-\W=3PGE/;A0 M9-X"AUGLGH_R8ZV"!03>>O0XLYZ=&'=^&%;W\T1.3:0 ^4?0E^@[44Z)-DJ+ M66<$FN:LU^=!95.8,Y/1/07DW^<)[^CHVMU5U=NQ"A%+/J4T$[YSD94 Z4R9 M7>4ARH&0KHN41$I&D53I=>N,^>J6N;H2C0!:9J2E72PZH]Z@;S(?KG: 38'B MQ\BU):L+MZ37#,(L7O\VFD*:X@'):N/H;;*]TIP+6PJEFJ#@.\'%;:5+;3.A M>%):SZQ**GDA?)>D=)*P94!BI-S+F.4DD;2G):$81*$:D2D^T>%(Q5?46PYM M^H-,G,!%+LI!TI*W.+) K!58M'_FT>QU4:;O%+X4==#M[JE;";I<0)-[HK!: M@3^UGJ5"B9D9 S%*_=]?(3XP$1C-/5QN."G]9!TZL1+#,8[XE\:=\?[6V&\W MHAD]I?>WRFF/4]4-E;*]G"Y[='>CA+G/VVVU\EILD<1S[AEO>N2(13U;54@7 M6LL?^K!X!='CA9D@&GF!JJL%C6W\RVV^-_9D)M%KBT6U.LJ7CX0\E8PI$08- M*].NO51JBP-D[$O?"ZE]65U)$R=D/VP$66UY8L4OHF:]%B]GAVZQ"S\+7C.K MCPLE+YCS#:*Q*"H'RJ]8QUQ?C]#M70.DQEG3(^+EOCSCY=[G&/_>$)PCQ8^4 M;J)'(\&U]:/'ABM*K#9! TUP[K*RS <$&6F97W4CTK+)F$UK/(UU6IGWD *( MC[)E[1%G?\)4>M3GJ];$O;7*!0!O)WH1H!D=<$>Z(S=;9E+(]X>GMNJY[IF( M:M.6UU.=2=P.[)MSGO_Y^\8OIO&LPFAKXRUY@_W*>'!IL1LEWP7D%%GX M*Y'N78*9'HQKY#"P!X4S>M'O_!Z)+[D+65I*N+-,YU>V]%A0:EZZ=J6":3;. MJVRU,2P;(!_2(]:V[&J65>2/B;0S!HD,GL;0%*!CF8:XZIK^,9JL=C8D2O#! MWGE_83;3>GF1P35")4\0N**,/E>L$PU!>;R9S9-;.SSCPBVX0X%4B41?$%/M M\^NE"$UKK;6>6^4_48:^L:VVEK$;/C6L,;H]N;F#)T-4$8JFZ5C9AID-B_$$ M1V)X>H0 /6#TB6>&M%#4<"W78#[H&7";A!@;B#OE*A(<0KD2)\G+$^&@>4 MUP3%V!Z;X-5EI7FU(%!V[F+4\TA6@+2D4^$]KTMA76)/-UG2Z3R.(NDFS>&G M<;S)<'@"RWCZR)(33%'35,LBNR&>-^89=#D)IQ6(3!1;NL&)5X4@D M;QN.%Q>V>M+$/MII#^B=4=!KAYQ(#Q&C$>!6'9&F5N\H\.-S6+#ES7%_"!$7 M.6F,UF7^B_Z+<*OK8\MM5;:5V0H'C-.,4P^;/%CIB)*)9O5%3[;;$J MB4#EV*R[5*/67T%(P\0I8O**X@/DU50EM4)HJ:><%&][;EZ9 8<$,;G@*G6>\Z]E'=-H-.VF)(FH/DYA*922J:E8M41)D0?8OCI-NI/*Q MJ37G\!3>(A\N"EQ7.I@)_.#BR/SRMVM&$\1BS# :8#'Q9#15Y5!)DTT<3(-- MVFX&I1^L\W!&DK6B ]'I8B2_V1/^,@0/'$,4HHUM_JS03,E +<7T@7*$L@JQ M?#;7K'DVT[05FMG>M<32H^+QA( C9"2Q>EG2PC-9JP>,OD!-) K">= = 08B M1#W2*"$6VIBAPD_:L/W*29T^)\+/?X8NOAH]&" MHD'Y0#3.:4/.)^'K/QLQ.%Y:-=R=LB%-M]<6UV1W"O1+&@%W.3L9#^^0^@GJ M4F/6UP;C=B]OE S>S!_[ K!UL:EJVC$39&>/9M^=+B A^X0\,7"L.^W6 AN4 ME3.2NIM9WX0A,Y)3Q?[#^A!>X#_J?%V+@HU3G8N_LO)6XCS@=5SN7+O,! .@KK)7& 0!@W"_CX2H MK+7A=GBP*^@="&]$_8+#XUER]"D'R$ )A[JSM$"V!@U#/5IXX\JS5_! $S< M@U$A8\"T2H"]JLDGJ*3 3V9^*"<0WTD/?D,/=W(:@XM]4(9=KD8D'"3A31=5 M7>;L);'C;]^;KDI+6DRZ8\FM,DYG,%?&1,)XG^XN*QN7PVMNG\0;:/Y.*G&_ M;X+[MU<"_.K>EP#O^<'[UQ&!1 \F8<('1!MIB1J;E)R:\.L.LM<1 1,9U(?\ M,]BSHA/-&CN>WYDP-8[Z[2$FKMYP-;\W-E+!/X*@U"!0_V#'G_A*RB9/!A[> M7SA%R&TM*]8X%$"20YA(J*( 'E7(B8@D@E29!7>0(_V%"O%H7R]$B=LVUR2D M@*#B\>?O+DFM\!1_HQ,%G=:96+WIM4%UA*6$*FL4X>*>ZMY@:6,*VNE18"/QK5X;4[EN-)!@?K6((QV MP<^Y X*N%L1E,E.1E)%>$43!/!RR1L-(S7E*9.T%IW))OCG]HX0>VSMTC%[E M(D8/W["J!S3ZSMI@/LRNS^'OU'/Y<[A(GZ48H?V.F1/A(,)MG0A"!)RBMH][ M1_*6^N3Z;BR8W9'NDOIT*SP1FO]@N3CIQ9M DPRF,OK%B2I?/GN;'Z--O\JU M:W869=(JL@ND M8ABVI9*K%_L%L>DAD/Y@ZJYW?R!_1O1Z";$=I:!:T0C.R^!"Y)R@U%(#>4/- M:765]T//9Y2H[M)R##/_8A85"4+XW,;H*7W]>+A^%#\,BS6;?%54[ M]F$7IB\$%?Z'(>Q8SF>+79[BY_S8S K\/V72R"00N? M/+M\U80GZ#W G]H5?19>F79 ,WM]B7^1D2=#Q!?](\4GR?WY[S_NLG?5ZWTP M+O\-VC4\U7/.NG[/V8AG57V@;Q:077R-/&QN[_:\8KS6Q*O_5YCM)CSRR\3F MAX?.-Y3F_(X/A_#O(Q5(<&/QM_0*/^>K L-^^6/X1T<'^X9^IY__.3Q 3>]- MG[]8A)B^R/I#]#($M&%[CR;[*W>;A,^C)A@,(G M>U*\/(X-,>W"_T^\R-F+TQ3W)W [R8'*YKE8CL&SI:LZ M'E=+A[1@B[S/1)J,4[]T'<%,&4?_%LHNT^SW.!1&"*XM59>R#(&X6Y(2:?9Y MPO*#MVQ;+ K!T_!3>ILE)UDP_^&G>C4'7R&H SCHV;KE[PKF"E>\-VHP@O-6 MAL6QP6?E!G=AN2K]!&X)906GG06"]VTK@GVA810Y^U/BU1V<(:,=7Q;ULMLW M>$$1MWB#0P;)%>:Z,,\_;?#][\FCVGQ'B%WLDA_M@C(R?'F G9<$7MW%1(!"6[%LS1 M&NG4N2((),>^G48^;] M>VJ'/W7NG@&"T:BHN-C0, :"K),'?\3'"IQC0D!>]0X+T4_7X-%R!-3(P'@ MQ (QDR(G:?-KNM536\7/\LT7 X*E:@Q\0A:1I,:TC"L&)Y*75A0 ,$\I["TM M/I-P\G3K$_<.B[Y@33U-WX4%%H&K83JEA)$ MX7)?>0$N3/OKX _D@'4\#3\.EWA"RZ1HHAG3Q 9?Q%!G]*=GVR)?S_YH1N,% M+Y>Y^_!/))*)^7DM=E._A3\2"19@3W']N/7Z?:Y$J;+<+9!V!_&Z$RY59X/% MJ'F:40]RB)9=\S#7-YGRA$8R. .W_9T>,BZ=)/1:QC]!&4+N :.L&R&C/)MT M_*'.*(X*!.\39TBOFN8V; ]XM"J(U;(G'9'%QY>,3IZ_U?HB7XMIH+6:%3U- M5;JM>FFPRQU#$_L2<#WL"1>=@0)DN#>K=9GL6P*Z(6[ HLZUBI?^A+)>0AGI MDS?>9P.DL:RN=_EJD_@"2CT1F:ZB>"T9261E!\-A2P)K+J9LLM:W"&K:Q4D= MP..$QX_B^ON=*LW; CW_Z8%A;H<5]8_.*\*2BRX30V^B0]%+2#(S=4%@%Y . MA+_)N]RT](?23W'?&2YM\+-(5YPF81$]<69>?KD.-X\EV7AF>2VJ/-N[0ZIW M>B4"=Z?DT1_@02*+D=*A\4AP/13J-WHN4?GX&&%NTN[S7OXB3BZ%BL@)-BKD M9,ETQ:21.8ADT,8 8TE>O74S>6]@[;R6[+FN;77MK^]]7?M>;2 N-,SV10-! M6)^MSS@>KV13%'NW%.W+JE$HAXJ@ +D,04+%.&TK,HX'Q\ 2-+)2\R*;G E#719V6@,+ MS=02D'(2-$[\499(Q,38,I(C%\X$I.&]&@)],+,'I2M@O,=K2AZ,U3^1B3-Y M"IS4(R9-7$@5F_0'AYU0XSRKH-'7%3&X0_QL[L5$O0SSZQ^>)0"ZN05P7,IC MP2XX/TOC$!A];^ZS6T'*-H].?;5\RQF^!WC*O:D0F"^90ATG1_0N6R.J%1^, M:RM' !G5+X';F>W(.<0FRQJJ\).E#@NLB4 Y M>?GJ]5^00@X/0',E?:EA!#@49]YWHC"QAR8L]. .=)FQJ^BZ3&%YWI??A^\F M^EYNOF,M=9$?*PG/=?NH?R ZZK@;:#:\<'(U$W)IZ+91Y777+:4H7!$K_SYO#D4KBM#BQV&Z<. /YS+$(8A1;0N=2'LDLIVY.I(1Q,Z]G?TXIF/) MFVUX%#+9M!UBU&+*.?%'?2EJ35NZ1^;B^OAO9#EQ*!L6.84#\9MJ88)Q+[7D M[;(SMEBDNI!G5UY<6R,EG;>Y/"'7[HD 3%\PTN:;LR6IZK<0D[:L-$U[C3S_ MH2+BD=PT9W:T32)$/>S&(KQ8)RK3R3?<*TBWO[X(PPXT-N(VHL@./>A0C>>@ MA#%S73E8M>'EKFBB>R'2C=FQVR;6QVW=9U_0_[O3+#J9$%K7MBL^>TRT?#6_ MON72$"R% Z0]ILW*$4B7GL[K<'876M0'K@0@C[JH:IT"":WU!"*.IXJ6V#HY M&GMH84W/F=C&A'C . W3Q4S8N,(6VSK..H5Y4Q%@V%L./8>8C([1-&7W28\ M N:7!>Z%,($\0RX978>YH?8H9@9BZRM.S1=??3$/3QB,6U;GME:HLR7\ZPEY MIN&[M9U> (,!?,5&^1!BM"U!EKH#_?.+^5=?/!ZY7B);,GM6E0I.M][3_J-! MG2"L7^19:#.7+M/#,"-;9P:Y,RXN KVP%44O&/K3!DM_3D_?=!D?5I&A@F[# M&2=(T'*;I"+8&Z*M E%L\+38B\LS0MV)5,;!DY&3$;_ ML]N/OA]?WI:#JSW]I5?#Z&TV5,4,K[VIR<$$6C[G6BW/_.^^>OSH<0B(=CO@ M1E^ZD6V])>+"0IA^AE#:/>/D*A)J:*K0F9DY,F322-DLJQOO867%RDTNFE/P>ALJZ>2G*]:[C=_)3I]/%_JT6VY-9N\URT4QO_HZ@ M<(TZA+)8_";Q8N?D_6R%Z'!DD^E%=>F!A0Z)CP^G679SI;57QZ]?C0E MTAC&+-%3)(6]X)&E&HMT E GE WPSV5RTJU,7T; MX(E)CFE%@@]D5Y56W*2PS#O(GZ1HA=\3\5[-YUE>PJ+&7 M96P;2G=4'8E4XE..BC(YXJGECS^_I(Q?N>'=-M)MXAE5FPH M:<2ZW9JKA8 ..N+?$=W/,6;$<>H?8V$48$5$X7$)^9^+AC^.5:Q0P\M10N84 M=+H@O)XLNSS)DABC,9C/K@KJ,+W*E]'+!XGTOMH%"QGF%6U0#]$.?I:..5&09,8(YU)]U0H"3&+1? =WTHS M$A\>12X*1RA1KX-#^0\$-1GS (*C*.\O0?K1]*($R MEX&92Q2F13XPP;;@.2IEU@_F,/2Z.WN$-PT\R7PRB; MC4Q]:GFX+8@3-V0^S-K3.$JH7%2."(D9G.) H:.I(O-!<#8@/!PM.YIKT[?2 M\>?',9X$SC MT&?TOW$>W=\I5:;.,;# K3XGLSSL\SQI$>'"V="W>S0S:E])Y0R]$2;N12NV MS"&GYZE._O,S-J_/OI%F"JS=QOM,>BE:',>25A+EN_"KQE.R%"59/7KO#"QU MARH8_>"L43F&%@6FN$V990A_1^TWN6?P97"0E?#1Q-P6W(PQ]GI]Y&^R^DTK MN0]YBOW?*'*B9NF.>\[]8,/PFJ^-0ADWE69N@;MY]I)'L^S2\E92M>'&K5 N33!&3 ML8(M\M RH>:@*]6HEL\;YRXWS@M0=TY915:L2G:5X#?-L^FY)&G'J67O>$.- MGN.^)0)N8>(&]H@<*%/0G)?*1ULJJOTT[E*JQQ <6EH?Z*Y@\('+_@I*T9I- M!E5'>YJ'Y. M%E"/7K,J-Y4D0(L0Q2[)#+E60#WM^D?I1GHYH)8'0G?!@;FSDA$W5*.(#3,; MRNV6.+CEC!_!BZ2YK:Y+JUFI MDP0(DB)16F9^Z;@ 22'\T:$JR!&4O@2&P"*O+4SGT^>M&,71PEZ?(N.\..Z3 MI\3%1\HB+[C^)15]AZ77U7L+S0)$FB>-Z_.F]>.DZ5W;EB5RI>CA:&*>(S.#;(\\H MJ6$0SA>@J8<_>RJ*[%V61?(T$-K27*T^\!V2")F5YL*FPAY%:TQ+7( MW[RVHN7(3V)%D>H+@Y5*P%>,?101?(![/7HYE&+L(S;\L*.3!RT@A4]8\T)#:1M^M75WB-?%0X!-)683/"@ MQH1(7N$(OZQ/N8;;7F'WQ@Q[#ZN@"5<3Y$Y!"Z/N@I;A84?"P6/Q>YT9FE+: M7SBKVQVT_Z4WJL+'NJM:L&A0PS%;/V5Y=%=DDEP:4^6GHAA^ ROW*8 1B>_O M@@G[8XD^GA+Y "\6RS"DM*?KSC!+/L>>"HF?SE,^0(OR8T[*852,A-;X./@B MCV7./=@GIH9/%<.CK&92X@B>-I?2(F4OD^K*N1&I;97-@7F$-;- C7%)6<2V M)C3 D'PH4$4['J3.JC\+"U^[K93"6$A"H#(FJV=;-4Q3JYF.'C258XYMGH#C M]!;#YVK2UV\;AR8J\DB%71 S M%I;?HA);784KEV<&@F@I/G]\QIZ\CWE(Z 2RMY;!H2T< M:W@8D[ L:R)+A>JORH$QIQB:+).LC>,&1B)Q2,"]3]24XCZ90)!;)E,3._L; M3'@J2R(>@S-%D0.,=;;H<*=.U<02)F9AO+B:N [=3.Z@:9^_F"8%.L=\7FSHR?4*N)OS?:_;^(H?.CL,(SMI=Y3ND8!=U ME:W.EOANYU3W5YC+M)^"9I@X!"0=?LB.P=SN^'OG2?HXDR2T$\?9FB0@NDP8 M3L;[3E7U:N4<6B%^50HU9C:6VJ,G%J\687HRY6!> L+*? 8)*@K-<1HEDBMU M/%OD._=VT>4!D5K/\PJN-B'IP=J)LM/G.;K3.8J,S=:JPEY.#"FOJ4]?3LNN MI,0*)5I$V1>4&NB"E7B3 MWS'-[I'$; ADFO.:J6/SY[>:GLZUG-23_9=0Y2 M=YZRNW56MZ2=B= R)YC ,@H%<8*\$UCW*0Q=O\;4;DG7:)@30FY4$OM*(B4H M "(=OA&GQXPG>]%/;ZF0<-[I'V>GQ_81\))F&U36&VCB;B297QXA3]IZ6BQ? M##!4>!\4D?3A2\!SGM^/DQ\,$0T@>TXAD\PUW7[N,-BT8>F;#1/*<9]AD^_6 M%P=2Z3@V;;Y7Z@-6;./$U+?TM_/5*Q]YG(9U2B98>7VF#&VNW=SK8)I9*1]\#QI0$]*0!/-A5*%.GJGN+A,6$LAOV6^ MJ4(0J())P/>&.)UZ B\@T+%/NJ'S=X]F/X=0H;H2?2J'UDG%-GJ,_*1>L=@5 MS98 (H/' 7VALI=F.['>)'?I5^VTD*WO+3YO(.,E]\P^N971; *4XN:F@&NHA!*6(P-R17$V!O Y7T8 M:(R)J*/SAA;)=!4U4H9=+TH;$8Y3.J0CYM6LJV-I;!+9E'$1TV!@-K4@T/?Q ML+7E[0CI]A[=S8B$1(&2\J5O3 &U-T_OF"="H-'6IP"QW,S#Y/S MW&0_3\@JET9E;!1IQDVI1.<$Y4MRZ=>I;&O4VE-VLU$6714F(?ILZ M5 .D/KGW@-1[[GN.Z;89R#\"%:R5>=3 MG!NG@P7/P/%Q<)O;PW0NH0&O=+/0+>C;5S^*4%C-PJ,^>_X]SGR5R H!Y7&Y M@QO)1&E#6S0C?#X$':^J35[N\F7>84+<[ 3S:O<3QD50%QO;,$C*V.N[V2J2 M(QF,3V$9)V8Q*)J1AP-3T755[U:$8&9"/*\H(5 ZZ<#R5"Q:1L1RZ:\5_I % M=>4=+_0 P+!+*JP$4Q@D95GS/7^7D0L5;TK\T$(O]9?_%HED,]?!=S"GB8^6 M0TW,H[DX*?V1"5;_AX[2L.,JB'$WE:=]0^%X4,VI)G5(*52SV\>PGWV*Q+[@=C/"2)#CWLZ%)+YFRI^$WNV3J8SG-PN/] M?'F9$E90!&7H2M8]L]')IY:'&[#7_.A\/!OA?Z6B!SSPZ@CSD[?JU='#X!7W MV=N\>!3'P MMA;+Z,.".;;85M4J":<2&AHBW(/2_!&Z4>&GY-*KC]6SJ,, A9:=U-IS98_C MO:/.B8?$>MHXMWFB6QA^O=QUJM7*='J\Z0;D)*A\O.=!,C]Q'&BG9:1*,69! MQNW)/V+'DU^4*JTC!9;XL_M^T+^ #'FDDDMC*NM0XW@=K!#, MZP#T9 BRZ[PUCU;C="XL\?R%!N>4RD&[[5RWQUPY.NB%+K85LZ_W#+>WR49$ MK6;9. #2<;+U'4YT%(SUYO,KZ!+A'HKT MW4435B)QNMQ(XB$>MSWA7QNK]?A@:=KI6.0[+F"=8!]I-#076!6+AR.0RZ%5 M;/0NP]&$NTH%JE;?4J0JX]XW()E9MN1@S)67' MN2LNFHFNJR,H)?H%X"6.1%,1H:Q ),E=Y.&TP6Z'QT=U&?(6)7".#(?NR*B0%>&!D47I(KO$ F;C:8-,Z#7 ^= 32+G5JX$^,=9K-1CMU6D_ ME4-'@X9(V=RH9$P8I7]D]8K&)'95%^G9ZVH.D0IZN0G "N/NVW\>]'*^-/, 8#SHC,8]2E%?53NE.&,6U4^?) M<;9!55DGPJ*]!$%$@AI&&^P8B!QQS$T,ONY):"K@YEJK5%H?07\(:&RU*T:+3XY;PGJ";3\N2; MC&EZ\V99%XO<<:"R!#03,FBZBLXB:0-%T%*MZ M;! 3+B_59GKB\'6&"6EO372(16WQ-OA;I[TJAP,ZG 5TN#>6Y)FLUV<_N?4WV7ATW MKN(^0R&+Z(!NN[V?]?IIG6QE7EX5=:4 Y'&#WD@[7UB40A\IOGIE!.GI9?RO M829B^*\^_7S@,SI O$"4TH;#@2,POPDE842IMP9)/" 7[D6$U#(DL"/756#B M0LI3(803_AU/5LNRTE0-0D[+^X H8UJ^<@5!0>"XELU^0]"+Q$"3XX*-I!Q[#+\ G:&W%"QI# M0BF+?C4_F%.'1W )778Z8YZ]JJ* MJO/Y>SP;G:Q8'MN3GTMA<8A9FZT&E3KUU/>R?"L5*'G?X 3F5M#CSZ%K[&B= M^P2]?(R=&A^?8& R?[(2D8'=5:)TS9UE&PG D&^* '.^K:*]>8R M*428E(Z_*E9=C&S_H=*<1LH]L@ U*0999:X$DH)UV7!9 M#$:9GL"?^2R*;8(!AVX1+$DD^\3")*(ZQ*$A.-UI(7H]/)%M4/O?FE@8X<]U MUK1UMXS=0NT6,08U2(1'OT)T3QV#NB.#T[#"T/KNCY$6%U*:C:4_'C9!;$_5 MKRHN<56X'<[F*ZJ?4 M_[=4X*%+)>D3)LF\2IG&ZJHS\O>E"EY+ I$;)7KO-!=HJ7IX^ZHL."\UGRV" M5;CH#A+6<4UW/FD"=(L*M<=*$6%EUWO[T1^1^8)[%C8@XU5I+S0-=DS9'US< MHVB% $:2-GSDS7MN#F_ (:Z-56 1S7 1G?0P$ILW!S0TO CY4/K,L;>*24V= M*BSGU6Y\D)^JZQSM-KZEQO3 ^!UONHH\PHWLFUT3]WG"E^T4"J)O93F#^2PO M6*?V>("SG^V)1V#.II8S%AX\[%)^%>?:=AA#_M^807O1 D MWR7A8.5(!ENB0CG1E#'BZ"OA.M$A/2Q7R_(,_5I/&NC>(JG0"X#GT6EW989# MV%)U)$,(ZS0<3Q0)=*75O"5TI=002MSNVVMBFR?L5##JV[]WV5OZXY8:"H-' MA,L=#]L*[[ N<(DPQ$3=2 2"BA_BJ:2TAZ34\D,!+)S'&4&-@CV',+P7D+H* M"RF;?-L M!08:_CSF"/"ZUT4C'J'K@&-D@12)>G"9<"E$3CP%T"MWDK[VU&O-1Z;DRWZ( M#*LFGM,G<331>C?XYSQQJ9U%G??-:<2F^&9B=L(E;BDWY*N'V=D3M*]4P5I> MM%:GCW5JOS+"-/5).5T&S&J7XF1&3MR'=>#YW ++H:^4-$D=0YV:68B(NI4; MOQU'D^:E2\K]0T_EH]G/OMU)+/$?9+_R M31AL>19<#=XH';!D/_ZS;VVX-B2[D&0JXGFHY?<>%QFMC$6U NLU +TK@NX2 M_Z-U87!HA@VND2O]83!XNW:[1%<79AF/N:#D MDB(,/ _\X+GPHPZ:X6ZKT4_GDFV@2#.>P?[%*\G).A2:".DIU+I7"3!4B:8L M/&L\QL\1W(]H$9Z+TU:J?6?&B<.XHH 9 ^2C]9;B%)E3Q M/2U?HZ-F7Q&TAV-JRL]*5="@JW$SXFZ'FBAM#_W02+OW!;(M I9)?I7.8IP^ M#@W;9+L<]5CMQX1G'H;5>$)0*ALXFM)YN*^D%X,N(^D=TPE9>YM76$$S+(RK M I S]VSJXYF;.\8KY"\7S%_34LZI!RM#88M !3S2JYRFUIIJD4"!)9W/WA;+ MMPM.?B-&6E$[>4(30]89'05TJ!8 XKA)[",:&'TK(ME5?AO&H]@":DL'CY_:% MSC2,2,8WG-B4:MT=24[)EIL;U=:]-JUO#S8T)V^D3L(G!B?1.+T/-QV,W!R0 M!0^B[HHV4K*D!5..6'%C:Q@89_#B\")7/V6.W+Y*N\;\_EG0Y$Y)[5"/%9C> M95B5%_\MNV[VN@VQ;FM-\+I;FG&+2)U&D,2Q1GVFJFF0"N<=9 )?^Z[4@N6OX^!"'VFYB L',).BE.U"$OJ#[13P\5;=INH/,/_FD.O M7OZ\E/^>"PA^R]\-UZ7^0)P$% =+'9R [ET-+9>8406_37CP6OTJ7PK"-ZU. MPQI85&W"_U3U2DO^."LIQ6[9[^-L4U7A&8+;*LGKHLV%CPRFV*60PF!A*VIC M3K9"-8$**MR78RU@?*!F-KO..(O=<2UZU#R/W)?TM?,_BI69J&D>T=^>Q_CY M??<8S^;Q@TDCR.99AEW.& 49/XPK,;[85=0,V[* TUC3' MWOR4)Y*_RY>=[9>L#0OQH/U*_!EEM&<-==<(^8KF@8[^\%3J/M=URUXTNFZ( MI@4)L[&M$;9EBY+*'- _[%&'OJ.8HFBX^>!HJ6\L=<'; >I279=(YN,W428 M\<5*7!UDQH'^._WT]"";K%[MA%X'S@N8JW^?/]J$:)T1)WS_XHJ<+0SKU"#3 M6X<-@U&6'2Q>'MPO^N_N@+(*27Z&..LM=\S"RW$ T77&,9K:CS(A"^X9$VYK MK,I2]',M>;G*=X4TL\]GS@#"51L.2C.7*#AZ7FE;F_O)GA90?59=N%M#(\8A M>*S9GE5>.1FN5H<6XW,7WKZ)_SX&S%$;WYX M]I,U A6U,N=2Y&[8\2)*07J&1Q!LY4E1!.W.M GRE1WJ"1!(\P3RG=1?ISPZ M50WXK^#IDK*\^]XR1!NTQ[85(\@3Z%[Z C'/H,DSM:-Y#39DVP!"N+3GCWUB MH6NLG3/BA+T#0QAH)GSBQBMY>)^ B*.K[]UTBZ1.XC<@9[6"'5I2FYE'+8'' M1=(NG.1XCX<@@U%1-L*!GS7=CF^;H]-$19H.7O)UKN9O>X(6%CF MM&6E"-TV-VY)([32C9;6W8E]N.[( >?3B)IHK;564J>"#C'TP3 L)Q8,D^;F MLWGH7&N6X-FVV*WJO+2*]M!W$A_C]PEI!+4@'2"&@J ZRO]F=: D93/.VK1JP3:3)9Z4.'Y\YNL"F MKH)?(6D7]C@\O]7(*)$7)>3!0#%0JIZG4,3'&^X974@[C1N%:+.*/:T),A>\ M,\(2(:GU1GFXE*PI//-GCS_[;*[(0WX=UY W@-+(XZ;S1YZ::(L8M=7T_,FI M8;E=2J^#^^M(/.I^8@6LR:7H$AE@3JG3??$ZEO7E3T6UB.>79H7HG)%M+P@5 M0QX[OD<0K'!K61;RKX:W5=.ZV_+"L OQK_?%ZCJ<56F_/<-:[^0CK M0( -L;C#&1;OA4G!4!PQJRCV>-BB;UO4RVYOE!9[B7-YX;!V$F>DT"DB&)LR MT5B@)"K;O758*U9 .E KP$$P>\*WQE'A>D?U/AR@$CXDC2Y"/!L&_"\E/>V/ M7&J;?4]XC)=QY;\RC\*R_#]^__*5K?I\"8$U%NRZ0J_.S]EQ]MD7\V#ZGWPM M8BLN.&@FQM !^K#ACAPM"),F\?Y0[[,">@1FF3DC#@('FE,2 4/3E+0EKEH,$\."OX5G[>4\@@R"NL-HT_+SE*4+8Y M 0!84WD/V+^N(Z')1M.(2A*(E6U1@0(BI>@(D$%VD62XI MQN'D$XNU#+,^4X+##')]$YFVAPF6Y,:M50632U22#-:UM(+BWP!7:<,H-5SP M+Q C@7$-];"9)R)WQ.A$_4;X:D->1DQ=Y&8)1G^9"5%M6 0ML7XC<=M&A4R& ME*2-S?IP3J0E&FX^-; +D:XLF144N5;N?%N)WAEX;V![I>XJIP7]2NHUB=!? MQ ,IR%I@+$O[ ZV]CJ)9:NC:1TE(Z][G^@Y#KB9 3E7MP]]'LQ^<] _:#"+W MT3C:).I-'0?,(?U]PGQ G!,::C:,"DA7H@6#>0(+0O&,CP&._2A++[)-^M9]0*A-77\X>I@C #.-D4'GF7T3 M)EFFW2/-6%UCBFSJU:0Z3B'X5N9$BH_"D#.7?5B"M9U]JBP;J!>2>F!" MR\8C\D+P7$JE=A_L2.A&B&8%OH';,0,L'1K<3GM^ABY#U%R>8+OM/_+.>J\F&Y2;%2\5VIG M2J/. D//&55BJ)(O[CNJY'[Y("FW4]HBC'A$$0Z3S"(CL'C?H"8=2.8AXC0" MN%)WJO#DCGN8/3PL'Y;<%I6XDH>N]UYVF+D =VT[D: M=C"K$":,Q8X%DO%4LD;AF?:.6W+3I.NA=R?W">/>YZEG?QU<"UR!?/&ZB?,; M=9 X -(VKB785 %H3^@X,R5;H3,;OCW3;R><685DJ!Y3.RA)[^3@1J:* :V: MTGLT['IF_"@$R2HW%087<+>62A6RL\&V8AGD#C6,V9^J)HSI)D2%D+$K%W7%8L>K:A=.WWS^([K(HQ+0=[DJB/\K'00:,%N M ; &^I=7^3)G=M"1#QV:EY^H6*^9<)#[6&R,+WJ3YI\E?T?(GD;'_:CM KU+ MR J0=G+7LL:+Y-'L&0^".%MT[I"6*'Q](@#A=IE6PMEAHMY1G NM;"(ARA/J M @FUP5,K_I:6F?K@QXPR15F ]KV7=?Z!S(T+@O#4C>I+:!W-QS.IDH*3\G5D MK:\&B9CP1 570Y$N0&-UUY);/K?%7.EPC]H"RQS^YQE[>*=5"L6,4L)H+QF_ MB?5TAH7>[=3(>2V\3C'0/L_#W/:;E5T+<<-$[\X0 M=*0YZ).,[/*=Y^ENY\D'!Y;G)YK %?;4B1.(4?K<&W^>M;N=-768J:BZ(P1F M]!ND-DG:*8.,B77"LV(3LA%T@)VG[VZG3^G/A;#P//QW._SYNVU&(Q5K"Q$( M'@4]C+B$1?7.1]3';#$HRH2Z>R*#'1,(P*">Y^FN7;Z<_(5<)1A8#)@H6O*' M6+UA 9?%EK&4T( M9UN1@&,];:%P)2;RC?!-HO'-P[U 6R,(9*VR_JVKBV8EKDJJ$+>GS#_/"93M MC5B9N=+UZ8SDV]@N55O=$"P1T&,%,(?QF)B8E"]6-%[L%:V M&W:SE;J4"S#,^U>UA4* LUF3M^U.<".$JW*J9NE@1I"4-?TST(J;]83OT V2 M>V%EK)Y+54 93;5=VJUY/0_EA1@NQ6\D50 I&_8%U>G55U2\ MJA9*DU'FAFX.NQ0.*'9U6,'71@RJ.T_ZE+)WU'M?%XM.-7L7QA/[L*"P/#I4 M1"5&M\^^(J#_9X_GLY?!J0.2=?:F[O:'F1"<05^60(9H_:OJ$#!!ZFEV2=07 MKTB62I&.ZIY-HW#$\.L+S<9A!!K' MYAP'R5I#XV$8X8[= V.I9=P[7O+[?(DVP]G3)[KF<%(0E'1#*/-6($LW[D\: M63HHWQ5[9AW]W>>??_WHJ79[B,9O>E$3]0P?O1V[V)+B[ MUEE"/_O=%_[FL5U]=U1FOQM?254Z#P5()3OE4V1.;3/>= RMUPUI=_/I491 M8=+"=/5LWQHSOFM )9!17S&VI8[.\#FA_X$USFTXV3L\"#5CTAG%/&>$Z3N# M(B,H\LLS*/)]QJMG&9Y\I0O'Z"-3R#XW*,L&D8U)7G'_!LRYP*W M?_KU9_CVTZ^?ZJGT7$4D7XF@R#-IF7GRS==?>DH3P6-7-9F_BNU">L@)#(4( MQ>BES/$E*XH'V53 [LT0T3_^-K:Z+[>$+,.?GWP[^[VT(SI^T9DV^ ,WJ$"_ MX!F4LR_"'/'O9[\/;C]ZS/] 4T^VG9 XK6^J1_-?!O68_ +S21*5U>H/7 MVY2X%RU__7$V7MQ#UK2^I4*8]'&Z*3SBLML$TP$TGI$N"4EF$E0!"1:?P(/T M)N\O1UP/"TI5FC!OM O"C]:MJ5PV;46\3'JUB6XW)]%@RJ?53CI>!L_"HB:Q M : WV;>*)HHH;QQ6JDP-I$:O4ZU@>=]X,6TW".O6&KVB0*>F&.1GM&9<%^ZM M@[A?W>:/QV>OT(OV*I)[_&C]5:YI^7:ILGL>BKY!%7XHP:J!0E@@N[SCVFL"E.X+E8X]PS2*\>&%&7]UVL+*&D)M"09MV1!Y4*VNDF+@VOR(X5(NM:^@U@< ZHC1SAU>.HLX%BT M*=&&:)'P8Y:51$K"E!X\=CI.C)T[3;;."31\B&Q2"!B73!H&7"^!==EQ7TE. M" X&GEH(M_G1D]ZZ4?(6K*QMOB^8'CT%_[H><&/>TD?'(40+5S0^J<%^QXI$ M^?3R0VT#Y[CI[@:+O*-]P@<$9^,<:9)?UCW(>)AJ&[87E+S#C=\43=-)M\#E MZBK#P1CV:IT=T $8KO#BS>6;>5A4C7E];@7;ZZ>#,R'L+!(P( "B%NM\%VD&Y&Q6_% MNJ0X*5V>F=#A2:H!2S^>BI$^X!<,M7<0T" FX,68'196KI8RO ,GA\UAUF[ MO^RDOSBOEXXM$811>0<,I%#T=-;E0M&_JTSQ_V=UWK[@LBQ3\!*\%8%UD*] M"19A$XTO@'/=_F[GLE:F.-<-G11$0WRP-R66RO@N>YBSIL!1@&0R?A";F[.R M5ZF+WHA6T4S&-J,XF*30O#R-='4RG1$2H"/W/J^;NUXWD#&AE6,-@@HTY*JC MT@SD7"%-)^T\77<[72'\8*)#F:&H'=??36 [4:D.3NFTY.X*T?-N5UU?=(?S M_-TQ?G[$Y(%8E?,Q7)SLP8#KJJW"$\_1$2N$OSR!LQ^?O>0X8E57AP/G:Y## M.N_3CPS/6K%0:+C^^"E7G2AGG6?D5YB1GOYEA-C\O?7S8:[NV.DK+8LV*SND5@Q97_),5F&%_NT1\JA-VT *1 2AHFO$#A$"09,H(R"QXMKS \>/NU(H>80$C1 (DBOI:1;FI1*.V9DW',H3 M61X"811YQR00S%U'%\O?%RK#KD0K'C=- )IP,RY%5_ )6%[;N7_W/Q MY>,G<>$$@X<4;K&D5U^2W>&5R47[K-WR=*AFH\R6/*AA6_4)ZGS''?/@**J@ M'6WU8WO5N<;"947F2F"OK!?-E3(U59(3YD>1\DG!XQXYEOK;&FE82B*& M?V\V5"V.EZBFK^XE MJNG>.%L_._DK.6^%_#I3R9E@P"B13OX(MH;;]EB02I.8F('!9B'?A0XXP2/* M1<6JEF(D?H5B[STOL[^P,A4G.;D=8J)L==HG)7B,;[4(%BAG^E\22N-9O8X& M,.4[/5DNN^&^<&MZ31X/KT)U)S.Q">=^" WS?# =:<,&4U5);\S8_0NFJQ^. M/6JDN]R1G>EY??,TCSVZ(;$R2LFS2Y<+"6DI7 TG4"*R/!I7-L9GJXY@O$CH M33SD6V)@+LE+)7*?K_0H-$ MB&L?:S@?R4,CFC9\G(^X_.$=7\MG"7Q"#* %5)/#K%TO*+!P/#<1+$SLNH>W MZ7Q9F"$O7OO](%(#$K=J UJ(]^M"R,4F1B==30X^)]--$\1<]%E_=:V]9*OC M>4S\SQ %6-L8@"G"AGT(ZP]Z/_$ML,9HL?4L9+0W"M49V4A-+(XZ0N&1'R2O MT!=8&,*NYM@BQ;+;&<Y(Q"RZ,RY)1K$@V2.%<< M5I!-$F?6R,-[-B1Y$X*\,IA7=B*/J_$[L\QY3][)K1\>1&XG;,,FR'5]F=VM M"8>A]6\U5^ M2W\L^/:*C79*1JE2&2!I7Q>^E+QQ)Q)UU+BI$Z3KZ::8WU@HN_HJ#W_@ M+$E%Q#>4F,1.'4NNJ@9(_[*,ZZ(\C9U")A@W([#O[ ?"WD<4PL_&1Q7.>@JY M-RP-_.J'GZ$ &/X;+4R5O&0^O1<21Z.K151LDJFBQ7G M:CTO))M)@X1.0VU5;*MJUR<)+]8^#YIAHP1'&'(/(X>?G.6Z4L 0/IT]2JLP M)M(T=R0ZAVSY-MLP+[![Q[EE2OEH,RT!8OJMJ#%;OM$6#5]'^7<@2!"^"P@? M:QV2;:*<\]L\/\BI?M/A, I\P=@.3:)?'-J@USLJ =T<%[J';]7$KI:X1Z2- M@VKYWF=)56-Y8%C,0YQNC)[7A5(+W7=68HV+*LN\K@<9PF@*-*V/)XK0V%2% M2%80E*J/ IVFF]OL#T:_\-1'KIWM2,0N*CCC3[DGP8^3X7UAK5W)5< MKTPA/[L#)@MHEF.[*&.44D@;BC2;<$6K6BM[4PX^W\YKMXGR MB%Y4Z@W.&_+;BJB6V$JPSIBD"3*"1JD,[^!E5J5$5HV\*W?3?NM6&!4/" M;XYT=S5V"9-68DA%3(C7E\1Y+$#*^5;(YPR[BI)Q<:Z"%ZZ-^POBT=@B!-/F MN(^<*ZK@K!Y1<4UN3E-1E=0/ "J6M@ZFD3(V-,S([!0-9=(&B'Q9EI&KG1#6 MI!=:"L@Z&UN=LW1U OC\)P3-)#M=B;R[;U-0Q:;;>"YI;.WL+JO?)9Y00Z)U M0K"^KM$YM>23UFX03%N]NB LV;$O+]RG^79G EW/UQ!O=-CFJ63P@!L .J9M$#.,/*/O%_774/B#Q$,X>*C@](Q^&0?("6' M@PM?[&1*OD>(&<&]\&\:]--PKWHXI:JET:>$'W'HK\'G>1G<-5&MGYP45-#O MS&N37N_TP_!?0AARGL&/0UK;Y,4_K+#4LL[6G'<<[W0DTNJ]T-MQI"R)+_S7 MU(E\)GV\^TDEX8@R0K0F%"A1[5(-2DN2GBCS_O: )E_?2Z#)O9#M%X]T1<\ZC@!*7O=X/CP+. M3=9_.A /EX!3T?Y<;*MJ-;<.\EHY<<+51I^6GPY9:6(WY(!$H( [2L+)UZ;P MEO-97F T>QFF#,+96HZ#E#>!U:"XK!"$;)4=D-5P@$\#-_>+&<@WD3:UF MJ M3^A_1^<,AT2Q]JJ[>L\QL$/,))H@U@[I+N3]^E4^RR :8D';I0=$F=36F%_E MXC+BMBP^:T+S#Z_&\D>5M-3%08V8,G]6W!A7CTWIF"?UP4RU.T/"!GIV7X!F MZFM.Q/_X_P!NAW(J^KEURE0^^%,K&PNVZ3VKQBXO$]7'B4E6Z_'2D8Q6LF-5NY/) ,^:7Y;$<3 8__X +<:; M6.+(R_"(.5B&WX2QV.W ZQQQ#OWQ OU/AK)M.00V1RP3>+YPXE"KML,UW?T, MS8!T58BK0+?7NXY94;8Y#LLI:=;:H;**,DD,6D[[+$9X]TP3EMF+)3E?<#DU MG9)/^O8\:7>:0G#[_A:[G0FB8F-Z23 ^HZD?FUHR2\ X"/Y#7!:[\GF^[WR3 MQF,$LVE:TQG15[79)C_5:\G?=3&>+D;&>D/;%*RWH5OM_P M/#L?)3>KA7M1"\/?BI*$K'M1>8+(.I5X.4_DG4YD3PE$ZIH,L$(V0QU0F^D^ M^N<\I_=M3FE6)-]'9A-\$*VA4LV)S4E> C2ID6<3/U48*VPN0_>F:RCGJ;WK MJ6VI+K+A,B82$B?:(WK.:H1/[@\Y,892;O/IXDA2_:EA:((%VE*?GJ M[(G>EYDB4;J3Z"YFI1YAHS3RB3HO]HNN;KB!&8?G:&;)U6?.1^C'G'-*VH4_ ME\J5X"8UI1"8L&QRL5M55X;73:/5+U//OW8/85.$!> M\%5>%A:!,O/&.JF!HCLC(HT;Z39APOYQ VY=EGH&M\JH?9[H.YUHDH/I%".F M=$'@2B.1\Y7TQ#AV=\DV@#PBN&'A$"BDE_- 7!.[V:J2?K]FN?A6" M-@55"7)4/F3JC\ B34[^>;8_6%RD.=I2Y.>@BF+4-K'.'[Y(/4@/L,D]91AR MZJ<*@F"E/[SD?E$?JQ .AF?,]U** [+.4*]BIR"HE M!FK93L)@-G8F.M$K9 M\+ )*K LL>P!_8:0-$U7UY4R<6W5^.4=<6!)@1#-@FV^W)9AS#: #[M6]:^Z:IKK0-8D27_M[UW[6[C2+)%_TJMGNZYTET@S9=>]IU9BZ+L MMF8L2T=4M\_Y=%8!*)!E%5!P58$4YM??C!T1F9'U $FUQ(>,#UX62: J'Y&1 M\=S[BV>F?41G.,49^JL52$)J:SP\E*TTN!(JZMX>)TM1Z^L"!A=^9 M_S*+X M@B,IM.H(!24>B-6&7D5%3?Y5J%XVPIM6 1!!R\KH=ZA=GJ47)36ZKK7'>QT5JGE;2X$S( M]M7966B>OD[C]3S]2.1G 0Q#\2^<@-1D# R4:F MR814496!DW'NO"N":1HE3BK/?27I H?QM/%1%LXT?,S6_5@MN\D[]W1;U1$ MI=&H1GCGJ7[!7-/( Q@$6@E0VI<"#0!;QJ@.BNIFRSK3GE!T1Y94BOJB9A'@ M*X?66LO>FIMN9\^(6U$Z5'JF:WQ+3-8 0X M$$HJ:*J\BWIP0C/5,O#SE4Z_$I!XS,WGP9X 5\4?YM)IB[#"=Z#(KO.=2?YI MA#&TF22J_&:+MQ )&8%;$*T;3ZC."/B#J7!QZKJ M]$B#D1K%4'#,V(E;Q=9 M=W=\=\$TFX!-S!XSIB%9$8V>VM(J5QAH=4$X!!ZZ#Z.4(0IH!FL;C 7EU;I< M?@:Z+L//1TE\T_-5,B(70].O@%US4Y&X+QOL)[7AN'0WV,"B7V^?>W MYX %X,%NW(0 WRC>(",*B3UZ%02,J-[X] O%4EVS,FSK&^V#(95&LBONF=_C4OX,Q@,2?F.0N3O 3J^'[J[&'@W-YPE;P"20%A7UL;) M-URK05&.>HW $3=[-&I#4L$1(W$$Z[!' OEZ4CGLL1Z")(\!H2ZF24'EYJ0? M5;8SFZ1YU)Q7'I'F#U[. 2\_@B'S FTF/UK8 M&VN\H?5)BA^+B+G,XQ@.JHC10.:IW_C2*(1R+%.Y?=-D\V4C\/J^LRI11K*>^#6D2H2B6@6'LI2F$U+LJ+-"I;T,2K,I+R+IVG2G' %4Q%>4F7 ML,@L^=H,U$+O,[J>NVH887V:N/F<@P$%@*D+]\VI=5N&'11%HEPKI;#"NG(2 MN7MD/"^L>^:)>],T]?EDVFYH[^6J:6'$LH405)*^(!B&H]9[Z*$<_4T]>*^ M&4I,EW8R=&WY%FP?(%>Z;=*KGH]" <)T3&QLFD["R"=<5M0S.&&W4]<5*WKF MCM+2[>'O*W+2P,X\$5;6.#/N_E2DESJBT'(9>#C]61R%DTB?[KB=&ZWHUKAY M^XB/@MU"PO):,Z0GK@94;T1'FR9OM0(?6G/45#NT "533[D !WO[>WSZQ/=-WE5.DTT\(MPQ96.FB,.=T%(>3QK@P:5S M9J:16L2?^4+ 1^AK/[JUXUO[?>;.&"$Y\(_X/D#DT0((SG@9P+OCD^,1-1.Y M9Y.4]9[S7?X< =U1IE T+C= \KDEEEZK+&KA)>7!(L+1<7)U0Z,+K45 *4D/ M=EO3:IY.D#GAII05$4\[J13G,>,K)^(UYG&3BXTNP;H1P 3%MMSP8"A]6$B@ M;D,3TJ/\,6Q6-"J2_TO;00(+L,4LZ^N[-/!9,"9Y +4/KXZ=\3X%/FD[-H(% M&><(A4^ \X9P]E+"%A3UT*D3VI>28C$[CUQ-''?1$.ZY:')]MSF:9O?TE/[@ MYLL3]CP[N[_#1/= M/PR-H**BHH?S=4KWHZY8JNP<;G6P8"-%C8.$8_@T?ERH7B^]HT#,JZ 'S](E M(["M@H(:!2:G&/T,,UR4E\S:*N!T;G#/]O[FU&>^0&$,W1_^D? TE&\UF\HM MC+** "2(&8-%>L--H"7*6VN$9+:J$"^ "*QY20['^AUR MX7H#G8J+W]*D:D+(XN*M[=>*4X-MG%7I:BK%9Q0+(:/'>E%0QK(\#)SRDUM5 M=T<6:>ZV[GC2>#ORV,UDY[_SR<+"70FY$"\LR6J6 MW'NV..?;*V!6PS(O%Z&!G %U:$Y>R>FG MAFVH09NI+RGT!;[WITOG/=G;IO-NV$Y/630*BP',-?N4358D',9]HK-RXJ2> MW#+!GCUW>C(#2@<=-BCT5!C0K(&XF_P&6A?]M@>.7:9U+:C+578N&-)5MLS( M)0M ,2-NUB,8OASM_7PH1651O!,.DL\3J?G5I)^R2*O"6@VS)&,8]Q[%&-++ M%E4??>-#^BDY64E1LW_!:W.-+1IC0 M%72M>CE$,>8XXY@F:Z?+/"8OI>4 Z>O=TM:3N/B)5R2G?:>TD9*',D,0 6C335!1&Q)Y92NNO[IR\,X#JV4W>?%5EBE:H<2E M_&K)5,QY-Y1O2%X^6565A.GF)E3DJ5<&%J1:L1"5AG_QN2[B.S<.7'#)2_J? M(#&37^&/L4+[BPTMEF&Y!C"+!UF21]53$>#L5G/..+C9/"SPN6 MF8E>\EJP8P062PT/C;,S*B%:.$ML7/$Y>,(S8:0CLWJELP[\0X]79^0(*+[1!E;,5M1UQ$C1::(WDBU@WM)$?"Y1U]< \;%05NW%9D(G4X+*L/K8 G^'Y MZW@Y)0G7W!V'148#I14?IY7S>+C8(&QL>R*;MM@/O:RLGG\-+>&$IH9YZ_E, MS*>,WBYB%?,M1[Z$G>\"8@\.7<&/A=Y%6Y(RH'ANN%T=FE!9.)0M5N3 M26;W.JT5K*YSKP8MH=E=EE%_J[U<38GMZ(0#V>;.]8RSB,FMG'D*LEL?UF1P M+W6J?8 S)%0KBYGU-U)VRZ)X;>6(L>"\4*O#:^]CIZ(+&<)B :,"' MK6#%2':010H9![=/.H\P_N>C@>M!%^5@[W O,$MEGZB\RK,H4TZDK.@ &SQ: MC@JG8DX<[/E'>9[APWW1KU+@8[SG^,BE$AIV"Y9^S!;(&P6ZW_U#>]6\':?S MM&U!L6\XIXB1F[TSC=P.N &\=_YN-C/+<" +W1\+F/&MZ-FM>O=3+4*_KP_P M./KKG[&HD+5G.[SFX\>?SFB)HQNLGE3NUENL^X\B5_]R7&K!*(HLUBCAB0-N M==9HR&SFR2+XUF9.)Y]K=;>=&XL*>052&5\@=45PE=@%247[<;V1HCQ(=R9:?M%S7U5BTF:]$0<=Y+ M; ,.R$I2Z#Q?NJUI+EDYA@Q<'$J5N)]>VMIO@!NHFZYI%PZ#NT@+M&>E+98[ M;J(H3>\F':C5?MB^R5:UT%&309D2RQ!.E%91@.?M.6M[%,])DEHT-L5+1 M-X]9L_&C4/S?,L7J8(FLU>1T?ZQ;EP$9M"LG^ ='HKWH6Z<$5@;513J'?KUA MCH$]72?:&8E)Y'4$U<^9_0C..TNPU"^./EGCY]$(?,37+T9/=5-$IYXB>U/ ME*05"//59;#NXJ].8%B/[^D?6>FAPW.53V&A(?KD8Z?C55[PI2W$E)*6,6Q; M6M,GZ3].%!N7Q'W0O_G O_GGGT]Y\$[-33%'#_KJ[C0W*@KA4@>+6-)ICBFN:XY]1C'-6,-19M6D&XF;YB*!7HCYQXR=NI,X0E*D2HOM/+\M<3[ M&XENDSDN5V*H)S 9TEI-:]@E"!!\Z(TW0$/07GK%+03MWI[ILS(Q]2@6<'! MLXU_=6HSU*-$2$67U M/U&=K%G^"6J9K+.*+$FI?U%U.;0+'04J[G1WH;4NVU7CF?OVBO+ (2 M/3)^\N;4^- H"\_G]LCZ@6D(JD\Q>;7PAN[(GZB5QCWPU]0#SK_YZ=>.UO0& M*#H\W"W2DO.7)FEO5MZ7'.^$51>4GZ6MW])KIOGZ2+'MYS3V2O6 MC&PV053.\Y^2?/5,HP50C7B)E-L0%1)]PFV*Q-YS:\GI9+Q1[EU_RMK!KJ% M%"(A=:B%<=.JB"M1+\84FGFQ@QB5)NG&SAY8P*&-]WM?,@_0FVWC^!F$P?]6 M@BM[)D+U*A?V+8[(:.[OUQ+Z@I)Z4 +F1/ M?7# /)GE'A7+2T2!63'W+M<9R,BG_<._V29QO"!%\ L0S7JC G:5%SQ<=-3= MBF)T3[3DCK*;^12<>!UM45-< G-"4P,]VHFK\XB8SMOY4)^:]:.G>X^3:;JN MI:F;FV&- *01P+K,69.9[\%LF%4MYDI?>>C1;COJ9E!C9I]0?T7K"W[&1CH< MELY.764]AAU'T\AC"W95%DQ6G&(U6-5D1R2F4_Q'_C33(07#'O5Z5NU:U6.L M?BU^:]L4UALQ]=/>U@^6KI05!BN^4UQ':Y0CV.93MR-/SJ?PX%XU*^LN!]?B MMG"X3_20HD3U'>30NB6ABPGGD#PE2FY/4O#!V7F[CSN11]N.,?4@H2WJ<5Z+ M5?&1]G)RCE4'_#]1^VJQLHD1J,D/:[()E;*]835?4A['BCAT-\)Y\O=XF^E; M_?UI1G=)N[HT=!$' C[%3UC$@;G8Q149_< M_DWNXZ&VS[45FD1 M.N9,.31)$4F('L6( B$<-_/(!@C!0-04U! P@OOA,JU"J9W-'IK6 :''%;#_ M4-*%A'ZV8+P'6Z#7)A2R&1X3HF(2'2T/"*VWU.M!E">9V"I2-G"=OK<^_0!( MDZCH6/UU:KI")*,N _I'NS.+H3&X!*^#N;QE) ;8 THA+,]S3\"V 7;P* DS,,84GA.)]\+@B M:Y]_Y2ZV&LP\\B%J^6]"A+QD'0'[4F*0331LA]AB;\5 MXA.=5J5M2 M:(M%,HT>TVKBZ^ B>-2$6>C/C;(00RL[LWY+5\9;+OHP, $Z[Q6@B8 :4!8C MG1D-10D&VH)]#:L?-;"GLI1/H$MN]S'[(%F UXAWX-C3C;\)& M%^I:I(3_(KNRM8S!,EJ'LXV+31<,/3551)FPABKW\2O;5=/J\=8 #+@PX:41*6]C4M MW.%Q/\[+*6PA*6QM2FZM1-AG1B$Y3SA'7O"$, @:\X5IQCI3S0UJ[R"+KC,T MP?; 4LZ$7R\XC%2L 0B]T,PUM!)N_;4JAMO7N82Q6"O^":F(EE<9BKQZBFK# M(G$+*<,R^,&+?8M-[27# RL=MB=D?8@4C_4TT^/QB'-2Z]-LA[)1TFQ93]R3 M1I[I+Q0>&'X)OCA]@Q=B?@'3)RJQQ>)(%#A:?CGBFLHRS'_^=I"GF\?QA[T M2'?"C#,H$>Y^2PKQQAYY\:=!%CGJO6:Q+JM!WV:#X(>U#I<+UI/#ZUPD*2%_ M%>W.0ZA'2B?4VF(MA6VWZDO/.]6VTI).LJC%?*UQ8HR%X:7FY2)K*'6PH=7$ MS"82!$Y&P7M?,&B274#,BR.&5%E"'=6T%/0IF3&.EMU[6MJ\S:M!$68 M2T6#91GZREI8\O$^JK\KEJE=)(4G":D^D2H[<9*_%ERF=.4,E1NB'[=%D1GE M/B[CZ!D75L'&HPQ!OF!?QNDIP93@FB)NB;+:CX$")&$&'%_GL\C [1!6FM;_#_=N__>BO%QH M$X09Q0E J]R&OA/YT#9Q?.[DW3%2$UJL06)HN@]4IBJ:KR3[Y7EU\BC5$%-9 M3>F24Y;*:3:+678N'W, A)1 ;< HKD-PZ[L5S]VG&.$B5MXS,Z22"K'=)7-> M%E.N?W)_CO/ODDRGF:N6K7VO*FM#*;NS7CJP4*Z= OK M=*F9.520@/#)\7TDN:EU'"A[')U/O/$BH*ADG^BVH+(*%KR+54$H$@'T+OHR M]4CK+399CY%Z)L&KS;5%]<8797%ALJO$O&1#VC8:$\F"1-D:CKWY]H%PBUVE M722O16#T1M^\V*1NMOFU5G[MX-[GUQZ<&Z^J L4ED@(33ZK)=R9E5:V6JBW< M+\C6)',,)8K<]?=)(F&H2G#.7;JP%[L4)U?IM-_YZH$5^8 /_^(^O)M0UIXJ M[1$VI65P*IB]E3^0+N"+XR(OBYN$H>_7)6^*N.=4GDOZ/JP!:9US9\HVY@81 MGX ]O9VJ7=IP\06U*ROFVFDI5".UCM:"P&7V9KI8B_-!4J8+8 M^\TDLW=!MP\CR;-G\C\0!C?6.>KF1PQNH+_D6EXG'.C;:O@#5<*@VPAPF*)6 M,A+X)QH"!% JNK$*!()939APB%!R1H;&!N"@YBC%(KYZN%D %K >V/PQ9W% MRU?,2&H5:\$#3%$N1]_(SKCD99Q6\L'T4T+FC'/U:FE^$P^8+1-L#A]: !^$ M6C2RCY>K1J%^*69F=] >(#YCDI6J,H9&;G$*> 5.(KM" JK]:Y(C4-)ZY@(<9R2T7\"S.N$=/D0_5V6T[5Q*X M"1'VT!JX)/>"UM() <&&,-8_7_YG/O8<#<32-$IBF<<#NT*\,#)'G,^]PYHT MV#( )3'H-TYW[*I:&U-A0S&%%UH$0%(C]3P 9U+AT)K':FP<5LH"!UD40!F. MJ%// L=_2?B9,)'<<'$("\\Y^3_P:R$"W*;[T1G\138]"UP/X<7?:#C;WW^^ MUEON0;G?-.P2KKHZNNNRN3NV9R4+<'1SBL,*8[OO"NV]%MVI//'!FR@R#CD( MWBX'Q@DHEX^[TXX-%=Z]5:")"$\W"-B]@C^;L'?ILA M^]CPL0+2;^?$<73(VX_\B.,XZ_7>?@N?.W%3+^=U_+R+E#=!:]NUMI*\1)7+ M.$QB*^1NTQ/_"GPS]%/ MG(CZ>N>1"Z4Q0U) NXDH=O>?X],GN\F_ M_]O^TV<_4,_ER,XHI00FXA'XY>EQ\N[XP_O7;S\(%EZ0960+Z&=_(G!,]?57 MG-M,=XG;>S #L-]O(R$[' M947WV+5M-VYP4O-MR$J[H6EV(Y/L-RXRNO;-7ZX:T!U)U+T=E^PRA[C5Q&HG M)51MQA7_@$%K(_03OBE275_?N'@H1MF7LV0^4Y)O;.)0?88;P$8;)P%2Z47D M#4B\L9L^G'JV##HN,U7,M?D$O'HT#>K>OP+9B")P()02:? MP3F3EE9>_=,?3\P2])THJ4W(%P%+\\"^5B-?4):6:62*E6!LKQ;N/%(Z]%H5YI^1 M1[CM@_$JK\6X]3) !R-LE-\=SU=14Q8*I13$Z1?L*46SMP"S+&,,V4-V6*!Z M7)MO]@A#W'O<6](WT&'E 4>*M Y@"9!;*T"A,;>TK;8'@,%[;KMS+\'L:'+NK$XFJXIS MQMBAN*K>P%7U:UVY\(SR5? EVEFS0$", /9*BW#P9L7R!DI"2A-Z9Q4B--VR M404D"RZ0,D]@V=O>Q22%=8Z^=H:[8ZR3C(@?Y(]DZDI9%1>!Q(IORX@8THF' MVW1B_WKU6\KO\_HCX1#[##F5\;]V&XCD'?E4[R"+S?I;\ M^RY0 JF2(##_+ MIW'P?B'K")^S3J5Q/6BK+9>,4KYN=S(8L*I4[Q#Q0C;W& M\GB9$S%C)Q# >_[*DRB!,Z56M8(R4(L MI#0(Y;J3$&;1.$25K)81K*^[-B[@*6!7GXR, VF_JUE6RJ[(" M1X2.3YQ<'VX<\ >X#6C-#D3KNV(E]#[" ZW7 70#04LDHITA*B U\>]"L:.4 MT7'6)\0"\!S3L,*%>G3HSYTS[A,.H8**E5%I%@<*,F&KZ!AX%+!C4#M8.4@IIH>074O'8 MFF38O7BFG+2M)'$;J1QS0)B;@P/9V)=C-XUZ[4[LZ\5D-WF4(JB73W-21.Y] MQS5I!K<;[P#)P1][S%\5/A$:^[O3D^,=;GMS(SLY?B]N]LN\_&&YJ\#^]ZH4!N:SUX(<(FCTR;?]CY M=E=(*E2+-[NP1?BCVSI.T5J9[V?Y>WB+_BJOEZO&.OC,;J9(:5*-'\Y<&=$1 M^@HCY[2EE130]]V^)O22=D^O<9O%9LE3\#RU=E9BL+MRH+"*4!)QE=Z&,]PY+E-FEM;Y#&CC$? M_Y#"I0YB:PA;(.+M0;_]S16KG?PETRW3-DBCCLLL.-Q&#;3ZZ?!LZS-%3H%6 M6&P 94";&'"B@K=5NV_5L[6X-;U#!\G65HQN^_8O+Q>2W4:#*/G9OE?/!W78 MB(Z )AED$SUCD(=*Q:S_[ABO>XQ(8UVJ)?D ;>C7,[2^KSS@??\*1*ZZ/X>: MX>="D9[:4 ][A*"&.A*[SN?W('F2;>ZE#RP!F]%546?A-U0Z^E M:BW$K\)B95&H>@!$*A<0(V !RY*/+)X>58C(P=)*;H^9SPC2]#Q.&#Y _4:! M&8,,RRT[\[Q&.M\MGH?7CNU'C<,:U(AHM2T8 0M=QOJ)US!']:M[V1^K?/*1 MU-2*XX@X$&XDA,W;VBC.:A-,F\:+FG,JO':RC5R^8!W0PYD&E#.AK1U*3C8F M$GR-B#8,R]7F]JXG+&EP^+4,#)91"L!6$(0)+5QM,>6Y%BB;HE'%@%<%8UTB MY#TC?( B]L'CPW@R':F_Z+0[JO\2HLJU[A]%N&=ED9<>JH!2.@" SRP,8=\C M%'-KEH-5KT33<"CTX&Z,-GXQE\C[8Y#M)C^7ES2!D<%)D)JAX<#6GR^??W3O M\_D';1_C\.DU/ RZ"K?^!?R+(_:U"* /[F#F<\7":4?QP6M%#;9[\87V HG8 M#&SV*#=-%YQ,-[8L):"$)B+:K92,)_;7A!G"7M*AKDX#D+$E@$?,PU0IYO,B$;DQX>2/2E!CT\T(P MV3)ZJIJN$F<@+@E"G+%/QP.9D'@PO:F"[NIZ<95R(;',U@&(LQW6?X,)535VX?$W5L2>..IL8^Y#,T-^XI2KA M_6BGG[42I.4OU; (M;&6* NC)BP[CH#.C>X3'1&U:"KL+Q!AK01#53&C%+7CY>-5XP'']J_;BS/ND M03&MN:\Z\-5S&3Z[[N8Q>6UX')@;4J/"A/-.3$D/47%^8(66+<[0^NJ/BAPQ MIS7;V>A8<;J#017Y"\("0R$4-7E\$F@%K.2$NI.ID"?Y8T7=Z)JYD,8MC]_. MY59]^L\$7+EWUT=Q4!THH=901=11*&YJ,C M##U*YT?F(J^U7J.7DD^B%R:5V075/9E1 _'3$X%X9I[U\3+DV0TVS<5RZV'V?*%K2;G((+?B!F M&$7WYN"/CN-[##)M ]B,O]B: M?;4F\^^-MZ2+ZN$[2TZ83&@X!R/++O^U>" M^+=.&@V=9]L:!2\]J'U8C]&L ;E9\.-31ALB$8'+/B9>IXQ(&=WW]I^.A)%= M&4IGU#DYL?Z!JF-J_RL_:A^MQ>:%\N-0N,$\87,0LJM8LY?G97(IG7*\0AQ. M8-O2URAI0D\L6..'!OVITY7C:I>%NPJ[JR70)FQ;X>L,8V 6RR_5P"I!M8() M(3G#&:R$Q($,"$,WHH ;/%3"? U@V&E=IV?>#A.6^^3U@LOQ"T!>= MV/+"X%2.3,DBB12+G8\L55EL28OE(6T0:Z49+K1B(BYC HOFA:()V2JH\%(> M%MNDO0,?Q>"]951S:2=EM)*79BAUT!#U.JSMXE[N]LMCL.H+I# !),U:R9^H$ZL+_/*N$_] MQ$QJN+O?*(+0-'3)F+J%C59YN_HUT,"U"CS?^F=>P^ ,E7517 -[R!@2X MMK @;F'7(3+/^3# P4A[PN&[<.L4\N%=TK=OHESG@[$*@X'6OVM1#$4"0AHW M@2=R3>4NM4';EON0HG_R(%+T]\8:>KNRV$X:E9'&1=:%:>6[]-*+,I\J\YR- M)=K@3KN16E2Y4N>HIE)R)7@4%L,LG9-VIL^;+ [;+<'LMO?G0-\TO_:Z(3LA M*-'BF$O"\$OK3:FCCE^@$51+RF+<2K9O"/%%.P7MT\3K\NXC\LO+D-6PYL+< M+2'TNGV R3-$]">[R7OA\AB)YV$=)79 1FV?IS4%;U59Z!.*.Z#E2G\+>!*(MU,#T*4BT$/'">3:2PC'*V$:W6 M;O(K\5H0JFFG0*L5(!7$O"%73R]%NM2I%'W:*20DY'HG.7X %!..T3L9E0#J M7(V+OFC(<7U3$284/S:+*3Y499&;P?-D XV*A#UX=!U,U9[8%5U39SD:P9G) MW5YR0]K ''X!2;ANH\3GT2KX-P(VD >NR=FLRF" M0LPK:BD&6JO*%\E'O&2JBCPM>8=XSIF=EY!= :WD7CB@?&;"3)<6:[))HTQ! MZ>T_YMJSX#7'8N.$I1*P5<0[D5]F6$\4B;OE ML3<,A]\OX(1Q.8VB443B0>./Z6L]>-9P2Y9!*P'2B+OE08NWJAG?C_/<<_># MA.,'WQ+))_@DPQWGYC76.YG$(UUR:D68@YV'(X$A_PB #\.5"=3!>>,^...) M$H>3<-?1!Z/,DXB>.F;CHIQ\;*V=%;*G>:"5I+2@6,IP [MZJ$?6J0: MIH-7$17=NGD1#])=(#D?7I_@PFP1(I"8MI9_G$NR$_4(>%R4-G.2GN5LN0#< MF#'C$INM5%_U(LT+C X!CWX\#W0'80>(=:G8S'ILH,WT?<@+=*7^RE>.PCNO M:$G9-QC!YO.^JI:M,#IK@%Q_[#NQW=>VZ$ 1%,X4J:YXO6J ML^RC1:K+%[\#*_8BU%\B.,5E.^Y&R;-9O)JVH:7WJ,TX:+7AR W=0:\H+.1; M5&LMHAD)J$0ANHUO=LIU4"1%MIBCL-;M,:4HV!NUYW,)E"#EZND[8M%W;#!\]@+( <>QT/*)VGP(@V:*=5 M1KLB?^& 6-.4U2);UP+_#RQ8#H<[8Y\&8M\_TFTO%X(T51EXF2XFV@BCJLJU MD)2" (B3X1)"P[/E5D#%S2BN 3O*8=M\66.1MMY19!;FO7EQ1*RKIN6$ONT[L M.PBC6WJN)Z'TNT%O]:Z"[&M9BNKG7MP@6@<[Y0DRW%B5KE*F0GV]"*3V"Q+. M@5 ]/.%F^-SCWL;Q;&GC6%L_=-T<0=,J.A&["[/^V].I!:/%H]K,\QQYWN35 MK\>P("MP0.#'.COC=!:%Y*$S'NT_)L7D_DD;?\Y"TN3C9H\.GC, M#,'S;#YV_Q>;>.V\QR*MJ4&-/RP6&('BEF?9@OQ^Q/:IL J%25)5I^W-+%]L MUQ34CK?1HM?F2I,/"TXQHAR\.B@Q0+\ZBHE9SEOEB&Z+*=PQ!_(%!SU\]C72 MR;6[[8QB]@4]^ME:_$PR ;OJ6XLQZ1P2:X_/;/C^B'ZO7I"0;;S+5F3!._!E MK&$X_N"S>]G7O%T(51"MM?5>2 1#XLTM8 #Q&:^#5RN:),X7Z%]UG&KIG#WC?%YW6N=U M5J5RO/&L<_L21)7 @1673CB-*\V] M?X]H"Q'$2'U9W"QRF;6OQDB@S##9F4I-6F0DH<5#L_,RF>ZI?6!ULFWE8>[^F]S./= M&WU^[)0!3-(BBPVTQG>DEZ&C\7,4O3U)D:8-Q4N7VOJ>??1<7D6Z8 ZL[*,E M]?#,4[!$@G%5MAM1O-%#BC2,3>)1S!XIMSQ<,:KB_>1+D<<=J@)YK3:NU+&5 MP>7U5( _QY6"U\@YAUK@K]E1(CAJ]#RQVS*") HZ0W6,P,:"[' )#SA.E(XB M>@5A9-&*'HX2S(I59NJ Z9V!<\&N4SHEK%=^,^*I M_K;3%:'LD\Z/$HC-YM7R^+_V4ETE&S$$ M.$/Z9#=Y"ZPH:WQSU/FJ4=S4#M_X0)S1#::YB0E+IBAE^[S.I'R[3F?DIU1C M/@-]HV+SY/")DA<>/-M_E#TFKXJZFCR5!^(:2@=5:C-TDE+H]L-I>DM[[9R6P,"\)(BS>90PSMG ,>B"RRW/:Z MTOWK&D>93=R,[%T\AP5%GS*X#9WJP-OURTJ; ?I2KEFHC-WHF'63#U_707N M-62_1>F06,QX/5$G$ KXT,/D4QQAK;V!2XVQ"UN68RJ0VX")RWR9T9BHR091 MD73B#KHM0 E-9ILPU!Y\ZEZ3RQ;W7-*W'+>WF#Q=5\(;+1H_-IVT/851FFAM MA;+I2V=5>1GZLGRL$84Q1?XQPV$%A4B[4,LR &$0(]LA**"'OOFT-:2''NQX M.YR @Q/MX_KC>R6 O)9L474"^M[+QQ).A26;#H MY?8Y MFI /,SGU8 42=5CAS/-Y%K55/G3Q_Q#C6(.(T2OR=NQH<_%DW:X0=[ZVFEC2 MO=G*H,%F\\7FPL -STZ[QLRFG+O% :GN*!Q.:K=;5QZJ> WK5F;YE:?-!VJM4?IS*I.IBMM MU<^I,X':6"=I?6[6B]9=5[&?)J87\GB2+OD^R/NH'AZ6;/_6BUX9F:_<;=]0 MY/6L;'(36"0HX#GW7 XB MOB>MKJT WG'])7,.5)EH,U-.FRFR4"#-9E)3X"R]7&-2'N,BK?=K_F)(Z!L!CU %B,DM*PGA!$ M*\ OQ)HUK_3O:*5FPOMH 6BUL/4/K0RJ83NC6Z9CL8DN:50<=^L+L_%JRD!5+N5!J"=$T$.N+]IE:MF0BW@;6:[U//:F4NG0VL7PUI,J%7) MW.&=:A!X-XV[$1KK.09+/V\"(XC$W;G[ QB%;VVTS=NC5/2733V65>M; M >RN) H"8,X&E_7*@L[!:RG>=\T,"N1,R$TQW""Z\G:X*\_ V*C.'[8F1D.7 M4!R3"=G'M*$!E0B&^21D*&I&L:A_C #0 M+XKX9O]JW4!*=Y-?3)'M (J0/4";MJENX96EL(YAW:@A*0<3+W)V)DY)P"+3 M?+PW 48=!+1PZ5%5+9^R*?I;I7W?*;,TY):TQ%XQ.+B*A^2TQPN7)G9GX!O0\"@";XV,$4$BQ$A=$"J)E2CQ"P5 5'B$M4/'@DB9-:4.*,,6L ) ML28"+7## P^01(7A8TUD>'"IGB[K "_@O4*LZ6*AZ&1Y,\#8$)68&X H^ G0 M7D#^Z&/4Z,4V07EPZ22$KSP#@N';NPS(:'AYIYTNJ[+PU"5(Y!("G:4^8@^@ MT\2DON=9"KPI)Z*EO^ ,5V0^;Y]I$WKC_#\!7E9*TYP6ZUHA5B[<825'WZW: M)$,^53+I_';NHUID9S !#5B>! ZCC>OPY\JM/C$+#T2%9T*\-%0>QP>5*'F>N!W]935K0?@B.%3G3IZ/Y7*E2 MHCET*RT>8HSK'? &W=G#+F8+S _N81]F/Q?P;'I5_;GM:N_:WY0'9B/N 4F MP6T#8)4 2G-DEI_D-H14B]EE'#V15", :B@]'9657?2GV M6-#"WHV:L1NST-1R.U,M;3@&/@ON#'>76TRLR\_AN+^>)K_G.:+7,?(!3,AA M%)-P#\Z 2#S4+HXR18^C+,9]U41 ^P_Q)@R,B(M6O$0#"*A0#006@ JW]J;Z M\*F)"*PCI$@]#6$KPKOZ&AH;\.I0H6':#FD;= FC@3?OL9**R9TP FR_;+.4 M*7:1 12OU2(]>5=L% _/#ZSF.+O)>0"+L?,.KH%B+&2RB%'LH3C2>E,M%!!( M,SX RQ!PGVBMZ<:2HE'SVKY7&OT/?-8V$ R*D%+"T=%;7^8EM,)[H"=TP<9M2-Z_"*&0S(Z\!. MM:K->\,W"!0J.D8G_17N6#>,[8'-3PT*ZG'F21,0/NYR%?X16*IZ^X_TI/"G\>B_EL/O;5_AN8,.Q7Z M&YA2V-5>&$HJ3H%0?P05 K*0$X2W_Q77,+A#.H&5,?7X*.!IP/O)&J$7 DF! MRO1;R-,L*. )-!B3)"9U#K O0I4QIQ9-!A(:HM+F$M&T>$6["]IWC$T_-Z&? M4HRPR-*ZP<$:"5I7=>[,+T'H:#$.F :W09RM 5-QLO&.)SR/KW/';]-(K332 M\WN91GI -MN)(*8[/=)"2_?D#+AXSE4_K0R;#[XF+%"AU)/A;-0H,'7'OA@H MG+8'&<,X%BJ+# ZTA+3A3HSSLH7 9XHB:=J*IIE3D7=ZD?MR[8SQA@;XKJ/P MMF^5B,-BK!PM'F8 NNR'!0S5ZX J;I$/NT>R6A:N&FA<1K/GK89=P@1IO>58 M^8(^)=!RGKRF'99EL2-NX4I *8D\>:*(CX2#[SNV/8@D^K6=<;-#S(\&HTT@ M),D2K LQIL4XHUH9]MEI)\ \0"5BW=>US95('3@9!SB,[U-_E2F('C4$2NJJ MCLC43IP=5@&-#0/,I@C8,8&9-\P]?X:F<;B4^\Q7Z'-HS@J_."_,KY O8NM+ MV#MA_>!SO%T#BP@D5%-^5T:UC(#T;,/01NA_5%.#Z(&'K++5H4D$K>*#4!!: MAD<[KNMRL@M+\ WCW3GWX%W:G'-N^V(W>;-V!L@T^;N3.'?"W;J]7DQVS?&* MY1Z%8!RZ4OGU6(Z$P1) ]30,%3@+-+:(&FVQ]@PLBN$M\2N&B$THL9?H3:"I MCKS_<5JSE0D159'I(:$F<'U%/^Q(EHI/1\JBJ $76;*Q%HFS<2&^CROQG]PP:"@Y@!@A+W[T 6!MJ$.)1M\J<;L&F+P1(=\=" 8]#YP<2U4V5VX[;!%52S\\C?A&6Q.Y MGPD[Y2E4LNG-252&.#&&\.O1SP;GA-FOH%.\,1,X=2._Z>3<6;L1P@;OK\%; M-U\5580R,:ZH-M)G3=XA#I_KN')2?80(#<.%=)VU=@VS1ET49R;'QIH])YPW-]JD9J+4B,&JW4; M)CM7-.J!'7\7]Q5UFXG,%=;[B$X(>:CRC=+E;-@SE8I6M+,FEOX![' +W#K0 MW/1U3FSNSMC8B'&S]@O;N\'%PDD7QI-S%AV$W0@!PH!/H$=%>[U\F[!DIH*7 MICT 7G62TX%$!2$134'Z"?CK",HA*H.E\@(W"71P?3AO(8N$W@MUTM PE*.Z MUKKC QJ@[Z2W@%,AS 066:W.+/)\96;59M>**6D1.Q@E-AO4S071E@K>@B^$ MU&8)KUEX[O#[Z\ZG^12<"363Q&A&20'>5FW@ 7E]W%S4:=-SYD)[V>B)/ZY( M95E^H9:"#!T@0;&^=NH\'0E_N!O2JJA+#[2-U G99 R%HODT&Q()H%-NA0NA MH>3$DV\(:?-;2[,OL-S?6=KOSOQEG7!90J5T# M=8KO+>SG.&RQ\W$9C<"$0; OR1;F&N:5$ (&=L#!:MLN$=/#LTE_\WB]**=M MS;;-0&5GW^TP:SFNE\K*0FN?7^2$&\ETDDAFTCU)=8+D;_.ND;T0,@(M=NZ! M_(!%!AF0BZ"%/E,Z3#5@L?:7 3RSFTH+8//:_4?1T'SO'[%Q^-]748/$0',2 MN07>*K$=I!$BR38-ZM.@+^Y]&O1>Z8JX)2;I15>+&Y>-#765'P%=@[9D[:*1 M/$Y/+XWIHKF7-]O&>^R]\SWJY'W@;&),Q?-\J1;N"7<=G%+7P;V.MOEFN1G3(W_;)?XPM,3!QH\9@\ F,,O4[J\U1*.UP[J=V*;D M[<(];IT\&24'>P?[7)LD>*K.&.:LEQD"SH0.X)=?3I)'PO'.?Q=R]\41+* ^4=_P3?@5]-CQ[ MQCUU[BD4BM$INE4>7BOM'PMUSW':3%;<["B]Y'"/ 3@I_T'E!MI(.Z4T['DZ M98Y(Y!202?CKX9/$"6;A&[E:O08RMG@%GN_O/9H\?G3X^-')X[#^"A>>TK^H MSQ(-*$)P]6MYD:$Y8U^W#<7U9VG>[2&B&7?6DG;5]B.EG47I+HB9G.^M9317 M<@/G*P T[&]:,;"T45&_!S]N3P3RZ']YH+.3=?,RN0J6)>T"U_F=<V.1I5..G(2V M*>V"1/U/H& , :AT<=,>R)%6U;AA7"#$S56ZBYY/:IM>N))Z/X9;2ZI%-1FY M)!S26;+V(G5F#GZ9>?^>7C8:-M@"]D,VYQW(WD.P$HG1..<$%1I..R(HQL]^,%T2!5 '$@ M*Y96.O)+KN*XXI0O%H<*') />5@RJH;]59IJT"0:;=8TBFE&+^6;,2V$8FK( M-7!O/0C0E2[ D%^DR$Q>+TO?A9FW1D^/EQBP M OO[,0!;04H7^LS&J#]=,S*C'EO>%/T[#4Z.1@!>YBP>9Q=8UX[I%?7'M:\% M:6,8@(@O+3*?Q N'SD.1VPP4GP.T%6=(K5 DWDQJL]NBSDTK$52[!3KPT[@QHE+Q6J&^@T;+_ILR[[FGN#]&RF7 R%4TGLV(U ML;W8W$W,&2O?\\YQXY&'ZPC<]N-L74IJ3=IXK2TF!X&$-/=OD!(!5G^AJ5EF MZ@:[XG*PZ37N'B M7^4(TG^_ M(+3@,BO2!1Q6Q3]N0$8_W.?JR;K%JFM]+V!"T_=P;4Y"EPRWR : 9;IH5AM> M]L-6=FY3=FA?P:&M!]PPPLQR[O=01=/'WTD*RCU"W4F[TW35"%C/M/<#?2T2 M%A'#<-,P#&^SEB29AT,C+Y$:5F6H5K'2TZGH%]K3,],G/[TZ]@^A"J!4[/Y4 M52+P;]-"<7U5*SHCLF&VP]2'/Q"%"O:42?IMI?AVI3A"":X],7RM4ETNSDKQ M=/NUV';#;G7#F#A'H/G0LR6H#6EK8T8(LF[ZA+08:7@1,#Z^QRC^Z':3[^A4 M>D7N.X^LIHZ >AC8A #8U#[6 MG4I6%83M?M_-,;98CO[+PP<[%:-!9K#6E]9R"#]HHR=7"E=MZ M)Q?Y=+N?]VX_M10N+ND>WJ@_70G9T[W[7D*V/3!?X<)#1!E,[BL& #_/*#TQ M2:L 2"DM5ENM=NL>A;/_0QF5EIE$?!X^F^?A]\M .@;@@M9'0*B:3;/M)77[ MVVG\@NMPR&UWZ);-"$U8(-I"626W68CL?LS628UF7G"#EE$=+R?Q%]G6&[_= M_5HMJ.AZDB]3KJ_CO!41HC=K-?_JP 7"X=A5O0'_4.:0ND/&K! M="#<>TPM]%EUD4]P F=9Y7%C)'AOFC"W^W;+*986:X)M^+,$X:-$V5HG'L_V M/%^ZW_]>NLVGXB-1L14QDJ*FAB[&O/'<\=O]OOO];H%B61)LO@:Q/TQ,OMV: M6\^4UPK0'E/#F6XG$IA;ZG0S,#&CB MIX0NHP^DC6 =2-W!V=9DN>VKCUO543\2;$^JF0K55'^LW%4'^@3J9^<29,GC M;G?KUD\?^-(U'+M=_[N,>S;Q0.J,"Z%%G+ '"?6_1ALUT8/ M'=M64NXR^6": 5*O SP%AH)C;/?H=A4W6-,*"FVB E!*"J&[N6-[ZT[[M?MNN=Q@T//QFTWY*XN'X(46"T$\!+ OMMKYM83 M #Z6B&92'[ER[C/W\Z&[:+LMM[LMU.6Y:BR,9U199=%JNVBPMB;2 UD6%O"+ MV@X"VO(0986EW-!^#0M?O96)V[4\3(I'@6"[6XVL73 ^S+YOM^M6MTO[+9U^+&*ZU MD?>FW[G##V$QM2)R,8#J#;-KM:-&#$G_B<">J(MT2D018,#AKFJP>TO7L6V& M1H 1WRUG3J$Q+-5JH44DC(])EUX)GD)!OJ6!AUA_UVFN,POS^9(X.G6*S.D@ M;%S:=@QL;(ES>60S&RW9 &O#A%"%,:@R]@ M9]B3P)C)H%L84HRVTS>I5!X1FB-C4 ;B'ULOLYC,%%@1 M831=7)=^N/>4 =\5=RF4=?EW!^1WYIRJW9I. C#*93\PRJB;_,%99QP?MFU9 M[N\I\N,-D!&?,_JN$"8$;*TEL-DI-$\:U!$G# &. T%@SCM::$V9AV_3-A(969TS(K<1EV^X)WSVQ?]^[)^ZQ M E%.32>WK[()0_L= DMP_\5(\7\"8[,;K72V.T5=@4M(*E_,M4$=[D[NF8!< M-/ (#Y(VO*E482\+H38,>' "@4T'$&4UH!;$=6Y;^!X8RM5S7N,Y@QJZ=\\H MB39S4W67T=HIFEH)EP"KXE3'A-$/_9;L/\>6'#$7'R\58\Y^_=]-?BXO"6V)W^KUYQ_.I,D)>[<.0 >GU)/GOLM8+B"F MB%_/R%"FG_/TQQ,B 0VW.2Z>VF/>P+#S>6;S14YWZO1BN4A>.A5]"5DC) A4 MC$>]GP3#HW"1+-J7 :+G'$4^4T_ (L#R]&X$25;]N%3*W&YP,VM*DI-5[.>/ M1#GS)#X*W"*I>]=B9YPS_+5UWR]*MF^Y4578+A:US_(JKEWV26%*2P(+<^;4 M8P]U%0_FC!X,2SV=G#O%_J5&UGZN6U=BAC7-ML-C[8,%(S'6*%5,%N5O5<.> MZJ8KPO*JG$YW?G*O_LA"3>!+1I:,9HEVK__;-M#67GJ84N=Y-NM.Z%J*Z;YX M@=!+)RVD62"@Q.)=!RI#%JV8;G@6M62,F PNP'%>3SL)D@\SYW2Q;TVE7C0V MXU@01;%<(S6C(3.O/8$D&LO?/SOX(43G)7J'?*X+=L)86W>9E9G8Y]K(;_?F MDC_I3;^(!G87SXJQ4K$DWY5$:S@]L[A[AC,'SEL+_!O*\4%=RVSZM)9"B1Z9 M#$PB$U:'M7C'O!_ G$2" ">,4/(PIOF."O7CY?9KK=>+9_U&-*"%S>L1EACZ MDIJE@B?BM%R=S0VS-.K O/P#F5&NRHAZJS\Y-[PD8#N1$(?_^"8I&K%F(9O! MC; 1HGKYDR [AA4J/#?P\/A?*U\JG7@V4129WMJ9?'NGZ' !NH2[[#+0E((E M@+R^JDREJ'XDYJH@P1)RK<1M /8M^.7]XSGV],NT@Q$IN2*XD@+U!ZD'-CF. M8GA0UU& MASUA3$T.J+ ;$$HKQ_@N#=ZZBT'7)WS*>Q\?:MMTQ^,?,^Y+&4Q M")^,UX,MPP#)&.J%S0%H2;6>]%4#F:%?G69@:MM/WE79+*M(TDXYJ'()XZ=1 MDG0)73(*]2S+E/OM@7DP/E[@OR(AYO:"V^[DGC/\YF\(T.?:W_]UE+6CD-*:PM$?/]T;)_5K<7\)Q MVWG%Z%BKO#['4A.<]H\H5+O;170ZA.BV@.6\],>4\4VA!N2(,R,[K-:,2*$I MG2Z%=K0/X4#W?272.XT ,\_"X%HIZN?NQ*9@ MWYPN-(G%0RF)DT0I*.9%X

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end